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Abstract 
Background: Psychiatric disorders are common in patients with autoimmune 
diseases such as rheumatoid arthritis. These disorders are poorly understood and 
are an important co-morbidity. They may occur as a consequence of the effects 
of the autoimmune inflammation on the central nervous system. Peripheral 
inflammation inducing central cytokine production in the CNS has been 
documented in acute inflammatory models such as after systemic LPS challenge, 
and cytokine administration has been shown to induce cognitive impairment and 
mood disorders. These disorders may be due to the central action of cytokines 
on neurogenesis and reduced hippocampal neurogenesis has been implicated in 
depression and cognitive decline. Peripheral inflammation and some specific 
cytokines have been reported to inhibit hippocampal neurogenesis, resulting in 
cognition impairment and depressive-like behaviour in animal models.  
Hypothesis: Based on this evidence, we hypothesized that peripheral 
inflammation associated with arthritis can induce central production of 
inflammatory mediators in the brain contributing to reduction in hippocampal 
neurogenesis thereby offering a mechanism and potential therapeutic targets for 
RA-associated psychiatric disorders.  
Aims and Methods: The aim of this project is 1) to investigate whether 
peripheral immune/inflammatory responses during arthritis can induce changes 
in inflammatory mediators in brains of collagen induced arthritis (CIA) mice, 
using this as a model for an adaptive immune response contributing to 
neurological disease development similar to the human disease. We used 
Luminex bead-based screening assays to determine a wide range of inflammatory 
mediator proteins in single small volume samples obtained from mouse brain 
tissues. In the same tissues, the transcription levels of genes encoding these 
inflammatory mediators were also quantified using real-time PCR and quantified 
as absolute copy numbers. 2) To investigate whether peripheral 
immune/inflammatory responses during arthritis can induce changes in 
hippocampal neurogenesis in brains of collagen induced arthritis (CIA) mice, we 
also measure changes in hippocampal neurogenesis in CII immunized mice using 
the immunohistochemistry of neuronal marker doublecortin (DCX). In order to 
confirm that changes in both inflammatory mediators and hippocampal 
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neurogenesis were due to peripheral inflammation, CII immunized mice were 
given peripheral anti TNF-α etanercept treatment. Inflammatory mediator 
profiles and hippocampal neurogenesis in brains of etanercept-treated CII 
immunized mice were compared to PBS -treated CII immunized mice and naive 
control mice. 
Results: Systemic etanercept treatment attenuated arthritis in CII 
immunized mice. IL-1β, IL-5, CXCL1 and FGF2 protein were increased in the 
serum of CII immunized mice. In addition, we found up-regulation of protein and 
gene concentrations of IL-1β, IL-1-α, TNF-α, IL-6, IFN-γ, IL-2, IL-12, IL-4, IL-5, 
CXCL1, CXCL0 and CCL2, VEGF and FGF2 in brains of CII immunized mice 
compared to those in naive control mice. The reduction in number of DCX-
positive neurons in the dentate gurus of CII immunized mice compared to those 
in naive control mice, suggesting the impairment in hippocampus neurogenesis in 
CII immunized mice. In addition, reduction of inflammatory mediators, including 
IL-1β, TNF-α, IL-12, CXCL1, and increases of IL-6, IL-2 and VEGF and FGF2 
protein concentrations were observed in brains of etanercept-treated CII 
immunized mice compared to those in untreated CII immunized mice. In 
addition, the impairment in hippocampal neurogenesis was reversed by 
peripheral etanercept treatment in CII immunized mice. In conclusion, the data 
of this thesis shows that peripheral inflammation during arthritis potentially 
induces production of inflammatory mediators in brains of CII immunized mice. 
Up-regulation of these inflammatory mediators in the brain may be associated 
with the impairment in hippocampal neurogenesis of CII immunized mice. In 
addition, peripheral etanercept treatment seems to have protective effect 
against peripheral-induced brain inflammation and the impairment in 
hippocampal neurogenesis in CII immunized mice.  
In summary, we demonstrated that peripheral inflammation resulting from 
arthritis may induce brain inflammation and contribute to the impairment of 
hippocampal neurogenesis. Systemic etanercept treatment not only attenuated 
joint inflammation, but also reduced brain inflammation and reversed the 
impairment in hippocampal neurogenesis resulting from peripheral inflammation 
in CII immunized mice. 
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Conclusion and prospect: These data provide an important new insight into a 
potential mechanism underlying psychiatric disorders in chronic inflammatory 
disease. We suggest that when considering management of chronic disorders, the 
potential physiological effects on the brain should also be considered. This may 
be difficult to quantify for example when assessing reduced hippocampal 
neurogenesis. Therefore we propose some experimental studies that could 
follow from this thesis might include a search for a systemic biomarker such as 
BDNF that might provide information of CNS changes, perhaps by a comparative 
transcriptional analysis of normal and inflamed brain. The experimental model in 
our study did not include a cognitive or memory end-point as an index of brain 
function, and this aspect could also be included in future experiments to 
complete the link from systemic inflammation to psychological changes. We also 
noted that there may be neurological changes that occur in immunized mice that 
do not yet show signs of arthritis, and if so perhaps depression may occasionally 
reflect a pre-clinical chronic condition.  
However, we feel we have provided sufficient evidence that there is a 
strong link between systemic inflammation with physiological changes in the 
brain that might suggest that therapeutic choices for RA could reduce 
inflammation as well as attenuate depression associated with arthritis. 
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1.1 Immune system 
1.1.1 Overview of immune system 
The immune system is a complex network of cells and molecules that has a 
fundamental role in homeostasis and in defending against infection and cancer. 
The immune system can be functionally divided into two categories, namely 
innate immunity and adaptive immunity, which usually work together to 
eliminate pathogens (Delves and Roitt, 2000a). Innate immunity is the first line 
of nonspecific immune defence, which involves phagocytic cells, including 
macrophages, neutrophils, basophils, mast cells, eosinophils, and natural killer 
(NK) cells. These cells bind to invading microorganisms using pattern recognized 
receptors (PRRs), which recognize a large number of molecules that share a 
common structural motif or pattern (Medzhitov, 2007). There are two main 
families of PRRs, which are the toll-like receptors (TLRs) and the neucleotide-
binding oligomerization domains (NODs) (Martinon and Tschopp, 2005). The 
ligands of PPRs on phagocytes are pathogen-associated molecular patterns 
(PAMPs), which are usually conserved microbial structures with repeat sugar or 
amino-acid motifs that do not occur on mammalian cells. Constituents of 
bacterial walls, including lipopolysaccharide (LPS), peptidoglycan, lipoteichoic 
acids and cell-wall lipoproteins are common bacterial PAMPs (Medzhitov, 2007). 
Phagocytes internalize and destroy pathogens by the process including 
phagocytosis followed by fusion of the phagosome with a lysosome containing 
proteolytic enzyme resulting in microbial lysis. The molecular components of 
innate immunity include complement, acute-phase proteins and cytokines 
including interferon (Medzhitov and Janeway, 2000).  
Adaptive immunity, by contrast, is a highly specific response that can recognise 
any antigenic epitopes on a particular pathogen. The adaptive immune response 
involves antigen recognition by lymphocytes, which are T cells and B cells. The 
main subsets of T cells function either as effector or cytotoxic T (Tc) cells that 
directly attack the pathogens, or as helper T (Th) cells that enhance immune 
response.  B cells function mainly to produce antibodies that are stimulated by, 
are conditioned by and can bind to antigens. When antibodies bind to a 
pathogen, the antibody can cause the activation of the complement system and 
Chapter 1  29 
assist phagocytosis by innate cells to internalize the pathogen and destroy this 
by enzyme lysis. Both T cells and B cells originate from pluripotent stem cells in 
the fetal liver and in the bone marrow. The bone marrow-resident stem cells 
develop to be B cells, while those that travel to the thymus develop into T cells 
(Delves and Roitt, 2000b).  
The activation and the proliferation of antigen-specific T and B cells (clonal 
expansion) occur in the secondary lymphoid tissues such as lymph nodes, spleen, 
and mucosa-associated lymphoid tissue. B cells migrate to germinal centre, 
where B cells hyper-mutate the variable region of their immunoglobulin genes 
and undergo class switching, leading to the production of diversity of specific 
antibodies. Each B cell has a unique antigen receptor, called the B cell receptor 
(BCR), which is activated by its specific antigen in the context of an antigen-
presenting cell. This leads to a differentiation and maturation of B cells into 
plasma cells that secrete specific antibodies with the same specificity as their 
antigen receptor (Kuppers, 2005) . 
The clonal expansion of T cells occurs in the peri-arteriolar lymphoid sheaths of 
the lymph node (Delves and Roitt, 2000b).  The professional antigen presenting 
cells (APCs), including dendritic cells, B cells and macrophages present antigen 
to naïve T cells in the context of the major histocompatibility complex (MHC) 
(Carter, 2000). B cells present antigens to T cells via their membrane-bound 
antibodies, while dendritic cells and macrophages pinocytose antigens and 
process them internally by combining antigen fragments into an assembling 
major histo-compatibility complex (MHC) and present to T cells in that context. 
These APC cells, particularly dendritic cells, express co-stimulatory molecules 
such as CD28 (the B7 ligand), CD154 (the CD40 ligand), and CD2 (the CD58 
ligand). These co-stimulatory molecules that bind to the appropriate ligands 
expressed on T cells generate signals that are essential for T cell activation 
(Delves and Roitt, 2000b). T cells express T-cell receptors (TCRs) that recognize 
specific antigen. T cell antigen recognition, in the context of the MHC 
presentation, results in clonal proliferation of T cells expressing the same TCR 
that target the specific antigen. T cells expressing the CD4 molecule recognize 
antigens presented by MHC class II, and usually act as helper T cells. CD4 T cells 
can be divided in 2 major types (Mosmann and Sad, 1996). Type 1 (Th1) helper T 
cells function to enhance bactericidal activity of phagocytic cells such as 
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macrophages by producing cytokines such as interleukin-2, interferon gamma 
(IFNγ). Type 2 (Th2) helper T cells function to help B cell differentiation and the 
production of antibodies by releasing growth and differentiation cytokines such 
as interleukin-4 (IL-4), interleukin-5 (IL-5), interleukin-6 (IL-6), and interleukin-
(IL-10). There are further subdivisions of T helper cell subsets characterised 
largely by the function of the characteristic cytokine they produce, for example 
Th-17 cells produce interleukin-17 (IL-17) that promotes autoimmunity.  T cells 
expressing CD8 molecule recognize antigens presented by MHC class I, and 
usually function as cytotoxic killer T cells. CD8+ cytotoxic T (Tc)-cells that 
recognize and directly bind and destroy cells that are infected with viruses, and 
CD3/56/16+ NKT-cells that recognise conserved microbial and cancer-related 
glycolipid structures presented in the context of CD1 (Delves and Roitt, 2000b).  
Antigen presentation to naïve lymphocytes during the primary immune response 
also generates memory T and B cells, which are characterized by the expression 
of CD45RO on their cell surface. After a subsequent encounter with the same 
antigen, the secondary immune response initiated by memory lymphocytes is 
more rapid than the primary immune response. In addition, the secondary 
immune response is quantitatively and qualitatively more sophisticated than the 
primary immune response. For example, memory lymphocytes enhance 
proliferation of specific T cells in larger numbers, and B cells to produced higher 
concentrations and producing higher affinity antibodies during the secondary 
immune response compared to those in the primary immune response (Parkin 
and Cohen, 2001).  
1.1.2  Cytokines 
 
Cytokines are a group of small peptides that are responsible for the 
communication between cells of the immune system. Cytokines are secreted by 
all cell types, especially lymphocytes and monocytes/macrophages, for example 
in response to pathogens (Marshall, 1992), and are recognised by cells that have 
cell membrane receptors for that cytokine in order to respond. Cytokines are 
structurally varied, but may share several characteristics. For example, the 
same cytokine may be generated from various cell types, and have differing 
effects on several different cell types. Individual cytokines seldom function in 
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isolation. They tend to work in networks and can function synergistically or 
antagonistically, which regulate positively and negatively other cytokine 
production or function. Most cytokines function locally in the tissue where they 
were produced, either affecting the function of the cell type that produced it 
(autocrine action), or binds to its receptor in nearby cells and affects their 
function (paracrine action). In addition, each set of immune cells synthesise a 
particular group of cytokines, depending on the type of cell and whether, and 
how, it has been stimulated (Tayal and Kalra, 2008). Pro-inflammatory 
cytokines, including interleukin 1beta (IL-1β), interleukin 6 (IL-6), tumour 
necrosis factor - alpha (TNF-α), are produced from mononuclear cells such as 
macrophages in response to infection, inflammation and tissue damage (Haddad, 
2002). TNF-α is one of the most potent cytokines because it up-regulates other 
cytokines, such as IL-1, IL-6, and some chemokines which can direct the cellular 
and behavioural signs of infection and inflammation, including fever and 
increasing the serum acute phase protein concentrations. TNF-α also stimulates 
the cell surface expression of the major histocompatibility antigens.  
The TNF-α receptor consists of two cell surface receptor proteins (p55, p75). 
This receptor complex can be shed from the cells surface and in this soluble 
form can bind TNF-α and prevent its inflammatory function. This observation has 
been developed for translational purposes, and the use of a recombinant form of 
the soluble tumour necrosis factor receptor as a TNF-α antagonist is now an 
effective therapeutic for autoimmune disease such as rheumatoid arthritis 
(O'Shea et al., 2002).  
Cytokines produced from lymphocytes are sometimes called lymphokines. 
They are non-immunoglobulin polypeptide substance produced by T cells and 
natural killer cells that regulate the functions of other cells. Lymphokines, 
including IL-2, interferon-gamma (IFN-γ), interleukin-12 (IL-12) and tumor 
necrosis factor beta (TNF-β) are produced from Th1 cells (Tayal and Kalra, 
2008). IFN-α is produced by phagocytes (monocyte and granulocyte), while IFN-β 
is produced mainly by stromal cells fibroblasts and epithelial cells. IFNs are 
produced in response to viral infection and function to inhibit viral replication 
and destroy cancer cells. IFNs, particularly interferon-alpha (IFN-α), are used 
widely as immunotherapy for cancers, hepatitis B and C (Jaeckel et al., 2001). 
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Th2 cells produce IL-4, IL-5, IL-6, IL-10, and IL-13, and the production of these 
Th2 cytokines is inhibited by Th1 cytokines such as IL-12 and IFN-γ. IL-4 and IL-
10 promote humoral immunity by stimulating the growth and activation of mast 
cells and eosinophils, and the differentiation of B cells into antibody-secreting B 
cells. In addition, IL-4 and IL-10 are considered to be major anti-inflammatory 
cytokines since they inhibit macrophage activation, T-cell proliferation and the 
production of pro-inflammatory cytokines (Opal and DePalo, 2000).  
1.1.3 Chemokines 
 
Chemokines are a large family of structurally homologous cytokines that regulate 
trafficking of various types of leukocytes from the blood to tissue by recognition 
of a concentration gradient. They are small (8–10 kDa) secreted proteins that are 
divided into four groups, namely XC, CC, CXC and CX3C, based on the number 
and location of the two N-terminal cysteine residues (Fernandez and Lolis, 
2002). There are approximately 50 chemokines recently identified and all of 
them can regulate leukocyte migration. Leukocytes are the major source of CC 
and CXC chemokines, but these are also produced by various cell types, such as 
endothelial cells, epithelial cells, and fibroblasts. Various CC chemokines are 
also produced by antigen activated T cells, acting as a connection between 
adaptive immunity and recruitment of inflammatory leukocytes (Slettenaar and 
Wilson, 2006). Chemokine production is mainly induced by pro-inflammatory 
cytokines IL-1, IL-2, TNF-α, γ-interferon and the bacterial product LPS, while 
TGF-β, IL-4, IL-10 can inhibit chemokine production (Rottman, 1999a). 
Chemokines are divided functionally into two major categories; housekeeping 
chemokines and inflammatory chemokines. Housekeeping chemokines, including 
CCL25, CCL17, CCL 27, CCL19, CCL21 and CXCL12, are homeostatic and 
constitutively produced and secreted. They regulate the trafficking of 
lymphocytes and dendritic cells to the lymphoid tissues (Graham, 2009). They 
also function to co-localize B and T cells with antigen on the surface of antigen 
presenting cells in the lymphatic system (Fernandez and Lolis, 2002). 
Inflammatory chemokines, including CCL1, CCL2, CCL3, CCL4, CCL5 and CXCL1, 
CXCL2, CXCL3, CXCL4, CXCL5, CXCL6, CXCL7, CXCL8, CXCL9, CXCL10 and 
CXCL11, are produced by various cells in response to inflammatory stimuli and 
induce the migration of leukocytes to these sites of inflammation. In the 
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inflammatory process, CXCL1, CXCL2, CXCL3, CXCL4, CXCL5, CXCL6, CXCL7, 
CXCL8 regulates neutrophil trafficking and CXCL9, CXCL10, CXCL11 regulate 
activated T-cell trafficking (Graham, 2009). The CC chemokines function mainly 
on monocytes, macrophages, lymphocytes, and eosinophils (Adams and Lloyd, 
1997).  Chemokines function by interacting with chemokine receptors containing 
seven-transmembrane α-helical domains, which belongs to the family of G-
protein couple receptors (GPCRs). These consist of single polypeptide chains 
with three extracellular and three intracellular loops, an acidic amino-terminal 
domain involved in ligand binding, and a serine/threonine-rich intracellular 
carboxy terminal domain (Mantovani et al., 2006). The amino acid sequence 
DRYLAIV in the second intracellular loop domain is the unique structure 
characteristic of chemokine receptors (Rottman, 1999b). Ten signalling 
receptors for the CC chemokines (CCR1, CCR2, CCR3, CCR4, CCR5, CCR6, CCR7, 
CCR8, CCR9, CCR10), seven CXCR chemokine receptors (CXCR1, CXCR2, CXCR3, 
CXCR4, CXCR5, CXCR6, CXCR7) and single receptor for XC and CX3C families are 
identified so far (Graham, 2009). Multiple chemokine ligands can bind to the 
same receptor. For instance, CCR1 is able to bind ten ligands with high affinity, 
while CCR3 has fifteen specific ligands (Rottman, 1999b). There is another group 
of chemokine receptors called silent chemokine receptors, which do not induce 
signal transduction due to alterations in the canonical DRYLAIV motif found in 
the second intracellular loop of the signalling chemokine receptor. The group of 
silent receptors are Duffy antigen receptor for chemokines (DARC), D6 (or 
CCBP2), CCX-CKR (or CCRL1) regulate inflammatory and immune response by 
various mechanisms, including acting as decoy receptors and as scavenger 
receptors (Graham, 2009); (Heinzel et al., 2007). For example, the D6 receptor 
has a role in the resolution of inflammation by binding chemokines that are 
expressed only in response to inflammatory stimuli (Mantovani et al., 2006). 
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1.2 Rheumatoid Arthritis  
Rheumatoid Arthritis (RA) is a systemic chronic inflammatory disease 
characterized by joint pain, stiffness, and swelling. There are associated 
remodelling changes including pannus formation and destruction of cartilage, 
bone and associated soft tissue (Klareskog et al., 2009). These pathological 
features eventually lead to disability. The annual incidence of RA has been 
reported to be around 20 to 50 cases per 100,000 of the population. Women are 
affected up to three times as often as men (Tobon et al., 2010). The immuno-
pathogenesis of RA is complex and appears to involve primarily auto-immune 
mechanisms.  IgM, IgA and IgG subclasses 1-4 anti-citrullinated protein 
antibodies (ACPA), anti-keratin antibodies (AKA), anti-perinuclear factor (APF) 
and anti-RA33 antibodies are elevated in the serum of RA patients, and their 
titres have also been associated with severity of the disease. These rheumatoid 
factors and auto-antibodies can also be used to predict the development of RA in 
early arthritis (Lin and Li, 2010); (Agrawal et al., 2007); (Nell et al., 2005). The 
major component of the RA pannus is hypertrophic synovial membrane, which 
consists of hyperproliferation of Type A synoviocytes (macrophage-like synovial 
cells) and Type B synoviocytes (fibroblasts-like synoviocytes) along with immune 
cells that infiltrate the synovial membrane. T cells can constitute up to 50 % of 
cells in RA synovial and most of these are CD4+ CD45RO+ memory T cells. Only 5% 
or fewer are B lymphocytes or plasma cells. Rheumatoid factors, ACPA and anti-
collagen antibody are also found in synovial tissue (Bartok and Firestein, 2010). 
RA is considered as a non-organ-specific autoimmune disease. This is because 
subcutaneous nodules, vasculitis, pulmonary fibrosis are common complication 
of RA (Williams, 2006). 
1.2.1 Aetiology of RA 
The aetiology of RA remains undefined. Both genetic factors and environmental 
factors contribute to the cause of the disease.  
A major risk factor that links genetic susceptibility and RA is the association of 
the disease with an antigenic epitope in the HLA-DR ß-chain that is shared with 
microbial antigens. This shared epitope is a highly conserved amino acid 
sequence (QKRAA) at residues 67, 70, 71, 72 and 74, which have been associated 
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with severe RA. It is located in the third hypervariable region of DR4, DR14 and 
DR1 ß-chains that are expressed on macrophages, B cells and antigen presenting 
cells. The 65 kD heat shock protein from Mycobacterium tuberculosis and 40kd-
Escherichia coli dnaJ, and Epstein-Barr virus (EBV) gp110 also contain the shared 
epitope (QKRAA) on DRß1*0401 (Albert and Inman, 1999); (Toussirot and Roudier, 
2008). The RA-associated HLA alleles are members of HLA-DRB1*0404 group (e.g. 
*0401,*0404, *0405,*0408, HLA-DRB1*0101, HLA-DRB1*0102, HLA-DRB1*1402 and 
HLA-DRB1*1001 (Holoshitz, 2010).  
Several genetic polymorphisms associated with RA have been identified by 
genome-wide association (GWA) studies. Several population studies have 
demonstrated an association between a missense SNP in the PTPN22 gene, which 
encodes a phosphatase involved in intracellular T cell signalling, with an 
increased risk and rate of progression of RA (Lie et al., 2007, Begovich et al., 
2004). In addition, other genetic polymorphisms of various cytokine and 
cytokine-receptor genes, such as those encoding TNF, IL-1, IL-10 and IL-18, have 
been studied intensively in RA. For example, a -857C/T SNP at the TNFA 
promoter has been associated with RA and with better responses to etanercept 
(recombinant human soluble TNF receptor) therapy (Kang et al., 2005). 
A strong association between cigarette smoking and the presence of HLA-
DBR1*0404 or other HLA alleles comprising the shared epitope has been reported 
for the ACPA-positive group of RA patients. One epidemiological study 
demonstrated that the relative risk of developing RA was increased 20-fold in 
the ACPA-positive group of RA patients who had two alleles for the shared 
epitope and had ever smoked cigarettes (Klareskog et al., 2006).  It is possible 
that smoking can induce citrullination in certain proteins in the lungs. These 
citrullinated proteins activate the immune response by binding specifically to 
HLA-DR molecules comprising the shared epitope on antigen-presenting cells, 
which eventually result in the production of ACPA. These antibodies to 
citrullinated protein can contribute to the development of RA in the joint 
(Klareskog et al., 2009). 
A twin study in heritability demonstrated that the genetic contribution to RA 
accounted for 50-60% of the variation in liability to disease, suggesting that 
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environmental factors, such as smoking, are also major contributors to RA 
(MacGregor et al., 2000). In addition, several viral and bacterial infections, 
including the Epstein-Barr virus (EBV), parvovirus and lentiviruses, and bacteria 
including Mycoplasma, Mycobacteria and Yersinia species, can be risk factors for 
the development of RA. Other environmental factors including breast feeding, 
oral contraceptives use, or regular alcohol consumption may be protective 
against the development of RA (Liao et al., 2009).  
1.2.2 Pathogenesis of RA 
The activation of T lymphocytes, particularly the CD4+ helper Th1 subset, is part 
of the initiation of the destructive immune response in RA (McInnes and Schett, 
2007). These cells infiltrate the synovial membrane and are activated by antigen 
presenting cells (e.g. dendritic cells and B cells). Along with antigen presented 
in the context of MHC, additional co-stimulation, such as CD28–B7 receptor 
family (CD80/86), is necessary for T cell activation. Activated Th1 cells produce 
cytokines including IL-2, IFNγ and TNF-α. These Th1 cytokines stimulate 
monocytes, macrophages, and synovial fibroblasts to produce IL-1, IL-6 and TNF-
α and to secrete matrix metalloproteinases (MMPs). Activated Th1 cells also 
stimulate B cells, via CD40 ligand mediated co-stimulation, to produce 
rheumatoid factor and auto-antibodies.  Immune complexes, formed by auto-
antibodies, induces macrophage to produce TNF-α by complement activation 
(Klareskog et al., 2009). These activated macrophages, lymphocytes and 
fibroblasts can also stimulate angiogenesis by activating synovial cells to produce 
angiogenic factors, such as macrophage angiogenic factor (MAF), vascular 
endothelial growth factor (VEGF), prostaglandins E1 and E2, IL-8 and 
angiopoietin-1 (Szekanecz et al., 2009). Endothelial cells in the synovium are 
activated and adhesion molecules such as intercellular adhesion molecule-1 
(ICAM-1), vascular cell adhesion molecule-1 (VCAM-1), P-selectin, and E-selectin, 
are upregulated to promote the recruitment of immune cells into the joint. 
Activated Th1 cells and synoviocytes also produce receptor activator of nuclear 
factor-kB ligand (RANKL) and macrophage colony-stimulating factor (M-CSF). 
These two cytokines promote the differentiation of osteoclast precursors (OCPs) 
into mature osteoclasts that have bone-resorbing activity. RANKL expression is 
also regulated by TNF-α, IL-1β, IL-6 and IL-17. The activity of RANKL is inhibited 
by osteoprotegerin (OPG), a soluble decoy receptor that belongs to the TNF-
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receptor superfamily. TNF-α and IL-1β also induce chondrocytes and fibroblasts 
to produce a disintegrin and metalloproteinase with thrombospondin motifs 
(ADAMTS) and MMPs, which degrade proteoglycan and collagen in the cartilage 
(McInnes and Schett, 2007). 
1.2.3   Roles of cytokines in RA 
1.2.3.1 Roles of pro-inflammatory cytokines in RA 
Cytokines play major roles at each stage of the pathogenesis of RA by regulating 
autoimmunity, chronic inflammatory synovitis and the destruction of joint 
tissue. Several cytokines, including granulocyte macrophage colony-stimulating 
factor (GM-CSF), IL-1, IL-6, IL-2, IL-12, IL-15, IL-13, IL-17, IL-18, IFNγ, TNFα, and 
TGF-β interact in a complex network contributing to RA pathogenesis (McInnes 
and Schett, 2007). TNF-α, IL-1 and IL-6 are considered as principle cytokines 
that regulates each stage of the pathogenesis of RA. Antibodies against these 
cytokines, especially TNF-α and their receptor antagonists are major therapeutic 
targets for RA drug development (Seymour et al., 2001). TNF-α (Cope et al., 
1992), IL-1 (Wood et al., 1983) and IL-6 (Waage et al., 1989) and their receptors 
are highly expressed in the inflamed synovial membrane tissue in RA patients 
and synovial macrophages are the major source of these pro-inflammatory 
cytokines (Brennan and McInnes, 2008). TNF-α is a pro-inflammatory cytokine 
that is highly expressed on macrophages and T cells. TNF-α acts by binding to 
TNF receptors, namely TNFRI (p55) and TNFRII (p75) (H. E. Seymour 2001). There 
are also soluble forms of TNFR that function to modulate inflammatory response 
by inhibiting TNF-α activity. These soluble forms of TNFRs, including p75 have 
been developed to be efficient therapy for arthritis such as etanercept or anti-
TNF-α; Infliximab (Seymour et al., 2001). TNF-α initiates the immune response 
by inducing the production of other pro-inflammatory cytokines, including IL-1β, 
IL-6, IL-23 and GM-CSF from antigen presenting cells. IL-1β also has been 
implicated in pathological mechanism of RA (Abramson and Amin, 2002), 
although so far to date it has not been well developed as powerful treatment for 
RA (Brennan and McInnes, 2008).  There are 2 distinct IL-1 receptors, namely 
type I and type II (Sims et al., 1988). Type I IL-1R is expressed predominately on 
T cells and fibroblasts, while Type II IL-1R is expressed on activated T cells, B 
cells, monocytes and neutrophils (McMahan et al., 1991). IL-1β and TNF-α have 
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synergistic effects on the process of inflammatory joint destruction of RA. 
However, TNF-α seems to play the main role in synovial Inflammation, while IL-
1β seems to regulate mainly bone erosion and cartilage damage (Zwerina et al., 
2007). IL-6 is produced by fibroblasts, activated T cells, activated monocytes or 
macrophages and endothelial cells (Van Snick, 1990). IL-6 signals via IL-6 
receptor, which is a complex of receptor subunits and two signal-transducing 
gp130 subunits (Jones et al., 2006). IL-6 can regulate the humoral immune 
response by activating B-cell maturation and the production of auto-antibodies 
(Dayer and Choy, 2010). In addition, IL-6 also enhances the acute phase response 
during inflammation by stimulating production of the full range of acute phase 
proteins in hepatocytes (Dayer and Choy, 2010). In addition, IL-6 also contributes 
to other inflammatory pathways of RA including osteoclast activation, pannus 
formation, and mediating chronic synovitis (Dayer and Choy, 2010). IL-1β, TNF-α 
and IL-6 share many similar activities and have synergic effects on several 
pathological pathways of RA, including the ability to enhance cytokine 
production, proliferation of T calls and B cells, and MMP production by synovial 
cells and chondrocytes. They also enhance the leukocyte recruitment process by 
activating the production of chemokines, including CCL5, CCL2, CCL8, and 
CCL12, together with adhesion molecules such as E-selectin and VCAM-1 on 
endothelium (Brennan and McInnes, 2008).  
1.2.3.2 Roles of T cell derived cytokines in RA 
Cytokines of T helper subsets play crucial roles in the regulation of the adaptive 
immune responses and the immuno-pathology of rheumatoid arthritis. CD4+T 
cells are divided on the basis of cytokine secretion patterns and effector 
functions into 2 distinct CD4+T cells subset, namely Th1 and Th2 cells. Th1 (IL-2, 
IFN-γ and IL-12) cytokines mediate macrophage-dependent inflammation and 
delayed-type hypersensitivity reactions (Schulze-Koops and Kalden, 2001), 
whereas Th2 (IL-4, IL-5, IL-10, IL-13) cytokines play important roles in antibody-
mediated allergic reactions and macrophage deactivation (Kozanidou et al., 
2005); (Xu et al., 2008). 
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1.2.3.2.1  Role of Th1 cell cytokines in RA 
The chronically inflamed RA synovial membrane is characterized by an 
accumulation of infiltrating CD4+T cells, which are predominately of the Th1 
phenotype (Dolhain et al., 1996). These Th1 cells and effector cytokines, 
including IL-2, IL-12 and IFN-γ produced by these Th1 cells are thought to play a 
pathogenic role in the immunopathology of RA. IL-2, IL-12 and IFN-γ were found 
to be highly expressed in synovial fluid, synovial tissue and peripheral blood of 
RA patients (Berner et al., 2000); (Canete et al., 2000); (Morita et al., 1998). IL-
2, IL-12 and IFN-γ are considered as important regulatory cytokines for different 
stages of the pathogenesis of RA. IFN-γ produced mainly by activated T-cells and 
NK cells is considered to be a major effector Th1 cytokine (Farrar and Schreiber, 
1993). IFN-γ and its IFN-γ receptor are known to function as a pro-inflammatory 
cytokine complex in RA (Tsuda et al., 2009). IFN-γ activates macrophages 
(Nathan et al., 1983), enhancing the ability of antigen presentation via up-
regulation of MHC class II expression in various cell types (Jahn et al., 1987). In 
addition, IFN-γ also promotes the production of IgG2a in mouse and IgG1 in 
human, which are involved in antibody-dependent cell cytotoxicity (Schulze-
Koops and Kalden, 2001); (Finkelman et al., 1988).  
IL-2 acts via the IL-2 receptor (CD25, IL-2R) and has a major role in clonal 
expansion of antigen-primed T cells (Schroeter and Jander, 2005). However, IL-2 
has also been reported to activate apoptosis of antigen activated T cells in IL-2 
deficient mice. This suggests that IL-2 also functions as a regulator of immune 
homeostasis following antigen clearance (Refaeli et al., 1998). The actual role of 
IL-2 in arthritis has not been well elucidated. Studies in experimental arthritis 
demonstrated that IL-2 could have both direct pro-inflammatory effects and 
indirect anti-inflammatory effects mediated by IFN-γ on the severity of arthritis 
disease (Thornton et al., 2000).  
IL-12 is a 70-kd disulfide-linked heterodimeric cytokine comprising p40 and p35 
chains that produced mainly by macrophage-lineage cells and dendritic cells 
(Malfait et al., 1998). IL-12 binds with IL-12 receptors consisting of 2 subunits 
designed IL-12β1 and IL-12β2 (Presky et al., 1996). IL-12 has a vital role in cell 
mediated immunity by inducing differentiation of T cell precursors into the Th1 
phenotype (Malfait et al., 1998). In addition, IL-12 also stimulates the 
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proliferation of activated T and NK cells and the production of IFN- γ by both T 
and NK cells (O'Garra and Arai, 2000).  However, the role of IL-12 in the 
pathological mechanism of RA is still unclear. The administration of IL-12 to the 
CIA mouse model of RA has been reported to dramatically attenuate the severity 
of arthritis disease (Malfait et al., 1998). In contrast, the induction of collagen-
induced arthritis (CIA) in IL-12 deficient mice has been reported to increase the 
severity of arthritis, suggesting that IL-12 paradoxically mediates protection 
from autoimmune inflammation (Murphy et al., 2003).  
1.2.3.2.2  Role of Th2 cell cytokines in RA 
Th2 cell cytokines, including IL-4, IL-5, IL-10 and IL-13 play a crucial role in the 
humoral immune response; including stimulating maturation of B lymphocytes 
into plasma cells, stimulating immunoglobulin class switching from IgM to IgE and 
IgG1 (in mouse) or IgG4 (in man) isotypes, promoting allergic immune responses 
and eosinophil activation (Schulze-Koops and Kalden, 2001); (Kurowska-Stolarska 
et al., 2008); (Punnonen et al., 1993); (Pope et al., 2001). 
IL-4 and IL-10 have been reported to play protective roles in autoimmune 
disease (Schulze-Koops and Kalden, 2001). Increases in IL-10 concentrations in 
the peripheral blood and serum have been reported in RA patients compared 
with healthy controls. IL-4 mRNA and IL-4 producing T cells were detectable at 
low levels in the synovial fluid of RA patients. The major cellular sources of IL-10 
are T cells, B cells, and monocytes/macrophages, whereas IL-4 is mainly 
produced by Th2 cells. In RA, IL-10 can be produced by cells in the synovial 
membrane. IL-10 functions via the IL-10 receptor which is composed of at least 
two subunits that are members of the interferon receptor (IFNR) family (Moore 
et al., 2001). IL-4 acts through the IL-4 receptor, which is a receptor complex 
consisting of IL-4R α chain and γ chain (Nelms et al., 1999). IL-4 and IL-10 have 
been shown to prevent autoimmunity by inhibiting Th1 proliferation, synovial 
inflammation and tissue destruction in RA (Schulze-Koops and Kalden, 2001). IL-4 
and IL-10 can down-regulate the production of IL-1 and TNF-α by peripheral 
blood monocytes and by synovial tissue from RA patients (Briolay et al., 1992); 
(de Waal Malefyt et al., 1991). Importantly, IL-4 and IL-10 also function to down-
regulate the production of Th1 cytokines IFN-γ and IL-2, and to suppress their 
cell-mediated immune response (Romagnani, 1994). The combination of IL-4 and 
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IL-10 has been shown to reduce severity of arthritis and protect cartilage 
degradation in experimental arthritis (Joosten et al., 1997). An imbalance of 
Th1/Th2 cytokine has been proposed to play an important role in the 
pathogenesis of rheumatoid arthritis (Canete et al., 2000). Therefore IL-4 and IL-
10 seem to be potential therapeutic agents for RA. 
IL-5 and/or IL-13 play an important role in allergic asthma and helminthic 
infection (Kurowska-Stolarska et al., 2008); (Artis et al., 1999). IL-5 is produced 
mainly by Th2 cells and mast cells (Gregory et al., 2003), while IL-13 is produced 
by T cells, mast cells, basophils, dendritic cells, and keratinocytes (Schmid-
Grendelmeier et al., 2002). IL-13 acts via the IL-13Rα1 and IL-13Rα2 (Mentink-
Kane and Wynn, 2004), while IL-5 function is via the IL-5 receptor consisting of 
IL-5α and IL-5β subunits . Both IL-13 and IL-5 function mainly to regulate 
eosinophil trafficking and activation (Pope et al., 2001); (Ogata et al., 1998). 
Little is known about their role in the immuno-pathogenesis of RA. Both clinical 
and experimental arthritis studies showed that IL-5 and IL-13 may play a crucial 
role during the development of arthritis. Increases in IL-13 and IL-5 protein 
levels have been reported in synovial fluid of RA patients and up-regulation of 
serum IL-5 has been reported in experimental arthritis during the early stages 
and onset of disease (Hitchon et al., 2004); (Schaefer et al., 1999).  Both IL-13 
and IL-5 have been reported to exacerbate the severity of arthritis by promoting 
IgE and IgG antibody isotype switching by B cells in CIA mice (Xu et al., 2008).   
1.2.3.3  Roles of chemokines in RA 
Chemokines and their receptors play crucial roles in RA pathogenesis mainly via 
the recruitment of leukocytes to the inflamed joint (Iwamoto et al., 2008). 
Recent studies also suggest that chemokines also play important roles in the 
destruction of bone and cartilage and fibroblast proliferation.  
CXCL1 (Lisignoli et al., 1999); (Bischoff et al., 2005), CXCL8 (Kraan et al., 2001), 
CXCL5 (Koch et al., 1995), CXCL9, CXCL10 (Kuan et al., 2010), CCL2 (Szekanecz 
et al., 2003), CCL5 (Yang et al., 2009)and CCL3 (Katschke et al., 2001) are 
elevated in the synovial fluid and in serum of RA patients. Synovial 
macrophages, T cells, synoviocytes and chondrocytes produce various 
chemokines stimulated mainly by IL-1β, TNF-α and IFN-γ, and bacterial 
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lipopolysaccharide (LPS) (Iwamoto et al., 2008). CXCL1 functions as a potent 
neutrophil chemo-attractant by binding both CXCR1 and CXCR2 receptors 
(Luttichau, 2010). CXCL1 has been reported in osteoblasts and in synovial fluid 
from rheumatoid arthritis patients (Lisignoli et al., 1999); (Bischoff et al., 2005). 
CXCL1 has also been reported to regulate angiogenesis during the inflammatory 
process (Barcelos et al., 2004). This group of C-X-C chemokines can bind to the 
same receptor CXCR2 (Charo and Ransohoff, 2006), and blocking the CXCR2 
receptor has been reported to inhibit the development of experimental arthritis 
(Barsante et al., 2008); (Lusitani et al., 2003). CCL2, CCL5 and CCL3 are potent 
chemokines that function predominantly by recruiting and activating monocytes, 
Th2 cells, B cells, NK cells, basophils, eosinophils and memory T lymphocytes. 
CCL2 and CCL5 can stimulate chondrocytes to produce MMP, increase 
proteoglycan release and inhibit proteoglycan synthesis by chondrocyes (Borzi et 
al., 2000). CXCL9 and CXCL10 function as potent T-lymphocyte chemotactic 
factors by binding into the receptor CXCR3, preferentially on the Th1-
lymphocyte subset. In addition, CXCL10 induced RANKL expression in CD4+ T 
cells, which promote bone resorption by inducing osteoclast formation and 
survival (Lee et al., 2009). Fibroblast-like synoviocyte proliferation is also 
induced by CXCL10 and CXCL9 and CCL13, leading to synovial hyperplasia 
(Garcia-Vicuna et al., 2004). 
1.2.3.4 The role of growth factors in RA 
Joint destruction in RA is mediated mainly by pannus formation (McGonagle, 
2010).  Changes in the synovium during the formation of pannus are 
characterized by neovascularisation, inflammatory cell infiltration and synovial 
hyperplasia (Brenchley, 2001).  The initiation of the pannus formation process, 
including angiogenesis and synovial hyperplasia in RA, is mainly regulated by 
angiogenic growth factor such as fibroblast growth factor 2 (FGF2) and vascular 
endothelial growth factor (VEGF) (Roccaro et al., 2005). Fibroblast growth factor 
2 is a wide-spectrum mitogenic, angiogenic, and neurotrophic factor that binds 
to FGF receptors (FGFR) and regulates various biological processes, including 
embryogenesis, wound healing, angiogenesis, and maintenance of neuronal 
networks (Manfe et al., 2010). In RA, mast cells and vascular cells are the major 
sources of FGF2 (Qu et al., 1995). FGF2 functions mainly in mediating cartilage 
and bone destruction and synovial hyperplasia in RA (Qu et al., 1995). FGF2 also 
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has a role in angiogenesis and recruitment of immune cells into the inflamed site 
(Malemud, 2007). Another growth factor that is also found highly expressed in 
synovial tissue of RA patients is VEGF (Nagashima et al., 1995). VEGF is a potent 
angiogeneic factor that functions via tyrosine kinase receptors, VEGFR1 (also 
known as Flt-1) and VEGFR2 (also known as KDR/flk-1) (Malemud, 2007). The 
major cellular sources of VEGF in RA are macrophages, fibroblasts surrounding 
microvessels, vascular smooth muscle cells and synovial lining cells (Nagashima 
et al., 1995).  VEGF not only has a crucial role in neovascularisation in pannus 
formation, but also stimulates endothelial progenitor cells and regulates the 
recruitment of leukocytes (Kim et al., 2001, Lyden et al., 2001); (Asahara et al., 
1999). In addition, VEGF in the inflamed synovium may stimulate and promote 
cartilage degradation via the production of MMPs (Martel-Pelletier et al., 2001). 
Both FGF2 and VEGF have been shown to have detrimental effects on the 
severity of arthritis in the experimental arthritis mouse model (Yamashita et al., 
2002); (Afuwape et al., 2003).  
1.2.4   Collagen induced arthritis: murine model of RA 
Collagen induced arthritis (CIA) is an important experimental rodent model of 
RA, which is extensively used to study pathogenesis, to generate hypotheses and 
to develop potential treatments for this autoimmune disease (Kannan et al., 
2005).  
Immunological changes associated with RA include an increase in the numbers of 
collagen type-II (CII) specific T cells and increased concentrations of anti-CII 
antibodies in the synovial fluid and serum of RA patients during the early phase 
of disease in RA (Kim et al., 2004); (Kim et al., 1999); (Ohnishi et al., 2003); 
(Mullazehi et al., 2007). This clinical evidence suggests that collagen type II is 
one of the major autoantigens that has a crucial role in the initiation of the 
destructive immune response in RA. Since collagen type II is a component of 
articular cartilage, immunization with CII of heterologous species may induce 
joint destruction (Cho et al., 2007). This concept of CIA pathogenesis was first 
applied in the rat model (Trentham et al., 1977), and subsequently in 
susceptible strains of mice (Courtenay et al., 1980). The genetically susceptible 
mouse strains are DBA/1, B10.Q and B10.RIII, which have H2q or H2r haplotypes 
on the MHC locus (Brand et al., 1996). The C57BL/6 (H-2b) mouse strain has also 
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been demonstrated to be susceptible to CIA induction (Campbell et al., 
2000);(Inglis et al., 2008). In addition, male mice are more susceptible to CIA 
than females (Nandakumar et al., 2003). Collagen type II from various species, 
including bovine, porcine, chicken and human have demonstrated their ability to 
induce arthritis in rodent models (Myers et al., 1995).  
After immunization with type II heterologous collagen in complete Freund’s 
adjuvant, mice usually develop asymmetrical polyarthritis at around 3 weeks 
(Inglis et al., 2008). Similar to human RA, pathological features of arthritis in CIA 
mice include synovial inflammatory cell infiltration, cartilage and bone erosion 
and synovial hyperplasia (Asquith et al., 2009b). The proliferation of CII-specific 
CD4+ T cells is observed in the local lymph nodes during 3-5  weeks after the first 
immunization (Lee et al., 2006).The joint inflammation in CIA mice lasts for 2-3 
weeks after the onset of disease, followed then by a recovery phase (Inglis et 
al., 2008).  
1.2.4.1 Immunopathogenesis of Collagen induced arthritis 
Similar to human RA, the pathological mechanisms in the CIA model involve both 
cell-mediated and humoral immune responses (Brand et al., 2003). Both T and B 
lymphocytes play crucial roles in the development of the disease (Holmdahl et 
al., 2002). The presence of collagen type-II specific T cells in the arthritic joints 
suggests that T cells may directly regulate the immuno-pathogenesis in the CIA 
model (Holmdahl et al., 1988). The initiation of a cell mediates immune 
response in the CIA model is presumably driven by Th1 cells via the production 
of IFNγ, lymphotoxin-β, (LTβ) and TNF-α (McInnes and Schett, 2007). The 
disease progression and the inflammation phases may be mediated by humoral 
factors including antibodies and complement (Schulze-Koops and Kalden, 2001). 
Mauri et al., 1996 described the relationship between Th1 and Th2 cytokines in 
CIA models by measuring cytokine levels of cultured draining lymph node cells 
isolated from CIA mice during the induction and the progression phases of 
inflammatory joint disease. IFN-γ was detected in the lymph node cell culture 
during the induction phase of the disease, and stimulation with collagen type II 
caused a 10-fold increase in IFN-γ production. In addition, the IFN-γ levels were 
further elevated throughout the progression phase of disease.  In contrast, the 
concentration of Th2 cytokines such as IL-4 and IL-10 were dominant during the 
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recovery phase of the disease. These data confirm that Th1 lymphocyte 
cytokines may be the important regulators for the onset and the development of 
arthritis (Mauri et al., 1996). B lymphocytes and plasma cells are responsible for 
the production of anti-collagen antibody. This antibody binds to cartilage and 
activates antibody and complement-mediated immune destruction (Holmdahl et 
al., 2002). IgG2 is the dominant subclass of anti-collagen antibody in the CIA 
model, and the concentrations of IgG2a and IgG2b antibody were markedly 
increased during the highest severity phase of the disease (Brand et al., 2003); 
(Brand et al., 1996).  
1.2.5  Rheumatoid arthritis as a systemic inflammatory 
disease and its association with neurological diseases 
Rheumatoid arthritis is a systemic autoimmune disease in which the peripheral 
inflammation (beyond arthritis) is reflected by the presence of extra-articular 
diseases such as systemic vasculitis (blood vessel inflammation), subcutaneous 
nodules and pulmonary nodules and fibrosis in approximately 30% of RA patients 
(Young and Koduri, 2007). A recent study demonstrated that the distribution of 
pro-inflammatory CD4+ T cells lacking the costimulatory molecule CD28 
(CD4+CD28null T cells) in the peripheral blood of RA patients has been associated 
with these extra-articular manifestations (Fasth et al., 2007). For example, RA 
patients with persistent expansion of CD4+CD28null T cells developed 
atherosclerotic disease more significantly than RA patients without this 
expansion. In addition, anti-TNF-α treatment in RA was shown to attenuate 
these atherosclerotic changes, demonstrating a contribution of this cell subset in 
atherosclerosis development in RA (Gerli et al., 2004). Therefore, it is suggested 
that the activation of peripheral adaptive immune responses during arthritis not 
only affects joints, but also contributes to the inflammation in other organs such 
as the skin, lung, cardiovascular system and peripheral nerves (Turesson and 
Matteson, 2004). 
Accumulating evidence suggests that the brain is also affected by peripheral 
inflammation during arthritis. Psychiatric disorders such as depression and 
anxiety are common in RA, suggesting that peripheral inflammation during 
arthritis may cause alterations in the brain neurobiology. However, the 
mechanism underlying psychological disorders in RA is still unclear. A preliminary 
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study using a single photon emission computed tomography (SPECT) scan of 6 RA 
patients showed a reduction in serotonin transporter (SERT)  density, along with 
improvements in physical and mental functions after receiving anti-TNF-α 
treatment, suggesting that circulating cytokines generated during autoimmune 
activation in RA may cause changes in the serotonin system that induce the 
development of depression (Cavanagh et al., 2010). Neuroimaging studies 
showed several CNS lesions in the brains of RA patients, which resolved after 
steroid treatment, suggesting that CNS inflammatory demyelination is also 
inducible by systemic inflammation during arthritis (Tsai et al., 2008); (Tajima et 
al., 2004). This CNS inflammatory demyelination is also the major clinical 
feature of multiple sclerosis (MS) (Zuvich et al., 2009). MS is generally 
considered to be a CNS autoimmune disease directed against CNS myelin 
proteins, including myelin basic protein (MBP), myelin oligodendrocyte 
glycoprotein (MOG) and proteolipid apoprotein (PLP) (Zozulya and Wiendl, 2008). 
However, the precise pathological mechanism of MS is unknown. The 
immunopathogenesis of MS has been investigated intensively by using animal 
models of MS, including experimental autoimmune encephalomyelitis (EAE), 
which shares some of the clinical and neuropathological features of MS (Sriram 
and Steiner, 2005). Both clinical studies in MS patients and animal studies in the 
EAE model suggest that Th1 and Th17 CD4+ cells, and trafficking of these cells 
from the periphery into the brain play an important role in the initiation of 
episodes of demyelination in the relapsing-remitting phase of MS  (Weiner, 
2008); (Pender et al., 2000); (Greer et al., 2008); (Das et al., 1997); (Kebir et 
al., 2007); (Stromnes et al., 2008); (Klein, 2004). Interestingly, rheumatoid 
arthritis is a systemic autoimmune disease that shares similar pathological 
mechanisms with MS. The aetiology of both autoimmune diseases is influenced 
by genes in the HLA region, particularly the class II genes. In addition, CD4+ T 
cells are thought to play a crucial role in both MS and RA pathogenesis. 
Therefore, it is possible that lesions of CNS inflammatory demyelination 
reported in brains of RA patients may be the result of circulating CD4+ T cells 
stimulated by the auto-immune inflammatory process and migrate into the 
brains during arthritis. These peripherally activated CD4+ T cells may include 
some that recognise and become activated by myelin proteins in the CNS or in 
secondary lymph nodes, and then exacerbate inflammatory demyelination 
process in the brains. However, to date, activation of the adaptive immune 
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response in the brain associated with peripheral joint inflammation of RA has not 
been well elucidated.  
1.3 Immunology of the central nervous system 
The central nervous system (CNS) is an important organ and needs to be 
protected from pathogens. Physiological mechanisms of immune defence in the 
CNS are still unclear (Carson, 2002). In the past, the CNS was viewed as ‘an 
immune privileged site’, characterized by the presence of an intact blood–brain 
barrier (BBB) (Carson, 2002). The BBB serves as a physical barrier preventing the 
influx of immune cells and inflammatory mediators into the CNS during 
inflammation (Abbott et al., 2010). Over the last 20 years, the CNS has been 
considered an ‘immune-privileged’ organ (Carson et al., 2006) however, more 
recent evidence suggests that the CNS is both immune competent and actively 
interactive with the peripheral immune system (Dantzer et al., 2008). In 
addition, immune cells such as macrophages and dendritic cells are present at 
the choroid plexus and meninges of the brain (Dantzer et al., 2008). 
Importantly, brain parenchymal cells such as microglia and astrocytes can 
initiate inflammatory processes by producing inflammatory mediators (cytokines 
and chemokines) (Whitney et al., 2009).  
1.3.1  Astrocytes 
The astrocyte is a non-neuronal cell type in the central nervous system (CNS), 
characterized as being a star shaped cell with numerous extended branches 
surrounding nearby neurons and blood vessels (Nair et al., 2008), (Wang and 
Bordey, 2008). Astrocytes are the most abundant subtype of glial cells in the 
CNS, comprising approximately 90% of CNS-resident cells in human brain (Nair et 
al., 2008). Unlike microglia that are derived from cells of the immune system, 
astrocytes are derived from the same lineage as neurons and oligodendrocytes 
(Bolton and Eroglu, 2009) That could be the reason why astrocytes also have 
neuronal function as well as regulation of immune response. Astrocytes are 
multifunctional cells and are involved in various essential CNS functions, 
including synaptic homeostasis and transmission, regulation of CNS blood flow, 
and supply of energy metabolites (Blackburn et al., 2009). In addition, 
astrocytes can also respond to inflammatory conditions such as infection, 
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trauma, ischemia and neurodegenerative disease by a process called reactive 
astrogliosis (Sofroniew, 2009). 
1.3.2  Microglia 
Microglia are central nervous system (CNS) macrophage-like cells, comprising 5-
20% of the total glial cell population (Graeber and Streit, 2010). Microglia in the 
normal brain are characterized by small cell bodies with a number of fine, 
branched processes, which is often called ramified microglia (Graeber and 
Streit, 2010). In response to virus or bacterial infections or CNS injury, activated 
ramified microglia exhibit morphological changes, including shortening of 
cellular processes and enlargement of their cell bodies. This phenotype is called 
amoeboid microglia (Town et al., 2005). The origin of the microglia lineage is 
still undefined. Microglia share a large number of cell surface markers with 
mononuclear phagocytes, including CD11b (Mac-1, β2 integrin), CD11c (LeuM5), 
CD45 (leukocyte common antigen), CD64 (Fc γ receptor 1), CD68 (macrophage 
antigen), complement type 3 receptor (CR3), B7-2 (CD86), and major 
histocompatibility complex (MHC) class I and II antigens, and Toll-like receptors 
(Yang et al., 2010). Based on these similarities in cell surface markers, it is 
implied that microglia may be derived from the same lineage as peripheral 
macrophages (Yang et al., 2010). 
1.3.2.1  Astrocytes and microglia as immune cells in the CNS 
1.3.2.1.1  Role of astrocytes and microglia in CNS innate immunity  
Both microglia and astrocytes play important roles in innate and adaptive 
immune responses in the brain (Yang et al., 2010). Astrocytes and microglia also 
play a potential role in mediating innate immunity by expressing various pattern 
recognition receptors (PRRs), especially TLRs in response to viral and bacterial 
infections (Farina et al., 2007). TLR2, TLR3, TLR4, TLR5 and TLR9 have been 
reported to be expressed in human and mouse astrocytes (Farina et al., 2007). 
Primary cultured mouse microglia express TLR1, TLR2, TLR3, TLR4, TLR5, TLR6, 
TLR7, TLR8 and TLR9 (Olson and Miller, 2004). Human microglia express TLR1, 
TLR2, TLR3, TLR4, TLR5, TLR6, TLR7 and TLR8 (Bsibsi et al., 2002). 
Interestingly, TLR expression by microglia is predominantly in the 
circumventricular organs (CVOs) and meninges; areas which can directly access 
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the blood circulation (Chakravarty and Herkenham, 2005), suggesting that 
microglia prevent the entry of pathogens into the CNS by recognising pathogens 
that are present in the periphery. Astrocytes and microglia seem to have 
different important roles in response to viral and bacterial infections. A study in 
cultured fetal human astrocytes showed that TLR3 is constitutively expressed 
under normal physiological conditions. Another in vitro study using cultured 
adult human astrocytes showed that TLR2, TLR3, TLR4 gene expression could be 
detectable under normal physiological conditions (McKimmie et al., 2005). 
However, stimulation with various cytokines, including TNF-α, IL-1β, IFN-γ, IL-
12, IL-4, IL-6, also strongly induced TLR3 gene expression, but had no effect on 
TLR4 gene expression and down-regulated TLR2 gene expression (Bsibsi et al., 
2006). TLR3 is implicated in host anti-viral response by recognizing double-
strand (ds) viral nucleic acid. This, in turn, activates immune cells such as 
peripheral blood monocytes to express anti-viral cytokines including IFN-α, TNF-
α and IL-1β (Pan et al., 2011). This evidence suggested that astrocytes may play 
a crucial protective role during CNS viral infection. In contrast, microglia 
predominately express TLR2 and TLR4, which are implicated in the protection 
against bacterial infections. Both TLR2 and TLR4 recognizing bacterial cell wall 
component have been associated with the pathology of neuro-degeneration 
(Carpentier et al., 2008);(Takeuchi et al., 1999);  in vitro studies have 
demonstrated that microglia respond to Group B Streptococcus (GBS) infection 
by expressing TLR-2, which then induces neuronal apoptosis in bacterial 
meningitis (Lehnardt et al., 2006). LPS-induced-TLR4 expression in microglia in 
vitro can cause dramatic neuronal loss and oligodendrocyte death (Lehnardt et 
al., 2002); (Lehnardt et al., 2003). Other components of innate immunity, 
including complement receptors, mannose receptor (MR) and scavenger 
receptors (SRs), have also been reported to be expressed on astrocytes and 
microglia (Farina et al., 2007); (Barnum, 1999). 
1.3.2.1.2  Role of astrocytes and microglia in CNS adaptive 
immunity  
Astrocytes and microglia can also function as non-professional antigen presenting 
cells (APCs); presenting antigen in the context of MHC molecules, and can 
contribute to adaptive immunity (Yang et al., 2010); (Constantinescu et al., 
2005). Under normal physiological conditions, resting microglia and astrocytes 
Chapter 1  50 
express very low levels of MHC class I and class II molecules (O'Keefe et al., 
2002); (Kreutzberg, 1996); (Massa, 1993). In normal human spinal cords, only 14% 
of the microglia population express MHC class II (Stoll et al., 2006). However, in 
various CNS diseases, including infection, injury, neurodegenerative disease and 
CNS autoimmune disease, the MHC is up-regulated on microglia and astrocytes 
(Yang et al., 2010); (Soos et al., 1998). IFN-γ is a potent inducer of MHC of both 
microglia and astrocytes (Wong et al., 1984); (Yang et al., 2004). The ability of 
astrocytes and microglia to present myelin basic protein (MBP) to CD4+T cells in 
the context of MHC requires an MHC class II transactivator called CIITA, which 
can be also induced by IFN-γ (O'Keefe et al., 1999); (Badie et al., 2002); (Soos et 
al., 1998). Astrocytes and microglia also require additional co-stimulatory 
molecules such as the CD28-B7 receptor family CD80 (B7-1)/CD86 (B7-2) in order 
to activate CD4+ and CD8+ T cells (Sedgwick et al., 1991); (Nikcevich et al., 
1997), (Tan et al., 1998); (Issazadeh et al., 1998). 
In addition to direct activation of T cells by antigen presentation, astrocytes and 
microglia also enhance T-cell activation by the production of a variety of 
cytokines. Astrocytes are cellular sources of interleukin IL-1, IL-6, IL-10, 
interferon (IFN)-α, IFN-β, tumour necrosis factor (TNF)-α,  transforming, growth 
factor (TGF)-β; and colony-stimulating factors, GM-CSF, M-CSF (Dong and 
Benveniste, 2001) in the CNS. Microglia produce a variety of cytokines, including 
IL-lα, IL-1β (Giulian et al., 1986), IL-5 (Sawada et al., 1993), IL-6 (Sawada et al., 
1992), TNF-α (Sawada et al., 1989), and TGFβ (Constam et al., 1992), IL-12 (Xu 
and Drew, 2007), IL-13 (Shin et al., 2004),  IL-16 (Liebrich et al., 2007), IL-17 
(Kawanokuchi et al., 2008), and IL-23 (Sonobe et al., 2008). These cytokines can 
activate the differentiation of Th1, Th2 and Th17 lymphocytes (O'Garra and Arai, 
2000); (Miljkovic et al., 2007). Astrocytes play a role in the activation and 
expansion of both Th1 and Th17 T cells via the production of IL-12 and IL-23 
(Constantinescu et al., 2005). Co-cultures of astrocytes, which produced IL-
23p19 and common IL-12/IL-23p40, and myelin basic protein-stimulated T-cells 
were demonstrated to up-regulate the production of Th1 and Th17 cytokines 
such as IL-17 and IFN-γ (Miljkovic et al., 2007). Astrocytes also play a role in T 
cell recruitment into the CNS via chemokine production (Kim et al., 2011). 
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1.3.3  Innate immunity in the central nervous system (CNS) 
Innate immune responses to CNS viral and bacterial infection, inadvertently 
leads to collateral neuronal damage and neurological dysfunction (Nguyen et al., 
2002). Resident microglia and astrocytes mediate host immune response against 
viral/bacterial infection by expressing innate immune receptors such as toll-like 
receptors (TLRs) that recognize pathogen related molecular patterns on 
pathogens. Activation of these toll-like receptors (TLRs) results in the production 
of cytokines to help protect the CNS against pathogens (Pan et al., 2011). 
However, the cytokines produced during this innate immune activation can also 
have detrimental effects on neurons. CNS bacterial infections such as Group B 
Streptococci (GBS) can activate TLR2 expressed on microglia to produce nitric 
oxide (NO) that is protective against the organism by its cytotoxicity, but also 
causes neuronal injury (Lehnardt et al., 2006). Neuronal apoptosis in HIV-1 
associated dementia is thought to be the induced by cytokines including TNF-α, 
IL-1β, IL-6 produced by activated microglia/astrocytes (Kaul, 2009); (Sheng et 
al., 2000). In addition, activation of the immune response in the CNS has been 
implicated in the neurodegeneration of some neurological diseases, including 
Alzheimer’s disease (AD) and Parkinson’s disease (Whitney et al., 2009). 
Accumulation of extracellular fibrils of amyloid-β and intracellular 
neurofibrillary tangles in the neuron causes the formation of senile plaques, and 
eventually leads to neurodegeneration in Alzheimer’s disease (Weiner and 
Frenkel, 2006). Amyloid-β peptides can also initiate innate immunity in the CNS 
(Weiner and Frenkel, 2006) by directly activating astrocytes and microglia to 
produce various cytokines and chemokines, including TNF-γ, IL-1β, IL-6 IFN-γ, 
CCL2, CXCL10, which can damage neurons (Akama and Van Eldik, 2000); (Zaheer 
et al., 2008). These observations may suggest that CNS innate immunity can play 
crucial roles in host defence against microbial/viral pathogens and pathologic 
amyloid-beta particles. Paradoxically, it also can cause neurotoxicity and 
damage neurons.  
1.3.4  Adaptive immunity in the CNS 
Medawar 1948 was one of the first to suggest that the inability of initiating 
lymphocyte responses within the CNS was due to the absence of major 
components of the adaptive immune system (Medawar, 1948). These include 
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professional APCs such as dendritic cells (DCs), adaptive immune cells such as T 
lymphocytes and B lymphocytes, constitutive MHC class I and II expression on 
CNS parenchymal cells, and lymphatic vessels in the brain parenchyma 
(Engelhardt, 2006). The CNS is also protected by the BBB, which prevents the 
influx of immune cells and inflammatory mediators into the CNS during 
inflammation (Abbott et al., 2010). Although low numbers of T cells are found in 
the CSF of healthy individuals, they seem to be involved in immune-surveillance 
of the CNS in the absence of inflammation (Engelhardt, 2006). Under this normal 
physiological condition, CNS-resident cells such as astrocytes and microglia 
express low levels of MHC class II and T-cell costimulation/adhesion molecules, 
which is restrictive for T-cell activation in the CNS (O'Keefe et al., 2002); 
(Kreutzberg, 1996); (Massa, 1993). It is still unclear how T cells recognize target 
antigens and initiate adaptive immune response within the CNS.  
It has been hypothesized that the antigen presentation by APCs can occur 
outside the CNS in the nearby lymph nodes such as in cervical lymph nodes (CLN) 
(Goverman, 2009). CNS myelin auto-antigens such as proteolipid protein (PLP) 
and myelin basic protein (MBP) that are synthesised by oligodendrocytes can 
drain from the brain tissue into the lymphatic systems through the perivascular 
space between the brain tissue and BBB (Ichimura et al., 1991). The perivascular 
space is connected to the brain- cerebrospinal fluid (CSF) barrier called the 
subarachnoid space (SAS), which is eventually linked to cervical lymph nodes via 
the lymphatics of the nasal mucosa (Koh et al., 2005). Evidence for this includes 
the observation that neuronal antigens and proteins, including MBP, PLP, NF-L 
(Neurofilament triplet L) and MAP-2 (Microtubule-Associated Protein) were 
detected in CLN of MS patients and EAE mice, and these have been associated 
with neuronal damage (Fabriek et al., 2005); (van Zwam et al., 2009). 
Langerhans' cells and lymph node dendritic cells in CLN can present CNS antigens 
such as MBP and PLP in the context of MHC class II (Cumberbatch et al., 1991), 
resulting in CD4+ T cell and CD8+ T cell activation (Goverman, 2009). It has been 
demonstrated that activated T lymphocytes migrate back from the CLN into the 
brain via the route of lymphatics of the nasal mucosa (Goldmann et al., 2006). 
The localization of type IV collagen auto-antibody was observed in the CLN after 
the injection of type IV collagen into the CSF (Walter et al., 2006). Several 
studies showed that the CLN could be the initial peripheral activation site for 
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autoimmune-mediated CNS demyelinating diseases (Goverman, 2009). The onset 
of clinical symptoms of EAE correlated with increased activation of PLP specific 
CD4+ T cells in the CLNs (Zhang et al., 2008). Surgical removal of the cervical 
lymph nodes reduced the severity and delayed the onset of EAE (Furtado et al., 
2008). 
In addition to the regional nodes, several recent studies also suggest that T cells 
can be activated by recognizing target antigens directly in the CNS and not 
necessarily in the cervical lymph nodes or other peripheral lymphoid organs. A 
study by Greter et al showed that adoptive transfer of pre-activated myelin 
oligodendrocyte/glycoprotein (MOG)-specific T cells into splenectomized mice 
with a complete absence of lymph nodes and Peyer’s patches resulted in the 
same development of EAE as seen in wild type mice (Greter et al., 2005). This 
study suggests that antigen presentation by APCs in the secondary lymphoid 
tissues is not necessary for the activation of T cells before their migration into 
the CNS and the development of disease (Greter et al., 2005). This is supported 
by another study by McMahon et al showing that activation of dye-labeled naive 
proteolipid protein (PLP)139-151-specific T cells occurred directly in the brain and 
not in the cervical lymph nodes or other peripheral lymphoid organs (McMahon et 
al., 2005).  
Dendritic cells (DC) have been demonstrated to play crucial roles in the 
distribution of CNS antigens and to present antigens to T lymphocytes and B 
lymphocytes at the peripheral and CNS levels (Zozulya et al., 2010). Both 
myeloid DCs and plasmacytoid DCs have been found in the CSF of healthy donors 
(Pashenkov et al., 2001). In addition, MHC class II+ DCs are also present in the 
perivascular space, meninges and the choroid plexus of the non-inflamed normal 
brain (McMenamin et al., 2003). DCs located at the CNS have been shown to play 
a role in transporting CNS antigens from the CNS to the CLN (de Vos et al., 
2002). Karman et al has demonstrated the migration of DCs from the brain to 
CLNs after the injection of DCs into the mouse brain parenchyma. After 
immunization with OVA, the number of increased OVA-specific CD8+ T cells in 
the CLNs correlated with increased injected OVA-loaded DC numbers. The 
injection of increasing numbers of OVA-load DCs also led to a dose-dependent 
increase in the number of OVA-specific CD8+ T cells in brain, suggesting that DCs 
also play a role in the homing of antigen (Ag)-specific T cells into brain (Karman 
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et al., 2004). In a murine EAE model, intracerebral microinjection of activated 
DCs increased the onset and clinical course of EAE, along with T-cell infiltration 
(Zozulya et al., 2009). Myeloid DCs originating from the bone marrow were 
shown to accumulate in the brain during the course of EAE, where they 
preferentially activated Th17 lymphocytes; producing IL-17 which is the key 
mediator for EAE immune responses (Bailey et al., 2007). Brain DCs also showed 
preference to migrate to B-cell follicles rather than T-cell areas in lymph nodes 
(Hatterer et al., 2006). Intra-CSF injection of mouse dendritic cells to EAE mice 
also resulted in increased serum MOG-specific-antibody (Hatterer et al., 2008). 
These data suggest that mDCs play an important role in B lymphocyte activation 
and in the antibody response in autoimmunity. DCs have been demonstrated to 
play crucial roles in T cells activation in the non-lymphoreticular environment of 
the CNS. A study in splenectomized mice lacking lymph nodes and Peyer’s 
patches showed that CNS-infiltrating CD11c+ dendritic cells were essential for 
the disease development of EAE (Greter et al., 2005). An ex vivo study also 
shiwed that CD11c+ dendritic cells were the most effective at activating the 
proliferation of (PLP)139-151-specific T cells in the CNS compared to CD11c
- 
microglia and CD11c- macrophages (McMahon et al., 2005). 
CNS antigen presentation can occur at the BBB level. The cerebrovascular 
endothelium of BBB constitutively expresses MHC class II and the co-stimulatory 
molecule CD86 (B7-2) (McCarron et al., 1991); (Omari and Dorovini-Zis, 2003). 
Upon stimulation by inflammatory cytokines such as TNF-α and IFN-γ, 
cerebrovascular endothelium can also express MHC class I, CD80 (B7-1) and the 
class II trans-activator (CIITA) (Tennakoon et al., 2001); (Seino et al., 1995); 
(Girvin et al., 2002). Recognition of CNS cognate antigens presented by cerebral 
endothelial cells has been demonstrated to be essential for CD4+ T lymphocyte 
and CD8+ T lymphocyte migration into the brain (Galea et al., 2007); (Manes and 
Pober, 2008). 
1.3.5  The role of inflammatory mediators in the CNS 
Neuro-inflammation has been long considered only to have a destructive role in 
the CNS, however accumulating evidence recently suggests that neuro-
inflammation also has a neuroprotective function (Minghetti L 1999); (Nordvall 
G, et al. 2000); (Stoll G, 2002). Interestingly, several studies suggest that the 
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balance between maintenance of homeostasis of the CNS and induction of neuro-
degeneration may be dependent on the initiation of specific types of immune 
response (Byram et al., 2004); (Polazzi and Contestabile, 2002); (Hofstetter et 
al., 2003). Inflammatory mediators such as cytokines and chemokines are now 
recognised to have both neuroprotective and neurotoxic aspects. Cytokines and 
chemokines produced from neurons have been reported to function as 
neuromodulators, which may be essential for the maintenance of normal CNS 
function including neuro-regeneration (Carson et al., 2006).  
1.3.5.1 The role of cytokines in the CNS 
Cytokines not only function to regulate the immune response in the CNS, they 
can also function as neuro-modulators. Pro-inflammatory cytokines, including IL-
1β, IL-6 and TNF-α can enhance excitatory synaptic transmission via alpha-
amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA)- and N-methyl-D-
aspartate (NMDA)-synaptic activation and suppress inhibitory synaptic 
transmission via GABA- and glycine synaptic inhibition (Kawasaki et al., 2008).  
IL-1β and TNF-α can cause neurodegeneration via excito-neurotoxicity. Excito-
neurotoxicity is the mechanism of neuronal cell death caused by prolonged 
exposure to glutamate, leading to the excitatory signal via NMDA receptor 
activation. This causes excessive influx of Ca2
+ into the neuron, which is 
neurotoxic and induces neuronal damage (Fan and Raymond, 2007). TNF-α 
induces glutamate release from microglia and the production of glutaminase, the 
enzyme that generates glutamate from glutamine, and together these eventually 
result in increased neuronal cell death (Takeuchi et al., 2006). IL-1β induces 
excito-neurotoxicity by activating tyrosine phosphorylation of NMDA receptors, 
resulting in increased intracellular Ca2
+ and loss of cultured hippocampal neurons 
(Viviani et al., 2006). In contrast, IL-6 showed a neuro-protective role against 
NMDA-induced death of cerebellar granule neurons (Wang et al., 2009a). This 
evidence suggests that pro-inflammatory cytokines can be either 
neuroprotective or neurotoxic via the modulation of neurotransmission. 
TGF-β has a major role in neuroprotection (Qian et al., 2008) and is considered 
to be a therapeutic target of neurodegenerative diseases such as Alzheimer’s 
disease. TGF-β1 and TGF-β2 demonstrated neuroprotective activities against 
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several neurotoxic stimuli, including excitotoxicity (Boche et al., 2003), and 
neuronal apoptosis (Zhu et al., 2002a). TGF-β has been reported to be neuronal 
protective against Aβ-neurotoxicity, which may be the cause of Alzheimer’s 
disease (Caraci et al., 2008); (Uribe-San Martin et al., 2009). These findings 
suggest that TGF- β has a protective role in the pathogenesis of Alzheimer’s 
disease. 
1.3.5.2 The role of chemokines in the CNS 
Chemokines and their receptors are expressed within the cytoplasm of neurons 
in several selective brain regions, including the cerebral cortex, nucleus 
accumbens, striatum, amygdala, thalamus, hypothalamus, hippocampus, 
substantia, nigra, mammillary bodies, raphe nuclei, neocortex, basal nuclei, 
brain stem and cerebellum (Westmoreland et al., 2002); (Banisadr et al., 2002). 
Accumulating evidence suggests that chemokines might function as 
neuromodulators. Similar to neurohormones, neuropeptides and neurotrophins, 
chemokines and their receptors such as CCL21, CXCR4, and CXCR5 are packaged 
to the large vesicle and transported into the dendritic processes and axons (de 
Jong et al., 2008); (Westmoreland et al., 2002). Injured neurons were shown to 
release CCL21 into the synaptic cleft and to activate microglia. This may provide 
a communication between neuron-microglia that might be the pathway to 
activate microglia that are located distant from the primary lesion (de Jong et 
al., 2005). Chemokines such as CXCL12 might be involved in neuronal 
communication such as during cholinergic and dopaminergic neurotransmission. 
It has been reported that CCR2 co-localized with neurotransmitters on 
cholinergic neurons, dopaminergic neurons and vasopressinergic neurons 
(Banisadr et al., 2003). In addition, CCL2 treated neurons isolated from 
hippocampus, hypothalamus and cortex showed increased Ca2
+ influx into the 
cells, suggesting that CCR2 may regulate the release of neurotransmitters 
(Banisadr et al., 2005). Interestingly, recent findings showed that CXCL12/CXCR4 
and CX3CL1/CX3CR1 co-localized with serotonergic neurons. Both CX3CL1 and 
CXCL12 enhanced the amplitude of inhibitory postsynaptic currents (sIPSC) via 
GABA synaptic activation in serotonergic neurons. In addition, CXCL12 could also 
induce glutamate-mediated membrane depolarization and increase the 
amplitude of excitatory postsynaptic currents (sEPSC) via glutamate synaptic 
activation. These data suggest the modulation effects of chemokines on 5-HT 
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neurotransmission that may lead to this being a therapeutic strategy of 
chemokines for depression (Heinisch and Kirby, 2009); (Heinisch and Kirby, 
2010).  
CXCL12/CXCR4 is also involved in neuronal death during HIV-1-associated 
dementia. HIV-1 glycoprotein gp120 induces neuronal death by binding to CXCR4 
(Kaul and Lipton, 1999); (Bachis and Mocchetti, 2004); (Choi et al., 2007). Other 
chemokines are involved in neuronal survival and exhibit their neuroprotective 
effects. CXCL1 and CXCL8 prevent cerebellar granule neurons from apoptotic 
death induced by low K+ (Limatola et al., 2000); (Limatola et al., 2002). 
CX3CL1/CX3CR1 showed neuroprotection against excitotoxity in hippocampal 
neurons (Lauro et al., 2008). CXCL1 protected hippocampal neurons from 
apoptosis induced by β-amyloid peptide (Watson and Fan, 2005). This evidence 
suggests that chemokines not only have an inflammatory function by regulating 
the recruitment of monocytes and leukocytes into the CNS, they also act as 
neuromodulators to regulate neural transmission and support survival and 
development of neurons.  
1.4  Inflammation in the CNS 
Inflammation not only has a crucial role in host defence responses, but also 
contributes to hypersensitivity diseases and in several central nervous system 
(CNS) disorders such as Alzheimer’s and Parkinson diseases (Whitney et al., 
2009). However, inflammation in the brain is different from that in peripheral 
tissues in several aspects, including  mechanism of initiation and degree of 
sensitivity (Whitney et al., 2009). The migration of peripheral T-cell and 
antibodies into the CNS is restricted by BBB (Banks, 2010). An inflammatory 
process in the CNS seems to be initiated mainly by the activation of resident 
microglia and astrocytes in response to cellular damage or exposure to 
pathogens (Whitney et al., 2009). Activated microglia and astrocytes release 
anti- and pro-inflammatory cytokines including IFN-γ, TNF-α, IL-1β, IL-6, IL-4 
and IL-10 (Whitney et al., 2009) . These inflammatory mediators can disrupt the 
BBB, which may or may not be associated directly with more recruitment of 
monocytes and lymphocytes to cross through the BBB into the site of 
inflammation (Hickey, 1999); (Lossinsky and Shivers, 2004). However, up-
regulation of pro-inflammatory cytokines such as IFN-γ, TNF-α, IL-1β, IL-6 can 
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activate BBB endothelial cells to produce chemokines and adhesion molecules 
that facilitate the infiltration of monocytes and lymphocytes from the peripheral 
circulation into the brain (Engelhardt, 2006). These recruited monocytes and 
lymphocytes become activated and produce more inflammatory mediators in the 
CNS, which can contribute to neuronal damage and changes in neurobiology in 
the CNS. However, inflammatory processes in the CNS may also contribute to 
neuroprotection essential in maintaining homeostasis in the CNS (Whitney et al., 
2009) .  
1.5  Immune signals from the peripheral circulation 
induce brain inflammation 
Peripheral inflammation-induced neuroinflammation has been well documented. 
Acute brain inflammation induced by viral/bacterial encephalitis causes 
transient increases in cytokine production and microglia activation in the CNS. 
Several studies in models of hypoxia-ischemia and LPS/virus induced acute CNS 
inflammation demonstrated that the CNS usually responds to acute inflammation 
by up-regulating inflammatory mediators in transient kinetic patterns (Barichello 
et al., 2010); (Bluthe et al., 1999); (Sakata et al., 1991); (Quan et al., 1994); 
(Barichello et al., 2009). For example, experimental intra-cerebroventricular LPS 
injection demonstrated that IL-1β, TNF-α, IL-6, MCP-1 reached their peak levels 
(4-7 fold increases compare to the control) at 6 hours after the challenge 
(Rankine et al., 2006), before a sharp reduction in cytokine levels back to the 
base line. Increases in cytokine production and microglia activation in the CNS 
have also been reported in chronic inflammatory disease such as the 
experimental models of arthritis. Microglia activation, along with increases in IL-
1β, TNF-α and IL-6 were observed in spinal cord of adjuvant induced arthritis 
(Bao et al., 2001). A similar observation has been reported in CIA rats. 
Longitudinal changes in IL-1β, TNF-α and IL-6 gene expression were observed in 
brains of CIA rats (del Rey et al., 2008). In addition, inducing a gut inflammation 
model of colitis using 2,4,6-trinitrobenzene sulfonic acid (TNBS) resulted in the 
activation of microglia and the production of TNF-α in rat brains. Interestingly, 
increases in the TNF-α protein level and the number of activated microglia in 
hippocampal dentate gyrus (DG) have been associated with brain excitability and 
seizure susceptibility (Riazi et al., 2008). A study by Terrando et al., showed 
that peripheral inflammation caused by peripheral surgical trauma could induce 
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increases in IL-1β, which was inhibited by peripheral treatment of anti-TNF-α 
(Terrando et al., 2010). However, the mechanism by which the inflammatory 
signal from the periphery induces brain inflammation is not well understood. 
Multiple mechanisms are implicated in peripheral inflammation-induced 
neuroinflammation, including blood brain barrier (BBB) breakdown and 
recruitment of immune cell from the periphery. However, changes in 
permeability of BBB and up-regulation of inflammatory mediators and adhesion 
molecule facilitating the immune trafficking to the CNS are primarily induced by 
peripheral/central inflammation.  
1.6  Barriers of the central nervous system 
There are three main barriers between blood and brain: (i) The blood brain 
barrier; which is the barrier between the lumen of cerebral blood vessels and 
brain tissue. (ii) The blood – cerebro spinal fluid barrier located between choroid 
plexus blood vessels and the CSF, which provides a non restrictive barrier: (iii) 
arachnoid barriers which form the middle layer of the meninges, covering the 
whole brain (Correale and Villa, 2009). 
1.6.1  Blood Brain Barrier (BBB) 
1.6.1.1  Structure of the blood brain barrier 
The BBB consists of the endothelial cells that form the walls of brain and spinal 
cord capillaries. These endothelial cells (ECs) are connected strongly to each 
other by tight junctions (TJs) and adherent junctions (AJs) (Correale and Villa, 
2009). 
The TJs function to restrict transport of macromolecules and hydrophilic 
molecules between blood and the brain interstitial fluid (ISF). The tight junction 
complex comprises integral membrane proteins occludin, claudins 3, 5 and 12, 
and junctional adhesion molecules (JAMs). Occludin and claudins consist of four 
transmembrane domains with two extracellular loops, which associate and bind 
to each other across the intracellular cleft. The end terminal cytoplasmic 
domain of occludin regulates trans-epithelial migration of neutrophils and also 
function to maintain TJs aggregation and barrier function. Claudins function to 
regulate size-selective diffusion of hydrophilic molecules. JAMs are members of 
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the immunoglobulin (Ig) superfamily, which play a role in leukocyte trafficking. 
JAMs have a single transmembrane domain and the extracellular portion consists 
of immunoglobulin-like loops formed by disulfide bonds. Carboxi-terminal 
cytoplasmic tails of occludin, claudins and JAMs are linked to cytoplasmic 
adaptor proteins such as zonular occludins-1 (ZO-1), ZO-2, ZO-3, which are 
connected to the actin/myosin cytoskeletal system within cells (Abbott et al., 
2010).  
Adherent junctions (AJs) consist of membrane proteins such as vascular 
endothelial (VE)-cadherin (also known as adherin 5, type 2 or CD144) and 
platelet-endothelial cell adhesion molecule (PECAM-1), which are linked to actin 
skeleton proteins via adaptor molecules called catenins. AJs are essential for the 
formation of tight junctions, since they provide support for BBB structure and 
attachment between cells (Abbott et al., 2010).  
CNS capillaries are surrounded by, and associated with, several cell types; 
including pericytes, astrocytes, microglia and neuronal processes, which form a 
functional unit called the neuronal vascular unit. The interaction between 
neuronal vascular unit and CNS capillaries results in the bi-directional regulation 
of blood flow, microvascular permeability, cell matrix interactions, 
neurotransmitter turnover, angiogenesis and neurogenesis (Zlokovic, 2008). 
Pericytes are vascular cells that extend their long cytoplasmic processes 
encircling the endothelial capillaries. Pericytes highly express the contractile 
protein α-smooth muscle actin, which regulates blood flow via endothelial cell 
contraction and relaxation (Zlokovic, 2008). Both endothelial cells and pericytes 
are enclosed and contribute to the local basement membrane, which consists of 
different extracellular matrix (ECM) structural proteins such as collagen and 
laminin (Correale and Villa, 2009). The local basement membrane is surrounded 
by the endfoot processes from astrocytes, which function mainly in the induction 
and maintenance of BBB properties (Abbott et al., 2006).  The structure of the 
BBB and a tight junction is shown in Figure 1.1. 
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Figure 1.1 Structure of the BBB and tight junction.  
(A) The structure of BBB mainly consists of capillary endothelial cells surrounded by the 
neuronal vascular unit (pericytes, astrocytes and neuronal processes). (B) The tight 
junction complex comprises integral membrane proteins (claudins, occludin, and junction 
adhesion molecule) on adjacent endothelial cells. The image were taken from (Chou and 
Messing, 2008) by kind permission of The Journal of Clinical Investigation. 
1.6.1.2 1.6.1.2. Transport across the blood brain barrier 
Under normal physiological conditions, tight junctions between endothelial cells 
only allow the entry of water, ethanol and small gas molecule such as O2 and CO2 
via the paracellular route. Most of the molecules are transported across the 
endothelial wall transcellularly into the brain. Small lipid-soluble and non-polar 
molecules including drugs such as barbiturates, diazepam, phenobarbital and 
phenytoin can diffuse passively through the lipid membrane to reach their 
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neuronal targets in the brain. However, the transcellular bidirectional 
transportation of water soluble compounds and macromolecules requires a 
variety of BBB transport systems (Abbott et al., 2006). Many essential polar 
nutrients such as glucose and amino acids are transported by carrier-mediated 
transport, which depends on concentration gradients in the direction from blood 
to brain (Abbott et al., 2010). Active efflux transport requires the energy from 
ATP to lipid-soluble compounds out of the brain. This active transport system 
also has neuroprotective and detoxifying functions by reducing influx of many 
drugs, including azidothymidine (AZT), and enhancing their efflux from the brain 
(Abbott et al., 2006). Large proteins including neuroactive peptides, cytokines, 
chemokines, transferrin, low density lipoprotein (LDL), IgG, insulin and insulin 
growth factor enter the brain by specific receptor–mediated transcytosis. This 
involves binding of circulating proteins to their specific receptors expressed on 
the endothelial cells.  The protein-receptor complex is internalised into an 
endocytic vesicle, which travels across the cytoplasm to be released at the 
opposite side of the cell (Jones and Shusta, 2007). Cationic proteins such as 
albumin and other plasma proteins are transported into the brain by absorptive 
mediated transport (AMT). This involves the interaction between an excess 
positive charge on the molecule and negative charge on the BBB surface, which 
induces endocytosis and subsequent transcytosis (Herve et al., 2008).  
1.6.1.3  Blood brain barrier disruption in neuro-inflammation 
 
Studies of models of CNS autoimmunity and virus induced neuro-inflammation 
have shown evidence of enhanced BBB dysfunction, associated with the 
development of a CNS inflammation. Increased BBB permeability can involve the 
entry and clearance of various viruses including West Nile virus (Wang et al., 
2004), rabies virus (Phares et al., 2006), and adenovirus type 1 (Gralinski et al., 
2009). In addition, retroviral-infected lymphocytes have been associated with 
BBB dysfunction and changes in BBB structure (Afonso et al., 2007). The blood 
brain barrier permeability in EAE mice showed a positive correlation with the 
disease severity (Fabis et al., 2007).  
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1.6.1.4 Peripheral inflammation-induced blood brain barrier disruption 
BBB disruption can also be induced from the periphery, and one good example is 
the case of systemic infection associated with sepsis (Sharshar et al., 2005). In 
experimental models of this, peripheral inflammatory stimulation by LPS causes 
microglia activation and increased concentrations of serum cytokines (Stolp et 
al., 2009), leading to a transient increase in BBB permeability in the white 
matter tissue of neonatal rats (Stolp et al., 2005a, Stolp et al., 2005b); (Stolp et 
al., 2007). Subcutaneous administration of complete Freund’s adjuvant (CFA) 
enhanced BBB permeability to [14C] sucrose and down-regulated tight junctional 
protein expression (Huber et al., 2001). Increased permeability of the blood-
brain barrier was also observed in murine experiments of induced surgical pain 
stress (Oztas et al., 2004) and systemic thermal injury (Berger et al., 2007). 
Interestingly, BBB breakdown in several non-CNS chronic inflammatory diseases, 
such as intestinal inflammation (colitis) (Natah et al., 2005), obesity (Hafezi-
Moghadam et al., 2007) and diabetes (Hawkins et al., 2007) are thought to be 
due to the effect of circulating inflammatory mediators.  
1.6.1.5 Mechanisms of inflammation-induced blood–brain barrier 
dysfunction 
Circulating cytokines for example TNF-α (Tsao et al., 2001) and IL-1β (Blamire et 
al., 2000) can induce BBB disruption and interfere with BBB function by several 
mechanisms. The effect of TNF-α on BBB permeability was demonstrated to be 
associated with microglial activation (Nishioku et al., 2010a). TNF-α and IL-1β  
have been reported to modulate the active transport system across BBB via the 
regulation of P-glycoprotein expression (Yu et al., 2007); (Bauer et al., 2007); 
(von Wedel-Parlow et al., 2009). IL-1β has been shown to regulate BBB 
permeability via the hypoxia-angiogenesis pathway (Argaw et al., 2006). 
Systemic administration of IL-1β results in the damage of BBB structure, 
including loss of the tight junctional protein, claudin-5 and basal lamina protein, 
collagen-IV (McColl et al., 2008). Adhesion molecules induced by cytokines also 
have a crucial role in BBB disruption. Blocking P-selectin and integrin alpha-v 
beta-3 resulted in the reduction of BBB leakage (Jin et al., 2010); (Shimamura et 
al., 2006). Chemokines such as CCL2 are also involved in changes in BBB 
permeability. Blocking CCL2/CCR2 in a mouse model of stroke caused a 
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reduction in BBB permeability, along with re-synthesises of tight junctional 
proteins such as occludin, zonula occludin-1 and 2, and claudin-5 (Dimitrijevic et 
al., 2006). Cytokines produced from neutrophils and T lymphocytes were also 
demonstrated to enhance BBB disruption (Joice et al., 2009).  IL-17 and IL-22 
released from Th17 cells were also shown to damage BBB via disruption of tight 
junctions (Kebir et al., 2007). 
1.6.1.6  Possible transport mechanisms for peripheral cytokines into 
the brain 
Circulating cytokines may enter the brain across a damaged BBB. However, there 
is no promising evidence demonstrating a direct association between 
concentrations of brain cytokines and BBB breakdown. This also suggests that 
the transportation of cytokine across BBB may be a complex mechanism that is 
still unresolved. It is likely that because of their biological importance that 
circulating cytokines can enter the brain by various well-controlled mechanisms. 
However, this has still to be established but some experimental results are 
shown below. 
1.6.1.6.1  Entry of cytokines into the brain at circumventricular 
sites  
Circumventricular organs (CVOs) are exceptional areas in the brain that are not 
covered by the BBB. They function to monitor changes in peripheral biochemical 
substances such as hormones and facilitate the secretion of neuroendocrine 
hormones into the blood (Johnson and Gross, 1993). Although CVOs are 
permeable to macromolecules, a study using 125I-IL-1β showed that CVOs were 
only responsible for less than 5% of total brain uptake of IL-1β (Plotkin et al., 
1996). A recent study in an EAE model demonstrated intensive staining of MHC 
class II+/CD45+ leukocytes, ICAM-1 and VCAM-1 at the CVOs, suggesting that CVOs 
are also the route for leukocyte infiltration into the CNS (Schulz and Engelhardt, 
2005). Since CVOs are areas without a BBB, it is possible that these are the first 
areas of brains that perceive inflammatory cytokine signals from the peripheral 
circulation. Several studies using in situ hybridization showed that TNF-α and IL-
1 β gene expression was induced rapidly during the first 2 hours after LPS 
administration in brain regions such as the circumventricular organs (CVOs) and 
the choriod plexus (Quan et al., 1998); (Breder et al., 1994). These data suggest 
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that peripheral immune signals can be passed transiently into the brain at the 
level of the choriod plexus and circumventricular organs (CVOs) (Price et al., 
2008). 
1.6.1.6.2  Direct entry of cytokines to the CNS across the BBB 
 
Cytokines are transported into the CNS by various transport mechanisms. TNF-α, 
IL-1α, IL-1β , IL-2 and IL-6 have been reported to be transported into the CNS by 
a saturatable transport system (Gutierrez et al., 1993); (Banks et al., 1994a, 
Banks et al., 1991); (Banks et al., 2004, Banks et al., 1994b). Recent findings 
show that chronic morphine exposure and withdrawal can enhance a saturatable 
transport of IL-2 into the CNS (Lynch and Banks, 2008). A saturatable efflux 
system has also been proposed as a mechanism to limit the accumulation of 
cytokines in the brain in order to limit neurotoxicity (Banks et al., 2004). In 
addition, the saturatable efflux system could mediate transportation of cytokine 
such as IL-2 used as cytokine therapy for patients with cancer (Banks et al., 
2004). It has been reported that patients with leptomeningeal metastases who 
were given intraventricular IL-2 injection showed transient up-regulation of IL-2 
and other cytokines such as IL-1β, TNF-α and IL-6 in the CSF (List et al., 1992) 
High concentrations of IL-2 in the periphery of these patients after the cytokine 
therapy may cause a saturatable efflux of IL-2 into the brain. It is still unclear 
how saturatable efflux systems could explain the transportation mechanism of 
cytokines during peripheral inflammation. This is because the up-regulation of 
peripheral cytokines between the example of peripheral inflammatory diseases 
and the example of cytokine therapy is different in terms of concentrations of 
cytokines in the periphery. Concentration of cytokines in the periphery could be 
increased during systemic inflammatory diseases, but whether it is higher than 
the concentration of the same cytokines in the brain that would cause a 
saturatable efflux of cytokines from the periphery into the brain is still unclear. 
A few studies suggest that the transport of TNF-α across the BBB requires p55 
and p75 TNF receptors. TNFR p55/p75(-/-) double knockout mice were unable to 
uptake 125I-TNF-α into the brain and the spinal cord (Pan and Kastin, 2002). This 
concept was supported by the observation in wild type mice that the up-
regulation of p55 and p75 TNF receptor gene expression in injured spinal cord 
corresponded to increased 125I-TNF-α uptake (Pan et al., 2003). A recent finding 
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demonstrated that p55 and p75 receptor-mediated TNF-α transport across BBB 
may involve endocytosis. Microvessel endothelial cells of rat brains showed the 
ability to endocytose 125I-TNF-α in a time-dependent manner. In addition, 
confocal imaging also exhibited the co-localization of p55 and p75 TNF receptors 
and caveolin-1; the endocytic membrane vesicle, in TNF-α treated RBE4 cells 
(Pan et al., 2007). An in vitro study using a blood–brain barrier model generated 
by co-culture of porcine brain microvascular endothelial cells with astrocytes 
demonstrated that the penetration of IL-1β occurred in a temperature-
dependent manner that appeared to depend on the IL-1 receptor (Skinner et al., 
2009). 
1.6.1.6.3 Activation of cytokine production in the CNS by 
stimulating peripheral afferent nerves 
The up-regulation of cytokines in the CNS can be regulated by the afferent vagus 
nerve (Thayer and Sternberg, 2009). Removing the abdominal site of the 
afferent vagus nerve (vagotomy) results in reduced expression of IL-1β mRNA in 
rodent brains after peripheral administration of either LPS (Laye et al., 1995) or 
IL-1β (Hansen et al., 1998). Interestingly, activating the afferent vagus nerve by 
electrical stimulation resulted in increased IL-1β gene expression in the rat brain 
(Hosoi et al., 2000). 
1.6.1.6.4 Peripheral inflammation induces local production of 
cytokines by microglia 
Peripheral inflammation can activate CNS immune cell such as resident microglia 
to produce local cytokines by unknown mechanisms. Activated microglia isolated 
from aged mice after intraperitoneal injection of LPS showed up-regulation of IL-
1β, IL-10, TLR2 and MHC class II mRNA (Henry et al., 2009). In addition, the 
activation of microglia and the production of TNF-α in rat brains have been 
reported in a model of gut inflammation (Riazi et al., 2008). Chemokines 
released from CNS activated microglia can also attract leukocyte recruitment 
into the CNS, leading to the production of cytokines by peripheral leukocytes. 
Elevated CXCL2 levels, increased numbers CCR2+ monocytes, and microglial 
activation were observed in the brains of mice with liver inflammation (D'Mello 
et al., 2009). It is still unclear how circulating cytokines enter the brain and 
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activate microglia in the brain parenchyma. One possibility is that circulating 
cytokines may activate microglia and astrocytes located at the CVOs such as in 
the subfornical organ (SFO), the organum vasculosum of the lamina terminalis 
(OVLT) and the area prostrema (AP) (McKinley et al., 2003). The important 
evidence suggesting that microglia at the CVOs are more sensitive to 
inflammatory cytokine signals from the periphery and may be activated quicker 
than microglia in other part of brain parenchyma is that the increased TLR 
expression by microglia is predominantly in the CVOs and meninges (Chakravarty 
and Herkenham, 2005). Transient increases in TLR4 and TLR2 gene expression 
were observed in choroid plexus subgroups of CVOs such as the organum 
vasculosum of the lamina terminalis (OVLT), and subfornical organ (SFO) in rat 
brains after systemic injection of LPS or gram-negative bacterial cell wall 
components (Laflamme and Rivest, 2001); (Laflamme et al., 2001). This was 
followed by rapid transcription of inflammatory mediators such as TNF-α and 
CCL2 within these areas (Laflamme et al., 2003).This suggests that microglia 
located at CVOs may play an important role as the first line of defence against 
the entry of pathogens into the CNS by recognising pathogens that are present in 
the periphery.  
1.6.1.7 Immune cell trafficking into the CNS 
 
Under CNS inflammatory conditions, the expression of adhesion molecules and 
chemokines is induced on BBB endothelium, and these promote adhesion and 
help attract circulating leukocytes to enter into the inflamed CNS (Banks, 2010). 
BBB disruption induced by CNS inflammatory conditions may facilitate greater 
immune cells recruitment from the periphery. However, it is still controversial 
whether BBB breakdown is directly associated with an increase in immune cells 
recruitment from the periphery. Several studies reported that BBB disruption is a 
neutrophil-mediated process, which is associated with leukocyte recruitment. A 
study by Bolton et al. reported the loss of BBB integrity including the proteins 
occludin and zonula occludens-1 from cerebral vascular endothelium during 
neutrophil-induced BBB disruption (Bolton et al., 1998). This suggests that 
neutrophils may activate a signalling cascade leading to the loss of BBB integrity 
and BBB disruption. In contrast, several studies also suggest that the loss of BBB 
integrity is not simply to facilitate more leukocyte recruitment from the 
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periphery into the brain (Carson et al., 2006). It has been reported that 
perivascular cells are continuously replaced by peripheral macrophages in the 
healthy CNS. This suggests that there may be homeostatic trafficking of 
monocytes from the periphery into the basement membrane at the surface of 
the BBB (Bechmann et al., 2001). This also means BBB integrity is designed to 
permit selective leukocyte trafficking into the CNS. In addition, to date there is 
no evidence demonstrating a direct correlation between the severity of BBB 
breakdown and the amount of leukocyte recruitment during CNS inflammation. 
One possibility is that the BBB is still able to restrict T-lymphocyte migration 
into the CNS during BBB disruption by selectively expressing adhesion molecules 
on the brain microvascular endothelial cells. For example, vascular cell adhesion 
molecule (VCAM), but not the mucosal addressin cell adhesion molecule 
(MAdCAM), has been shown to be highly expressed on the endothelial cells of the 
lesions from MS patients (Allavena et al., 2010). Therefore, only T-lymphocytes 
that express specific receptors for these adhesion molecules can enter into the 
inflamed CNS (Engelhardt et al., 1998). T-cells from inflamed mouse brains 
expressed a high level of α4β1integrin, the receptor for VCAM-1, but a low level 
of α4β7 integrin; the receptor for MAdCAM (Engelhardt et al., 1994).   
Immune cell trafficking into the CNS is a multiple step process. The initial step 
involves a weak interaction between leukocytes and endothelium and the 
leukocyte rolling along the microvascular wall (Banks, 2010). This step is 
mediated mainly by E- or P- selectins, which bind to P-selectin glycoprotein 
ligand-1 (PSGL-1) (Alon and Ley, 2008). Peripheral CD4+ T cells in CSF of MS 
patients expressed higher PSGL-1 and transmigrated through BBB endothelium at 
a faster pace compared with those of healthy controls, suggesting an essential 
role of PSGL-1 in the CD4+ T cell entry into the inflamed CNS, and also suggesting 
an essential role of P-selectin-PSGL-1 binding in the early phase of leukocyte 
entry into the CNS (Bahbouhi et al., 2009).  Rolling leukocytes are exposed to 
chemokines, leading to further reduced rolling speed, and eventual tethering to 
endothelial cells by α4β1integrin-VCAM-1 binding (Engelhardt, 2006). 
Additionally or alternatively, T cells may be captured by the endothelium 
without rolling, via α4β1integrin-VCAM-1 binding (Banks, 2010). The 
α4β1integrin has an essential role in EAE development; T cells isolated from 
integrin β1 deficient mice showed the inability to adhere firmly to endothelium 
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(Bauer et al., 2009). Natalizumab, the anti-α4 integrin antibody, inhibited α4 
integrin-mediated firm adhesion, but not the initial contact, of human T cells 
with the endothelium during EAE (Coisne et al., 2009). These findings 
demonstrated that the α4β1integrin functions mainly in firm adhesion rather 
than the initial contact of T cell to the BBB. Integrin activation is mediated by 
the signalling from G protein coupled chemokine receptors (Constantin, 2008). 
The binding of chemokines expressed by endothelium and chemokine receptors 
on the surface of leukocytes causes integrin conformational changes, resulting in 
the firm adhesion of leukocytes with the  endothelium (Alon and Dustin, 2007).  
The production of several chemokines is up-regulated by endothelial cells upon 
the activation of cytokines during CNS inflammation. CXCL12 gradients 
stimulated VCAM/ICAM-mediated T-lymphocyte-endothelium adhesion, and 
promoted the migration of CD4+ T cells and CD8+T cells through human brain 
microvessel endothelial cells (HBMECs) (Liu and Dorovini-Zis, 2009). In situ 
hybridization and immuno-histochemistry showed that CCL19 and CCL21 were 
predominately expressed in the brain and spinal cord tissue of EAE mice (Alt et 
al., 2002). These chemokines also activated the firm adhesion of CCR7+ T cells to 
the endothelium of inflamed CNS in binding assays on frozen sections of EAE 
brains (Columba-Cabezas et al., 2003). Long term genetic over-expression of IL-
1β in the hippocampus of the mouse brain resulted in BBB leakage, up-regulation 
of CCL2, CXCL1, CXCL2 and a dramatic infiltration of neutrophils into the 
hippocampus. Interestingly, knocking out the CXCR2 gene in these mice with CNS 
over-expression of IL-1β exhibited a significant reduction in neutrophil 
infiltration, but failed to prevent BBB leakage (Shaftel et al., 2007). The 
infiltration of CD45+ T cells into the sub-ventricular zone (SvZ); a preferential 
site of inflammatory lesions in EAE, has been associated with the constitutive 
expression and the up-regulation of CXCL10 in SvZ during EAE development 
(Muzio et al., 2010).  
The firm adhesion of leukocytes with endothelial cells leads to the diapedesis of 
leukocytes across the BBB. The mechanism underlying the penetration of 
leukocytes through the tight junction is still undefined. Some in vitro studies 
suggested that it may involve the transient down-regulation of tight junctional 
elements such as claudin-1/3 and occludin-1 (Xu et al., 2005). The occludin loss 
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in monocyte diapedesis has been associated with the activity of matrix 
metalloproteinase enzymes (Reijerkerk et al., 2006). 
1.7 Communication between the immune system and 
the central nervous system (CNS) 
The communication between peripheral and the CNS immune systems is bi-
directional. The brain perceives the peripheral inflammatory signal and can 
coordinate responses via the autonomic nervous system (ANS) and hypothalamo–
pituitary–adrenal (HPA) systems (Maier, 2003). The activation of both the 
autonomic nervous system (ANS) and HPA system is considered to be the 
negative feedback from the brain to regulate the levels of immune response in 
the periphery (Kin and Sanders, 2006) (Figure 1.2).  
CNS modulates stress and the immune response via the sympathetic nervous 
system (SNS) and the parasympathetic nervous system (PNS). Nerves of the 
autonomic nervous system originate from the spinal cord, and both sympathetic 
catecholamine fibres and parasympathetic cholinergic fibres distribute and 
innervate various effecter organs and immune organs, including thymus, bone 
marrow, lymph nodes and spleen (Nance and Sanders, 2007). Activation of the 
SNS during stress and peripheral inflammation results in the release of 
catecholamines, including norepinephrine (NE; noradrenalin) and epinephrine (E; 
adrenalin), from nerve terminals and from the adrenals (Tjurmina et al., 1999). 
NE and E bind to two types of receptors: alpha (α) and beta (β) adrenoceptors 
(AR). Most adaptive and innate immune cells such as CD8+ and CD4+ T cells, and 
NK cells express predominately β2AR (Nance and Sanders, 2007), whereas 
monocytes and macrophages express α1AR (Kavelaars, 2002).  The sympathetic 
system has a crucial role in regulation of the immune response; particularly 
immuno-suppression. Deletion of the mouse peripheral sympathetic nervous 
system has been shown to increase the proliferation of CD8+ T cells in response 
to viral infection (Grebe et al., 2009). Enhancing NE level using the 
noradrenaline reuptake inhibitors (NRIs) desipramine and atomoxetine, has been 
shown to inhibit the expression of the chemokines, CXCL10 and CCL5, and 
adhesion molecules VCAM-1 and ICAM-1 in the cortex and hippocampus in mice 
with LPS-induced systemic inflammation, suggesting a role for NE in preventing 
leukocyte recruitment into the brain (O'Sullivan et al., 2010). The 
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parasympathetic nervous system (PNS) has recently been renamed the 
cholinergic anti-inflammatory pathway. Activation of the parasympathetic vagus 
nerve results in release of acetylcholine (ACH), which binds with nicotinic 
acetylcholine receptors and inhibits cytokine production in immune cells 
(Tracey, 2002).  Stimulation of the nicotinic acetylcholine receptor α7 subunit 
has been shown to inhibit TNF-a production in macrophages, suggesting that the 
PNS is an essential regulator of inflammation (Parrish et al., 2008); (Wang et al., 
2003).  
The CNS also responds to stressors by activating the hypothalamo–pituitary–
adrenal (HPA) axis in order to maintain homeostasis (Kern et al., 2008). Stress 
initiates the HPA processes by activating the paraventricular nucleus (PVN) of 
the hypothalamus to release corticotrophin-releasing hormone (CRH) and 
arginine–vasopressin (AVP). CRH and APV then stimulate the anterior pituitary 
gland to release adrenocorticotropic hormone (ACTH) into the circulation. 
Circulating ACTH stimulates glucocorticoid-producing cortex cells in the adrenal 
glands to release corticosteroid hormones including cortisol (in human) or 
corticosterone (in rodents) (Lanfumey et al., 2008). These corticosteroids 
function as anti-inflammatory hormones and their levels are normally up-
regulated during inflammation and infection (Hadid et al., 1999).  It has also 
been reported that increased HPA activity, which is characterized by increased 
serum cortisol and ACTH levels, has been associated with degrees of anxiety and 
social stress (Takahashi et al., 2005). Corticosteroids bind with two types of 
intracellular steroid receptors, the mineralocorticoid (MR) or type I receptor, 
and the glucocorticoid receptor (GCR) or type II receptor. These receptors are 
constitutively expressed in the limbic brain areas, thus they are believed to be 
involved in development of various mood and anxiety disorders (e.g. depression 
and social phobia) (Lanfumey et al., 2008). Both receptor types are expressed in 
various immune cells (monocytes and lymphocytes), and play a role in immune 
regulation (Miller et al., 1994).  GCRs have been shown to be inducible during 
adaptive and innate immune responses (Spies et al., 2007); (Bartholome et al., 
2004). GCR is a cytoplasmic nuclear factor receptor that forms a complex with 
cortisol and then translocates to the nucleus. This complex is a transcription 
factor and binds to sites on DNA leading to regulation of gene transcription of 
proteins involved in immune function (e.g. suppressing the transcription of pro-
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inflammatory cytokines) (Lekander et al., 2009). Activation of the HPA by 
cytokines has been reported to induce somatic signs and symptoms such as 
fever.  It has been hypothesized that cortisol released after HPA axis activation 
creates energy by supporting the breakdown of glycogen and the conversion of 
amino acids, leading to an increase in the core body temperature (Maier, 2003). 
An increase in core temperature is involved in host defence against infection and 
in inflammation by inhibiting the rapid proliferation of bacteria and assembly of 
outer coat proteins of viruses.  In addition, host immune functions including T-
cell activation and complement activation are much more efficient at fever 
temperatures (Watkins and Maier, 1999). Fever is one of the major symptoms of 
sickness behaviour, which is characterized by fever, fatigue, loss of appetite 
(anorexia), loss of interest in social and sexual interaction, reduced reactivity to 
reward (anhedonia), decline in mood and cognitive function. Sickness behaviour 
is common in peripheral inflammation/infection such as during sepsis and 
autoimmune disease (Dantzer et al., 2008). However, whether activation of HPA 
by cytokines underlies sickness behaviour in peripheral inflammatory conditions 
is still controversial. IL-1β antagonism has been reported to inhibit sickness 
responses such as fever, increased HPA activity and reduced food and water 
intake (Milligan et al., 1998). In contrast, IL-6 has been reported to induce HPA 
activation and fever, but not sickness behaviour (Lenczowski et al., 1997).   
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Figure 1.2 The communication between the brain and the peripheral immune system. 
The brain can regulate peripheral inflammation via the automatic nervous and 
neuroendocrine systems. The autonomic pathway of the nervous system is further divided 
into the sympathetic and parasympathetic nervous systems. The sympathetic system 
activates the immune response via the neurotransmitter norepinephrine, while the 
parasympathetic nervous system inhibits the immune response via the neurotransmitter 
acetylcholine. Peripheral inflammation and cytokines activate the hypothalamus to release 
corticortropin-releasing hormone, which in turn activate the pituitary gland to release 
adrenocorticotropic hormone. This hormone, in turn, activates the adrenal gland to produce 
glucocortocoids which suppress inflammation. The image were taken from (Sternberg, 
2006) by kind permission of Nature Reviews Immunology.  
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1.8  Depression 
Depression is characterized by a combination of behavioural, emotional, 
psychomotor and cognitive symptoms, including significant weight loss, insomnia 
or hypersomnia, reduced appetite, fatigue, extreme feelings of guilt or 
worthlessness, concentration difficulties and suicidal thoughts (Gotlib and 
Joormann, 2010).  Depression is a common psychiatric disorder that affects up to 
25% of women and 12% of men (Gelenberg, 2010).  Depression is often a 
comorbid condition with other mental and physical illnesses; most frequently 
with anxiety disorders (Castaneda et al., 2008).  
Major depressive disorder (MDD) affects some 6% of the population during 
their lifetime. Major depressive disorder is a heteregenous disorder with 
complex aetiology. Many mechanisms have been investigated including, 
sociological, psychological and biological. There are no clear, unequivocal 
mechanisms specific to depression and the majority of cases may be a 
combination of aetiologies. Abnormalities of the monoamine neurotransmitter 
system have been proposed to be the main pathological mechanism of 
depression. Based on this monoamine hypothesis, low levels of one or more of 
the monoamine neurotransmitters, which are serotonin, noradrenalin and 
dopamine, can induce depression (Singh, 1970). Among these, serotonin is 
considered to play a major role in the pathological mechanism of depression. It 
has been demonstrated that depression is caused by abnormalities of the 
serotonin transporter (SERT) at several levels, including the expression of the 
SERT gene in different functional polymorphisms (5-HTTLPR), the re-uptake 
activity of SERT and the level of SERT expressed in the brain. Therefore SERT is 
considered to be an important therapeutic target site for anti-depressants 
(Belmaker and Agam, 2008). Several effective anti-depressants that are designed 
to modulate the serotonergic system, including selective serotonin re-uptake 
inhibitors (SSRI) and 5-HT2 receptor antagonists and 5-HT1A receptor partial 
agonists, are reported to be efficient treatments for depression (Williams et al., 
2000a).  Recently, there are a number of new psychological theories about the 
aetiology of depression. The ‘neurotrophin hypothesis of depression’ is based on 
accumulating evidence suggesting an association between the cytokine brain 
derived neurotrophic factor (BDNF) and the psychological and cognitive aspects 
of depression (Martinowich et al., 2007). Serum BDNF concentrations are lower 
Chapter 1  75 
in depressed patients, and increase in response to anti-depressant treatment 
(Matrisciano et al., 2009). Although clinical evidence for this theory exists, the 
direct in vivo evidence showing that reduced endogenous gene expression of 
BDNF can lead to depression/ depression-like behaviour is still controversial 
(Sakata et al., 2010); (Chourbaji et al., 2004). It has been suggested that the 
absence of BDNF in the brain does not cause depression- or anxiety-like 
behaviour, but rather inhibition of an improved behavioural response to anti-
depressants (Saarelainen et al., 2003); (Chen et al., 2006). 
Clinical evidence suggests that the neuroendocrine system has a crucial 
role in regulating psychological conditions (Heiser et al., 2008). HPA axis 
activation and dysregulation are common in depression and stress-related 
psychological disorders. Approximately 43% of depression patients exhibit 
increased concentrations of cortisol and corticotropin-releasing hormone (CRH), 
and a poor ability to reduce cortisol release as measured by an impaired 
feedback response to exogenous dexamethasone. Activation of the HPA axis in 
depression patients can also be attenuated by long-term anti-depressants 
(Varghese and Brown, 2001). Adult brain neurogenesis is a novel theory of 
depression that has generated enormous interest over the past decade and will 
be discussed in the next section.  
1.9 Hippocampal neurogenesis 
The hippocampus is the major brain region that has a crucial role in encoding 
episodic memories, especially spatial memory and working memory, which are 
often considered as parts of cognition (Burgess et al., 2002). Within the 
hippocampus, the dentate gyrus (DG) generates new neurons throughout life; 
this is known as neurogenesis (Deng et al., 2010). Neuronal progenitor cells 
(NPCs) in the subgranular zone (SGZ) of the dentate gyrus differentiate into 
granular neurons. These cells develop electrical properties and integrate into 
functional circuits by extending their axonal projections along mossy fibre 
pathways to the CA3 area of the hippocampus. Neuronal circuits in the 
hippocampus have been implicated in cognitive memory and learning, involving 
the processing of new information (Bruel-Jungerman et al., 2007). The memory 
formation depends on changes in synaptic long term potentiation (LTP) and long 
term depression (LTD) (Howland and Wang, 2008). Bliss et al., in 1973 first 
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demonstrated that LTP was inducible by stimulating dentate gyrus granule cells, 
which transmit the nerve signals to the CA3 region via the mossy fibre pathway 
(Bliss and Gardner-Medwin, 1973). CA3 pyramidal neurons then transmit 
excitatory synaptic signals to the CA 1 region; which has been implicated in 
memory storage and consolidation, via glutamate release and NMDA/AMPA 
receptor activation (Kullmann and Lamsa, 2007). Hippocampal neurogenesis and 
neuronal circuit s shown in Figure 1.3. 
 
Figure 1.3. Hippocampal neurogenesis and neuronal circuit.  
Neuronal progenitor cells (NPCs) differentiate into granular neurons and integrate into the 
circuit by extending their axonal projections along mossy fibre pathways to the CA3 area of 
the hippocampus (red). These mossy fibre pathways function to transmit neuronal signals 
in the form of synaptic long term potentiation (LTP). Neurons at CA3 then transmit 
excitatory synaptic signals to the CA 1 region (green). The image were taken from (Amrein 
and Lipp, 2009) by kind permission of Biology Letters.  
1.9.1 The role of neurogenesis in hippocampal function 
How neurogenesis contributes to hippocampal function is largely unknown. 
Accumulating evidence suggests that hippocampal neurogenesis has a crucial 
role in hippocampal-dependent learning and memory (Deng et al., 2010). 
Therefore, deficits in adult hippocampal neurogenesis may underlie the 
cognitive deficits developed in depression (Sahay and Hen, 2007). Biogenic rtTA-
Bax mice with genetic deletion of neurogenesis show an impairment in 
performance on hippocampal-dependent learning and memory tasks, including 
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water maze and contextual fear conditioning (Dupret et al., 2008).  Farioli-
Vecchioli and colleague demonstrated that changes in differentiation timing of 
neurons in the adult dentate gyrus also resulted in spatial learning and memory 
deficiency, along with a reduction in long-term potentiation of synaptic 
plasticity (Farioli-Vecchioli et al., 2008); (Farioli-Vecchioli et al., 2009). These 
findings suggested that these immature DG neurons are highly active and able to 
transmit synaptic plasticity and encode the memory at a specific stage of their 
differentiation.  
Computational models of DG newly born neuron function also suggested that 
neurogenesis also has a crucial role not only in encoding memory, but also in the 
consolidation of memory. Without neurogenesis, a spare subset of mature DG 
neurons encode the initial memory via a synaptic transmission to a limited set of 
pyramidal cells in CA3, leading to a unique pattern of activated CA3 cell 
networks for the initial memory. The later memory is encoded by another subset 
of mature DG neurons, resulting in another unique pattern of activated CA3 cell 
networks for the later memory. The patterns of both activated CA3 cell 
networks for the initial and the later memories thus do not overlap. On the 
other hand, with neurogenesis, both initial and later memories are encoded 
equally by immature DG neurons. This leads to two overlapping patterns of 
activated CA3 cell networks, suggesting that the initial memory is consolidated 
and protected from encoding the later memory. However, these immature DG 
neurons will mature and die in a short period of time (~ 3 weeks to ~ 2 months) 
(Zhao et al., 2006). Therefore, the memory of a new event that occurs at a 
much later time is encoded by a different set of immature DG neurons, which 
are no longer able to encode the initial memory. This leads to two independent 
patterns of activated CA3 cell networks. This finding suggested that hippocampal 
neurogenesis may be responsible for encoding and consolidating memories of 
events that occur closer in time. However, the retrieval of long-term memory in 
human may be hippocampal-independent or regulated by other brain regions 
(Aimone et al., 2006).  
1.9.2 Hippocampal neurogenesis and depression 
The ‘hippocampal neurogenesis hypothesis of depression’ is based on 
accumulating evidence showing a reduction of hippocampal neurogenesis in the 
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model of stress-related mood disorders. Animal experiments showed that stress 
or chronic treatment with corticosterone caused reduced hippocampal 
neurogenesis, along with a decreased hippocampal volume (Brummelte and 
Galea, 2010); (Czeh et al., 2001). Other important evidence supporting this 
hypothesis is that anti-depressants increase hippocampal neurogenesis in both 
animals and humans. Anti-depressants such as fluoxetine, agomelatine, 
imipramine and electroconvulsive therapy (ECT) have been reported to increase 
neurogenesis in various species, including rodents, nonhuman primates and 
humans, and reverse reduced neurogenesis that is induced by stress and cerebral 
ischemia (Perera et al., 2007); (Malberg et al., 2000); (Banasr et al., 2006); 
(Schiavon et al., 2010).  A neurogenesis study of frozen hippocampus isolated 
from depression patients showed a reduction in neurons expressing neural 
progenitor (NPCs) markers compared to those of healthy control subjects. 
Interestingly, the number of neural progenitor (NPCs) cells in the hippocampus 
of depression patients who received long-term SSRIs- and tricyclic 
antidepressants (TCAs)-treatment was higher than those of untreated depression 
patients (Boldrini et al., 2009). Importantly, hippocampal neurogenesis is 
considered to be a potential therapeutic target site of the action of anti-
depressant drugs because hippocampal neurogenesis was shown to be essential 
for behavioural effects of anti-depressants in mice. Serotonin 1A receptor 
deficient mice treated with fluoxetine or imipramine treatment showed higher 
level of appetite, measured by a depressive-like behaviour test called the 
suppressed feeding test, compared to untreated serotonin 1A receptor deficient 
mice. However, after ablation of neurogenesis by x-irradiation, serotonin 1A 
receptor deficient mice that received antidepressants showed no difference in 
the level of appetite compared to those without the treatment (Santarelli et al., 
2003). However, it is still unclear whether impairment in hippocampal 
neurogenesis is an aetiological factor for depression. Reductions in hippocampal 
volume have been reported in depressed patients (von Gunten and Ron, 2004); 
(Frodl et al., 2006). It has been hypothesized that the decrease in neurogenesis 
in the SGZ of the dentate gyrus may also be the main contributor to decreased 
hippocampal volume. However, there is no direct evidence showing that changes 
in adult hippocampal neurogenesis account for the reduction in hippocampal 
volume in patients with depression. Decreased numbers of progenitor cells were 
observed in the hippocampus of depression patients. Immuno-histochemical 
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staining showed a reduction in the number of neurons expressing the progenitor 
cell marker, MCM2, in frozen hippocampus tissues isolated from 10 depression 
patients, compared to those from 10 sex- and age-matched healthy control 
subjects (Lucassen et al., 2010). However, methods and devices for imaging of 
neurogenesis in live human brains are still not fully developed. Therefore, the 
indirect approach is to use proton magnetic resonance spectroscopy (1H-MRSI) to 
identify changes in neuro-metabolites that reflect neuronal dysfunction, glial 
reaction and energy metabolism. N-acetylaspartate (NAA) is one of the neuronal 
markers that is commonly used in proton MR spectroscopic (MRS) imaging. This is 
because NAA is a metabolite of aspartate, which is the main amino acid 
consumed by CNS neurons (Maletic-Savatic et al., 2008). Patients with mild 
cognitive deficiency also showed a reduced NAA in the hippocampus (Wang et 
al., 2009b). However, it has been reported that inhibition of hippocampal 
neurogenesis using X-irradiation does not cause a reduction of hippocampal 
volume (Santarelli et al., 2003). Pathohistological studies of post-mortem tissue 
suggested that increased apoptosis of mature neurons or glial cells are the cause 
of the reduction in hippocampal volume (Czeh and Lucassen, 2007); (Sahay et 
al., 2007). Preclinical studies showed that changes in the hippocampal 
neurogenesis volume resulted from changes in morphology of neurons such as 
reduced dendritic complexity, but not from ablation of hippocampal 
neurogenesis (Santarelli et al., 2003); (McEwen, 2005). In addition, it is still 
controversial whether the impairment in hippocampal neurogenesis is directly 
associated with depression-like or anxiety-like behaviour. Transgenic mice with a 
neurogenesis deficiency exhibited an increase in anxiety-related behaviour 
(Revest et al., 2009). In contrast, a study by Saxe et al reported that the 
inhibition of hippocampal neurogenesis does not influence anxiety-related 
behaviour tested by open field, light-dark choice test, and elevated plus-maze 
tests (Saxe et al., 2006). Moreover, an increase in hippocampal neurogenesis by 
anti-depressants does not always correlate with an improvement in depression-
like or anxiety-like behaviour in animals. A study in BALB/cj mice showed that 
chronic fluoxetine treatment improved depressive behaviour without inducing 
changes in hippocampal neurogenesis (Huang et al., 2008). This finding is 
supported by another study by Bessa 2009 showing that the effect of anti-
depressants on depression-like behaviour depended on neuronal remodelling, but 
not hippocampal neurogenesis (Bessa et al., 2009). In contrast, hippocampal 
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neurogenesis has been reported to be the essential target site for the effects of 
anti-depressants on depression-like or anxiety-like behaviour in animals 
(Santarelli et al., 2003). This evidence suggests that anti-depressants may have 
both neurogenesis-dependent and –independent effects on depression-like or 
anxiety-like behaviour (David et al., 2009). The evidence in support of and in 
conflict with the ‘hippocampal neurogenesis hypothesis of depression’ suggests 
that the role of hippocampal neurogenesis in the aetiology of depression need to 
be further investigated. 
1.10  Cytokines, peripheral inflammation and 
depression 
Recent attempts have been made to classify this disorder and one approach has 
been to explore the co-morbid depression seen in many medical illnesses. There 
is increasing evidence of association between inflammation and major 
depressive disorder (MMD) and this comes primarily from 3 clinical observations.  
i) Inflammatory medical illnesses – both CNS and peripheral – are 
associated with greater rates of major depression. 
ii)  MDD even in the absence of medical illness is associated with raised 
inflammatory markers.  
iii) Patients treated with cytokines for various illnesses are at risk of 
developing major depressive illness.  
Sub-typing depression may help uncover the role of biological mechanisms 
that may be specific to these subtypes. Depression with a prominent 
inflammatory component may be one such subtype. The uncovering of 
different biological mechanisms relating to depressive subtypes may also aid 
the development and targeting of new treatment strategies.  
1.10.1  Depression and rheumatoid arthritis 
Depression is associated with several chronic inflammatory diseases such as RA, 
MS, psoriasis as well as diabetes (Engum et al., 2005), obesity (Atlantis et al., 
2009), and cardiovascular disease (Pitt and Deldin, 2010). In RA, the prevalence 
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of depression is 14%-46% (Katz and Yelin, 1993); (Dickens et al., 2002). A recent 
clinical study of 82 RA patients showed that the prevalence of depression was 
41.5% and the degree of depression was positively associated with the duration 
of RA disease (Isik et al., 2007). Depression was shown to increase the risk of 
mortality in RA; a study of 1290 RA patients showed that those who had suffered 
from persistent or recurrent depression over the first 4 year period of disease 
had higher mortality rates compared to those without depression during an 18-
year observation period (Ang et al., 2005). Higher rates and specific pasterns of 
suicide have also been reported in RA patients with depression. 11% of hospital 
outpatients with rheumatoid arthritis (13 of 123) experienced suicidal thoughts 
(ideation) (Treharne et al., 2000). In a study of 19 suicide victims who had 
hospital-treated RA, 52.6% were female. In addition, 90% of these female RA 
patients had suffered from co-morbid depression and had chosen a violent 
suicide method, compared to male RA patients who committed suicide (Timonen 
et al., 2003). The cause of depression in RA is unclear. Similar to other painful 
conditions, depression associated with RA is often considered to be a simple 
consequence of the experience of chronic pain. This concept was supported in a 
large–scale study of 22131 RA patients, using a questionnaire of the Symptom 
Intensity Scale, showing that pain and fatigue were the strongest predictors of 
self-reported depression (Wolfe and Michaud, 2009). However, a relation 
between pain and depression in RA is still unclear because a study by Mindham 
et al indicated that pain and disability in RA are not potent factors that can 
contribute to depression (Mindham et al., 1981), and a clinical study of 218 RA 
patients showed that depression in RA patients is not only associated with pain, 
but correlated with the concentration of the acute phase response inflammation 
marker C-reactive protein (CRP) level in the blood (Kojima et al., 2009). This 
suggests the hypothesis that ‘peripheral inflammation may participate in 
depression in RA’.  
Several reports also suggest that sleep disorders are associated with chronic 
inflammatory diseases such as rheumatoid arthritis (RA), asthma and systemic 
lupus erythematosus (SLE) (Janson et al., 1996, Gudbjornsson and Hetta, 2001, 
Bourguignon et al., 2003, Keefer et al., 2006). However, it is still unclear 
whether sleep abnormalities in patients with these chronic inflammatory 
diseases are the result of pain, stress or depression that is associated with these 
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chronic inflammatory diseases. It is also possible that sleep disturbance itself 
could be a result of disease-related immune changes, which increased risk of 
depression in patients with these chronic inflammatory diseases. Vice versa, 
sleep deprivation has been reported to alter immune system functions by 
increasing the activity of natural killer (NK) cells and monocytes (Dinges et al., 
1994). Prolong periods of wakefulness can also result in an increase in serum IL-6 
and TNF soluble receptor concentrations (Shearer et al., 2001). The activation of 
immune responses caused by sleep deprivation may have a negative impact on 
the availability of tryptophan to the brain and hence reducing synthesis of 
serotonin (5-HT), which could be a possible underlying pathological mechanism 
of depression (Fernstrom et al., 1990). A study by Song et al., demonstrated an 
inverse relationship between the low availability of plasma tryptophan and high 
serum IL-1RA, IL-6 and IL-8 concentrations in patients with primary sleep 
disorders associated with major depression (Song et al., 1998). This study 
suggests that sleep disruption plays a detrimental role in immune-inflammation 
that possibly causes or contributes to depression. Therefore, it seems logical to 
consider sleep disturbances as one of the factors that negatively influences 
chronic inflammatory diseases and that it possibly plays a role in depression in 
the context of chronic inflammatory diseases.  
1.10.2   Immune activation in depression patients  
 Important evidence supporting the ‘inflammation-induced depression in RA’ 
hypothesis includes the increased concentrations of cytokines, immune cells and 
inflammatory marker such as CRP in the blood of depression patients.  
Alterations in the serum concentrations of various cytokines, including TNF-α, IL-
1β, IL-6, IL-4, IL-10, IL-8, IL-4, IFN-γ, GM-CSF and IL-12, in depression patients 
have been reported. However, some of these cytokine changes have not been 
consistent in different studies, depending on the particular cytokine and the 
measurement technique used. For example, a study of serum cytokine 
concentrations in 49 depression patients using a human 22-plex multi-cytokine 
detection (Luminex) system showed increased concentrations of 15 
cytokines/chemokines including IL-10 and GM-CSF (Simon et al., 2008). In 
contrast, a study in 12 depressive patients using an Enzyme-linked 
immunosorbent assay (ELISA) method showed lower than normal serum IL-10 
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concentrations (Dhabhar et al., 2009). Serum levels of GM-CSF within normal 
levels, measured by using a Bio-Plex human cytokine kit, was observed in 122 
depression patients (Lehto et al., 2010a). A recent meta-analysis of 24 studies 
looking at serum cytokine concentrations in major depression demonstrated that 
IL-6 and TNF-α were 2 cytokines that were consistently found to be higher than 
normal (Dowlati et al., 2010). An increased serum TNF-α concentration has been 
associated with suicidal tendency in depression patients (Eller et al., 2009) and 
the concentrations of both soluble TNF-α receptors, sTNFR-1 and sTNFR2 were 
also increased in the serum of depression patients (Grassi-Oliveira et al., 2009). 
IL-6 and TNF-α were also up-regulated in the CSF of depression patients 
(Palhagen et al., 2010).  A positive correlation between CSF TNF-α and IL-6 with 
the depression score; measured by Postpartum Blues Scale and Edinburgh 
Postnatal Depression Scale (EPDS), was observed in depressive women during 
delivery and during the postpartum period (Boufidou et al., 2009). Suicide 
attempters showed higher than normal IL-6 concentration in the CSF, and this 
correlated with Montgomery-Åsberg Depression Rating Scale (MADRS) (Lindqvist 
et al., 2009). These data suggest that TNF-α and IL-6 may have a major role in 
the immuno-pathology of depression. Interestingly, chemokines have recently 
been shown to have a role in depression. Serum concentrations of MCP-1, MIP-1β 
and IL-8 were reduced in patients with major depression, suggesting that 
chemokines may play a protective role in the pathology of depression (Lehto et 
al., 2010b).  
Several studies have demonstrated that cell-mediated immune activation may be 
a key component in the pathogenesis of depression (Maes, 2010).  Several 
studies demonstrated an imbalance of Th1 and Th2 cytokines in depression 
patients. The Th1/Th2 ratio, as indicated by the serum IFN-γ/IL-4 concentration 
ratio was increased in depressive patients, but this ratio returned to the normal 
baseline after anti-depressant treatment (Myint et al., 2005); (Kim et al., 2008). 
The serum IL-1β/IL-10 ratio was also increased in patients with acute 
melancholic depression (Huang and Lee, 2007).  A recent study of 27 patients 
with major depression showed a 3-fold increase in the Th1/Th2 cell ratio as 
shown by the concentration ratio of serum IL-2/IL-10. In addition, in depression 
patients a reduction in CD4+CD25+ regulatory T cells in peripheral blood, along 
with a reduced 5-HT1a receptor expression on these regulatory T cells were 
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observed. A shift in the Th1/Th2 ratio in depression suggests that activation of 
the inflammatory response may play a role in immuno-pathological mechanism 
of depression. The association between reduced CD4+CD25+ regulatory T cells 
and a decrease in 5HT receptor also suggests that the immune dysregulation 
during depression may affect the serotonergic system, which eventually 
contributes to the development of depression (Li et al., 2010).  
1.10.3 The cytokine hypothesis of depression  
The ‘cytokine hypothesis of depression’ states that peripheral inflammation can 
cause changes in cytokine expression profiles in the brain, leading to various 
neurological outcomes such as alterations in the neurotransmitter and 
neuroendocrine systems. These eventually may result in somatic and 
psychological symptoms such as sickness behaviour, depression and cognitive 
dysfunction (Schiepers et al., 2005). This hypothesis is based on the evidence 
showing that cytokine therapy can induce neuro-psychiatric symptoms in 
patients with cancer or chronic hepatitis C. Cytokines such as IFN-α and IL-2 can 
be used as immunotherapy for the treatment of chronic hepatitis C and cancer 
(Bonaccorso et al., 2001); (El-Zayadi, 2009); (Pasquini et al., 2008). 
Approximately 30% of patients who received IFN-α therapy develop sickness-like 
symptoms, anxiety and major depression, which are the major side effects of 
immunotherapy (Quarantini et al., 2007). The sickness-like symptoms, including 
lack of sleep, loss of appetite, weight loss and fatigue usually occurred during 
the first 2-4 weeks of the therapy and can be early indicators for depression 
which usually developed 1-3 months after the treatment (Robaeys et al., 2007); 
(Franzen et al., 2010). IFN-α therapy also has an effect on other neuro-
psychological functions such as locomotor activities. Chronic hepatitis C patients 
who receive IFN-α exhibited slower response times in the rapid visual 
information processing task. This locomotor impairment has also been associated 
with increased depressive symptoms and fatigue (Majer et al., 2008). IFN-α 
induced impairment of locomotor activity and depressive behaviour have also 
been observed in a non-human primate model, using rhesus monkeys and in a 
mouse model (Felger et al., 2007). In addition, changes in behavioural symptoms 
have also been associated with alterations in neurotransmitter levels such as 5-
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HT and dopamine in the CNS of these models (Felger et al., 2007); (Litteljohn et 
al., 2010). 
1.10.4  Possible mechanism underlying cytokine-induced 
depression 
Possible mechanisms underlying cytokine-induced depression are still unclear. 
The central effects of pro-inflammatory cytokines on the neurotransmitter 
system, neuroendocrine, neurotropic factor and hippocampal neurogenesis may 
contribute to the development of depression.  
Peripheral inflammation and cytokines can modulate neurotransmitter systems 
such as serotonin (5-HT), dopamine (DA), and noradrenaline (NA) via the 
regulation of neurotransmitter biosynthesis and their transporter activities. 
(MohanKumar et al., 1999). A study by Zhu et al demonstrated that interleukin-
1β and tumor necrosis factor-α stimulated the transport activity of the serotonin 
transporter in serotonergic neurons of mouse midbrain and striatum, in a dose- 
and time-dependent manner (Zhu et al., 2006). The effect of pro-inflammatory 
cytokines on tryptophan metabolism, particularly the indoleamine 2,3-
dioxygenase (IDO) pathway, has recently been considered to be one potential 
mechanism underlying inflammation-induced depression. The IDO pathway seems 
to be the most important link between inflammation and serotonin metabolism. 
IDO degrades L-tryptophan (L-TRP), an amino acid precursor of serotonin (5HT), 
via the kynurenine pathway during immune activation (Kwidzinski and 
Bechmann, 2007). L-tryptophan is catabolized into L-kynurenine (L-KYN), which 
is metabolised further to quinolinic acid (QUIN) and kynurenic acid (KA) 
(Kwidzinski and Bechmann, 2007). The expression of IDO is induced mainly by 
IFN-γ and TNF-α in several immune cells, including macrophages (Thomas et al., 
2001), dendritic cells (Jurgens et al., 2009, Dai and Gupta, 1990), and fibroblast 
(Dai and Gupta, 1990). IFN-γ induction of IDO was also found in astrocytes (Suh 
et al., 2007) and microglia (Yadav et al., 2007). IDO also has a crucial role in 
immuno-suppression by inhibiting the proliferation of CD4+ T cells and CD8+ T 
cells (Forouzandeh et al., 2008) and of regulatory T cells (Munn and Mellor, 
2007). Both clinical and experimental studies have demonstrated that 
depressive-like behaviour induced by systemic inflammation or cytokines could 
be mediated by IDO activation. Systemic LPS injection–induced IDO activation, 
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along with increased IL-6 and TNF-α production by microglia in the cortex and 
hippocampus of the mouse brain, caused depressive-like behaviour in mice 
(O'Connor et al., 2009); (Connor et al., 2008). A decrease in peripheral 
tryptophan, and the positive correlation between CSF QUIN, CSF cytokine and 
depressive symptoms were observed in depressive patients during hepatitis C 
treatment with IFN-α (Raison et al., 2010). This evidence suggests that 
peripheral inflammation may induce the expression of IDO enzyme as a negative 
feedback to suppress inflammation. However, IDO enzyme causes the reduction 
of precursor of 5HT, leading to depression during inflammation. In addition, 
peripheral inflammation and chronic inflammatory diseases induce the HPA axis 
to release CRH and glucocorticoids that in turn affect the neurobiology of 
cognition and mood (Pace et al., 2007). The central action of cytokines may also 
account for the reduction of the neurotropic factors such as BDNF. Several 
experimental studies showed that a reduction of BDNF in the hippocampus 
caused by cytokines, has been reported to cause an impairment in cognition. 
Peripheral inflammation in mice caused a reduction of hippocampal BDNF and 
also showed an impairmentin hippocampal-dependent memory (Bilbo et al., 
2008). A potential mechanism underlying cytokine-induced depression can be 
suggested; this is that cytokines can mediate decreased neurogenesis, thereby 
causing depression. 
1.10.5  Cytokine-mediated inflammation and decreased 
hippocampal neurogenesis in depression 
Hippocampal dysfunction due to a reduction in neurogenesis has been 
demonstrated to be a major contributor to the cognitive impairment aspect of 
depression. Adaptive and innate immune responses, immune cells and 
inflammatory mediators resulting from peripheral inflammation have their roles 
in the regulation of neurogenesis. It has been hypothesised that ‘impairment of 
hippocampal neurogenesis by immune activation may be an underlying 
mechanism of the depression that develops during systemic inflammation’. This 
hypothesis is based on several recent studies showing that alterations in 
hippocampal neurogenesis by cytokines, immune cells and immune activation 
can contribute to behavioural changes in animal models. Socially isolated mice 
over-expressing interleukin-1 receptor antagonist in the hippocampus showed an 
improvement in memory impairment and a recovery from suppressed 
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neurogenesis (Ben Menachem-Zidon et al., 2008). Learning experience-induced-
neurogenesis has been associated with the recruitment of CNS-specific T cells 
and the activation of microglia (Ziv et al., 2006). In contrast, autoimmune-prone 
cytokine B-cell-activating factor (BAFF) transgenic mice; a model of systemic 
lupus erythematosus, rheumatoid arthritis and Sjögren’s syndrome, showed 
decreased hippocampal neurogenesis and LTP, along with increased anxiety 
behaviour (Crupi et al., 2010). These findings suggest different roles for T cells 
and B cells in the regulation of neurogenesis, which can contribute to different 
aspects (cognition and mood) of depression. Based on this evidence, 
hippocampal neurogenesis can be considered as an important link between 
inflammation and depression.  
1.10.6  Role of peripheral inflammation in hippocampal 
neurogenesis 
Accumulating evidence suggests that inflammatory processes, both local and 
systemic, can reduce the proliferation and survival of new neurons. Ekdahl et al 
found that administering LPS locally into brains gave rise to microgial activation 
in the hippocampus which resulted in strongly impaired neurogenesis (Ekdahl et 
al., 2003). Monje ML et al also demonstrated the effect of systemic 
inflammation on adult hippocampal neurogenesis. Inducing peripheral 
inflammation using i.p. injection of LPS in female rats, leads to the inhibition of 
neurogenesis in the adult dentate gyrus. Interestingly, the reduced neurogenesis 
can be reversed by indomethacin, a cyclooxygenase COX1/COX2 inhibitor. This 
result also indicated that the decrease of neurogenesis caused by chronic 
inflammation was associated with a progressive decline in learning and memory 
(Monje ML et al., 2003). 
1.10.6.1 Role of cytokines in hippocampal neurogenesis 
There are various possible mechanisms underlying peripheral inflammation 
suppression of hippocampal neurogenesis. This may be due to the direct effect 
of pro-inflammatory cytokines produced during the inflammatory process on 
morphological development in the hippocampus. IL-1β is an important regulator 
of brain cytokine networks that contribute to the inflammatory process of 
various neurodegenerative diseases (Allan et al., 2005). Peripheral LPS 
administration resulted in increased IL-1β concentrations in the rodent 
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hippocampus (Csolle and Sperlagh, 2010). In addition, the hippocampus itself is 
the brain area with the most intense expression of IL-1β and its receptor (Allan 
et al., 2005). In vivo cell cycle and proliferation analysis using 
bromodeoxyuridine (BrdU) demonstrated that after 1 week of IFN-α 
administration in rats, a reduced number of BrdU labelled proliferating cells was 
observed in the dentate gyrus. Interestingly, following the injection of IFN-α, an 
increased concentration of IL-1β was also observed in the hippocampus. 
Moreover, with co-administration of IL-1β receptor antagonist, the IFN-α-
induced suppression of the neurogenesis in the adult dentate gyrus was 
completely blocked. This suggests that the IFN-α inhibits neuronal proliferation 
in the dentate gyrus via IL-1β signalling (Kaneko N et al., 2006). 
1.10.6.2  Role of chemokines in hippocampal neurogenesis 
Chemokines, particularly the CXCL12/CXCR4 ligand and receptor, have crucial 
roles in hippocampal neurogenesis; particularly in the regulation of the survival 
and maturation of neuronal progenitor cells. CXCR4 has a direct role in the 
regulation of the migration of granule cells. CXCR4 gene-deficient mice showed 
a dramatic decrease in the distribution of dividing precursor cells from the 
ventricular zone to the dentate gyrus (Bagri et al., 2002). CXCL12 also enhanced 
human neuronal progenitor cell proliferation (Wu et al., 2009). Smaller and 
morphologically immature cells of the hippocampal dentate gyrus were observed 
in CXCR4 gene-deficient mice (Lu et al., 2002). CXCL12, which functions as a 
chemo-attractant for leukocytes, also shows a chemo-attractive activity for 
embryonic cerebellar neurons in the meninges (Zhu et al., 2002b). CXCL12 also 
has an effect on the maturation and differentiation of hippocampal neurons by 
regulating axonal patterning at an early stage of neuronal development. 
Hippocampal neurons treated with CXCL12 showed specific morphology with 
shorter axons and more axonal branches compared to normal hippocampal 
neurons (Pujol et al., 2005). CXCL12 also showed an effect on axon outgrowth 
into other types of neurons and acts as a chemotactic molecule that influences 
axonal guidance in cultured retinal ganglion cells (Chalasani et al., 2003). 
Increased axonal elongation was observed in cerebellar granule neurons treated 
with CXCL12 in a dose-dependent manner (Arakawa et al., 2003). 
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1.10.6.3  Role of innate immunity in hippocampal neurogenesis 
Recent findings showed that innate immunity is also involved in hippocampal 
neurogenesis; mainly via TLRs. TLR2 gene-deficient mice showed a reduction in 
hippocampal neurogenesis. In contrast, TLR4 deficient mice exhibited increased 
proliferation and neuronal differentiation (Rolls et al., 2007); (Keene et al., 
2009). Activating TLR3 suppressed neural progenitor cell proliferation in vivo, 
while hippocampal neural progenitor cells in TLR2 deficient mice showed greater 
maturation compared to controls (Lathia et al., 2008).  
1.10.6.4 Role of adaptive immunity in hippocampal neurogenesis 
The role of the adaptive immune response in hippocampal neurogenesis is still 
controversial. A study by Ziv et al., suggested that T cells supported 
hippocampal neurogenesis (Ziv et al., 2006). This observation is confirmed by a 
study showing an increase in hippocampal neurogenesis in arthritis model mice 
(AIA model). The author of that study suggested that the increase in 
hippocampal neurogenesis was regulated by T cells (Wolf et al., 2009a). In 
contrast, a study by Wang et al showed that activated T cells inhibited 
neurogenesis (Wang et al., 2010).  In addition, B cells also showed to reduced 
hippocampal neurogenesis (Crupi et al., 2010). It seems therefore that 
lymphocytes can contribute to neurogenesis but that little is known about the 
mechanisms.  
1.10.6.5 Potential indirect regulation of hippocampal neurogenesis 
associated with inflammation 
As well as the direct effect of cytokines, immune cells and immune activation, 
hippocampal neurogenesis could be regulated by indirect pathways associated 
with inflammation such as from the neuroendocrine system or neurotrophic 
factors. Peripheral inflammation and chronic inflammatory diseases induce the 
HPA axis to release CRH and glucocorticoids that in turn affect the neurobiology 
of cognition and mood (Rohleder et al., 2010). Animal experiments showed that 
stress and chronic treatment with corticosterone caused reduced hippocampal 
neurogenesis, along with a decreased hippocampal volume (Brummelte and 
Galea, 2010); (Czeh et al., 2001). Chronic administration of corticosterone was 
shown to inhibit hippocampal neurogenesis and reduce hippocampal volume, 
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along with increased anxiety (light dark box test) and depression (forced swim 
test) -like behaviour, suggesting that corticosterone not only induces depression 
via the serotonergic system, but also via neurogenesis (Murray et al., 2008). 
Chronic stress and glucocorticoid treatment may suppress hippocampal 
neurogenesis by inhibiting BDNF production in the hippocampus (Smith et al., 
1995). A swim stress test was shown to inhibit BDNF mRNA expression and TrkB 
signalling in the mouse hippocampus (Shi et al., 2010). However, there is no 
direct evidence showing that peripheral inflammation-induced 
CRH/glucocorticoids suppress hippocampal neurogenesis. However, a recent 
study of human hippocampal progenitor cells showed that the anti-depressant 
sertraline increased hippocampal neurogenesis via the glucocorticoid receptor 
(Anacker et al., 2011). This finding revealed a new concept of glucocorticoids 
action on hippocampal neurogenesis, suggesting that glucocorticoids may not 
only suppress neurogenesis, but can also support hippocampal neurogenesis. This 
finding could be significant in the case of glucocorticoid resistance in patients 
with chronic inflammatory disease. Glucocorticoid resistance is common in 
patients with RA and asthma (Barnes and Adcock, 2009), and it is characterized 
mainly by glucocorticoid receptor dysfunction of lymphocytes (Rohleder et al., 
2010). Glucocorticoid resistance exaggerates inflammation and hyperactivity of 
corticotropin releasing hormone and sympathetic nervous system pathways, 
which may have detrimental effect on hippocampal neurogenesis (Pace et al., 
2007). It is possible that the anti-depressant may also have an effect to activate 
the glucocorticoid receptor at the peripheral level and reduce HPA activation. 
This may result in enhanced hippocampal neurogenesis. However, it would be 
interesting to test this hypothesis.  
BDNF has also been shown to modulate proliferation, survival, differentiation 
and dendritic development of hippocampal progenitors. Ablation of BDNF 
expression in the hippocampus with gene-deleted mice resulted in decreased 
hippocampal neurogenesis (Choi et al., 2009). Interestingly, ablation of BDNF in 
the hippocampus resulted in a reduction in neurogenesis, along with increased 
behaviour associated with depression, suggesting a role for BDNF-induced 
neurogenesis in the psychological aspect of depression (Taliaz et al., 2010). 
Although the association of BDNF and depression has been demonstrated by 
several clinical and experimental studies, the role of BDNF in inflammation-
Chapter 1  91 
induced-depression via neurogenesis has not been well documented. Several 
animal studies suggested that induction of peripheral inflammation, using LPS or 
IL-1β can induce a reduction of BDNF protein and mRNA in various regions in the 
brain (Guan and Fang, 2006), particularly in the synaptosome of pyramidal cells 
in CA1, CA3 and dentate gyrus in the hippocampus (Lapchak et al., 1993); 
(Schnydrig et al., 2007). Paradoxically, preventing learning experience by 
isolating mice socially caused reduced hippocampal BDNF, which was reversed 
by IL-1β antagonist (Barrientos et al., 2003). IL-1β-induced memory deficits may 
be mediated via BDNF mRNA reduction in the hippocampus. The role of BDNF in 
hippocampal neurogenesis associated with depressive-like behaviour requires 
further investigation.  
Based on experimental evidence, the peripheral inflammation-induced changes 
in hippocampal neurogenesis seems to be one of the putative mechanisms 
underlying inflammation-induced depression. However, there is no clinical 
evidence in humans emerging to support this hypothesis. The ‘hippocampal 
neurogenesis hypothesis of depression’ was originally based on observations 
showing that anti-depressants could increase hippocampal neurogenesis. 
However, so far there is no direct evidence of anti-depressants modulating 
immune response and inducing changes in hippocampal neurogenesis. Although 
several clinical studies have shown that anti-depressant therapy might help to 
reduce interferon-induced psychiatric or depressive symptoms (Raison et al., 
2007). One mechanism underlying the protective effect against cytokine 
therapy-induced depression is that many anti-depressants have anti-
inflammatory effects that can modulate cell-mediated immune responses 
(Capuron et al., 2002). Anti-depressants can also have direct effects on 
microglia. Anti-depressants such as fluvoxamine, reboxetine, imipramine and 
risperidone were shown to reduce IL-6 production by IFN-γ-activated microglia in 
vitro (Hashioka et al., 2007). However, there is no direct evidence showing that 
anti-depressants can reverse impairment of hippocampal neurogenesis via the 
suppression of inflammation. Therefore, further investigation for peripheral 
inflammation-induced changes in hippocampal neurogenesis in depression is 
required.  
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1.11  Aims and hypothesis 
To summarise the main points of the Introduction linking depression with 
immunity:  Clinical depression has been associated with chronic inflammatory 
diseases. This appears to be an important clinical co-morbidity and the 
mechanisms are poorly understood. The active involvement of the immune 
response was implicated when cytokine therapy itself was shown to induce 
depression in cancer and hepatitis C patients. In experimental models, systemic 
LPS challenge can induce an innate systemic inflammatory response as well as an 
immune response in the CNS. The involvement of cytokines in this process was 
shown by systemic administration of cytokines (TNF-α, IFN-γ) which caused a 
reduction in hippocampal neurogenesis in the brain. An impairment in 
hippocampal neurogenesis has been implicated in depression, cognitive decline 
and depressive-like behaviour in humans and in animal models. However, there 
are very few studies that have investigated the effects of peripheral 
inflammation on hippocampal neurogenesis in chronic inflammatory disease 
models. An investigation of this may lead to better understanding of depression 
in chronic inflammatory diseases, leading to an evidence based approach to 
treatment.  
Therefore, the hypothesis of this project is that: 
‘Peripheral inflammation and cytokines associated with Rheumatoid Arthritis 
affect central production of inflammatory mediators in the brain which in 
turn impair hippocampal neurogenesis. This may lead to cognitive decline 
and mood disorders often seen in arthritis patients.’ 
In order to test this hypothesis, the aims of this project are:  
Preamble: Rheumatoid Arthritis is one of the most studied chronic inflammatory 
diseases associated with psychiatric disorders. The major aim of this project is 
to investigate evidence of brain inflammation and changes in hippocampal 
neurogenesis in collagen induced arthritis (CIA), a well-established murine model 
of RA.  
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Several experimental approaches have been conducted using this CIA model in 
order to address this general question, with the following specific aims: 
1. To investigate changes in central production of inflammatory mediators in 
the brain, which may be associated with peripheral joint inflammation in 
arthritis. We determined changes in protein concentrations and mRNA 
expression levels of inflammatory mediators in brains of CII immunized mice 
compared with control mice.  
2. To investigate the association between peripheral inflammation and central 
production of inflammatory mediators. We determined longitudinal changes 
in serum of inflammatory mediators along with longitudinal changes in 
protein and mRNA concentrations of inflammatory mediators in brains CII 
immunized mice. An extended aim of this experiment included providing 
additional information of brain immune activation and the interplay between 
inflammatory mediators in the brain of CII immunized mice throughout the 
development of disease and clinical signs of arthritis.  
3. To investigate the effect of systemic (peripheral) treatment using the 
recombinant humanised soluble TNF receptor drug etanercept to mediate 
TNF-blockade on central production of inflammatory mediators in brains of 
CII immunized mice during the period of clinical signs of arthritis. We aim to 
determine changes in inflammatory mediators in the brains of etanercept-
treated compared with PBS-treated CII immunized mice and each of these 
with antigen-naive healthy control mice. An extended aim is to confirm that 
changes in inflammatory mediator profiles in brains of CII immunized mice 
were due to peripheral inflammation during arthritis.  
4. To investigate a possible mechanism of associated depression by studying the 
effect of peripheral inflammation on hippocampal neurogenesis. We aim to 
analyze changes in hippocampal neurogenesis in CII immunized mice by 
determining changes in the number of DCX-positive neurons as a marker of 
neurogenesis. To confirm that any changes in hippocampal neurogenesis were 
a result of peripheral inflammation, we aim to investigate the effects of 
etanercept on changes in hippocampal neurogenesis in CII immunized mice.  
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2.1  General reagents & buffers 
2.1.1  Materials and reagents 
General Chemicals: All chemicals were purchased from Sigma-Aldrich (Poole, 
Dorset, UK) or Fisher Scientific (Loughborough, Leicestershire, UK), unless 
otherwise indicated.  
Plastics:  Plastics used for quantitative PCR assays and nuclease free centrifuge 
tubes were purchased from Applied Biosystems (Warrington, UK), Fisher 
Scientific (Leicestershire, UK). ELISA plates were purchased from Thermo 
Labsystems (Cheshire, UK) 
Gelatin-coated slides: Gelatin-coated slides were prepare by dipping glass slides 
(VWR International, Ltd, Leighton Buzzard, UK) in a solution consisting of 5 g 
Type I Gelatin (Sigma, Poole, Dorset, UK) and 0.5 g chrome alum (Sigma, Poole, 
Dorset, UK) in 1 litre of water. After leaving to air dry, slides were stored at 4°C 
until required.   
2.2 Buffers and culture media 
0.2 M Phosphate buffer, pH 7.4: 0.2 M phosphate buffer (PB) was prepared by 
mixing 1120 ml Solution A (37.44g NaH2PO in 1200 ml dH2O) and 2880 ml Solution 
B (37.44g Na2HPO in 1200 ml dH2O), and then adjusting the pH to 7.4. PB buffer 
was diluted to 0.1 M with dH2O before use. 
0.3 M Phosphate buffered saline [PBS]: double strength PBS was prepared by 
mixing 200 ml 0.2 M PB buffer with 72g NaCl and 1800 ml dH2O.  
Phosphate buffered saline: PBS was purchased from Invitrogen (Paisley, UK).  
Tris-acetate-EDTA (TAE) buffer: 50x stock solution of TAE was prepared by 
dissolving 242g of Tris base in 750 ml dH2O. The solution was then mixed further 
with 57.1 ml glacial acetic acid and 100 ml 0.5 M EDTA (pH8). The final volume 
was then made up to 1000 ml with dH2O. This stock buffer was then diluted 1:50 
with dH2O before use.  
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ELISA wash buffer: wash buffer consisted of PBS and 0.05% Tween 20.  
4% paraformaldehyde in 50 mM phosphate buffer: 100 ml of 37-40% 
formaldehyde, 6.5g Na2HPO4   and 4g NaH 2PO4 were mixed in 900ml distilled 
water.  
2.3 In vitro procedures  
2.3.1 Animal welfare  
All animals were maintained in the pathogen-free facilities of the Joint Research 
Facility (JRF), and the Clinical Research Facility (CRF) at the Biological Services 
of the University of Glasgow. All procedures were conducted under project 
licences approved by the United Kingdom Home Office and in accordance with 
the Animal (Scientific procedures) Act 1986.  
2.3.2 Mice  
Male DBA/1 mice: Male mice weighing 20g were purchased from Harlan 
Laboratories Inc. (Bicester, Oxon, UK) at approximately 8 weeks of age and were 
kept in quarantine for one week before experimental procedures.  
All mice were culled according to a licenced schedule 1 method.  
2.3.3 Induction of collagen-induced arthritis in DBA1 mice 
Preparation of collagen in Freund’s complete adjuvant: 
CIA (collagen-induced arthritis) is a commonly used experimental animal model 
of arthritis since it shares several similarities in pathology and/or pathogenesis 
to that of RA disease in humans. This concept of CIA pathogenesis was first 
applied in the rat model (Trentham et al., 1977), and subsequently in 
susceptible strains of mice (Courtenay et al., 1980). In our study, we chose to 
induce arthritis using collagen in DBA/1 mice (H-2q) since it is considered to be 
the most susceptible and most widely used strain (Inglis et al., 2008). To induce 
arthritis, male 8-week-old DBA/1 mice (Harlan, Bicester, Oxon, UK) weighing 20 
g were immunized with Type II bovine collagen (MD Biosciences, St.Paul, MN, 
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USA). Briefly, this involved preparation of 2 mg/ml type II bovine collagen 
dissolved in 0.05 M glacial acetic acid overnight at 4°C. To make a final 
concentration of 1 mg/ml, the collagen was emulsified with an equal volume of 
4 mg/ml Complete Freund’s Adjuvant (CFA) (MD Biosciences, St.Paul, MN, USA). 
The collagen /CFA emulsion was prepared on ice using a hand-held homogenizer 
freshly on the day of immunization (day 0).  
The stability of the emulsion was tested by adding one drop of the emulsion into 
a beaker of water. If the emulsion is stable, the drop will remain intact. If the 
emulsion spreads onto the water surface, then the emulsion is not stable, and 
the preparation should be re-emulsified. 
Experimental arthritis model: 
Mice were sensitised on day 0 and challenged on day 21. From day 17 onward, 
mice were examined every 2 days for signs of arthritis. In detail, on day 0, the 
area at the base of the tail of each mouse was shaved with clippers and the skin 
was sterilized with 70% ethanol. The emulsion of collagen/CFA was transferred 
to a 1ml plastic syringe fitted with a gauge 26 needle. Each mouse was injected 
intradermally with a sensitisation dose of 50 µl of collagen/CFA emulsion at 
approximately 1-2 cm from the tail base. A whitish bolus beneath the dermis 
should be visible. 50ul ul of the collagen/CFA emulsion was administered at both 
side of the tail base so that each mouse received a total of 100 µg of collagen. 
Mice were monitored daily for any signs of local ulceration. The second collagen 
challenge immunization was conducted on day 21. This consisted of 200 µg of 
bovine collagen in 200 µl of PBS injected intra-peritroneally into each mouse 
Figure 2.1.  
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Figure 2.1 Summary of the CIA experimental procedure  
The total experimental duration was 6 weeks. The animals were immunized (sensitised) with 
type II collagen (CII) + CFA at the beginning of the experiment and boosted (challenged) with 
type II collagen (CII) + PBS 3 weeks later. The signs of arthritis were monitored from day 17 
after immunization onwards. Details in the text above. 
Evaluation of arthritis 
CII immunized mice usually developed signs of arthritis around day 19 after 
immunization, but these were monitored from day 16 after immunization 
onwards. Two clinical evaluations were used to measure the severity of joint 
inflammation in arthritic mice; clinical arthritic score and paw thickness 
measurement. The arthritis severity in all CIA experiments was verified 
independently by expertises including Dr. Darren Asquith, Mr. Maurice Dixon and 
Dr. Bernard Leng. 
A. Clinical arthritic score; Paw inflammation of arthritic mice was monitored 
using a subjective scoring method. Individual paws were assigned a score based 
on the criteria shown inTable 2.1. The scores of each paw were summed, giving 
a maximum severity score of 16. The mean arthritis index is the sum of the score 
of all mice divided by the number of mice in each group.  
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Severity score Appearances Description 
 
Score 0; Normal 
 
 
Score 1; 
inflamed digits 
 
Score 2; 
Erythema 
 
Score 3; 
Erythema plus 
swelling 
 
Score 4; 
ankylosis plus 
loss of function 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
No inflammation 
 
 
 
Definite redness and swelling 
limited to individual digits 
("sausage digits"). 
 
 
Moderate redness and swelling of 
ankle and wrist with swelling of 
one or more digits. 
 
Severe swelling and erythema 
extending over whole paw/joint 
including digits. 
Maximally inflamed paw or 
ankylosed paw. If the paw is 
ankylosed, the mouse cannot grip 
the wire top of the cage using 
front paws or walk up a cage lid 
held at a 45 degree angle. 
Table 2.1 Clinical scores of C57BL/6 mice with CIA  
Images were taken from (Inglis et al., 2008) and (Rosloniec et al., 2010) by kind permission 
of the Editor of Nature Protocols and Current Protocols. The scores of each mouse were 
summed, giving a maximum severity score of 16. 
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B. Paw thickness measurements; Paw thickness measurements were used as an 
objective measure of arthritic swelling to confirm the subjective clinical 
arthritic score. Mice were held by the scruff of the neck and paw thickness was 
measured with a dial calliper (Kroeplin, Munich, Germany). Mean paw thickness 
index is the sum of the paw thickness of all mice divided by the number of mice.  
2.3.3.1  Preparation of paws for H&E histological analysis 
2.3.3.1.1  Paw tissue processing  
Mouse paws were dissected just above the ankles and the skin and the toes were 
removed for better penetration of fixation buffer into the tissue. The joints 
were transfer to a universal container with 7 ml of 4% paraformaldehyde in 50 
mM phosphate buffer. After fixation for 72hr, joints were then decalcified using 
a 5 – 10% solution of nitric acid in distilled water for 2-3 weeks with a daily 
change of solution. After decalcification, mouse decalcified joint tissues were 
transferred to 70% ethanol and embedded in paraffin. Paraffin-embedded tissues 
were cut to 6 µm using a microtome (Bright lnstrument Co Ltd, Huntingdon, UK) 
which produced a continuous paraffin wax ribbon of sections. To separate 
individual sections, the ribbon of sections was floated onto a flotation water 
bath set at 40ºC and each section were separated using a scalpel blade and 
transferred onto a charge slide (Superfrost plus, VWR International, Ltd, 
Leighton Buzzard, UK).  Slides were air dried on a hotplate (Raymond A Lamb 
Hotplate, Thermo Labsystems, Cheshire, UK) at 55ºC for 30 minutes. The slides 
were then stored at 4ºC until required. 
2.3.3.1.2  Haematoxylin and Eosin immunohistochemistry 
Haematoxylin and Eosin (H&E) immunohistochemistry is a standard histological 
method. Haematoxylin is a blue basic dye binding to negatively charged DNA or 
RNA, which is commonly used for nuclear staining. Eosin is a pink acid dye that 
binds to positively charged cell elements such as mitochondria or other 
cytoplasmic elements.  
The slides were put into an oven (GenLab, Cheshire, UK ) at 60°C for 2-3 min to 
melt the wax and were re-hydrated following these re-hydration steps; 
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          Dewax in Xylene  - 3 minutes x 2 
 100% Alcohol (Ethanol) - 3 minutes x 2 
 90% Alcohol   - 3 minutes x 2 
 70% Alcohol   - 3 minutes x 2 
 Running Water   - 3 minutes 
Sections were dipped in Harris Haematoxylin (Sigma, Poole, Dorset, UK) for 2 
minutes and in running water for 3 minutes to remove excess stain. Slides were 
then counter stained with 1% Eosin (Sigma, Poole, Dorset, UK) for 2 minutes and 
excess stain was washed off in running water. Finally, sections were dehydrated 
following these dehydration steps; 
          70% Alcohol   - 30 seconds 
 90% Alcohol   - 1 minute 
 100% Alcohol   - 3 minute x 2 
 Xylene   - 3 minutes x 2 
Sections were mounted in DPX (VWR, UK) and a cover slip (VWR, UK) using a 
Pasteur pipette. After drying overnight, all the sections were examined by 
microscopy.  
2.4 Collection of serum from mice and processing of 
brain tissue for gene and protein analysis  
Mice were terminally anesthetized with a halothane:oxygen mixture. Once 
anaesthetised, the thoracic cavity was opened and the blood collected by 
cardiac puncture.  The blood was allowed to coagulate for 1hour at room 
temperature, and the serum was separated from blood by centrifugation (3,000 
rpm for 30 minutes). The serum was collected and stored at -80° C for later 
analysis. 
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The brain was removed and dissected bilaterally across the midline. The right 
hemispheres were snap frozen immediately in liquid nitrogen and stored at -80 
°C. The left hemisphere of each brain was homogenised and the soluble 
component was separated by centrifugation (3,000 rpm for 30 minutes) and 
stored at -80°C for subsequent protein analysis. The right hemisphere of each 
brain was processed for RNA extraction and gene expression analysis as detailed 
below.  
2.5  cDNA synthesis by reverse transcription (RT)-
PCR  
Reverse transcription and polymerase chain reaction (RT-PCR) is a two-step 
protocol. Firstly converting extracted RNA to stable cloned (c)DNA using reverse 
transcriptase enzymes. Secondly the PCR creates an equivalent number of the 
more stable cDNA molecules which are then analysed by Real-time PCR (Gallo, 
1972).  
In detail, cDNA was sythesized from typically 1.5 µg of total extracted RNA using 
a commercial Superscript II® reverse transcriptase kit (Invitrogen, Paisley, UK) as 
per manufacturer’s instruction. The following components were set up in a 1.5 
nuclease-free microcentrifuge tube: 
Component Volume per reaction 
 
500 µg/ml Oligo(dT)12-18 
1.5 µg of total RNA 
10 mM dNTP mix 
DEPC* water 
 
1 µl 
X µl 
1 µl 
Up to 10 µl 
 
* This is water treated with 0.1% v/v diethylpyrocarbonate (DEPC) for at least 1 
hour at 37°C to inactivate ribonucleases, and then autoclaved to inactivate 
traces of DEPC. 
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To denature the RNA, the mixture was heated at 65°C for 5 minutes in the 
heating block of a polymerase chain reaction (PCR) machine (Eppendorf® 
Mastercycler Gradient PCR, Hamburg, Germany) and quick chilled on ice for 1 
minute. A reverse-transcriptase (RT) master mix was prepared to contain the 
following components (supplied in the kit) per reaction; 
Component Volume per reaction 
 
5X First-Stand Buffer 
0.1 M DTT 
50 mM MgCl2 
40 units/µl RNase OUTTM ( RNase inhibitor) 
 
4 µl 
2 µl 
2 µl 
1 µl 
 
9 µl of master mix was added to each denatured RNA sample and incubated for 2 
minutes at 42 °C. 1 µl of 200 units of Superscript II was added and incubated for 
50 minutes at 42 °C followed by a 15-minute inactivation step at 70 °C. cDNA 
was then diluted 1: 5 with DEPC water and stored at -20°C until use in real-time 
PCR analysis of required target gene. 
2.6 Real-time PCR using SYBR Green I dye 
Real-time RT-PCR is widely used to determine biologically relevant changes in 
mRNA transcription levels in cells and tissue (Nolan et al., 2006). Instead of 
mRNA levels being directly measured, real-time PCR measures complementary 
DNA (cDNA) because this is more stable molecule than mRNA (Nolan et al., 
2006). Real-time PCR employs fluorescent reporter dyes to bind with the cDNA 
amplification products of the PCR reaction (Nolan et al., 2006). Therefore, the 
fluorescence signal increases as the dye binds to the increasing amount of cDNA 
in the reaction tube. In real-time PCR, we determine the number of PCR cycles 
at which the increased fluorescent signal (and therefore cDNA) first crosses a 
pre-determined threshold background fluorescence. The point at which the 
fluorescent signal first rises above the baseline signal is called the threshold 
cycle (Ct). Therefore, the greater the copy number of initial target genes at the 
beginning of the assay, the fewer threshold cycles are required for the 
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fluorescence to reach the threshold level of detection (Nolan et al., 2006). 
There are several approaches to monitor PCR products, including dyes that bind 
to the double-stranded DNA (i.e. SYBR® Green) or sequence specific probes (i.e. 
Molecular Beacons or TaqMan® Probes). Both detection approaches are 
potentially rapid and sensitive (Nolan et al., 2006). However, their principles of 
detection and optimisation are different, resulting in different advantages and 
disadvantages. In our study, we used the simple, inexpensive SYBR-Green system 
to detect the PCR product as it accumulates during Real-time PCR cycles.  
2.6.1 Primer design and optimization 
Real-time PCR reaction consists of multiple cycles of denaturation, anneling and 
extension steps. This requires a pair of the specific oligonucleotide primers that 
bind to the cDNA template as a start point of real-time PCR reaction. Optimal 
design of the PCR primers is an important initial step for accuracy and specific 
quantification of the real-time PCR assay. There are several considerations when 
designing real-time PCR primers for the SYBR-Green I system. The annealing 
temperature is restricted to 58–60°C, which corresponds to the optimal working 
conditions for the Taq DNA polymerase enzyme and the length of the PCR 
product is set between 80 and150 bp. In addition, Forward & reverse primers 
should have similar Tms (ideally within 0.5
oC of each other but no more than 1 oC 
apart) for the greater PCR product yield. Finally, to avoid primer dimmers, the 
primers should have low or no self complementarity (Ponchel et al., 2003). All 
primers used in this project were designed using Primer3 software (available 
online @: http://www.broad.mit.edu/cgi-bin/primer/primer3_www.cgi/).   
Primer specification: 
- between 18 and 20 base-pairs (bp) in length 
- between 45 and 55% GC content (50% optimal) 
- melting temperatures (Tms) between 59.5°C and 61°C 
- Max self complementarity:  3 
- Max 3’self complementarity:  1 
- product size between 100-140 base-pairs (bp) in length 
- BLAST analysis (http://www.ncbi.nlm.nih.gov/BLAST/) was used to 
ensure that primer sets amplify the genes of interest with high specificity. 
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The primers used are listed in Table 2.2. 
Genes Forward Reverse 
mouse IL-1β 5’-GTGTAATGAAAGACGGCACA-3’ 5’-AGAAACAGTCCAGCCCATAC-3’ 
mouse IL-1α 5’-GATGTCCAACTTCACCTTCA -3’ 5’-ACAAACTTCTGCCTGACGA -3’ 
mouse IL-2 5’-CTGAGCAGGATGGAGAATTACAG-3’ 5’-CGCAGAGGTCCAAGTTCATC-3’ 
mouse IL-4 5’- CGGCATTTTGAACGAGGT-3’ 5’- TTGGAAGCCCTACAGACGAG-3’ 
mouse IL-5 5’- GCTTCCTGCTCCTATCTAACTTCA-3’ 5’- TCAACCTTCTCTCTCCCCAAG-3’ 
mouse IL-6 5’-TTCCATCCAGTTGCCTTCTT-3’ 5’-ATTTCCACGATTTCCCAGAG-3’ 
mouse IL-10 5’- CAACATACTGCTAACCGACTCCT-3’ 5’- TGGGGCATCACTTCTACCA-3’ 
mouse IL-12 5’- ATGTGGAATGGCGTCTCTGT-3’ 5’- AGTTCAATGGGCAGGGTCT-3’ 
mouse IL-13 5’-AGGGAGGAGGGTTGAGGA-3’ 5’-TTTCTGTAGGGATGGGATGG-3’ 
mouse CCL1 5’-ATGGGCTCCTCCTGTCCT-3’  5’-TCTCTGGTGCTGGGATGG-3’ 
mouse CXCL1 5’-AACCGAAGTCATAGCCACACTC-3’  5’-TGGGGACACCTTTTAGCATC-3’ 
mouse CCL2 5’-CTCACCTGCTGCTACTCATTCA-3’  5’-CCATTCCTTCTTGGGGTCA-3’ 
mouse CXCL2 5’-AAGTTTGCCTTGACCCTGAA-3’  5’-TCTCTTTGGTTCTTCCGTTG-3’ 
mouse CCL3 5’-CAGCCAGGTGTCATTTTCCT-3’  5’-CAGGCATTCAGTTCCAGGTC-3’ 
mouse CXCL10 5’-GCTCAAGTGGCTGGGATG-3’ 5’-GAGGACAAGGAGGGTGTGG-3’ 
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mouse IFN-g 5’-ATTGCGGGGTTGTATCTGG-3’ 5’-TCCTCCCATCAGGAGCAC-3’ 
Genes Forward Reverse 
mouse TNF-α 5’-CCCTTTACTCTGACCCCTTT-3’ 5’-AACCTGACCACTCTCCCTTT-3’ 
mouse FGF2 5’- CGTCAAACTACAACTCCAAGCA-3’ 5’- CAGCAGCCGTCCATCTTC-3’ 
mouse VEGF 5’-CCTCGTCTCCTCTCCTTACCC-3’ 5’-CACTCACACACACAGCCAAGT-3’ 
mouse GAPDH 5’-AACCTGACCACTCTCCCTTT-3’ 5’-TATTATGGGGGTCTGGGATG-3’ 
Table 2.2 Primer sequences used for the amplification of brain tissue cDNA  
All primers were purchased at Vhbio (www.vhbio.com) and diluted at the appropriate 
dilution (Vhbio, Gateshead, UK). 
2.6.2 Optimizing primers for SYBR Green real-time PCR 
The optimization of the primer concentration is essential for sensitivity, 
specificity, reproducibility of the real-time PCR assay. Each set of primers work 
efficiently under different concentration conditions. Inappropriate primer 
concentrations in the real-time PCR assay results in non-specific primer binding 
and the creation of primer-dimers. For optimization, a primer titration was 
performed from 50 to 12.5 µM final concentration using conventional PCR. cDNA 
synthesized from a tissue or cell line known to express the gene(s) of interest 
was used as the template for testing the specificity of the primer. The mRNA 
from various cell types and tissue expressing genes of interest was used to 
generate cDNA control templates for optimizing primers as listed on Table 2.3.   
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Mouse cDNA template sources Mouse Primers 
macrophages  IL-1β,  IL-1α,  IL-10,  IL-12,  TNF-α,  GAPDH                                                 
LPS–stimulated macrophages  IL-6,  CCL1,  CXCL1,  CCL2,  CXCL2,  CCL3, 
CXCL10                                                                                                           
Th1 cells   IL-2,  IFN-g, IL-12                                                              
Th2 cells  IL-4,  IL-5,  IL-13, IL-10                                                                               
NIH3T3 fibroblast  FGF2,  VEGF                                                         
Table 2.3 Control tissue used to test specificity of primers 
 
Conventional PCRs for the validation of the specificity of the designed primers 
against target genes were performed in 50 µl reactions with the addition of 1.5 
mM MgCl2 and employing ReddyMix
TM PCR Master Mix (Abgene, Epsom, UK).  
Reactions were performed using the PCR machine (Eppendorf® Mastercycler 
Gradient, Hamburg, Germany) under the following conditions: One cycle at 94°C 
for 10 min, and 35 cycles of 94°C for 20s, 59°C or 60°C or 61°C for 20s, and 72°C 
for 20s, one cycle of 72°C for 10 min. The PCR product were analysed by running 
in 2% agarose gels containing ethidium bromide (Sigma, Poole, Dorset, UK) and 
visualizing for a single specific band and the absence of primer dimer products.  
2.6.3 Agarose gel electrophoresis 
PCR products were visualised in 2% w/v agarose gels. Agarose gels were prepared 
by heating 3 g agarose (Invitrogen, Paisley, UK) in 150 ml Tris-acetate-EDTA (TAE 
buffer) in a microwave at full power for approximately 5 minutes until the 
agarose was completely dissolved. Approximately 5 µl ethidium brominde 
(Sigma, Poole, Dorset, UK) were added and mixed by swirling the flask. The 
melted agarose was then poured into a gel tray, the ends of which were sealed 
with two layers of tape. A well-comb was placed into the melted agarose to 
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form wells large enough to accommodate at least 25 µl. When the gel solidified, 
the comb and the tapes were removed and the gel was placed into an 
electrophoresis chamber containing TAE buffer. 25 µl of the PCR products were 
load into each well of the agarose gel next to a well containing a size-marker 1 
Kbp DNA ladder (Invitrogen, Paisley, UK). The gel electrophoresis was run at 
100V for 40 minutes. DNA bands were visualized under UV light in a lightbox (Gel 
logic 200 imaging system, NY, US) and images recorded using Kodak camera and 
software. 
2.6.4  Generation of a DNA standard for real-time polymerase 
chain reaction 
A known real-time PCR standard is required as a positive control as well as a 
reference for measuring the absolute copy number of a transcript in an unknown 
test sample. DNA plasmids containing cloned target sequences are used as 
standards in quantitative PCR. These constructions of DNA plasmids were 
generated by cloning DNA fragments that contain genes of interest into a 
commercial TOPO vector (Invitrogen, Paisley, UK) using the manufacturer’s 
instructions. Briefly, PCR products generated using the QPCR primers were 
isolated and purified from the agarose gel by the QIAquick PCR Purification Kit 
according to manufacturer’s instructions (Qiagen, West Sussex, UK). 4 µl PCR 
product, 1 µl salt solution (Invitrogen, Paisley, UK), and 1 µl PCR4 TOPO vector 
were mixed together. 3 µl of the mixture was added to a preparation of 
competent bacteria containing TOPO vector. Following incubation on ice for 30 
minutes, the bacterial preparation was subjected to heat shock at 42°C for 30 
seconds, and then 2 minutes on ice. 300 µl of supermedium (Invitrogen, Paisley, 
UK) was added into the mixture of bacteria with TOPO vector before 15 minutes 
incubation in a shaking incubator (Innova 4400, New Brunswick, Cambridge, UK) 
for 40 min. 200 µl of the mixture of bacteria with TOPO vector was plated by 
spreading onto a selective growth medium in a petri dish; i.e. LB agar containing 
50 µg Ampicillin (Sigma, Poole, Dorset, UK) under aseptic conditions, and 
incubated overnight at 37°C. Next day, a single typical colony containing TOPO 
vector was picked and inoculated into 5 mL of LB broth and incubated for 16 
hours at 37°C in a shaking incubator. Cells were harvested by centrifugation at 
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1200 rpm for 4 minutes. Plasmids was isolated and purified by Qiaprep Spin Mini-
Prep Kit according to manufacturer’s instructions (Qiagen, West Sussex, UK).  
2.6.5  Plasmid verification and quantification  
The existence of the genes of interest in the resulting DNA fragments can be 
verified by checking the length of the DNA fragments obtained after digestion 
with specific restriction enzymes. The digestion scheme was as follows:  
10 µl aqueous solution containing DNA plasmid, 7.5 µl DEPC water, 0.5 µl ECoRI 
enzyme (Invitrogen, Paisley, UK) and 2 µl 10 X buffer H (Invitrogen, Paisley, UK) 
were mixed together and incubated in a 37°C water bath for 1 hour. Agarose gel 
electrophoresis was used to confirm the length of the DNA fragments separated 
from cut vectors.  
The concentration of plasmids was measured by UV spectrophotometry 
(Eppendorf® BioPhotometer, Hamburg, Germany) at 260 nm wavelength in 
µg/ml. Plasmid copy numbers were then calculated using the following 
formulae, with IL-1β used as an example: 
The PCR® 4-TOPO® vector containing a DNA fragment of the IL-1β gene was 
4,500 bp in size and had a concentration of 2.059 x 10-8 g per µl.  
Copies of molecule per mole = 6.023 x 1023 (Avogadro’s constant) 
Average molecular weight for double stranded nucleotide = 660 Daltons 
Molecular weight of double stranded DNA = 660 Daltons * PCR product 
length  
                = 660 * 4500 bp 
                                                                      = 2,970,000 Daltons 
Copies DNA per µl  = (6.023 x 1023 * mass per µl) / Molecular weight DNA 
   = (6.023 x 1023 * 2.059x10-8) / 2,970,000 Daltons 
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   = 4,175,541,077 copies per µl 
2.6.6  Real-time PCR assay 
Absolute quantification was used to measure the amount of transcription of the 
gene of interest by real-time PCR assay. The absolute quantification uses a 
standard curve to calculate the absolute number of transcripts in unknown 
samples. The standard curve for the required target gene was generated from a 
10-fold serial dilution of DNA plasmids containing cloned target sequences as the 
template described in 2.5.5.  The template was diluted in DEPC water to 
generate the dynamic range between 108 and 102 copies in a volume of 500 µl. 
The amount of cDNA (and thereby the amount of tissue mRNA) is measured by in 
index called the cycle threshold (CT). This is the number of denaturing and re-
annealing cycles required for the fluorescent signal to exceed the background or 
‘threshold’ level; ie more mRNA will require fewer cycles for the fluorescent 
signal to exceed background levels. The values in each dilution were measured 
in triplicate using a real-time QPCR with the primer sets to generate the 
standard curves for the gene of interest. This range of the template 
concentration resulted in a Ct of between 20 and 32 since a 10-fold difference in 
concentration corresponds to 3.3 cycles. Standard curves were run at least once 
for every primer pair in order to check the efficiency of the real-time PCR assay.  
A graph is made of the standard curve by plotting the Ct values on the y axis and 
the log of the number of copies on the x axis.  The slope of the line of this plot 
will give the efficiency of the reaction according to the equation E=10-(1/slope)-1.  
A reaction of 100% efficiency represents a slope of –3.33 (Nolan et al., 2006).  
All amplification reactions of samples or standards were performed in triplicate. 
Each reaction consists of components listed in Table 2.4; 
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Component Stock concentration Volume to add 
for single 20 µl 
reaction 
DEPC water  8 µl 
Power SYBR Green 
PCR Master Mix  
X2 10µl 
Primers; 
Forward primer 
Reverse primer 
 
50µM, 25µM, 12.5µM 
 
0.5 µl 
0.5 µl 
Sample/standard 1:5 diluted sample cDNA synthesis or 
the template concentration 
containing 108 and 102 copies 
 
2 µl 
Table 2.4 List of components in the mastermix used for real-time PCR assay  
A working batch of mixture consisted of water, Power SYBR Green PCR Master Mix (Applied 
Biosystems, Warrington, UK) and primers (VHBio, Gatehead, UK) was made sufficient for all 
real-time PCR reactions. To prepare a master-mix in triplicate for each sample, 6µl of cDNA 
or standard was added in a “mixing” well of a nuclease-free 24-well plate (Thermo 
Labsystems, Cheshire, UK), along with 54.5 µl mixture. Approximately, 19.8 µl of this 
master-mix was added to each well of a 96-well optical reaction plate (MicroAmp, Applied 
Biosystems, Warrington, UK). The plate was sealed by an adhesive sealing film and gently 
centrifuged to ensure that the components settle to the bottom of the wells. The plate assay 
was run on a real-time PCR instrument (ABI PRISM 7900HT Sequence Detection System, 
Applied Biosystems, Warrington, UK] using the protocol in Table 2.5.  
 Denaturation 10 seconds at 95°C 
40 cycles Annealing 15 seconds at 95°C 
 Extension 1 min at 60°C. 
Table 2.5 Conditions for real-time PCR protocol 
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A melting curve analysis was performed with a temperature gradient of 0.1°C/s 
from 70 to 95°C following each PCR run to identify the specific amplified 
product and distinguish them from primer dimers and other small amplification 
artifacts. The principle of melting curve analysis is that the two strands of 
double-standed DNA separate or “melt” apart at the specific temperature, 
depending on both its size and the energy required to disrupt the different 
hydrogen bonds of its nucleotide composition. This temperature is called the 
melting temperature (Tm). During the melt curve analysis, each sample was 
heated gradually from the user defined temperature below the Tm of the 
products to a temperature above their melting point. Within this temperature 
gradient, fluorescent dye released by the double-stranded DNA product at the 
Tm is detected by the real-time machine and the accurate Tm data reported for 
every single amplified product. The melting peak of a single amplified product 
appears as a single sharp peak at the Tm, whereas peaks of small primer dimers 
appear at lower temperatures (Nolan et al., 2006).  
 
2.6.7 Normalization of cDNA samples 
Although real-time RT-PCR is considered to be an efficient and sensitive 
approach to determine biologically relevant changes in gene expression levels, 
technical as well as biological variation can cause variability of the data. Various 
errors resulting from inter-sample variability in RNA degradation during storage, 
variation introduced during RNA isolation and variation during cDNA synthesis, 
can cause unavoidable variation in the amount of the final cDNA product 
(Huggett et al., 2005). One common approach to minimize these errors is to 
normalize the cDNA sample using housekeeping genes as internal comparative 
standards. Housekeeping genes are typically constitutive genes that are 
expressed at a relatively stable level. Since these housekeeping genes are 
essential for cell metabolism, but not cell differentiation, it is therefore 
commonly assumed that the transcription of the housekeeping gene is 
unaffected by experimental conditions (Suzuki et al., 2000). There are several 
housekeeping genes that have been used as reference genes for real-time PCR 
assays. In our study, a housekeeping gene GAPDH (glyceraldehyde-3-phosphate 
dehydrogenase) was used as the reference gene for normalization. GAPDH is one 
of the most commonly used housekeeping genes that has been reported to be 
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appropriate for certain experimental situations (Andersen et al., 2004). The 
gene expression level of each sample was normalized against a ratio of its 
GAPDH content in relation to the 75th percentile of GAPDH levels of all samples 
assayed (an example of the normalisation process is shown in Table 2.6). The 
75th percentile of GAPDH gene copy number is calculated from GAPDH levels of 
all samples assayed and used as a reference to avoid a false calculation resulting 
from the percentage of gene level expression below the standard curve. This is 
because real-time PCR also reports an intensity value although the gene is below 
the standard range. These intensity values are considered as background assay 
‘noise’ and are less reliable, and therefore more likely to fall into the lower 
percentile ranking on the array. The difference of each sample calculated from 
the 75th percentile is reliable and the change of gene X levels in the sample is 
on the assumption that the ratio of GAPDH is consistent. Any sample having a 
GAPDH content/75th percentile varying by more than a factor of 2 from the 75th 
percentile was discarded from the analysis due to an assumption of compound 
errors during sample processing.  
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A B C D E 
Sample Name 
Level of GAPDH 
   copies 
 
Level of gene x 
   copies 
  
Ratio to 75th 
Percentile 
(column C/71.25) 
Normalised level of 
gene X 
(column B/D) 
Sample 1 200 800 0.889 225 
Sample 2 1000 4000 4.444 225 
Sample 3 240 900 1.000 240 
Sample 4 200 200 0.222 900 
Sample 5 160 800 0.889 180 
          
  75th percentile 900     
Table 2.6 An example of normalisation using a housekeeping gene to determine levels of 
gene “X”  
Before normalization, sample 2 in column B has a higher value of gene X (1000 copies) than 
sample 4 (200 copies). After normalization, the results show that the level of gene X in 
sample 2 was similar to the other samples. This was due to the high level of cDNA in this 
sample. The opposite situation is seen in the pre-normalised levels of gene X in sample 4 
which appears low, although the actual level is much higher, indicating that there was 
actually only a small amount of cDNA in this sample.  
2.7 Cytokine and chemokine protein expression 
analysis 
2.7.1  Protein extraction from brain tissue  
The snap-frozen brain tissues were thawed, weighed, transferred to tubes on ice 
containing approximately 3.4 ml of T-PER (Fisher Scientific UK Ltd., 
Loughborough, UK), and HaltTM Protease inhibitor cocktail (Fisher Scientific Ltd., 
Loughborough, UK) at a proportion of 1:100 of T-PER stock reagent. The brain 
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tissues were homogenized, incubated at room temperature for 10 minutes and 
centrifuged at 10,000 × g for 10 minutes at 4°C. Supernatants were transferred 
to clean microcentrifuge tubes, frozen at –80˚C and thawed on ice. These 
protein preparations were further analysed for cytokine and chemokine protein 
levels by Luminex and ELISA.  
2.7.2 Normalization of a relative total protein concentration 
using BCA protein assay 
2.7.2.1 Protein assay 
Total protein concentrations in the brain tissue homogenates were determined 
using a BCA protein assay kit (Pierce Biotechnology, Cheshire, UK) according to 
the manufacturer’s instruction. Briefly, the homogenate supernatant samples 
were diluted 1:10 with PBS and quantified in triplicate. BSA was diluted in PBS 
to give concentrations suitable for a standard curve (20-2,000 µg/ml). 25 µl of 
each standard and unknown sample replicate was added into a microplate well 
(Thermo Labsystems, Cheshire, UK). Working Reagent (WR) was prepared by 
mixing 50 parts of BCA reagent A and 1 part of BCA reagent B supplied in the kit, 
followed by adding 200 µl of the WR to each well and mixing thoroughly on a 
plate shaker for 30 seconds. The plate was covered with an adhesive plastic 
plate-cover and incubated at 37°C for 30 minutes. After cooling the plate at 
room temperature, the optical density was measured at 560 nm on a plate 
reader (Dynex Technologies Ltd., Worthing, UK). The test sample protein 
concentrations were generated by interpolation of their optical density to the 
optical density curve of the known protein standards. 
2.7.2.2  Normalization of protein samples 
An example of the calculation used to quantify the concentration of one 
cytokine normalised for the total protein in one brain extract is given below: 
The mean OD value of triplicate measurements of a protein extract of brain 
tissue from a wild type mouse (WT 1) is 0.464, which corresponded to a protein 
concentration of 708.7 µg/ml.  
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However, this is the concentration of a sample at 1:10 dilution, therefore the 
concentration of the neat sample is 10 x 708.7 µg/ml = 7087µg/ml. 
50 µl of each sample is used for one multiple cytokine Luminex assay.  
1,000 µl (1 ml)    contains     7087.03                           µg total proteins 
     50 µl              contains     50 x 7087.03  =  354.35   µg total protein 
                                               1,000 
According to the Luminex result, for example, the mean protein concentration 
of triplicate measurements of, for example, IL-13 is 55.03 pg/ml  
1,000 µl   contains          55.03                      pg  IL-13 protein 
     50 µl   contains         50 X 55.03   =  2.75  pg  IL-13 protein                            
                                       1,000  
Based on these calculations, a 50 µl solution of WT 1 mice brain proteins 
contains 354.35 µg total proteins and 2.75 pg for IL-13.                 
354.35 ug total protein   contains    2.75  pg  IL-13 
1,000 ug total protein  contains  1,000 X 2.75  = 7.765 pg IL-13/mg total brain 
protein                                         354.35 
In summary, 1 mg total brain proteins of the WT1 sample contains 7.765 pg IL-
13.  
2.7.3 Measurement of multiple cytokines using a suspension 
bead array assay and a Luminex platform 
 
Quantifying the concentrations of many cytokines and chemokines in a small 
volume of biological fluid is now possible using a muliplex system.  Multiple 
cytokines (TNFα, IFNγ, IL-1α, IL-1β, IL-2, IL-4, IL-5, IL-6, IL-10, IL-12 [p40], IL-12 
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[p40/ p70], IL-13, IL-17), chemokines (IL-8, IP-10, KC, MCP-1, MIG, MIP-1α, MIP-
1β, MIP-3β, RANTES), and growth factors (FGF basic, GM-CSF, PDGF-BB, VEGF) 
were quantified in the soluble extracts from brain tissue and in mouse serum 
using a mouse 20-plex Luminex kit (Invitrogen, Paisley, UK) on a Bio-Plex system 
(Bio-Rad Laboratories Ltd. Hemel Hempstead, UK), according to the user 
manual. The steps are detailed as follows: 
2.7.3.1  Plate preparation for Luminex assay 
A 96-well filter bottom microplate was used for the luminex assay. 15 ml 
working solution concentrate x 20 was diluted with 285ml of deionized or 
distilled water. This diluted working solution was used to pre-wet the filter 
bottom of the plate (100 µl/well) and the content in the wells was removed by a 
vacuum pump.  
2.7.3.2 Preparation of beads 
The principal of the Luminex assay is based on a bead-based suspension array 
using capture antibodies against an analyte immobilized onto a microsphere 
(bead). Captured analytes (including standards of known analyte concentration, 
control specimens and unknown test samples) are detected mostly using the flow 
cytometry principle. 2.5 µl of capture bead stock solution was resuspended by 
sonication for 2-3 minutes and then diluted in 2ml of working solution. 200 µl of 
diluted capture beads were pipetted into each well. The fluid containing these 
capture beads was removed through the filter base of the plate using a vacuum 
pump, and the plate was similarly washed twice with working solution. The plate 
was dried by blotting the filter onto paper towel. 50 µl incubation buffer was 
added to each well. This was immediately followed by pipetting 50 µl assay 
diluent to sample wells, but not in the standard wells. 
2.7.3.3 Preparation of standard curve 
The standard curve was generated by using serial dilutions of the kit lyophilized 
standards reconstituted in assay diluent: T-PER reagent (1:1). This was chosen 
because T-PER reagent was used as the diluent for brain tissue homogenates. For 
serum analysis, the standards were diluted in assay diluent buffer provide in the 
kit. A mixture of 50% assay diluent plus 50% T-PER reagent was also used as the 
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blank in this assay. 1 ml of mixture of 50% assay diluent plus 50% T-PER reagent 
was added into the bottle containing the lyophilised kit cytokine standard and 
left for 10 minutes to reconstitute. A series of 1:3 serial dilution standard 
samples was generated by diluting 150 µl top standard from the standard stock 
solution into the first of a series of eppendorf tubes containing 300 mixture of 
50% assay diluent plus 50% T-PER reagent and serially diluted 1 in 3. 100 µl of 
standard and blank was added into standard wells containing diluted antibody-
coated bead complexes and incubation buffer.  
2.7.3.4 Assay procedure and analysis 
50 µl of sample was added into sample wells containing diluted antibody-coated 
bead complexes, assay diluent and incubation buffer. The assay plate was 
covered with tinfoil (to minimise light quenching of the fluorochrome) and 
incubated at room temperature for 2 hours on a plate-shaker to agitate the 
beads. At this first incubation, the test analytes will bind to the capture 
antibodies on the beads. The fluid content in the wells are removed by a vacuum 
pump, followed by 2 washes with working buffer (100 µl/well) and the filter-
bottom of the plate was dried using paper towel. Analyte-specific biotinylated 
detector antibodies were diluted in biotin diluent (1:10), 100 µl of detection 
antibody was added to each well and incubated for 1 hour at room temperature 
on the plate-shaker. During this second incubation, the analyte-specific 
biotinylated detector antibodies recognize their target cytokines that are bound 
to the appropriate beads. The excess fluid contents in the wells were removed 
by a vacuum pump, followed by 3 wash with working buffer (100 µl/well). 
Streptavidin conjugated to the fluorescent protein, R-Phycoerythrin 
(Streptavidin-RPE) was diluted (1:10) in Streptavidin-RPE diluent and add into 
each well (100 µl/well). The plate was then incubated for 30 minutes at room 
temperature on the plate-shaker. During this final incubation, the Streptavidin-
RPE binds to the bionylated detector antibodies linked with immune complex on 
the beads, forming a four-member solid phase sandwich. The excess fluid 
content in the wells was removed by a vacuum pump, followed by 3 wash with 
working buffer (100 µl/well) to remove unbound Streptavidine-RPE. The plate 
was dried by blotting on paper towel and incubated overnight with working 
solution (100 µl/well) at 4˚C. Next day, the beads were analysed with the 
Luminex 100 analyzer instrument (Luminex Corp., Austin, TX). The 
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concentrations of one or more analytes were determined by monitoring the 
spectral properties of the beads and the amount of associated R-Phycoerythrin 
(RPE) fluorescence. The fluorescence was proportional to the concentration of 
the analyte and quantified with reference to the fluorescence of the known 
concentration of the standard curve. 
2.7.4 Enzyme immuno-assay (ELISA) protocol 
Individual concentrations of IL-1α, IL-1β, IL-2, IL-4, IL-5, IL-6, IL-10, IL-12 [p40/ 
p70], IL-13, IL-17, IP-10, KC, MCP-1, VEGF and TNFα were measured using 
enzyme linked immuno-assay (ELISA) in protein preparations from brain tissue. 
The concentrations of antibodies and buffers used for the analysis of each 
cytokine are shown in Table 2.7 and Table 2.8. 
 Chapter 2                                                                                                                              120 
Cytokines Coating buffer Blocking buffer 
& Antibody 
diluents 
Concentration 
of capture 
antibody 
Concentration 
of detection 
antibody 
Streptavidin 
HRP dilution 
Substrate 
Solution 
Standard 
curve 
range 
mouse TNF-α 
Cat # 559603 
BD Bioscience 
0.1 M Sodium 
Carbonate, pH 
9.5 
PBS with 10% 
FBS, pH 7 
1:250 
(50 µl/well) 
1:250 
(50 µl/well) 
1:250 
(50 µl/well) 
TMB 2 ng/ml-4 
pg/ml 
mouse IL-1β 
eBioscience 
ELISA/ELISPOT 
coating buffer  
 
5x Assay Diluent 
 
1:250 
(50 µl/well) 
1:250 
(50 µl/well) 
1:250 
(50 µl/well) 
TMB 4 ng/ml-4 
pg/ml 
mouse IL-2 
Peprotech 
PBS 0.05% Tween -
20, 0.1% BSA in 
PBS 
1 µg/ml  
(100 µl/well) 
0.25 µg/ml  
(100 µl/well) 
1:2000 
(100 µl/well) 
ABTS 8 ng/ml-4 
pg/ml 
mouse IL-4 
Peprotech 
PBS 0.05% Tween -
20, 0.1% BSA in 
PBS 
1 µg/ml  
(100 µl/well) 
1 µg/ml  
(100 µl/well) 
1:2000 
(100 µl/well) 
ABTS 4 ng/ml-4 
pg/ml 
mouse IL-5 
eBioscience 
ELISA/ELISPOT 
coating buffer  
 
5x Assay Diluent 
 
1:250 
(50 µl/well) 
1:250 
(50 µl/well) 
1:250 
(50 µl/well) 
TMB 2 ng/ml-2 
pg/ml 
mouse IL-6 
Peprotech 
PBS 0.05% Tween -
20, 0.1% BSA in 
PBS 
2 µg/ml  
(100 µl/well) 
0.5 µg/ml  
(100 µl/well) 
1:2000 
(100 µl/well) 
ABTS 6 ng/ml-4 
pg/ml 
 mouse IL-12 
Peprotech 
 
         PBS 
0.05% Tween -
20, 0.1% BSA in 
PBS 
1 µg/ml  
(100 µl/well) 
0.25 µg/ml  
(100 µl/well) 
1:2000 
(100 µl/well) 
ABTS 5 ng/ml-
300 pg/ml 
Table 2.7 Cytokine analysis by ELISA.  
Mouse cytokines, chemokines and growth factors were analysed using capture and detection antibody listed above. The capture antibody was diluted in 
appropriate coating buffer and the detection antibody was diluted in the diluent supplied by the manufacturer. The final concentration of each antibody, the 
volume added to each well, and standard ranges are shown.  
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Cytokines Coating buffer Blocking buffer 
& Antibody 
diluents 
Concentration 
of capture 
antibody 
Concentration 
of detection 
antibody 
Streptavidin 
HRP dilution 
Substrate 
Solution 
Standard 
curve 
range 
 
mouse IL-13 
eBioscience 
 
ELISA/ELISPOT 
coating buffer  
 
 
 
5x Assay Diluent 
 
 
1:250 
(50 µl/well) 
 
1:250 
(50 µl/well) 
 
1:250 
(50 µl/well) 
 
 
TMB 
 
2 ng/ml-4 
pg/ml 
mouse CCL2 
eBioscience 
 
ELISA/ELISPOT 
coating buffer  
 
5x Assay Diluent 
 
1:250 
(50 µl/well) 
1:250 
(50 µl/well) 
1:250 
(50 µl/well) 
TMB 4 ng/ml-4 
pg/ml 
 
mouse VEGF 
Peprotech 
PBS 0.05% Tween -
20, 0.1% BSA in 
PBS 
1 µg/ml  
(100 µl/well) 
0.5 µg/ml  
(100 µl/well) 
1:2000 
(100 µl/well) 
ABTS 4 ng/ml-4 
pg/ml 
Table 2.8 Cytokine, chemokines and growth factor analysis by ELISA.  
A mouse cytokine (IL-13), a chemokine (CCL2) and a growth factor (VEGF) were analysed using capture and detection antibody listed above. The capture 
antibody was diluted in appropriate coating buffer and the detection antibody was diluted in the diluent supplied by the manufacturer. The final 
concentration of each antibody, the volume added to each well, and standard ranges are shown.  
 Chapter 2                                                                                                                              122 
The ELISA procedure involved briefly, 96-well microtitre plates (Thermo 
Labsystems, Cheshire, UK) were coated with capture antibody diluted in coating 
buffer at appropriate concentrations according to the manufacture’s 
instructions. The plates were covered with an adhesive plastic cover and 
incubated overnight at 4°C. The coating buffer containing capture antibody was 
removed the next day and the plates were washed 3 times by repeatedly filling 
and emptying the wells with 200 µl wash buffer, and soaking the wells for 5 
minutes in between each wash. Washing was by flicking empty the plate over a 
sink. The remaining drops were removed by patting the plate upside down on a 
paper towel. To block the remaining protein-binding sites in the coated wells, 
200 µl blocking buffer was added into each well and the plates were incubated 
at 37°C for 1 hour. Following 3 further washes as above, 50 µl of protein sample 
were added to each well in duplicate or triplicate in different experiments. For 
quantitative data, the optical density of the unknown test samples was 
compared against the optical density of a standard curve consisting of serial 
dilutions of a known quantity of the cytokine to be assayed. Standards in 
duplicate, and blank wells with no cytokine were run with each plate to ensure 
accuracy. The plates were covered with adhesive plastic covers and then 
incubated on the shaking machine for 2 hours at room temperature. The samples 
were removed and the plates were washed 5 times, followed by adding 50 µl of 
diluted detection antibody in blocking buffer and incubation at room 
temperature for 1 hour. The detecting antibody was an antibody that specifically 
recognised the cytokine to be measured and that was conjugated to an enzyme 
that would allow subsequent detection. In this case, the plates were washed and 
streptavidin-horse radish peroxidase (HRP), diluted 1:1000 with diluent, was 
added to each well, followed by incubation on a plate-shaker for 1 hour at room 
temperature. After this, and following 3 washes, the activity of the bound 
enzyme was detected by a colour change by adding 100 µl of colourless substrate 
solutions including TMB (3,3’,5,5’-tetramethylbenzidine) or ABTS (2,2’-azino-di-
[3-ethyl-benzothiazoline-6 sulfonic acid] di-ammonium salt), which changed 
colour after enzyme activity.. The optimum optical density was read at 630 nm 
for TMB and 410 nm for ABTS on a microplate spectrophotometer (Dynex 
Technologies Ltd., Worthing, UK). A standard curve was prepared from the 
optical densities produced from the serial dilutions of known standard, with 
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concentration on the x axis (log scale) vs absorbance on the Y axis (linear). The 
concentration of the sample was interpolated from this standard curve. 
2.8  Free-floating section staining for doublecortin 
(DCX) 
The immature neuronal marker doublecortin (DCX) is commonly used to quantify 
change in hippocampal neurogenesis. DCX is a highly hydrophilic microtubule-
associated protein that is specifically expressed in migrating neuronal precursors 
in the dentate gyrus in the hippocampus (Couillard-Despres et al., 2005). The 
doublecortin (DCX) antibody is hydrophilic which restricts penetration into the 
hydrophobic brain tissue, therefore, immunohistochemistry of DCX is best 
achieved by free-floating Immunohistochemistry, in which thick frozen-cut 
sections were incubated floating free in plastic wells containing diluted DCX 
antibody solution. Increasing the penetration of antibody into the tissue is a 
major advantage of the free-floating Immunohistochemistry since free-floating 
tissue in antibody solution allows tissue to be exposed to the antibody from both 
(back and front) sides. High salt solution (0.3 M PBS) was used as diluent and 
washing solutions, and these reduced non-specific staining by decreasing charge-
induced non-specific binding (Pastor-Soler et al., 2010).  
2.8.1  Tissue processing 
Mice were terminally anesthetized with halothane:oxygen. The brains were 
removed, and immersion-fixed in 4% paraformaldehyde in 50 mM phosphate 
buffer for 48 h. Brains were then cryoprotected by immersion in a 30% (W/V) 
sucrose; PBS solution at 4°C until the brains sink (usually 24 hours). Brains were 
stored in liquid nitrogen until required.  
2.8.2  Cryostat cutting and free-floating section process 
The middle segment of a mouse brain, which contains the hippocampus, was 
dissected, mounted in OCT embedding compound (Tissue-Tek O.C.TTM Sakura 
Finetek, Zoeterwoude, Natherlands) and frozen in the cryostat (Thermo Electron 
Corporation, Thermo Labsystems, Cheshire, UK) set at -20°C. The brain was cut 
into sequential 60 µm coronal sections. Each 60 µm brain section, containing 
hippocampus as illustrated between plates 24 and 48 of the histology mouse 
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brain atlas of Paxinos and Watson et al.,1998 (Paxinos and Watson, 1998) (Figure 
2.2, Figure 2.3), was lifted out from the blade serially with a paintbrush to 
minimize folding or wrinkling. Each section was transferred serially into wells 
containing 0.1 M PB buffer, and immuno-histochemistry of doublecortin was 
performed in that 24 well plate on an orbital shaker. 200 µl of all washing buffer 
and antibody solutions was transferred to each well and removed from the well 
in each step using a Pasteur pipette. 
 
Figure 2.2 A coronal rat brain atlas diagram (Paxinos and Watson, 1998).  
A black box shows the hippocampal region characterized by butterfly-shaped area. Dentate 
Gyrus (DG) is a part of hippocampus (a smaller red box), which is the specific area of DCX 
immunohistochemistry.  
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Figure 2.3  Coronal brain sections at the level of hippocampus. 
Diagrammatic illustrations displaying levels of coronal brain sections that were taken, 
which are based on a standard mouse brain stereotaxic atlas (Paxinos and Watson, 1998). 
Images were taken from (O'Neill and Clemens, 2001) by a kind permission of the Editor of 
Current Protocols in Neuroscience. 
2.8.3  Immunohistochemistry 
Free-floating sections were immersed in 50% ethanol for 30 min before 
immunostaining to enhance antibody penetration. The sections then were 
washed 3 times with 0.1 M PB buffer for 5 minutes each. To block endogenous 
peroxidase, sections were incubated with 0.3% H2O2 (Sigma, Poole, Dorset, UK) in 
0.1 PB for 30 min.  
2.8.3.1  Chromogenic immunostaining of doublecortin (DCX) 
For chromogenic immuno-staining, sections were washed in 0.3 M PBS for 3 times 
5 minutes each, and then incubated overnight at 4°C with rabbit α-doublecortin 
polyclonal antibody, 1:500 (ab18723, Abcam, Cambridge, UK) in a solution 
containing 0.3 M PBS, 0.3% Triton-X 100. Sections were then washed extensively 
3 times for 5 minutes each, with 0.3 M PBS and further incubated with goat anti-
rabbit IgG conjugated with biotin (Vector Laboratories, Peterborough, UK) at 
1:200 dilution in 0.3 M PBS, 0.3% Triton-X 100 for 1 hour at room temperature. 
To form the avidin-biotin-peroxidase complex, the sections were subsequently 
incubated in 200 µl 0.2 M PB buffer containing Avidin DH and biotinylated 
horseradish peroxidase H from VECTASTAIN® ABC kits (Vector Laboratories, 
Burlingame, CA, USA) for 30 minutes at room temperature. This was followed by 
2 washes with 0.3 M PBS and 1 wash with 0.1 M PB buffer. The peroxidase 
activity was quantified by using a diaminobenzidine substrate (DAB kit, Vector 
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laboratories, Peterborough, UK), prepared in H2O according to the 
manufacturer's instructions, before briefly rinsing 3 times with 0.1 M PB buffer. 
Sections were placed on gelatin-coated slides using a wet paintbrush in a 4 serial 
section sequences per slides according to the columns in a 24 well plate. 
Sections were dried overnight in a glass chamber soaked with 4% 
paraformaldehyde in 50 mM phosphate buffer. The sections were alcohol 
dehydrated and cleared with xylene following these steps:  
H2O               5 minutes 
70%   Ethanol                        5 minutes 
90%   Ethanol                        5 minutes 
100% Ethanol                        5 minutes 
100% Ethanol                        5 minutes 
100% Ethanol                        5 minutes 
70%   Ethanol                        5 minutes 
Xylene               5 minutes 
Xylene               5 minutes 
One drop of DPX mounting media (VWR International Ltd., Lutterworth, UK) was 
transferred over the tissue sections using a Pasteur pipette and a cover slip 
(VWR International Ltd., Lutterworth, UK) gently placed over tissue section. The 
DCX was allowed to dry before visualising with a Zeiss Axiostar plus microscope 
(Carl Zeiss, Germany) with a x40 objective.  
2.8.3.2  Fluorescence immunostaining of doublecortin (DCX) 
For fluorescence immunodetection, sections were washed extensively and 
incubated with the mixture of species-specific primary antibodies consisting of 
goat polyclonal α-doublecortin antibody 1:500 (DCX C-18, Santa Cruz 
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Laboratories, Santa Cruz, CA, USA), mouse α-NeuN, 1:500 (Chemocon, 
Temecula, CA, USA) and Cy-5 dk-mouse, 1:100 (Stratech Scientific, Luton, UK).  
Sections were then incubated with a cocktail of fluorochrome-conjugated 
species-specific secondary antibodies comprising of donkey antigoat IgG 
conjugated with Alexa 488, 1:500 (Molecular Probes, Eugene, OR, USA) and 
antimouse IgG conjugated with Rhodamine Red-X, 1: 1000 (Stratech Scientific, 
Luton, UK) for 2 hours at room temperature. Sections were then stained with 
propidium iodide (Sigma, Poole, UK; 1% in PBS) in the presence of RNase (Sigma; 
10 mg/ml) to reveal cell nuclei. Sections were placed on glass slides and 
mounted in glycerol-based anti-fade medium (Vectashield; Vector Laboratories, 
Peterborough, UK) and examined with a Bio-Red MRC 1024 Confocal laser 
scanning microscope (Hemel Hempstead, UK) equipped with a krypton argon 
laser, through a x60 oil immersion objective lens. 
The process of DCX immunohistochemistry is shown in Figure 2.4.   
  
Figure 2.4 Steps involved in tissue processing, cryostat cutting and DCX staining.  
(1) Fixation and Cryoprotection of brain tissue. (Kim et al.) & (3) Remove the middle 
segment (which contains the hippocampus). (4) Embed this segment in OCT embedding 
matrix and freeze it in -20°C in the cryostat machine, cryostat cut sections into 60 µm. (5) 
Collect and transfer sections serially in 0.2 M PB buffer in a 24-well tissue culture plate. (6) 
Perform DCX immuno-histochemistry in the 24-well tissue culture plate. (7) Pick sections 
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one by one with a wet paintbrush and transfer to gelatine-coated slides serially 
corresponding to each of the 24-well plate columns. Mount slides with DPX mounting 
media. Images were taken from (O'Neill and Clemens, 2001) by a kind permission of the 
Editor of Current Protocols in Neuroscience. 
2.8.4  Quantifying doublecortin [DCX]-positive cells 
Simple cell counting is a rapid method to quantify neuron numbers in the 
hippocampus in several publications (Couillard-Despres et al., 2005). The 
numbers of DCX-positive cells in our study were counted by a similar counting 
method in a double-blind fashion. The slide labels were masked and DCX-positive 
cells in the dentate gyrus were counted by a blind observer. Each brain, DCX 
stained brain sections were placed in a horizontal serial fashion on gelatine 
coated-slides. DCX-positive cells were counted on every sixth (60 µm) coronal 
section through the dentate gyrus by using a Zeiss Axiostar plus (Carl Zeiss, 
Germany) with a x40 objective lens. This means the 6th, 12th, 18th and 24th 
sections were selected. The numbers of DCX-positive cells in the dentate gyrus 
were counted in both hemispheres (Figure 2.5). The sum of these counts was 
multiplied by six to generate estimates of absolute numbers.  
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Figure 2.5 The order of DCX-stained brain sections of one mouse brain onto slides.  
Twenty-four DCX-stained brain sections were placed in a horizontal serial fashion on 6 
gelatin-coated slides (from left to right). This order corresponded to the serial order in the 
24-well tissue culture plate. 6th, 12th, 18th and 24th sections located at the 6th slide (red 
box) were used to quantify the number of DCX-positive neuron in the dentate gyrus.  
2.9 Statistical analysis 
Inflammatory mediator levels below the detection limits of Luminex, ELISA or 
real-time PCR assays were allocated the value of the detection limit for 
statistical analysis rather than zero, in order to use the information that the 
level was low. 
Continuous variables were summarised as mean and standard deviation if 
normally distributed, or median and inter-quartile range if they had a skewed 
distribution. The distribution of the continuous variable data was inspected by 
Bartlett's test to confirm the normal distribution. The appropriate parametric 
test used to compares three or more unmatched groups is the one-way ANOVA. 
Therefore, this was used as the multiple comparison test for comparing 
inflammatory mediator concentrations and protein/gene expression levels 
between 3 groups of mice (arthritic, non-arthritic and naïve control groups). 
Bonferroni test was used as a post-hoc test for a multiple-comparison correction. 
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The Student’s t-test was occasionally used to compare inflammatory mediator 
concentrations and protein/gene expression levels between 2 experimental 
groups (arthritic and non-arthritic groups).  
In our longitudinal studies, we compared inflammatory mediator concentrations 
in brains of CII immunized and naïve control mice across time points and 
between these 2 groups of mice at each time point. Two-way ANOVA is the most 
suitable test for these longitudinal studies because it determines how a response 
is affected by two different factors (different groups of mice and different time 
points). Therefore, two-way Analysis of Variance (ANOVA) with Bonferroni 
multiple comparison tests were used to evaluate longitudinal inflammatory 
mediator production, with overall significance for factors of CII 
immunized/naïve control mice and time. In addition, Two-way Analysis of 
Variance (ANOVA) with Bonferroni multiple comparison tests were also used to 
confirm any significant difference in arthritis score, paw thickness and arthritis 
incidence between CII immunized/naïve control mice. Pearson’s correlation 
coefficient was used for correlation analysis. Calculations for statistical analysis 
were performed with Prism software version 4 (Graphpad Software, San Diego, 
CA, US). P < 0.05(*), P < 0.01(**) and P < 0.001(***) were considered as 
statistically significant. 
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Increased concentration of inflammatory mediators 
in the brain associated with collagen-induced 
experimental arthritis. 
 
 
 
 
 
 
 
 
 
Chapter 3  132 
3.1  Introduction and aims 
Rheumatoid arthritis is a systemic autoimmune disease in which, in addition to 
joint disease, the peripheral inflammation is reflected by the presence of extra-
articular organ manifestations such as systemic vasculitis (blood vessel 
inflammation), subcutaneous nodules and pulmonary fibrosis in approximately 
30% of RA patients (Young and Koduri, 2007). Accumulating evidence suggests 
that the brain may also be affected by peripheral inflammation during arthritis. 
For example, neuroimaging studies showed several CNS lesions in the brains of 
RA patients, which resolved after steroid treatment, suggesting that CNS 
inflammatory demyelination may also be inducible by systemic inflammation 
during arthritis (Tsai et al., 2008); (Tajima et al., 2004). Psychiatric disorders 
such as depression and anxiety are also common in RA, and this observation may 
be a potential novel area of clinical research based on the hypothesis that these 
may be due to peripheral inflammation during arthritis causing alterations in 
brain neurobiology. To date, there are few studies investigating the potential 
mechanisms underlying psychological disorders in RA. One preliminary study 
using a single photon emission computed tomography (SPECT) scan of 6 RA 
patients showed a reduction in serotonin transporter (SERT)  density, along with 
improvement in physical and mental functions after receiving anti-TNF-α 
treatment, suggesting that circulating cytokines generated during autoimmune 
activation in RA may cause changes in the serotonin system that induced the 
development of depression (Cavanagh et al., 2010). A hypothesis based on this 
clinical observation is supported by studies in animal model of RA; a study using 
a transient model of RA by Bao et al., showed that both mRNA and protein 
concentration of IL-1β, IL-6 and TNF-α were elevated in the spinal cord of AIA 
rats (Bao et al., 2001). Similar observations were reported in a chronic model of 
RA; brains of CIA rats showed up-regulation of the expression of various cytokine 
genes, including TNF-α, IL-1β and IL-6 (del Rey et al., 2008).  In addition, a 
transient increase in hippocampal neurogenesis has been reported in the brains 
of AIA rats, suggesting that neuroinflammation induced by peripheral 
inflammation may contribute to neurobiological changes during the course of 
arthritis (Wolf et al., 2009b).  
Based on this evidence, we hypothesised that the systemic immune response 
activated during arthritis can induce brain inflammation and neurobiological 
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changes, which may help explain the mechanism underlying psychological 
disorders associated with RA. Therefore, the aim of this chapter is to investigate 
changes in a wide range of inflammatory mediator proteins in the brain of CIA 
mouse model of arthritis using Luminex bead-based screening assays. We also 
determine changes in concentration of mRNA encoding these inflammatory 
mediators using real-time PCR and quantified as absolute copy numbers.  
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3.2  Results 
3.2.1  Induction of arthritis in DBA1 mice 
The aim of this experiment is to investigate whether peripheral 
immune/inflammatory responses occurring during arthritis can change the 
protein and gene expression profiles of inflammatory mediators (cytokines, 
chemokines, growth factors) in the brains.  
Experimental procedure: 19 DBA1 mice were immunized by intradermal 
injection of type II collagen in complete Freund’s adjuvant on day 0. On day 21, 
mice were given an i.p. booster injection of type II collagen dissolved in PBS. 7 
sex- and age-matched DBA1 mice were used as the naïve control and were not 
immunized or boosted with type II collagen. The signs of arthritis in CII 
immunized mice were monitored from day 16 after immunization onwards and 
arthritis severity in this experiment were verified independently by Dr. Darren 
Asquith. Groups of both CII immunized and control mice were sacrificed on day 
42 and serum was collected for the determination of peripheral inflammatory 
mediator proteins by a luminex multi-parameter assay. The brain of each mouse 
was isolated and snapped frozen in liquid nitrogen and stored at –80˚C.  Half of 
each brain was processed for protein extraction and inflammatory mediator 
protein analysis by luminex; the other half was processed for RNA extraction and 
inflammatory mediator gene expression determined by real-time PCR. The 
experimental procedure of collagen II-induced experimental arthritis (CIA) model 
is summarized in Figure 3.1. 
 
 
 
 
Chapter 3  135 
 
Figure 3.1 The experimental procedure of collagen II-induced experimental arthritis (CIA) 
model  
DBA1 mice at 6-8 weeks of age were separated into two groups: i) 7 control mice; ii) 19 
immunized mice.  Mice were immunized with 100µg type II bovine collagen + complete 
Freund’s adjuvant (CFA) at day 0 and then challenged on day 21 with 200µg type II collagen. 
A group of 7 naïve DBA1 mice which were not immunized and not treated with type II 
collagen was use as a control group.  Serum and brains from control and CII-immunized 
mice were harvested at Day 42. Each mouse brain was dissected into left and right 
hemispheres. One half was processed for mRNA extraction and measurements of 
inflammatory mediator transcripts by real-time PCR. Protein was extracted from the other 
half brain after homogenisation of the tissue and used to determine inflammatory mediator 
protein concentration a Luminex assay.  
Clinical response: Some of the CII-immunized mice started to show clinical signs 
of arthritis from day 19 onwards and there were 12 out of the 19 CII immunized 
mice that developed arthritis (63% incidence) on day 42 (Figure 3.2A). 7 of the 
19 mice did not develop arthritis although they had an identical immunization 
and challenge, and these were therefore considered as potentially different and 
formed a separate ‘immunised but non-arthritis’ study group.  
CII immunized mice showed a significant increase in paw thickness 
compared to those in naïve control mice (P<0.0001). The mean paw thickness 
and the mean arthritis score for the whole group of CII-immunized mice (n=19) 
on day 42 were 1.9 ± 0.1 mm and 4.5 ± 1.2 respectively (Figure 3.2B), (Figure 
3.2C). Haematoxylin and eosin staining of a hind paw tissue section of an 
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arthritic mouse (this mouse had a clinical score of 12 on day 42) showed 
cartilage and bone damage/erosion and synovial hyperplasia in the joint (Figure 
3.3) 
 
Figure 3.2 development and severity of arthritis disease in CII immunized mice over 42 days 
of experimental arthritis course  
The signs of arthritis in CII immunized mice were monitored from day 16 after immunization 
onwards. (A) shows the percent incidence of arthritis in CII immunized mice, which was 
calculated from the number of CII immunized mice with arthritis divided by the total number 
of CII immunized mice used. The signs of arthritis were observed in CII immunized mice 
from day 18 onwards and there were 12 out of total 19 CII immunized mice developed 
arthritis on day 42. Mean clinical arthritic score and mean paw thickness were used as 
clinical evaluations to measure the severity of joint inflammation in arthritic mice. (B) shows 
the mean paw thickness of CII immunized mice which was calculated from the sum of the 
paw thickness of all mice divided by the number of mice. (C) shows the mean clinical score 
of CII immunized mice which was calculated from the sum of the clinical scores of all mice 
divided by the number of mice. Mean paw thickness, mean clinical score and %incidence in 
19 CII immunised mice (filled squares) were compared with those values of 7 naïve control 
mice (open circles). Data represent as mean ± SEM. (n=19 CII immunised mice). Statistical 
analysis of data was performed using two-way ANOVA for multiple comparison, compared 
with a group of control naïve mice; *P<0.05, ** P<0.01, *** P<0.001.  
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Figure 3.3 Paw histology of an arthritic mouse  
(A) a representative histological image (10 x magnification) of a section of an arthritic 
mouse paw (this arthritic mouse had a clinical score of 12 on day 42). A smaller box section 
shows the area of joint inflammation in this arthritic mouse. Cartilage and bone 
damage/erosion, cartilage loss and synovial hyperplasia were observed in an inflamed hind 
paw of this arthritic mouse compared to a representative histological image (10 x 
magnification) of a section of a naïve mouse paw (B). Abbreviations; B = Bone, C = 
Cartilage, J = Joint space, SM = synovial membrane.  
3.2.2 Changes in inflammatory mediator protein 
concentration in serum of CII immunized mice (both arthritic 
mice and non-arthritic mice) 
To investigated systemic inflammatory signals in the periphery of CII immunized 
mice, inflammatory mediator proteins in serum collected from naive control 
mice and CII immunized mice on day 42 were determined using a Luminex 
cytokine 20-Plex assay. Serum concentrations of CXCL1 and FGF protein were 
within the assay detection limits (CXCL1 35 – 3023 pg/ml; and FGF2 27 – 3552 
pg/ml). Concentrations of the other serum inflammatory mediators ( TNF-α, IFN-
γ, IL-1α, IL-1β, IL-4, IL-5, IL-6, IL-10, IL-12 [p40], IL-12[p40/p70], IL-13, IL-17), 
chemokines (CXCL10, CCL2, CXCL9, CCL3, CCL4, CCL19, CCL5), and growth 
factors (GM-CSF, PDGF-BB, VEGF) in brain tissue of mice of all experimental 
groups were lower than the detection limit of the Luminex assay.  
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One-way ANOVA analysis demonstrated that there were significant differences in 
serum concentration of CXCL1 among the three groups of mice (P < 0.0001). Post 
hoc analysis with Bonferroni correction demonstrated significant increases in 
serum concentration of CXCL1 in CII immunized mice (both arthritic and non-
arthritic) compared to those in naïve control mice. The mean values of serum 
CXCL1 (arthritic versus naïve control) was 51.1 ± 2.6 pg/ml versus 33.6 ± 1.5 
pg/ml (P < 0.001). The serum concentration of CXCL1 was also elevated in CII 
immunized mice that did not develop arthritis compared to those in the naïve 
controls. The mean values of serum CXCL1 (non-arthritic versus naïve control) 
was 54.8 ± 6.8 pg/ml versus 33.6 ± 1.5 pg/ml (P < 0.001). There was no 
significant difference in serum CXCL1 concentration between arthritic and non 
arthritic mice (Figure 3.4A). These results are consistent with a study in CIA 
model by Kurowska et al., showing an elevation of serum CXCL1 detected using a 
Luminex assay in CII immunized mice compared to the controls. FGF2 was 
another inflammatory mediator detected in serum of mice from all the 
experimental groups. However, one-way ANOVA analysis showed that there was 
no significant difference in serum FGF2 concentration between naïve control 
mice and CII immunized mice (P = 0.4093) (Figure 3.4B) 
 
Figure 3.4 Serum inflammatory mediator profiles in CII immunized mice  
Concentrations of inflammatory mediator protein concentration (pg/ml) determined by 
Luminex-based multiplex cytokine assay in serum of naïve control mice (n=7 naïve control 
mice) and CII immunized mice (n=19 CII immunized mice). The group of CII immunized mice 
consisted of 7 non-arthritic mice and 12 arthritic mice. Mice from all experimental groups 
were sacrificed and serum samples were collected on day 42.  Only CXCL1 and FGF2 
protein concentration were detectable at the detection limit Data are presented as the mean 
values. (*P < 05 ; **P < 01; ***P < 001 by one-way ANOVA analysis) 
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3.2.3  Changes in inflammatory mediator protein 
concentrations in brains of CII immunized mice (both 
arthritic mice and non-arthritic mice) 
To investigate changes in inflammatory mediator profiles in brains of CII 
immunized mice that did (arthritic mice) or did not (non-arthritic mice) develop 
arthritis compared to naïve control mice, Luminex cytokine 20-Plex assay was 
used to measure the protein concentration of various inflammatory mediators 
including proinflammatory cytokines (IL-6, IL-1 β, TNF-α and IL-1 α ), Th1 
cytokines (IL-2, IL-12 and IFN-γ), Th2 cytokines (IL-4, IL-5, IL-10, IL-13), 
chemokines (CXCL1, CXCL10, CCL2, CCL3) and growth factors (FGF2, VEGF) in 
half brain tissue homogenate samples from mice of all experimental groups. 
Each sample was measured in triplicate. Values were reported as pg/ml. These 
values were extrapolated from the standard curves of known concentrations of a 
single mixed inflammatory mediator standard. Examples of the standard curves 
for each inflammatory mediators generated in the Luminex assay used in the 
experiment are shown in Appendix 1A and Appendix 1B. The standard curves of 
this Luminex assay demonstrated the dynamic range and sensitivity desired for 
the assay. In addition, these standard curves were to show that the Luminex 
assay was run in an acceptable performance manner.  
Values of inflammatory mediator concentrations in each brain tissue homogenate 
sample (pg/ml) were then normalized with the total protein concentration of 
brain tissue (µg/ml) of that sample, and presented as pg/mg total brain protein. 
To calculate the amount of inflammatory mediator protein level as pg/mg total 
brain protein, amounts of inflammatory mediator proteins and of total brain 
protein in 50 µl of each sample were firstly calculated. For example, the protein 
concentration of IL-13 in sample A measured by Luminex was 55.03 pg/ml, 
therefore 50 µl of sample A contains 2.8 pg IL-13. The protein concentration of 
sample A measured by BCA protein assay was 7087.03 µg/ml, therefore 50 µl of 
sample A was 354.35 µg total brain tissue. Finally, amount of IL-13 protein in 1 
mg total brain protein (pg/mg total brain tissue) was calculated using the 
following equation 
                                  1000 X Amount of IL-13 protein in 50 µl (pg) 
                                   Amount of total brain protein in 50 µl (mg)    
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Therefore, 1 mg total brain proteins of sample A contained 7.765 pg of IL-13.  
Values of protein concentrations of IL-1α, IL-2, IL-4, IL-5, IL-6, IL-10, IL-13, 
CXCL1, CXCL10 and FGF2 obtained from the Luminex assay in brain tissue 
homogenate samples of mice from all experimental groups were all within the 
detection limits of the assay. Table 2.1 shows the dynamic range for each 
inflammatory mediator generated in the Luminex assay, and the mean values of 
protein concentrations (pg/ml) of these inflammatory mediators in brain tissue 
homogenate samples of both naïve control mice and CII immunized mice before 
normalization. This is to show that the actual values of these inflammatory 
mediator protein concentration in brain tissue homogenate samples of mice from 
all experimental groups were within the detection limit of the assay, although 
the amount of some brain inflammatory mediators protein in these mice seemed 
lower than the detection limit of the Luminex assay after the normalization by 
total brain protein (pg/mg total brain protein).  
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mean concentrations of brain 
inflammatory mediator proteins in  
50 µl brain tissue homogeneous 
(pg/ml) 
 
 
Inflammatory 
mediators 
 
Dynamic range of 
detection limits 
(pg/ml) 
Naïve control 
mice 
CII immunized mice 
          
IL-1α 
 
20.9 - 14733.5 
 
 
13.8 ±  4.0 
 
 
36.4 ±  14.1 
          
IL-2 
 
17.6 - 13999.8 
 
 
47.2 ± 23.1 
 
107.3 ±  44.3 
          
IL-4 
 
12.7 - 13452 
 
 
10.1 ±  1.6 
 
 
23.5 ±  11.7 
 
IL-5 
 
6.4  - 10204.5 
 
 
18.9 ± 2.4 
 
31.4 ± 9.6 
 
IL-6 
 
8.3  - 9161.9 
 
 
7.8 ± 2.1 
 
15.1  ± 6.9 
 
IL-10 
 
46.2 - 40630.0 
 
 
200.9 ± 60.0 
 
454.4 ± 294.1 
 
 
IL-13 
 
25.3 – 20070.0 
 
 
22.2 ± 6.9 
 
46.5 ± 25.3 
 
CXCL1 
 
33.4 -14796.0 
 
 
85.4 ± 9.7 
 
168.5 ± 58.0 
 
CXCL10 
 
33.5 - 38592.1 
 
 
76.1 ± 8.2 
 
154.1 ± 55.6 
 
FGF2 
 
34.8 - 11084.3 
 
 
522.8 ± 47.0 
 
927.7 ± 296.4 
Table 3.1 Values of protein concentrations of inflammatory mediators detected by a 
Luminex assay in brain tissue homogenate samples of naïve control mice and CII 
immunized mice  
Dynamic range of detection limits of the Luminex assay were generated by standard curve 
of known quantities of mouse recombinant inflammatory mediators. Protein concentrations 
of IL-1α, IL-2, IL-4, IL-5, IL-6, IL-10, IL-13, CXCL1, CXCL10 and FGF2 obtained from the 
Luminex assay in 50 µl brain tissue homogenate samples of mice from all experimental 
groups were obtained from the Luminex assay as pg/ml. Values of protein concentrations of 
these inflammatory mediators were eventually normalized by total brain protein as 
presented as pg/mg total brain protein. The mean value of total protein concentration of 
brain tissue in 50µl of brain tissue homogenate samples of naïve control and CII immunized 
mice were 4694 ±473µg/ml and 4795 ±683 µg/ml. Protein concentrations of mean 
concentrations of brain inflammatory mediator proteins were presented by (pg/ml) ± SD.  
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3.2.3.1  Pro-inflammatory cytokine profiles in the brains of CII 
immunized mice (both arthritic mice and non-arthritic mice) 
Pro-inflammatory cytokines, including IL-1β, IL-1α, IL-6 and TNF-α, are produced 
by mononuclear cells such as macrophages and are involved in the initiation of 
the immune response. The amounts of these proinflammatory cytokines were 
determined in the brains of naïve control mice, arthritic mice and CII immunized 
mice with no arthritis, but only IL-1α and IL-6 were detectable. One-way ANOVA 
analysis showed that there was no significant difference in brain IL-1α and IL-6 
protein concentration between naïve control non arthritic mice and arthritice 
mice (P = 0.0543 and P = 0.8445 repectively) (Figure 3.5A, Figure 3.5B). 
 
Figure 3.5 Changes in pro-inflammatory cytokine concentration in brains of CII immunized 
mice  
The dots represent protein concentration of IL-1α and IL-6 (pg/mg total brain protein) 
determined by Luminex-based multiplex cytokine assay in brain tissue homogenate of naïve 
control mice (n=7 naïve control mice), non-arthritic mice (n=7 non-arthritic mice), and, 
arthritic mice (n=12 arthritic mice). All mice were sacrificed and brains were collected on 
day 42.  Data are presented as the mean values. (*P < 05 ; **P < 01; ***P < 001 by one-way 
ANOVA analysis). Bars represent the mean values. 
3.2.3.2 Th-1 cytokines profile in the brains of CII immunized mice (both 
arthritic mice and non-arthritic mice) 
Th-1 cytokines, including IL-12, IL-2 and IFN-γ, were determined in the brain of 
naïve control mice and CII immunized mice with and without arthritis. IL-2 was 
the only cytokine in this category that was up-regulated in arthritic mouse brains 
compared to those in the naïve control group. One-way ANOVA analysis 
demonstrated that there was a significant difference in protein concentration of 
IL-2 among the three groups of mice (P = 0.0343). Post hoc analysis with 
Bonferroni correction demonstrated the significant difference in protein 
concentration of IL-2 between arthritic mice and naïve control mice. The mean 
value of IL-2 (arthritic versus naïve control) was 24.4 ± 10.2 pg/mg total brain 
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protein versus 11.6 ± 2.2 pg/mg total protein (P < 0.05). There was no significant 
difference in brain IL-2 protein concentration between naïve control mice and 
non-arthritic mice (Figure 3.6). There were no significant differences in brain IL-
2 concentrations between arthritic and non-arthritic mice. 
 
Figure 3.6 Changes in a Th1 cytokine level in brains of CII immunized mice  
The dots represent protein concentration of IL-2 (pg/mg total brain protein) determined by 
Luminex-based multiplex cytokine assay in brain tissue homogenate of naïve control mice 
(n=7 naïve control mice), non-arthritic mice (n=7 non-arthritic mice), and, arthritic mice 
(n=12 arthritic mice). All mice were sacrificed and brains were collected on day 42.  Data are 
presented as the mean values. (*P < 05 ; **P < 01; ***P < 001 by one-way ANOVA analysis). 
Bars represent the mean values. Bars represent the mean values. 
3.2.3.3  Th-2 cytokine profiles in the brains of CII immunized mice (both 
arthritic mice and non-arthritic mice) 
Th-2 cytokines, including IL-4, IL-5, IL-10 and IL-13 were determined in the 
brains of naïve control mice and CII immunized mice with and without arthritis. 
One-way ANOVA analysis showed that there was no significant difference in brain 
IL-4 protein concentration between naïve control mice and CII immunized mice 
(P = 0.6696) (Figure 3.7A). One-way ANOVA analysis demonstrated that there 
were significant differences in protein concentration of IL-5 and IL-13 among the 
three groups of mice (P = 0.0199 and P = 0.0355 respectively) (Figure 3.7B and 
Figure 3.7D). Post hoc analysis with Bonferroni correction demonstrated 
significant increases in concentration of IL-5 and IL-13 in brains of arthritic mice 
compared to those in naïve control mice. The mean values of IL-5 (arthritic 
versus naïve control) were 6.8 ± 2.0 pg/mg total protein versus 4.10 ± 0.69 
pg/mg total protein (P < 0.05). The mean value of IL-13 (arthritic versus naïve 
control) was 10.0 ± 3.6 pg/mg total protein versus 5.4 ± 0.6 pg/mg total protein 
(P < 0.05). There was no significant difference in brain IL-5, IL-10, and IL-13 
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protein concentration between naïve control mice and non-arthritic mice (Figure 
3.7B and Figure 3.7D). There were no significant differences in brain IL-5 and IL-
13 concentrations between arthritic and non-arthritic mice. One-way ANOVA 
analysis suggested that there was no significant difference in brain IL-10 protein 
concentration between naïve control mice and CII immunized mice (P = 0.1196) 
(Figure 3.7C).  
 
Figure 3.7 Changes in Th2 cytokine concentration in brains of CII immunized mice  
The dots represent protein concentration of IL-4, IlL-5, IL-10, IL-13 (pg/mg total brain 
protein) determined by Luminex-based multiplex cytokine assay in brain tissue homogenate 
of naïve control mice (n=7 naïve control mice), non-arthritic mice (n=7 non-arthritic mice), 
and, arthritic mice (n=12 arthritic mice). All mice were sacrificed and brains were collected 
on day 42.  Data are presented as the mean. (*P < 05 ; **P < 01; ***P < 001 by one-way 
ANOVA analysis) Bars represent the mean values. 
3.2.3.4 Chemokine profiles in the brains of CII immunized mice (both 
arthritic mice and non-arthritic mice) 
Chemokines produced by activated immune cells, including CXCL1, CXCL10, CCL-
2 and CCL3, were determined in the brains of naïve control mice and CII 
immunized mice with and without arthritis. One-way ANOVA demonstrated that 
there were significant differences in protein concentration of CXCL1 and CXCL10 
among the three groups of mice (P = 0.0012 and P = 0.0037 respectively) (Figure 
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3.8A and Figure 3.8B). Post hoc analysis with Bonferroni correction 
demonstrated that brain protein concentrations of CXCL1 and CXCL10 in CII 
immunized mice were significant higher than those in naïve control mice. The 
mean values of CXCL1 and CXCL10 (arthritic versus naïve control) were 37.4 ± 
12.7 pg/mg total protein versus 14.1 ± 1.5 pg/mg total protein (P < 0.01), and 
35.6 ± 11.1 pg/mg total protein versus 16.5 ± 2.4 pg/mg total protein (P < 0.01) 
respectively.  There was no significant difference in the brain CXCL-10 protein 
level between naïve control mice and non-arthritic mice. However, there was a 
significant increase in CXCL1 protein level in CII immunized mice without 
arthritis compared to those in the naïve control group. The mean value of CXCL1 
(non-arthritic versus naïve control) was 33.6 ± 14.8 pg/mg total protein versus 
14.1 ± 1.5 pg/mg total protein (P < 0.05) (Figure 3.8A and Figure 3.8B). There 
were no significant differences in brain CXCL1 and CXCL10 concentrations 
between arthritic and non-arthritic mice.  
 
Figure 3.8 Changes in chemokine concentration in brain of CII immunized mice  
The dots represent protein concentration of CXCL1 (A) and CXCL10 (B) (pg/mg total brain 
protein) determined by Luminex-based multiplex cytokine assay in brain tissue homogenate 
of naïve control mice (n=7 naïve control mice), non-arthritic mice (n=7 non-arthritic mice), 
and, arthritic mice (n=12 arthritic mice). All mice were sacrificed and brains were collected 
on day 42.  Data are presented as the mean values. (*P < 05 ; **P < 01; ***P < 001 by one-way 
ANOVA analysis). Bars represent the mean values.  
3.2.3.5  Growth factor profiles in the brain of CII immunized mice (both 
arthritic mice and non-arthritic mice) 
Growth factors such as FGF2 and VEGF were quantified in the brains of naïve 
control mice and CII immunized mice with and without arthritis. FGF2 which is 
produced abundantly by CNS resident cells was detected in high concentration in 
brains from all groups of mice. One-way ANOVA demonstrated that there were 
significant differences in serum concentration of FGF2 among the three groups 
of mice (P = 0.0136). Post hoc analysis with Bonferroni correction demonstrated 
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that the protein level of FGF2 in arthritic mouse brains was significantly higher 
than those in the naïve control group. The mean value of FGF2 (arthritic versus 
naïve control) was 204.0 ± 58.5 pg/mg total protein versus 109.9 ± 19.1 pg/mg 
total protein (P < 0.05). There was no significant difference in brain FGF2 
protein level between naïve control mice and non-arthritic mice (Figure 3.9). 
There were no significant differences in brain FGF concentrations between 
arthritic and non-arthritic mice. 
 
Figure 3.9 Changes in a growth factor level in brain of CII immunized mice  
The dots represent protein concentration of FGF2 (pg/mg total brain protein) determined by 
Luminex-based multiplex cytokine assay in brain tissue homogenate of naïve control mice 
(n=7 naïve control mice), non-arthritic mice (n=7 non-arthritic mice), and, arthritic mice 
(n=12 arthritic mice). All mice were sacrificed and brains were collected on day 42.  Data are 
presented as the mean values. (*P < 05 ; **P < 01; ***P < 001 by one-way ANOVA analysis) 
Bars represent the mean values. 
In summary: numerous inflammatory mediator protein, including IL-1α, IL-2, IL-
4, IL-5, IL-6, IL-10, IL-13, CXCL1, CXCL10 and FGF2 were detected by the 
Luminex assay in brain tissue homogeneous of mice from all experimental 
groups. Significant increases in protein concentration of IL-2, IL-5, IL-13, CXCL1, 
CXCL10 and FGF2 were observed in brain tissue of CII immunized mice that 
develop arthritis compared to those in the naïve control mice. The inflammatory 
mediator protein concentration seemed to increase in non-arthritic mouse 
brains, although one-way ANOVA analysis showed that the concentrations were 
not significantly different compared to those in naïve control mice. Only CXCL1 
protein concentration was significantly elevated in non-arthritic mouse brains.  
Table 3.2 shows a summary of these data as mean ± SD of fold changes of 
inflammatory mediator protein profiles in brains of CII immunized mice (both 
arthritic and non-arthritic) in comparison to those in brains of naïve control 
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mice. Data were categorized into 5 groups (pro-inflammatory cytokines, Th1 
cytokines, Th2 cytokines, chemokines and growth factors). Our data showed that 
inflammatory mediator protein concentration in brains of CII immunized mice 
significantly increased from 1.7 – to 2.6 – fold compared with those in naïve 
control. Among these inflammatory mediators, the greatest mean fold change 
was observed in the group of chemokines (CXCL1 and CXCL10). The highest mean 
fold change of 2.6 was observed for CXCL1 protein concentration in brains of 
arthritic mice. Interestingly, the second highest fold change was still CXCL1 (2.4-
folds), however, observed in brains of non-arthritic mice. The lowest mean fold 
change of 1.7 folds was observed in IL-5 in arthritic mouse brains.  
 
                  Arthritic                             Non-arthritic 
 
Inflammatory 
mediator 
protein 
concentration 
    Fold changes        P value         Fold changes         P value 
             of                                             of 
    Protein concentration             Protein concentration 
 
Pro-inflammatory cytokines 
 
         IL-1α                            1.8 ± 0.8                  NS                          1.7 ± 1.3               NS 
 
Th1 cytokines 
 
         IL-2                              2.1 ± 4.6               < 0.05*                       1.7 ± 4.8               NS   
 
Th2 cytokines 
 
         IL-5                              1.7 ± 2.6              < 0.05*                        1.5 ± 4.1               NS 
 
         IL-10                            2.0 ± 4.5                NS                            1.9 ± 5.7               NS 
 
         IL-13                           1.9 ± 6.5                < 0.05*                       1.8 ± 9.1               NS 
 
Chemokines 
 
          CXCL1                      2.6 ± 8.7               < 0.01**                         2.4 ± 10           < 0.05* 
 
         CXCL10                     2.2 ± 4.7               < 0.01**                         1.7 ± 6.1             NS 
 
Growth factors 
 
         FGF2                         1.9 ± 3.5              < 0.05*                       1.7 ± 4.4              NS 
 
Table 3.2 summary of inflammatory mediator protein profiles in brains of CII immunized 
mice  
Data summary was presented as mean ± SD of fold changes of inflammatory mediator 
protein profiles in brains of CII immunized mice (both arthritic and non-arthritic) in 
comparison to those in brains of naïve control mice. One-way ANOVA analysis (*P < 005; **P 
< 002; ***P < 001) was used to demonstrate significant increase in inflammatory mediator 
protein concentration in arthritic and non-arthritic mouse brain compared to those in 
control mouse brains. NS = not statistically significant. 
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3.2.4 Cytokine gene expression profiles in the brains of CII 
immunized mice (both arthritic mice and non-arthritic mice) 
Significant increases in various inflammatory mediator protein concentration 
including IL-1α, IL-2, IL-5, IL-10, IL-13, CXCL1, and CXCL10 were detected by the 
Luminex assay in brains of CII immunized mice, especially in brains of arthritic 
mice, compared to those in naïve control mice. However, we could not define 
the cellular source of these inflammatory mediator proteins in the brains of 
arthritic mice. It is possible that they were either produced from peripheral 
immune cells and transported into the brains, or produced from local immune 
cells such as astrocytes and microglia. To investigate this, we therefore 
investigated the mRNA expression levels of these brain inflammatory mediators 
at the transcription level, which can be another indicator of neuro-inflammation 
during the process of peripheral joint inflammation. Changes in mRNA expression 
level of these inflammatory mediators in brains of CII immunized mice may 
suggest local production by astrocytes, microglia or by peripheral immune cells 
trafficking into the brain. Real-time PCR was employed to determined mRNA 
expression levels of the same 20 inflammatory mediators as measured by 
Luminex (above); including proinflammatory cytokines (IL-6, IL-1 β, TNF-α and 
IL-1 α), Th1 cytokines (IL-2, IL-12 and IFN-γ), Th2 cytokines (IL-4, IL-5, IL-10, IL-
13), chemokines (CXCL1, CXCL10, CCL2, CCL3), growth factors (FGF2, VEGF) 
using RNA extracted from the other half of the brain tissue.  
The expression level of mRNA of these inflammatory mediators in brains tissue of 
mice from all experimental groups were quantified as cycle threshold (Ct) values 
by real-time PCR assays. These Ct values were then calculated as absolute copy 
number of target genes using standard curves generated from amplification of 
10-fold serial dilutions of known quantities of a plasmid containing the target 
sequences. The absolute mRNA copy numbers of inflammatory mediators were 
normalized to GAPDH expression as described in the Materials and Methods 
chapter and reported as arbitrary units. mRNA expression levels of IFN-γ, CXCL1, 
CXCL10, VEGF and FGF in brains of mice from all experimental groups were 
detectable within detection limits of the assay. This was demonstrated by the 
transcription values of these brain samples being within the linear dynamic 
range of the standard curve (Appendix 2). Specificity of the real-time PCR assay 
was determined by melting curve analysis as described in the Materials and 
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Methods section. Examples of melting curve analysis of each inflammatory 
mediator are shown in Appendix 3. 
3.2.4.1   Pro-inflammatory cytokine mRNA profiles in the brains of CII 
immunized mice (both arthritic mice and non-arthritic mice) 
The gene expressions of pro-inflammatory cytokines including IL-6, IL-1 β, TNF-α 
and IL-1α were determined in brains of mice from all experimental groups. 
However, the expression levels of these pro-inflammatory cytokines in all brain 
samples were lower than the detection limit. Despite an increase in IL-1α 
protein concentration in arthritic mouse brains, there was no equivalent 
increase in IL-1α mRNA expression levels detected in brains of these arthritic 
mouse brains. These may suggest that the timing of induction and half-life of 
mRNA had finished while the protein was maintained, and/or there may be 
active transportation of IL-1α protein from the periphery into the brains of 
arthritic mice.  
3.2.4.2 Th-1 cytokines mRNA profiles in the brains of CII immunized 
mice (both arthritic mice and non-arthritic mice) 
Gene expression of Th-1 cytokines, including IL-12, IL-2 and IFN-γ, were 
determined in the brain of control mice and mice with and without arthritis. 
One-way ANOVA followed by Bonferroni's post-hoc comparison tests showed that 
the expression of IFN-γ was up-regulated significantly in CII immunized mouse 
(both arthritic and non-arthritic mice) brains compared to those of control mice 
(P = 0.0131). The mean value of IFN-γ (arthritic versus naïve control) was 305 ± 
132 versus 138 ± 43 (P < 0.05). There were no significant differences in brain 
IFN-γ gene expression concentration between arthritic and non-arthritic mice. 
There were also no significant differences in brain IFN-γ gene expression 
concentration between arthritic and non-arthritic mice (Figure 3.10). Despite 
up-regulation in IFN-γ mRNA expression levels in both arthritic and non-arthritic 
mouse brains, there was no significant IFN-γ protein level detected in brains of 
these CII immunized mouse brains. This may be difficult to interpret. It may 
suggest that the local mRNA translation of IFN-γ in brains of CII immunized mice 
was still ongoing, or that any newly synthesised  IFN-γ was metabolised, or 
indeed that there was epigenetic or post-transcriptional modifications that 
prevented synthesis of IFN-γ .  
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Figure 3.10 Changes in Th1 cytokine mRNA levels in brains of CII immunized mice  
The dots represent mRNA expression levels of IFN-γ determined by real-time PCR in half 
brain tissue homogenate of naïve control mice (n=7 naïve control mice), non-arthritic mice 
(n=7 non-arthritic mice), and, arthritic mice (n=12 arthritic mice). The levels of mRNA were 
normalized to GAPDH expression and shown as arbitrary units. All mice were sacrificed and 
brains were collected on day 42. Data are presented as the mean values. (*P < 05 ; **P < 01; 
***P < 001 by one-way ANOVA analysis) Bars represent the mean values. 
3.2.4.3 Th-2 cytokines mRNA profiles in the brains of CII immunized 
mice (both arthritic mice and non-arthritic mice) 
The mRNA of Th-2 cytokines, including IL-4, IL-5, IL-10 and IL-13 gene expression 
were determined in the brains of naïve control mice and CII immunized mice 
with and without arthritis. However, there was no transcription of these Th2 
cytokines detected in the brain of mice from all experimental groups. 
Interestingly, Th2 cytokines including IL-5, IL-10 and IL-13 protein concentration 
were increased significantly in arthritic mouse brains compared to those in naïve 
control mice, while there was no significant mRNA expression levels detected in 
the same brains of theses arthritic mice. These observations may suggest that 
the timing of induction and half-life of mRNA had finished while the protein was 
maintained, and/or transportation of these Th2 cytokine proteins from the 
periphery into the brains of arthritic mice.  
3.2.4.4  Chemokine mRNA profiles in the brains of CII immunized mice 
(both arthritic mice and non-arthritic mice) 
Expression levels of mRNA for CXCL1, CXCL10, CCL2 and CCL3 were determined 
in the brains of mice from all experimental groups. One-way ANOVA 
demonstrated that there were significant differences in protein concentration of 
CXCL1 and CXCL10 among the three groups of mice (P = 0.0009 and P = 0.0002 
respectively) (Figure 3.11A and Figure 3.11B). Post hoc analysis with Bonferroni 
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correction demonstrated that CXCL1 and CXCL10 were increased significantly in 
brains of both arthritic and non-arthritic mice compared to those in naïve 
control mice. The mean values of CXCL1 (arthritic versus naïve control) was 3160 
± 828 versus 1212 ± 162 (P < 0.001). Similar to the protein profile, mRNA level of 
CXCL1 was also increased in non-arthritic mouse brains. The mean values of 
CXCL1 (non-arthritic versus naïve control) was 2818 ± 991 versus 1212 ± 162 (P < 
0.05). There were no significant differences in brain CXCL1 gene expression 
levels between CIA and non-CIA mice (Figure 3.11A). The data suggest that there 
was local production of CXCL1 in the brains of CII immunized mice by CNS 
immune cells and peripheral immune cells trafficking into the brains. The 
possibility that there was also a transportation of CXCL1 protein into the brain of 
CII immunized mice was supported by the data showing the same CXCL1 protein 
profiles in serum of these CII immunized mice. Increases in serum CXCL1 protein 
concentration were observed in CII immunized mice as well as an increase in 
mRNA and protein concentration in their brains.  
CXCL10 was another chemokine that was increased in the brains of CII 
immunized mice. The mean values of CXCL10 (arthritic versus naïve control) was 
442 ± 150 versus 163 ± 35 (P < 0.001). The up-regulations of CXCL10 gene 
expression was also observed in brains of non-arthritic mice compared to those 
in naïve control mice. There were no significant differences in brain CXCL10 
gene expression concentration between naïve control mice and non-arthritic 
mice. CXCL10 gene expression in arthritic mouse brains was significant higher 
than those in non-arthritic mouse brains. The mean values of CXCL10 (arthritic 
versus non-arthritic) was 442 ± 150 versus 283 ± 120 (P < 0.05) (Figure 3.11B). 
The significant higher level of CXCL10 in arthritic mice compared to those in 
non-arthritic mice suggests that the production of CXCL10 in the brain may be 
associated with peripheral joint inflammation in arthritic mice.  
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Figure 3.11 Changes in chemokine mRNA expression levels in brains of CII immunized mice  
The dots represent mRNA levels of CXCL1 (A) and CXCL10 (B) determined by real-time PCR 
in half brain tissue homogenate of naïve control mice (n=7 naïve control mice), non-arthritic 
mice (n=7 non-arthritic mice), and, arthritic mice (n=12 arthritic mice). The levels of mRNA 
were normalized to GAPDH expression and shown as arbitrary units. All mice were 
sacrificed and brains were collected on day 42. Data are presented as the mean values. (*P < 
05 ; **P < 01; ***P < 001 by one-way ANOVA analysis) Bars represent the mean values. 
3.2.4.5  Growth factor mRNA profiles in the brains of CIA mice 
Growth factors such as FGF2 and VEGF were detectable in the brains of control 
mice and mice with and without arthritis. One-way ANOVA analysis showed that 
there was no significant difference in the gene expression level of FGF2, 
although the FGF2 protein concentration in arthritic mice was increased 
compared to the naïve control mice (P = 0.4803) (Figure 3.12A). The data 
suggest that there may be the transportation of FGF2 into the CNS in the 
arthritic mice during the course of the disease. One-way ANOVA analysis showed 
that there was no significant difference in brain VEGF between naïve control 
mice and CII immunized mice (P = 0.0674) (Figure 3.12B).   
 
Figure 3.12 Changes in growth factor mRNA levels in brains of CII immunized mice  
The dots represent mRNA levels of FGF2 (A) and VEGF (B) determined by real-time PCR in 
half brain tissue homogenate of naïve control mice (n=7 naïve control mice), non-arthritic 
mice (n=7 non-arthritic mice), and, arthritic mice (n=12 arthritic mice). The levels of mRNA 
were normalized to GAPDH expression and shown as arbitrary units. All mice were 
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sacrificed and brains were collected on day 42. Data are presented as the mean values. (*P < 
05 ; **P < 01; ***P < 001 by one-way ANOVA analysis) Bars represent the mean values. 
In summary: Real-time PCR detected increases in the Th1 cytokine (IFN-γ), 
chemokines (CXCL1 and CXCl10) and growth factors (FGF2 and VEGF) in brain 
tissue of mice from all experimental groups. Expression levels of IFN-γ, CXCL1, 
CXCL10 and VEGF were significantly increased in the brains of CII immunized 
mice (both arthritic and non-arthritic) compared to those in naïve control mice. 
Table 3.3 shows a summary of these data as mean ± SD of fold changes of 
inflammatory mediator gene expression in brains of CII immunized mice (both 
arthritic and non-arthritic) in comparison to those in brains of naïve control 
mice. Data were categorized into 3 groups (a Th1 cytokine, chemokines and a 
growth factor). Our data showed that inflammatory mediator mRNA expression 
levels in brains of CII immunized mice were significantly increased from 1.7 – to 
3.0 – fold compared with those in naïve control. Among these inflammatory 
mediators, the greatest mean fold increase was for the growth factor VEGF 
mRNA expression levels in brains of non-arthritic (3-fold) and arthritic (2.9-fold) 
mice. This also suggest that there was a similar degree of elevation of VEGF 
mRNA expression levels in brains of immunised and challenged mice irrespective 
of whether they developed frank arthritis. This observation was also seen for 
CXCL1 mRNA and protein concentration which were similar in both arthritic and 
non arthritic mouse brains, and both were higher than control mice. This 
suggests that there may be a biological association between gene expression and 
protein level in brains of CII immunized mice.  
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                   Arthritic                                 Non-arthritic 
 
Inflammatory 
mediators 
genes 
  Fold changes        P value         Fold changes          P value 
           of                                             of 
  mRNA concentration             mRNA concentration 
 
Th1 cytokines 
 
         IFN-γ                     2.2 ± 3.0                     < 0.05*                1.9 ± 2.8                      NS 
 
Chemokines 
 
          CXCL1                 2.6 ± 5.1                     < 0.001***              2.3 ± 6.1                 < 0.05* 
 
          CXCL10               2.7 ± 4.3                     < 0.001***              1.7 ± 3.4                    NS 
 
Growth factors 
 
         VEGF                    2.9 ± 7.3                         NS                   3.0 ± 9.0                      NS 
 
          FGF2                    1.8 ± 0.9                        NS                   1.2 ± 2.2                       NS 
Table 3.3 Summary of inflammatory mediator gene expression profiles in brains of CII 
immunized mice  
Data was presented as mean ± SD of fold changes of inflammatory mediator mRNA profiles 
in brains of CII immunized mice (both arthritic and non-arthritic) in comparison to those in 
brains of naïve control mice. One-way ANOVA analysis (*P < 05 ; **P < 01; ***P < 001) was 
used to demonstrate significant increase in inflammatory mediator mRNA expression levels 
in arthritic and non-arthritic mouse brain compared to those in control mouse brains. NS = 
not statistically significant. 
 
3.2.5  Comparisons of gene and protein expression of 
inflammatory mediators in arthritic and non-arthritic mouse 
brains 
In summary, our data demonstrated different profiles of inflammatory mediator 
gene and protein expression in arthritic mouse (arthritic mouse) brains and non-
arthritic mouse brain (Table 3.4). Most of the inflammatory mediator proteins 
detectable by Luminex including IL-1α, IL-2, IL-5, IL-10, IL-13, CXCL10, and FGF2 
were increased significantly in arthritic mouse brains, while CXCL1 was the only 
inflammatory mediator that up-regulated significantly in both CIA and non-CIA 
mouse brains. By contrast, increases in inflammatory mediator mRNA, including 
IFN-γ, CXCL1, CXCL10, VEGF, were observed in both arthritic and non-non-
arthritic mouse brains.  
IL-2 protein was the only Th1 cytokine up-regulated in brains of arthritic mice 
compared to those in naïve control mice, while IFN-γ mRNA concentration were 
increased in brains of both arthritic and non-arthritic mice compared to those in 
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naïve control mice. There was no Th2 cytokine (IL-5, IL-10, IL-13) mRNA 
detectable in either arthritic and non-arthritic mouse brains, while protein 
concentration of these Th2 cytokines were significantly increased in brains of 
arthritic mice compared to those in naïve control mice. Interestingly, similar 
protein concentration and gene expression profiles of CXCL1 were observed in 
both arthritic and non-arthritic mouse brains. Similarly, CXCL10 gene and protein 
expressions were increased in both arthritic mouse brains. Differences between 
CXCL10 mRNA concentration of arthritic and non-arthritic mouse brains were 
also observed. In the category of growth factor, FGF2 protein was increased only 
in arthritic mouse brains, while elevations of VEGF mRNA were observed in both 
arthritic and non-arthritic mice. 
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Protein and mRNA expression levels in brains of CII-
immunized compared with naïve control mice.  
Protein mRNA 
 
Inflammatory  
Mediators 
Arthritic Non-arthritic Arthritic Non-arthritic 
 
Pro-inflammatory  
cytokines 
 
 
IL-1α 
 
NS 
 
NS 
 
undetectable 
 
undetectable 
 
Th1 cytokines 
    
 
IL-2 
 
< 0.05* 
 
NS 
 
undetectable 
 
undetectable 
 
IFN-γ 
 
undetectable 
 
undetectable 
 
< 0.01** 
 
NS 
 
Th2 cytokines 
    
 
IL-5 
 
< 0.05* 
 
NS 
 
undetectable 
 
undetectable 
 
IL-10 
 
NS 
 
NS 
 
undetectable 
 
undetectable 
 
IL-13 
 
< 0.05* 
 
NS 
 
undetectable 
 
undetectable 
 
Chemokines 
  
 
CXCL1 
 
< 0.01** 
 
0.05* 
 
< 0.001*** 
 
< 0.05* 
 
CXCL10 
 
< 0.01** 
 
NS 
 
< 0.001*** 
 
NS 
 
Growth factor 
    
 
FGF2 
 
< 0.05* 
 
NS 
 
NS 
 
NS 
 
VEGF 
 
NS 
 
NS 
 
NS 
 
NS 
Table 3.4 A summary of inflammatory mediator gene mRNA expression and protein profiles 
in arthritic mouse brains and non-arthritic mouse brains  
Differences between inflammatory mediator concentration in immunized mouse brains 
(Arthritic/Non-arthritic mouse brains) and control groups were analyzed by Student's t-test 
(*P < 05 ; **P < 01; ***P < 001). NS = not statistically significant. 
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3.2.6  Correlations between chemokine mRNA and protein 
concentration in arthritic and non-arthritic mouse brains 
Inflammatory mediator gene expression concentration measured by real-time 
PCR have been shown to correspond with protein concentration in several 
studies (Young et al., 2008); (Stemme et al., 2001). A study by Mehra et al., 
suggest that the positive relationship between protein and mRNA concentration 
may reflect the post-transcription, post-translation and protein synthesis process 
within the tissue. Our data showed similar patterns of gene and protein profiles 
of CXCL1 and CXCL10 (Mehra et al., 2003). Particularly, both CXCL1 mRNA and 
protein concentration were increased in brains of both arthritic and non-arthritic 
mice. The relationship between protein and mRNA expression concentration of 
CXCL1 and CXCL10 within the same samples was examined using the Pearson’s 
correlation coefficient analysis. However, there was no statistically significant 
correlation between their protein and mRNA expression within the same samples 
across all experimental groups (Figure 3.13A, Figure 3.13B, Figure 3.13C).  The 
data suggest that CXCL1 and CXCL10 in brains of these CII immunized mice may 
not be produced locally in the brain. However, it is also possible that there were 
productions of CXCL1 and CXCL10 in the brain as well as transportation of these 
chemokines from the periphery.  
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Figure 3.13 Correlations of mRNA and protein concentration for CXCL1 and CXCL10 in 12 
arthritic and 7 non-arthritic mouse brains  
Dot plots show relationships between CXCL1 and CXCL10 mRNA (arbitrary units) and 
protein level (pg/ug total brain protein) within the samples from 12 arthritic and 7 non-
arthritic group analysed by Pearson’s correlation coefficient analysis. (A) shows the 
correlation between CXCL1 mRNA value and CXCL1 protein value for arthritic mouse brains 
(r
2
 = 0.010, P = 0.752). (B) shows the correlation between CXCL1 mRNA value and CXCL1 
protein value for non-arthritic mouse brains (r
2
 = 0.254, P = 0.249). (C) shows the correlation 
between CXCL1 mRNA value and CXCL10 protein value for arthritic mouse brains (r
2
 = 
0.01795, P = 0.678).  
3.2.7  Correlations between inflammatory mediator protein 
concentration and mRNA expression levels and arthritis 
scores 
To determine whether the disease severity of the experimental arthritis was 
associated with up-regulation of brain inflammatory mediators in arthritic mice, 
brain inflammatory mediator protein and /mRNA and the arthritis score of each 
arthritic mouse was compared using the Pearson’s correlation coefficient 
analysis. None of the brain inflammatory mediator protein or mRNA levels  
correlated with arthritis scores in arthritic mice (Figure 3.14A-Figure 3.14D, 
Figure 3.15A-Figure 3.15H). It appeared that the mediator measurement at a 
single time point was not a good measure of clinical expression of this chronic 
disease. 
Chapter 3  159 
 
 
 
Figure 3.14 Correlations of inflammatory mediator protein concentration and arthritis score 
in 12 arthritic mice  
Dot plots show relationships between brain inflammatory protein concentration (pg/µg total 
brain protein) and arthritis score within the samples from arthritic group (n = 12 arthritic 
mice) analysed by Pearson’s correlation coefficient analysis. (A) shows the correlation 
between brain IL-2 protein value and arthritis scores in CIA mice (r
2
 = 0.033, P = 0.575). (B) 
shows the correlation between brain IL-5 protein value and arthritis scores in arthritic mice 
(r
2
 = 0.05, P = 0.834). (C) shows the correlation between brain IL-13 protein value and 
arthritis scores in arthritic mice (r
2
 = 0.000, P = 0.984). (D) shows the correlation between 
brain CXCL1 protein value and arthritis scores in arthritic mice (r
2
 = 0.020, P = 0.665). (E) 
shows the correlation between brain CXCL10 protein value and arthritis scores in arthritic 
mice (r
2
 = 0.015, P = 0.706). (F) shows the correlation between brain FGF protein value and 
arthritis scores in arthritic mice (r
2
 = 0.122, P = 0.267). 
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Figure 3.15 Correlations of inflammatory mediator gene expression levels and arthritis 
score in arthritic mice  
Dot plots show relationships between brain inflammatory mediator mRNA (number of 
copies/GAPDH copies) and arthritis score within the samples from arthritic group (n = 12 
arthritic mice) analysed by Pearson’s correlation coefficient analysis. (A) shows the 
correlation between brain IFN-γ mRNA value and arthritis scores in arthritic mice (r
2
 = 0.257, 
P = 0.092). (B) shows the correlation between brain CXCL1 mRNA value and arthritis scores 
in arthritic mice (r
2
 = 0.313, P = 0.059). (C) shows the correlation between brain CXCL10 
mRNA value and arthritis scores in arthritic mice (r
2
 = 0.214, P = 0.130).  
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3.3  Result chapter 3; Summary of findings.  
The aim of this chapter was to investigate the evidence for and the potential 
process of peripheral inflammation-induced-brain inflammation in an 
autoimmune disease model of RA. A Luminex bead-based assay and real-time 
PCR assays were used to explore changes in inflammatory mediator protein 
concentration and expression levels respectively in brains of CII immunized mice 
that may be involved in the process of immune or inflammatory response 
activation in the brain during arthritis. We found; 
1. Increased concentrations of IL-2, IL-5, IL-13, CXCL1, CXCL10 and FGF2 protein 
in brains of CII immunized mice with arthritis compared to naïve control mice. 
2. Increased concentration of serum CXCL1 protein in both arthritic and non-
arthritic mice compared to naïve control mice. 
3. CXCL1 was the only inflammatory mediator that was increased in brains of 
non-arthritic mice compared to naïve control mice. 
4. Increased IFN-γ, CXCL1 and CXCL10 mRNA expression levels were observed in 
brains of both arthritic and non-arthritic mice compared to naïve control mice. 
5. The patterns of serum CXCL1 protein concentration, brain CXCL1 mRNA 
expression levels and brain CXCL1 protein concentration of mice of all 
experimental groups were related. 
6. There was a significant increase in CXCL10 mRNA expression level in arthritic 
compared with non-arthritic mouse brains. 
7. The degrees of fold-increase compared to control mice of CXCL1 mRNA and 
protein concentration were similar in both arthritic and non-arthritic mouse 
brains. 
8. There was no significant correlation between CXCL1 and CXCL10 gene and 
protein expression levels of both arthritic and non-arthritic brains. 
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9. There was no significant correlation between the brain inflammatory mediator 
mRNA and protein levels and the arthritis scores.  
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3.4  Discussion 
For clarity, I will set out the discussion in logical sections interpreting the results 
in sequence. I will summarise and draw conclusions from these at the end. 
3.4.1  Elevations of inflammatory mediator mRNA and protein 
concentration in CII immunized mouse brains.  
 
In this chapter we have shown elevations of IL-1α, IL-2, IL-5, IL-10, IL-13, CXCL1, 
CXCL10 and FGF2 protein and mRNA expression levels in brains of CII immunized 
mice, particularly in those CII immunized mice that developed arthritis. We also 
found increases in serum CXCL1 protein in these CII immunized mice. Compared 
with control healthy mice, our data suggest that peripheral inflammatory signal 
may be associated with the activation of an immune or inflammatory response in 
the brain during arthritis.  
3.4.1.1  Increased pro-inflammatory cytokine protein concentration in 
arthritic mouse brains  
Among the pro-inflammatory cytokines (IL-1β, IL-1α, IL-6 and TNF-α) 
investigated in brain tissue of both CII immunized and naïve control mice. The 
brain IL-1α protein levels in arthritic mice seemed to be higher than those of 
naïve control mice on day 42. However, one-way ANOVA suggested that there 
was no significant difference in brain IL-1α protein among all 3 groups (naïve 
control, non-arthritic and arthritic groups). This may reflect small sample 
numbers. Therefore, it is worthwhile to repeat these experiments using the 
larger numbers of animals.  
IL-1α is a potent pro-inflammatory cytokine produced by glial cells, macrophages 
and synovial fibroblasts. IL-1α was found highly expressed in the inflamed 
synovia of RA patients (Brennan et al., 1989). The activities of IL-1α also play a 
pathogenic role in rheumatoid arthritis, particularly in cartilage destruction (RA) 
(Dayer and Fenner, 1992). Transgenic mice over-expressing IL-1α showed chronic 
synovitis and cartilage destruction, as a result of stimulation of matrix protein 
degrading enzymes; matrix metalloproteinase (MMP)-3 and MMP-13 produced by 
chondrocytes (Niki et al., 2004); (Rowan et al., 2003). Under physiological 
conditions, IL-1 (both IL-1α and IL-1β) is almost undetectable in the CNS. 
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However, after injury (e.g. stroke, haemorrhage, trauma), IL-1 family cytokines 
are produced by microglia, the resident brain immune cells (Luheshi et al., 
2009). In experimental models, peripheral immune challenge results in increased 
production of IL-1 both peripherally and centrally (Higgins and Olschowka, 
1991); (Quan et al., 1994); (Maness et al., 1998). Our data showed an increase of 
IL-1α protein concentration in the brain of CII immunized mice that developed 
arthritis, but not non-arthritic mice and suggests that the local increase may be 
associated with the peripheral joint inflammation. The increase of IL-1α protein 
concentration in brains of arthritic mice may also indicate an inflammatory 
process in brains of these mice during the course of arthritis disease. Our data 
also showed that there was no gene expression of IL-1α detectable in brains of 
these arthritic mice despite significant amount of IL-1α detectable in the same 
brains. This suggests that there may be the transportation of IL-1α protein from 
the periphery to the brain. However, we found no serum IL-1α in these arthritic 
mice therefore other possibilities are that IL-1α may enter the brain via 
migration of peripheral immune cells into the brain during the course of the 
arthritis, or that IL-1α is involved at another time-point. The question of how 
and when IL-1α is localized and/or transported from the periphery into the brain 
is unresolved, especially since there was no significant serum IL-1α detectable at 
that time point in these arthritic mice. This is an important and complex topic 
that needs further investigation. Useful experiments might include time-point 
experiments as outlined in results chapter 4.  
3.4.1.2  Elevations of a Th1 cytokine protein and gene expression 
concentration in CII immunized mouse brains  
RA is thought to be a Th1-cell driven disease, and Th1 (IL-2, IFN-γ and IL-12) 
cytokines may be part of the initiation of the destructive immune response in RA 
(McInnes and Schett, 2007). We found significant elevation of Th1 cytokine 
concentration in brains of arthritic mice. IL-2 protein concentration and IFN-γ 
were increased in CII immunized mice compared to those in the naïve control 
mice. It is possible that there is an association between the increases of these 
Th1 cytokines in the brains and the inflamed joints of these arthritic mice.  
In systemic immune responses, IL-2 is produced by activated CD4+ T-cells 
and this augments the secretion of IFN-γ. IL-2 acts via the IL-2 receptor (CD25, 
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IL-2R) and functions in clonal expansion of antigen-primed T-cells (Schroeter and 
Jander, 2005). Increases in IL-2 protein concentration were detected in both 
synovial fluid and peripheral blood of RA patients (Berner et al., 2000). 
Importantly, it has been reported that IL-2 was also highly expressed in paws of 
arthritic mice (Thornton et al., 1999). We found increases in IL-2 protein 
concentration and it is possible that circulating IL-2 produced by inflamed joints 
and associated lymphoid organs migrate into the brains of these CII immunized 
mice. IL-2 can also be producible by microglia locally in the CNS (Sredni-
Kenigsbuch, 2002). However, IL-2 gene expression was undetectable in brains of 
these arthritic mice, suggesting that IL-2 protein in arthritic mouse brains may 
be transported mainly from the periphery. However, we found no IL-2 protein 
level in serum these arthritic mice, suggesting that IL-2 protein may possibly 
enter the brain via trafficking of peripheral Th1 cells into the brain. The issue of 
when and how IL-2 enters the brain during the course of arthritis still remains 
unclear and needs further investigation.  
IFN-γ is an important regulator that has been implicated in the pathology of RA 
and also found highly expressed in both synovial fluid and peripheral blood of RA 
patients (Canete et al., 2000). IFN-γ is produced by activated T cells and NK 
cells (Farrar and Schreiber, 1993). IFN-γ is usually undetectable in the CNS 
except in the context of inflammation, when immune cells cross the blood-brain 
barrier and enter the CNS (Millward et al., 2007). During the CNS inflammatory 
process, IFN-γ is produced by microglia and functions to amplifies the adaptive 
immune response in the CNS by activating astrocytes and microglia to express 
MHC class I and class II (Yang et al., 2004); (Wong et al., 1984). IFN-γ also plays 
an important role in leukocyte migration into the CNS via activation of 
chemokine production by astrocytes and microglia (Sredni-Kenigsbuch, 2002). 
Our data showed elevations of IFN-γ gene expression concentration in brain of 
CII immunized mice, suggesting that there may be the production of IFN-γ locally 
in the brain. The increased level of IFN-γ mRNA concentration in brains of these 
CII immunized mice may also indicate the CNS inflammatory process and immune 
cell migration into the brains of these CII immunized mice. However, the 
mechanism of how IFN-γ gene expression was induced and the cellular source of 
IFN-γ in the brain of these CII immunized mice are still unclear. This may be 
associated with the elevations of IL-2 protein that also function to enhance the 
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expression of IFN-γ in Th1 cells (Schroeter and Jander, 2005). This question can 
be addressed by using immunohistochemistry of both IL-2 protein and markers 
for Th1 or/and microglia to investigate the co-localization of IL-2 with these 
immune cells in brain sections of CII immunized mice.  
3.4.1.3  Elevations of a Th2 cytokine protein and gene expression 
concentration in arthritic mouse brains  
Th2 cytokines such as IL-4, IL-5 and IL-13 play crucial roles in humoral immunity 
such as regulating B lymphocytes to mature to plasma cells and to stimulating 
immunoglobulin class switching from IgM to IgE and IgG1 (in mouse) or IgG4 (in 
man) isotypes (Schulze-Koops and Kalden, 2001). Anti-inflammatory cytokines 
produced by Th2 such as IL-4 and IL-10 also function to inhibit Th1 proliferation, 
prevent autoimmunity, synovial inflammation and tissue destruction in RA 
(Schulze-Koops and Kalden, 2001). Both clinical and animal studies demonstrated 
that Th2 cytokines were expressed in a low level in synovial fluid of RA patients 
and in draining lymph node cells during the onset, and the highest severity phase 
of the disease (Kusaba et al., 1998); (Mauri et al., 1996). Our data showed the 
up-regulation of IL-5, IL-13 and IL-10 protein concentration, but not gene 
expression, in arthritic mouse brains compared to those in the control mouse 
brains.  
IL-5 and/or IL-13 play an important role in allergic asthma and helminthic 
infection (Kurowska-Stolarska et al., 2008). IL-5 is produced mainly by Th2 cells 
and mast cells (Gregory et al., 2003), while IL-13 is produced by T cells, mast 
cells, basophils, dendritic cells, and keratinocytes (Schmid-Grendelmeier et al., 
2002). However, little is known about the role of IL-5 and IL-13 in pathogenesis 
and immune responses of RA. IL-5 and IL-13 expression has been reported in 
synovial tissues of RA patients. A study by Xu et al., in CIA model suggest that IL-
5 and IL-13 exacerbate the severity of arthritis disease by  promoting the 
production of specific IgG and IgE synthesis by B cells and antibody isotype 
switching in CIA. These antibodies then could bind to Fc receptors on mast cells 
and subsequently activate mast cell degranulation or/and form immune complex 
with antigen (Xu et al., 2008). Although IL-5 and IL-13 could also be produced by 
microglia and astrocytes in the brain (Sawada et al., 1993); (Shin et al., 2004), 
we found no gene expression of either IL-5 or IL-13 in brains of arthritic mice. 
Chapter 3  167 
This suggests that there was no local production of these Th2 cytokine in the 
brain. In addition, elevations of both IL-5 and IL-13 were observed only in CII 
immunized mice with arthritis, suggesting that IL-5 and IL-13 may be transported 
from the periphery to the brain during the course of RA. However, the issue of 
whether IL-13 and IL- 5 are transported to the brain by themselves or via the 
peripheral Th2 trafficking into the brain need further investigations. 
The brain IL-10 protein levels in arthritic mice seemed to be higher than those of 
naïve control mice on day 42. However, one-way ANOVA suggested that there 
was no significant difference in brain IL-10 protein among all 3 groups (naïve 
control, non-arthritic and arthritic groups). This may reflect a small sample 
number. Therefore, it is worthwhile to repeat these experiments using the larger 
numbers of animals.  
IL-10 predominantly an anti-inflammatory cytokine that is produced by 
monocytes, T cells, B cells, DCs, epithelial cells (McInnes and Schett, 2007). IL-
10 could inhibit the production of Th1 cytokine such as IFN-γ (Rizzo et al., 
1998). CIA mice receiving neutralizing anti-IL-10 antibodies demonstrated a 
delay of the onset and an increase in the severity of arthritis (Kasama et al., 
1995). In the CNS, IL-10 is produced by microglia and astrocytes and also plays a 
potent anti-inflammatory and neuroprotective role in several CNS diseases 
(Schroeter and Jander, 2005). Increases in IL-10 protein concentration were 
observed in brains of arthritic mice, but no gene expression detectable. This 
suggests that there may be a transportation of IL-10 from the periphery into the 
brain of these arthritic mice. It has been reported that the protein concentration 
of IL-10 were elevated in the lymph nodes of CII immunized mice transiently 3 
day after immunization and the low concentration of IL-10 protein were 
detectable throughout the time of clinical manifestation (Mauri et al., 1996). We 
could not detect serum IL-10 in the arthritic mice and we determined the brain 
IL-10 protein level in these mice at only one time point (day 42 after 
immunization). It is also possible that the transportation and the accumulation 
of IL-10 protein may occur at the earlier time point throughout 42 day of 
experimental period. Therefore, conducting time point experiment to 
investigate overtime changes of brain inflammatory mediators in brains of CII 
immunized mice would be useful to test this hypothesis.  
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3.4.1.4  Elevations of a chemokine protein and gene expression 
concentration in CII immunized mouse brains  
Chemokines are a group of inflammatory mediator that function to regulate 
recruitment of leukocytes and angiogenesis in the inflammatory process (Koch, 
2005). In RA, synovial fibroblasts produce chemokine, which function to attack 
leukocytes into the synovial tissue (Koch, 2005). In our study, we found 
elevations of CXCL1 and CXCL10 protein and gene concentration in brains of CII 
immunized mice (both arthritic and non-arthritic mice). Our data may indicate 
the recruitment of immune cells into the brain of CII immunized mice. 
CXCL1 functions as a potent neutrophil chemo-attractant by binding both CXCR1 
and CXCR2 receptors (Luttichau, 2010). CXCL1 have been reported in osteoblasts 
and synovial fluid from rheumatoid arthritis patients (Lisignoli et al., 1999), 
(Bischoff et al., 2005). An administration of CXCL1 antibody has shown to delay 
the onset and reduce in the disease severity of CIA mice (Kasama et al., 1995). 
We found the up-regulation of CXCL1 protein in serum of CII immunized mice. 
Our data are consistent with a study by Kurowska-Stolarska et al showing the 
increase concentration of serum CXCL1 in CIA mice (data are in press PNAS). 
Interestingly, the serum CXCL1 protein profiles of these CII immunized mice 
were similar to brain CXCL1 protein profiles for both arthritic and non-arthritic 
mice. These data suggest that there may be transportation of CXCL1 from the 
periphery into the brain of these CII immunized mice. We also found up-
regulation CXCL1 gene expression in these CII immunized mice, suggesting that 
there was also the local production of CXCL1 in the brain of these CII immunized 
mice. Interestingly, degrees of fold elevations of brain CXCL1 mRNA and protein 
concentration were quite similar for both arthritic and non-arthritic mice. This 
seems pretty convincing evidence suggest that both brain CXCL1 protein and 
gene could be generated locally within the CNS and by the same cellular source. 
However, we found no significant correlation between mRNA and protein 
concentration of brain CXCL1 in CII immunized mice. Therefore we cannot 
conclude from our data set about the location and the cellular source of the 
CXCL1 production in brains of these CII immunized mice. Microglia and 
astrocytes are the major source of CXCL1 in the brain and it has been 
demonstrated that the induction of peripheral inflammation by LPS could induce 
microglia activation and the production of CXCL1 in the brain (Brown et al., 
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2010). CXCL1 was transiently expressed at circumventricular organs (CVOs), 
which are exceptional areas in the brain that are not covered by BBB, after the 
peripheral LPS induction (Reyes et al., 2003). On the other hand CXCL1 can be 
produced inside the brain during the neuroinflammatory process such as 
encephalomyelitis (Rubio and Sanz-Rodriguez, 2007) or injury via IL-1β 
signalling, leading to the infiltration of neutrophils into the brain (McColl et al., 
2007).The elevations of CXCL1 may indicate leukocyte infiltration into the brains 
of CII immunized mice. However, the location, cellular source of brain CXCL1 
and the relationship between peripheral CXCL and brain CXCL1 need further 
investigation. 
CXCL10 functions as a potent T-lymphocyte recruiter by binding into the 
receptor CXCR3, preferentially on the Th1-lymphocyte subset. In RA, CXCL10 
induced CCL5 expression in CD4+ T cells, which promote bone resorption by 
inducing osteoclast formation and survival (Lee et al., 2009). The up-regulation 
of CXCL10 has been reported in serum and inflamed joints of CIA mice sacrificed 
on day 42 (Kwak et al., 2008). CXCL10 has also been implicated in pathogenesis 
of neuroinflammatory diseases. CXCL10 and its receptor, CXCR3, are highly 
expressed by the CNS and by CNS infiltrating lymphocytes, respectively, only in 
patients with ongoing CNS inflammation such as viral encephalitis and multiple 
sclerosis (Klein, 2004). The pathological mechanism of these neuroinflammatory 
diseases involves the infiltration of leukocytes into the CNS and CXCL10 has been 
reported to regulate peripheral Th1 infiltration into the CNS during these 
neuroinflammatory diseases (Klein, 2004). Therefore, the elevations of both 
CXCL10 gene and protein concentration in brains of CII immunized mice could be 
an important indicator of the presence of neuro-inflammation that may/may not 
associated with the peripheral joint inflammation. Interestingly, elevations of 
CXCL10 protein were only observed in brains of CII mice with arthritis and there 
were differences in CXCL10 mRNA concentration between arthritic and non-
arthritic mice. These observations in our study may suggest that the elevations 
of brain CXCL10 in arthritic mice may be associated with Th1 infiltration from 
the peripheral inflammatory joints into the brains. This hypothesis is supported 
by a study in CIA model showing that non-arthritic mice showed a significant 
deficiency in T cell responses and significantly lower concentration of anti-CII 
Abs after the secondary challenge compared to mice that developed arthritis 
Chapter 3  170 
(Pan et al., 2004). Another interesting observation is that there were increases 
in CXCL10 mRNA concentration in non-arthritic mouse, but no CXCL10 detectable 
in the same mouse brains. This suggests that there was a local production of 
CXCL10 in the brain of non-arthritic mice. It has been reported that the 
induction of CXCL10 gene expression in the brain depends on IFN-γ (Carter et 
al., 2007). Therefore, it is possible that elevations of CXCL10 mRNA 
concentration may be associated with elevations of IFN-γ mRNA concentration 
observed in non-arthritic mouse brain.  It is also possible that the pathway of 
brain CXCL10 production in non-arthritic mice is different from those in arthritic 
mice. This is because the peripheral administration of CFA can also cause 
microglia activation and cytokine production in the CNS (Raghavendra et al., 
2004). Therefore, CII immunized mice received CFA that did not develop 
arthritis could also induce the production of brain cytokines/chemokines without 
migration of immune cells and cytokines/chemokines from inflamed joint to the 
brain. 
3.4.1.5  Elevations of a growth factor protein and gene expression 
concentration in CII immunized mouse brains  
 
We also found elevations of FGF2 protein concentration in brains of arthritic 
mice and elevations of VEGF mRNA concentration in both arthritic and non-
arthritic mice. The elevations of these angiogenic factors may indicate changes 
in BBB properties that occurred during the systemic joint inflammatory process. 
Fibroblast growth factor 2 is a wide-spectrum mitogenic, angiogenic, and 
neurotrophic factor that bind to FGFR (FGF receptors and regulates various 
biological processes, including embryogenesis, wound healing, angiogenesis, and 
maintenance of neuronal networks (Manfe et al., 2010). In RA, FGF2 is produced 
mainly by endothelial cells and fibroblast; predominantly at the sites of chronic 
inflammation (Malemud, 2007). Elevation of FGF2 was observed in the synovial 
tissue of patients with RA (Thomas et al., 2000), and this worsened the joint 
inflammation in CIA rats (Yamashita et al., 2002).  FGF2 play a crucial role in the 
final step of osteoclastic bone resorption in rheumatoid arthritis joint 
destruction that is preceded by recruitment and differentiation of osteoclasts by 
other factors (Chikazu et al., 2000). FGF2 also play a role in angiogenesis and 
recruitment of the immune cell into the inflamed site (Malemud, 2007). An in 
Chapter 3  171 
vivo study showed that FGF2 synergistically enhanced the recruitment of 
monocytes, T cells and PMNs in response to a variety of inflammatory mediators, 
including IFN-γ, TNF-α and CCL-2. FGF2 also enhanced leukocyte recruitment to 
sites of inflammation by inducing endothelial adhesion molecule expression such 
as ICAM-1 and integrins (Zittermann and Issekutz, 2006). We found elevations of 
FGF2 protein in brains of arthritic mice, but no FGF2 gene expression detectable 
in the same brain, suggesting that there may be the contribution of FGF2 from 
the peripheral inflamed joint into the brain. However, we could detect FGF2 
protein concentration in these arthritic mice but the concentrations were not 
different from those in naïve control mice. Therefore, we cannot conclude from 
our experiment about the location and cellular source of FGF2 in the brains of 
these arthritic mice. One reason is that we only investigated the expression of 
the protein concentration at one time point on day 42, it is possible the 
contribution of FGF2 from the periphery into the brains of arthritic mice may 
occur at the earlier time point. Therefore, it is important to investigate changes 
of these brain inflammatory mediators in other time point throughout 
experimental time period. 
The brain VEGF protein levels in arthritic mice seemed to be higher than those 
of naïve control mice on day 42. However, one-way ANOVA suggested that there 
was no significant difference in brain VEGF protein among all 3 groups (naïve 
control, non-arthritic and arthritic groups). This may reflect a small sample 
number. Therefore, it is worthwhile to repeat these experiments using the larger 
numbers of animals.  
VEGF and its receptor VEGFr play a crucial role in angiogenesis process in RA 
because the pannus formation in RA requires neovascularisation that regulate 
mainly by VEGF. VEGF was highly expressed by RA synovium (Nagashima et al., 
1995) and also thought to play an important role in the chronic edema and 
swelling in arthritis joint (Malemud, 2007). We found elevations of VEGF mRNA 
in both arthritic and non-arthritic mice, but there was no VEGF protein 
detectable in brains of these CII immunized mice. This suggests that they may be 
the local production in the brains. However, the mechanism of how VEGF mRNA 
expression was induced in the brains of these CII immunized mice is still unclear. 
One possibility is that FGF2 also has an autocrine effect on angiogenesis by 
inducing vascular endothelial growth factor (VEGF) in endothelial cells (Seghezzi 
Chapter 3  172 
et al., 1998). Therefore, the increased VEGF gene expression in arthritic mouse 
brains could be associated with the up-regulation of FGF protein level. We could 
not address the question of why VEGF mRNA concentrations were increased in 
non-arthritic mouse brain. One possible explanation is that VEGF is also an 
angiogenic factor that enhance BBB permeability, and BBB disruption is observed 
in several models of neuroinflammation such as EAE and viral encephalomyelitis 
models (Kirk and Karlik, 2003); (Sasaki et al., 2010). The up-regulations of VEGF 
mRNA concentration in CII immunized mouse brains could be an indicator of BBB 
breakdown in this model. The BBB breakdown in the brain is often followed by 
the infiltration of leukocyte into the brain. The administration of VEGF into 
mouse brains result in breakdown of the blood–brain barrier, leukocyte 
recruitment into the brain (Croll et al., 2004b). Therefore, the up-regulation of 
VEGF mRNA concentration in brains of non-immunized mice may be associated 
with the increases in CXCL1 and CXCL10 that may function to regulate peripheral 
leukocyte recruitment into the brain.  
In this study, we demonstrated increases of various inflammatory mediators, 
including IL-1α, IL-2, IFN-γ, IL-5, IL-10, IL-13, CXCL1, CXCL10 and FGF2 in brains 
of CII immunized mice. However, we could not detect some inflammatory such 
as IL-1 cytokines, including IL-1β, TNF-α and IL-6, that have been reported to be 
increase in the CNS of mouse models of RA (Bao et al., 2001); (del Rey et al., 
2008). A study by Boa et al., reported elevations of both protein and mRNA 
concentration of these pro-inflammatory cytokines (IL-1β, TNF-α and IL-6) in 
spinal cord of AIA mice (Adjuvant-induced arthritis model) (Bao et al., 2001). 
Differences in the procedure for inducing arthritis and immunopathogenesis may 
account for contradictory results from the literature. Adjuvant induced arthritis 
(AIA) is an arthritis model, induced by a single intradermal injection of complete 
Freund’s adjuvant (CFA) consisting of heat-killed Mycobacterium tuberculosis 
(Mt) and incomplete Freund’s adjuvant (IFA) (Hossain et al., 2001). Polyarthritis 
rapidly develops around 10 days after immunization using adjuvant and the 
whole course of the disease lasts for 21 days (Bendele, 2001). In addition, the 
AIA model is Th1-cell and neutrophil dependent, and complement-independent. 
There is no evidence demonstrating that B-cells play a role in the pathogenesis 
of AIA. By contrast, the immune response of CIA involves both CII-specific T-cells 
and B-cells, which produce antibodies to type II collagen. The differences in the 
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immunopathological mechanism of both arthritic models may cause different 
peripheral inflammatory mediator profiles, which may result in different brain 
inflammatory mediator expression patterns. For example, TNF-α, IFN-γ, IL-1, IL-
6, and IL-17A are dominant in the periphery of AIA model, while several pro- and 
anti-inflammatory cytokines, including TNF-α and IL-1β, IL-6, IL-12, IL-1Ra, IL-10 
and TGF-β, are highly expressed in the periphery of mice with CIA (Hegen et al., 
2008). In addition, time course studies of inflammatory mediator expressions in 
periperal tissue (paws and lymph nodes) of CIA mouse model reveal increases of 
different cytokines/chemokines expressions at different time points (Thornton et 
al., 1999);(Rioja et al., 2004);(Mauri et al., 1996). A study by Mauri et al., show 
increases of IL-10, IFN-γ and TNF-α in the culture lymph node of CIA mice 
between day 3 – day 6 after immunization (Mauri et al., 1996). Another study by 
Rioja et al showed transient increases of IL-1β and IL-6 mRNA and protein 
concentration in paws of arthritic mice during the first 4 days after 
immunization, while the prolonged expression of TNF-α mRNA and protein 
concentration throughout 15 days after immunization (Rioja et al., 2004). 
Another study by Thornton et al., demonstrated different cytokine expression 
patterns in paws of CIA mice. Transient increases in IL-2, IL-6 and TNF-α mRNA 
were observed during the early disease stage (day 21-day 28 after 
immunization), while CXCL2 and IL-1β mRNA concentration were increased later 
during day 35 after immunization (Rioja et al., 2004). These evidence suggest 
the possibility that the contribution of inflammatory mediators from inflamed 
joint to the brain could be manifested at anytime throughout the experimental 
course. In this chapter, we only determined brain inflammatory mediator 
concentration in brain of CII immunized on the final day of the experimental 
course on day 42. Therefore, we hypothesized that some cytokines, particularly 
pro-inflammatory cytokines IL-1β, TNF-α, IL-6 that we could not detect in CII-
immunized mouse brain at this time point, may be up-regulated at earlier time 
point. This hypothesis is supported by a recent data showing the transient 
elevations of IL-1β mRNA concentration during first 10 days after immunization 
and elevations of IL-6 mRNA concentration during early stage of arthritis disease 
in CIA rat brains (day 20 – day 30 after immunization) (del Rey et al., 2008). In 
addition, experimental evidence showing the elevations of cytokine/chemokine 
expression in paws of CIA mice during the early time point of CIA experimental 
course (Rioja et al., 2004) and  (Thornton et al., 1999) can also explain our 
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observation of disassociation between arthritic scores and brain inflammatory 
mediator concentration in arthritic mice in our study. It is possible that 
peripheral joint inflammation may involve production of brain inflammatory 
mediators at earlier time point in the CIA experimental course, but the 
elevations of these inflammatory mediator concentration observed in these 
arthritic mice at late time point of the CIA experimental course (day 42) may be 
generated from local cellular sources in the brain. Therefore, time course 
experiment of inflammatory mediator expressions in brains of CII-immunized 
mice is essential for further investigations of brain-immune system-joint 
communication. 
In summary: this chapter we demonstrated elevations of various inflammatory 
mediators, including IL-1α, IL-2, IFN-γ, IL-5, IL-10, IL-13, CXCL1, CXCL10, FGF2 
in brains of CII immunized mice, which may indicate the immune activation and 
inflammatory process in the brains of CII immunized mice. However, our data 
raised several questions; (i) how these inflammatory mediators access from the 
periphery into the brain, (ii) when these inflammatory mediators access from 
the periphery into the brain, (iii) what cellular sources of these inflammatory 
mediators in the brain, (iv) how peripheral joint inflammation signals CNS 
immune cells to produce these inflammatory mediators in the brain. In an 
attempt to address these questions, in the next chapter, we conducted time 
course experiment of inflammatory mediator expressions in brains of CII-
immunized mice. This was to investigate the association between arthritis 
disease development and overtime changes in inflammatory mediator 
concentration in brains of CII-immunized mice, which may indicate brain-
immune system-joint communication in this model. 
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4.1 Introduction and aims 
In the previous results chapter (Chapter 3), we showed increased concentrations 
of inflammatory mediator mRNA and protein, including IL-α, IL-2, IL-5, IL-10, IL-
13, CXCL1, CXCL10, FGF2 and VEGF in brains of mice immunized with collagen II 
in Freund’s adjuvant; particularly in those mice that subsequently developed 
arthritis. However, we could not demonstrate a clear association between the 
increased concentrations of these brain inflammatory mediators and peripheral 
joint inflammation as indicated by the lack of association between the arthritis 
scores and the concentrations of the inflammatory mediators in the brains. In 
addition, we could not detect some cytokines such as IL-1β, TNF-α and IL-6, that 
have been reported to be elevated in the CNS of arthritic mice (Bao et al., 
2001). One reason for that may have been because we only determined brain 
inflammatory mediator expression mice at only one time point on day 42; which 
was the final day of the experimental course of the collagen induced arthritis 
(CIA) model. Therefore, the aim of this chapter was to determine the changes in 
brain inflammatory mediators at other time points during the development of 
experimental arthritis to investigate potential pathological pathways of how 
peripheral joint inflammation might signal to the brain to increase synthesis of 
inflammatory mediators.  
Background: Collagen induced arthritis (CIA) in mice is considered to be a 
disease model of chronic inflammatory arthritis (Luross and Williams, 2001). In 
this model longitudinal changes in cytokine concentrations are found in 
peripheral tissues including the joints and lymph nodes following initial 
sensitisation with collagen (Rioja et al., 2004). Several studies investigated a 
cytokine expression cascade in the progression of RA by measuring cytokine 
expression in the peripheral tissues at different time points throughout the CIA 
experimental course (Thornton et al., 1999); (Rioja et al., 2004); (Mauri et al., 
1996). These studies often divided the CIA experimental course into several 
phases such as the acute phase (onset phase) and the chronic phase (Geng et al., 
2008); (Mauri et al., 1996), and investigated longitudinal changes in cytokine 
patterns at different phases of the course of experimental disease. The acute 
phase (onset phase) occurs after immunization and is characterized by rapid 
disease progression (Mauri et al., 1996). The chronic phase of the disease course 
is characterized by erosion of cartilage but the disease progression becomes 
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slower than during the acute (onset) phase (Geng et al., 2008). Studies suggest 
that different cytokine expression patterns that occur during these different 
phases are associated with differences in pathological stages of arthritis. A study 
by Thornton et al., showed that elevation of IL-2, IL-1β and CXCL2 mRNA in the 
paws may be associated with more leukocyte and neutrophil infiltration into the 
paw during the onset of disease. In contrast, TGF-β may be associated with 
increased in fibrosis and the number of fibroblast/macrophage type cells in the 
paw during the chronic stage (Thornton et al., 1999). In addition, accumulating 
evidence also showed the contribution of different cytokines in different 
peripheral tissues at different phases of disease. For example, Th1 cytokines 
such as IL-12 and IFN-γ are predominately expressed in lymph nodes and the 
spleen and in the peritoneal cavity during the acute phase (onset phase). In 
contrast, IFN-γ is expressed for a limited period around the time of disease onset 
in the joint, but prolonged expression of IL-1, IL-10, TNF-α, TGF-β and IL-6 are 
detected in the joint during the chronic phase (Okamoto et al., 2000); (Stasiuk 
et al., 1996); (Mussener et al., 1997). If there is a contribution of inflammatory 
mediators from the peripheral inflamed tissues (joints and lymph nodes) into the 
brain in the CIA model, then the longitudinal changes in brain inflammatory 
mediators should correspond or be associated with longitudinal changes in 
peripheral inflammatory mediators throughout CIA experimental course. This 
hypothesis is supported by a study by del Ray et al showing that the longitudinal 
change in brain IL-β mRNA concentrations corresponded to the longitudinal 
change in IL-β protein in lymph nodes in CIA rats (del Rey et al., 2008) .    
Based on this evidence, we hypothesized that there may be longitudinal changes 
in brain inflammatory mediators associated with peripheral inflammatory 
mediator changes throughout the progression of disease in CII immunized 
arthritis mice. The aims of this chapter are:-  
(i) To determine changes in inflammatory mediators in brains of CII 
immunized mice at different time points. 
(ii) To determine changes in peripheral inflammatory mediators at 
different time points by measuring inflammatory mediator protein 
concentrations in the serum of CII immunized mice. 
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The data obtained from this time-course experiment may provide the additional 
evidence of how peripheral joint inflammation signals to the brain to produce 
local inflammatory mediators. In addition, the results from this experiment may 
also provide interesting insights into up- and down-regulation of the brain 
cytokine network, which may reflect the biological interplay and the local 
cellular sources of brain inflammatory mediators over the course of arthritis 
disease. 
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4.2 Results 
4.2.1  Induction of arthritis in DBA1 mice 
In the type-II collagen-induced arthritis model, the disease progression always 
develops from the acute phase into the chronic phase (Ohmachi et al., 2002). 
Several studies suggest that the CIA experimental course can be divided into 
several phases; (i) disease onset period, where CII immunized mice started to 
develop disease; (ii) acute phase period, where arthritis disease severity and 
disease progression increase rapidly, (iii) chronic or transition to chronic phase, 
where arthritis disease severity and disease progression increases slower than 
the last period but the paw swelling and the cartilage erosion are still manifest 
(Geng et al., 2008). A report by Ferraccioli et al., divided the CIA experimental 
period into 2 phases after the secondary immunization (or boosting). The early 
disease was defined as occurring on days 12–15 after day 21 (corresponding to 
the first clinical signs of joint swelling). The late disease phase was defined as 
days 23–25 after boosting (corresponding to the maximum clinical signs of joint 
swelling) (Ferraccioli et al., 2010). Based on mean arthritis score, mean paw 
thickness and %incidence of arthritis in CII immunized mice of the previous 
chapter (Chapter 3; section 3.2.1), all of the CII immunized mice started to show 
signs of arthritis during day 22-day 28, therefore we considered this period as a 
disease onset period. Arthritis disease severity and disease progression in the CII 
immunized mice increased dramatically during day 28-day 35, we therefore 
considered this period as early disease phase. We considered that last stage of 
CIA experimental course (day 35-day 42 after immunization) as a late disease 
phase since most of CII immunized mice developed paw swelling slower than the 
last period and paw swelling in some of the mice stopped or decreased. 
Several studies have reported the increases in inflammatory mediators, including 
IL-2, IL-6, TNF-α, CXCL1 and IL-10 in peripheral tissue such as paws and lymph 
nodes of CIA animals at both early and late stages of the experimental course of 
CIA (day 22- to day 42) (Thornton et al., 1999);(Rioja et al., 2004);(Mauri et al., 
1996). These suggest the possibility that the contribution of inflammatory 
mediators from peripheral inflamed tissues (paws and lymph node) to the brain 
could be manifested at anytime during the stage of disease progression. We 
hypothesized that some cytokines, particularly pro-inflammatory cytokines IL-
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1β, TNF-α, IL-6  that we could not detect in CII immunized mice on day 42, may 
be detectable in earlier time points  throughout the stage of disease progression 
( day 22 –day 42). This hypothesis is supported by a study showing up regulation 
of IL-1α, IL-6 and TNF-α in CNS tissue of arthritis rats on day 21 (Bao et al., 
2001). Based on this evidence and hypothesis, we measured the expression of 
inflammatory mediators in brains of CII immunized mice in 4 appropiate time 
points after immunization; throughout both early and late stages of disease 
progression. We started on day 22 after immunization because day 22 is 
considered to be the time point of the RA disease onset in this experimental 
arthritis model.  
In this chapter, we randomly divided CII immunized mice into 4 groups (n=6 
each), which were culled on days 22, 28, 35 and 42 respectively. 24 DBA1 mice 
were immunized by intradermal injection of type II collagen in Freund’s 
complete adjuvant on day 0, and rechallenged by intraperitoneal injection of 
collagen II in PBS on day 21 and then culled at different time points (days 22, 28, 
35, 42) throughout the disease course. The signs of arthritis in CII immunized 
mice were monitored from day 16 after immunization onwards and arthritis 
severity in this experiment were verified independently by Mr. Maurice Dixon. 4 
groups (6 mice per group) of sex- and age-matched untreated non-immunized 
DBA1 mice were used as antigen-naïve control groups, which were also culled on 
days 22, 28, 35, 42. Serum and brains of all experimental groups of mice were 
harvested and snap-frozen in liquid nitrogen and stored at –80˚C. Half of each 
brain was processed for protein extraction and inflammatory mediator protein 
analysis by luminex; the other half was processed for RNA extraction and the 
inflammatory mediator gene expression was determined by real-time PCR 
(Figure 4.1).  
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Figure 4.1 CIA experimental procedure for time course experiment  
24 DBA1 mice at 6-8 weeks of age were immunized with 100µg type II bovine collagen + 
complete Freund’s adjuvant (CFA) at day 0 and then challenged on day 21 with 200µg type II 
collagen. Mice were randomly divided into 4 groups (6 mice/group), which were culled on 
different days (days 22, 28, 35, 42) as indicated. Another 4 groups of untreated normal mice 
culled on the same days indicated were used as controls. Brain and serum from mice of all 
experimental groups were collected and processed for inflammatory mediator 
measurements using Luminex, ELISA and real-time PCR. 
4.2.1.1 Development and severity of arthritis disease of each group of 
CII immunized mice at each time point. 
All 6 CII immunized mice in Group 1 were culled on day 22 after immunization, 
there was no mice in that group developed arthritis.  
On day 28 after immunization, another 6 CII immunized mice in Group 2 were 
culled. There were 2 CII immunized mice in that group with arthritis (33.33% 
incidence) at the day of cull. The onset of arthritis disease of CII immunized 
mice in Group 2 occurred between days 26 and 28 after immunization. The mean 
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clinical score and the mean paw thickness of CII in Group 2 calculated on the 
cull day were 1.67 ± 0.7 and 1.84 ± 0.05 mm, respectively. CII immunized mice 
in this group also showed a significant increase in paw thickness compared to 
those in naïve control mice (P=0.0022) (Figure 4.2A, Figure 4.2B, Figure 4.2C). 
CII immunized mice in Group 3 (n=6) were culled on day 35 after immunization. 
At that time point, there were 3 CII immunized in Group 3 developed arthritis 
(50% incidence). Arthritic mice in this group started to show signs of arthritis 
between day 22 and day 28 after immunization. The mean clinical score and the 
mean paw thickness of CII in Group 3 calculated on the cull day were 3.17 ± 1.87 
and 1.95 ± 0.14 mm, respectively. A significant increase in paw thickness was 
observed in CII immunized mice in this group compare to those in naïve control 
mice (p=0.0032) (Figure 4.2A, Figure 4.2B, Figure 4.2C). 
At the final time point on day 42, 6 CII immunized mice in Group 4 were 
harvested. 3 CII immunized in this group developed arthritis and the clinical 
signs of arthritis were observed in these arthritic mice between day 20 and day 
28 (50% incidence) after immunization. The mean arthritis score and the mean 
paw thickness of CII in Group 4 calculated on the cull day were 3.33 ± 1.63 and 
2.04 ± 0.09 mm, respectively. Overall mean paw thickness of CII immunized mice 
of Group 4 was significantly higher than those in naïve control mice (P<0.0001) 
(Figure 4.2A, Figure 4.2B, Figure 4.2C). 
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Figure 4.2 Development and severity of arthritis disease of each group of CII immunized 
mice at each time point  
24 CII immunized mice were divided into 4 groups (6 mice/group), which were culled on 
different days (days 22, 28, 35, 42 after immunization) throughout CIA experimental course. 
(A) shows incidence of arthritis of each group of CII immunized mice at each time point, 
which was calculated from number of CII immunized mice with arthritis/total number of CII 
immunized mice used and present as percentage. The signs of arthritis in CII immunized 
mice were monitor from day 16 after immunization onwards. The first group of CII 
immunized mice (Group 1) were culled on day 22 after immunization. There was no CII 
immunized mice in that group developed arthritis (yellow line). CII immunized mice in Group 
2 started to show signs of arthritis from day 26 after immunization onwards and all the CII 
immunized mice in Group 2 were culled on day 28 (green line). CII immunized mice in Group 
3, which were culled on day 35 after immunization, started to show signs of arthritis from 
day 22 onwards and on the day of cull there were 3 CII mice in that group developed arthritis 
(blue line). At the terminal day of CIA experimental course (day 42), another 6 CII immunized 
mice were culled and there were 3 CII immunized mice developed arthritis on the day of cull. 
These arthritic mice in Group 4 started to develop arthritis from day 20 after immunization 
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onwards. (B) shows mean paw thickness of CII immunized mice which was calculated from 
the sum of the paw thickness of all mice divided by the number of mice in each time point 
group. (C) shows mean clinical of CII immunized mice which was calculated from the sum of 
the clinical scores of all mice divided by the number of mice in each time point group. Both 
mean clinical score and mean paw thickness of each time point were calculated on the day 
of cull. Mean paw thickness, mean clinical score and %incidence in CII immunised mice (n= 
6 CII immunised mice /group) were compared with those values of naïve control mice (n = 
6/group) at each time point. Data represent as mean ± SEM. (n=6 CII immunised mice 
/group). Statistical analysis of data was performed using two-way ANOVA for multiple 
comparison, compared with a group of control naïve mice; *P<0.05, ** P<0.01, *** P<0.001.  
Individual clinical scores and thickness of the paws of individual CII immunized 
mice in each group calculated on the cull day are show in Figure 4.3. The 
numbers of arthritic mice, mean arthritis scores, and mean swelling scores in 
each group are shown in Table 4.1. 
 
Figure 4.3 Individual clinical scores and thickness of the paws of individual CII immunized 
mice in each group  
(A) the dots represent mean paw thickness for each mouse calculated by sum of thickness 
of all four paws divided by 4. (B) the dots represent a cumulative arthritis score for all paws 
of each mouse, with a maximum score of 16 per mouse. Each group of CII immunized mice 
(n=6 CII immunised mice/group) were culled of different time points as indicated (Group 1; 
day 22, Group 2; day 28, Group 3; day 35 and Group 4; day 42) and both individual clinical 
scores and individual paw thickness were calculated on the day of cull. Bars represent the 
mean values. (*P < 05; **P < 01; ***P < 001 by one-way ANOVA analysis) 
 
 
 
 
 
 
Chapter 4  185 
Number Mean Maximum Mean  
Group 
 
Day  
of 
cull  
of 
arthritic mice 
(6 mice/group) 
arthritic 
scores 
arthritic 
scores 
paw 
diameter 
(mm) 
 
1 
 
 
 Day 22 
 
0/6 
 
0 
 
0 
 
1.7 
 
2 
 
 
Day 28 
 
2/6 
 
1 
 
4 
 
1.84 
 
3 
 
 
Day 35 
 
3/6 
 
3.17 
 
 
10 
 
1.95 
 
 
4 
 
 
Day 42 
 
3/6 
 
3.33 
 
12 
 
2.04 
Table 4.1 Numbers of arthritic mice, mean arthritis scores, and mean swelling scores of CII 
immunized mice in each time point groups  
Mice immunized with type II collagen were divided into 4 groups (group 1, 2, 3 and 4) which 
were culled on days as indicated. Numbers of immunized mice developed arthritis from 
each time point group were counted on the cull day. Mean arthritis scores (total arthritis 
score/number of mice in the group), maximum arthritis score and mean swelling of 
immunized mice from each time point group were calculated on the cull day. 
4.2.2  Time course analysis of serum inflammatory mediator 
protein concentration in CII immunized mice. 
To investigate changes in peripheral inflammatory mediators over the time 
course of arthritis, a Luminex cytokine 20-Plex assay was used to determine the 
protein concentration of several cytokines and chemokines in serum collected 
from control mice and CIA mice on days 22, 28, 35 and 42. Longitudinal changes 
in serum IL-1β, IL-5, CCL2 and FGF2 were observed in CII immunized mice. 
4.2.2.1  Changes in serum pro-inflammatory cytokine protein 
concentrations in CII immunized mice 
 
The pro-inflammatory cytokines TNF-α, IL-1β and IL-6 were measured in serum 
of CII immunized and naïve control mice. Protein IL-1β was the only cytokine in 
this category that showed a change in CII immunized mouse serum compared to 
those in the naïve control group. Two-way ANOVA analysis followed by 
Bonferroni posttests demonstrated that IL-1β in serum was significantly higher in 
CII immunized mice compared to those in naïve control mice on day 22 and 28 
after the immunization (P < 0.0001). The mean value of serum IL-1β (CII 
immunized versus naïve control) on day 22 and day 28 was 237.3 ± 21.3 pg/ml 
versus 176.6 ± 0.9 pg/ml (P < 0.0001), and 254.9 ± 64.5 pg/µg total protein 
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versus 176.5 ± 1.3 pg/ml (P = 0.0139) respectively. This was followed by a 
significant decline in serum IL-1β protein concentrations to the base-line 
concentration from day 28 to day 42 (Figure 4.4A). One-way ANOVA 
demonstrated that there were significant differences in serum IL-1β 
concentrations among the four groups of mice culled on day 22, 28, 35 and 42 (P 
= 0.0027). Post hoc analysis with Bonferroni correction demonstrated that 
concentrations of serum IL-1β in CII immunized mice on day 22 and day 28 were 
significantly higher than serum IL-1β concentrations on day 35 and day 42. The 
mean value of serum IL-1β of CII immunized mice (day 22 versus day 42) was 
237.3 ± 21.3 pg/ml versus 178.5 ± 1.3 pg/ml (P < 0.01). The mean value of serum 
IL-1β of CII immunized mice (day 28 versus day 35) was 254.9 ± 64.5 pg/ml 
versus 189.9 ± 21.7 pg/ml (P < 0.05), while the mean value of IL-1β of CII 
immunized mice (day 28 versus day 42) was 254.9 ± 64.5 pg/ml versus 178.55 ± 
1.3 pg/ml (P < 0.05) ((Figure 4.4B). These data suggest that serum IL-1β protein 
concentration peaked during 22 to 28 days after immunization, and then 
decreased to the base line concentration from day 28 to day 42.  
 
Figure 4.4 Time-course of a serum pro-inflammatory cytokine in CII immunized mice  
 (A) Mice immunized with type II collagen (filled squares) were culled on day 22, 28, 35, 42 
and serum samples from CII immunized mice of all time points were collected for peripheral 
inflammatory mediator measurement using a Luminex assay. Serum samples collected from 
naive control mice (open circle) culled on the days indicated were used as controls. IL-1β 
protein concentrations in serum are expressed as pg/ml. Data represent means ± SEM (n = 
CII immunised mice/group). Statistical analysis of data was performed using two-way 
ANOVA, compared with naïve control mice: *P<0.05, **P<0.01, ***P<0.001. (B) shows 
longitudinal changes of serum IL-1β  concentrations in a group of CII immunized mice 
culled on the days indicated. Bars represent mean values: (*P < 05; **P < 01; ***P < 001 by 
one-way ANOVA analysis). 
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4.2.2.2 Changes in serum Th1 cytokine protein concentrations in CII 
immunized mice 
IFN-γ, IL-2 and IL-12 were Th1 cytokines that were selected for analysis in the 
serum of CII immunized and control mice. However, there were no Th1 cytokines 
detectable in serum of any mice from all the experimental groups. 
4.2.2.3  Changes in serum Th2 cytokine protein concentrations in CIA 
mice 
Th-2 cytokines, including IL-4, IL-5, IL-10 and IL-13 were selected for analysis in 
the serum of naïve control mice and CII immunized mice. IL-5 was the only one 
of these Th2 cytokine that was detectable in the serum of CII immunized mice. 
Two-way ANOVA analysis followed by Bonferroni posttests demonstrated that IL-
5 in serum was significantly higher in CII immunized mice compared to those in 
naïve control mice on day 22 and 28 after the immunization (P = 0.037). The 
mean values of serum IL-5 (CII immunized versus naïve control) on day 22 and 
day 28 were 209.8 ± 39.1 pg/ml versus 160.8 ± 2.0 pg/ml (P = 0.012), and 195.2 
± 29.2 pg/ml versus 161.2 ± 1.6 pg/ml (P = 0.0171) respectively (Figure 4.5A). 
The serum IL-5 concentration of CII immunized mice thereafter decreased 
continuously during day 28 to day 42. One-way ANOVA followed by Bonferroni's 
post-hoc comparison tests demonstrated that there were significant differences 
in serum IL-5 concentrations among the four groups of mice culled on day 22, 28, 
35 and 42 (P = 0.0067). The serum IL-5 concentrations of CII immunized mice on 
day 22 were significantly higher than those on day 35 (209.8 ± 39.1 pg/ml versus 
164.2 ± 14.4 pg/ml; P < 0.05), and on day 42 (209.8 ± 39.1 pg/ml versus 159.6 ± 
2.5 pg/ml; P < 0.05). There were no significant differences between serum IL-5 
concentrations of CII immunized mice on day 28 and those on day 35 and day 42 
(Figure 4.5B). These data suggest that serum IL-5 protein concentrations peaked 
during 22 days after immunization, and then decreased to the baseline 
concentration from day 28 to day 42.  
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Figure 4.5 Time-course of a serum Th2 cytokine in CII immunized mice  
 (A) Mice immunized with type II collagen (filled squares) were culled on day 22, 28, 35, 42 
and serum samples from CII immunized mice of all time points were collected for peripheral 
inflammatory mediator measurement using a Luminex assay. Serum samples collected from 
naïve control mice (open circle) culled on the days indicated were used as controls. IL-5 
protein concentrations in serum are expressed as pg/ml. Data represent means ± SEM (n = 6 
CII immunised mice/group). Statistical analysis of data was performed using two-way 
ANOVA, compared with naïve control mice: *P<0.05. (B) shows longitudinal changes of 
serum IL-5 concentrations in a group of CII immunized mice culled on the days indicated. 
Bars represent mean values: (*P < 05; **P < 01; ***P < 001 by one-way ANOVA analysis) 
4.2.2.4 Changes in serum chemokine protein concentrations in CII 
immunized mice 
Among the chemokines analysed (CXCL1, CXCL10, CCL2 and CCL3), only the 
serum concentration of CCL2 in CII immunized mice increased significantly at 
day 22 and day 28 compared to those of the naïve controls. Two-way ANOVA 
analysis followed by Bonferroni posttests demonstrated that CCL2 in serum was 
significantly higher in CII immunized mice compared to those in naïve control 
mice on day 22 and 28 after the immunization (P = 0.001). The mean value of 
serum CCL2 (CII immunized versus naïve control) on day 22 and day 28 were 
175.5 ± 18.5 pg/ml versus 139.0 ± 1.0 pg/ml (P = 0.0007), and 174.8 ± 22.4 
pg/ml versus 137.9 ± 1.7 pg/ml (P = 0.0025) respectively (Figure 4.6A). One-way 
ANOVA followed by Bonferroni's post-hoc comparison tests demonstrated that 
there were significant differences in serum CCL2 concentrations among the four 
groups of mice culled on day 22, 28, 35 and 42 (P = 0.0007). There was a 
decrease in serum CCL2 concentration of CII immunized mice after day 28. The 
serum concentration of CCL2 in CII immunized mice on day 35 and day 42 were 
significantly lower than those on day 22. The mean value of serum CCL2 of CII 
immunized mice (day 22 versus day 35) was 175.5 ± 18.5 pg/ml versus 146.3 ± 
11.4 pg/ml (P < 0.05), while the mean value of serum CCL2 of CII immunized 
mice (day 22 versus day 42) was 175.5 ± 18.5 pg/ml versus 139.7 ± 1.4 pg/ml (P 
< 0.01). A significant reduction of serum CCL2 was also observed in CII 
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immunized mice on day 35 and day 42 compared to those on day 28. The mean 
value of serum CCL2 of CII immunized mice (day 28 versus day 35) was 174.8 ± 
22.4 pg/ml versus 146.3 ± 11.4 pg/ml (P < 0.05), while the mean value of serum 
CCL2 of CII immunized mice (day 28 versus day 42) was 174.8 ± 22.4 pg/ml 
versus 139.7 ± 1.4 pg/ml (P < 0.01) (Figure 4.6B). 
 
Figure 4.6 Time-course of a serum chemokine in CII immunized mice   
(A) Mice immunized with type II collagen (filled squares) were culled on day 22, 28, 35, 42 
and serum samples from CII immunized mice of all time points were collected for peripheral 
inflammatory mediator measurement using a Luminex assay. Serum samples collected from 
naïve control mice (open circle) culled on the days indicated were used as controls. CCL2 
protein concentrations in serum are expressed as pg/ml. Data represent means ± SEM (n = 6 
CII immunised mice/group). Statistical analysis of data was performed using two-way 
ANOVA, compared with naïve control mice: **P<0.01, ***P<0.001. (B) shows longitudinal 
changes of serum CCL2 concentrations in a group of CII immunized mice culled on the days 
indicated. Bars represent mean values: (*P < 05; **P < 01; ***P < 001 by one-way ANOVA 
analysis). 
4.2.2.5  Changes in serum growth protein concentrations in CII 
immunized mice  
Growth factor concentrations including fibroblast growth factor (FGF2) and 
vascular endothelial growth factor (VEGF) were determined in the serum of 
naïve control mice and CII immunized mice. Two-way ANOVA analysis followed 
by Bonferroni posttests demonstrated that FGF2 in serum was significantly 
higher in CII immunized mice compared to those in naïve control mice on day 22 
and 28 after the immunization (P <0.0001). Significantly higher concentrations of 
serum FGF2 protein were observed on day 22 and day 28 compared to those of 
the naïve controls. The mean value of serum FGF2 (CII immunized versus naïve 
control) on day 22 and day 28 were 3243.8 ± 644.4 pg/ml versus 719.4 ± 0.7 
pg/ml (P<0.0001), and 2482.0 ± 1283.2 pg/ml versus 719.7 ± 1.0 pg/ml (P = 
0.0072) respectively (Figure 4.7A). One-way ANOVA demonstrated that there 
were significant differences in serum FGF2 concentrations among the four groups 
Chapter 4  190 
of mice culled on day 22, 28, 35 and 42 (P <0.0001). Post hoc analysis with 
Bonferroni correction demonstrated that concentrations of serum FGF2 protein 
of CII immunized mice dropped significantly between days 28 to 42. The mean 
value of serum FGF2 of CII immunized mice (day 22 versus day 35) was 3243.8 ± 
644.4 pg/ml versus 803.3 ± 135.7 pg/ml (P < 0.001), while the mean value of 
serum FGF2 of immunized mice (day 22 versus day 42) was 3243.8 ± 644.4 pg/ml 
versus 719.7 ± 1.2 pg/ml (P < 0.001). Serum FGF2 concentration of CII 
immunized mice on day 35 and day 42 were also significant lower than those of 
immunized mice on day 28. The mean value of serum FGF2 of CII immunized 
mice (day 28 versus day 35) was 2482.0 ± 1283.2 pg/ml versus 803.3 ± 135.7 
pg/ml (P < 0.01), while the mean value of serum FGF2 of immunized mice (day 
28 versus day 42) was 2482.0 ± 1283.2 pg/ml versus 719.7± 1.2 pg/ml (P < 0.01) 
(Figure 4.7B).  
 
Figure 4.7 Time-course of a serum growth factor in CII immunized mice   
(A) Mice immunized with type II collagen (filled squares) were culled on day 22, 28, 35, 42 
and serum samples from CII immunized mice of all time points were collected for peripheral 
inflammatory mediator measurement using a Luminex assay. Serum samples collected from 
naïve control mice (open circle) culled on the days indicated were used as controls. FGF2 
protein concentrations in serum are expressed as pg/ml. Data represent means ± SEM (n = 6 
CII immunised mice/group). Statistical analysis of data was performed using two-way 
ANOVA, compared with naïve control mice: **P<0.01, ***P<0.001. (B) shows longitudinal 
changes of serum FGF2 concentrations in a group of CII immunized mice culled on the days 
indicated. Bars represent mean values: (*P < 05; **P < 01; ***P < 001 by one-way ANOVA 
analysis). 
4.2.3  Time-course analysis of inflammatory mediator protein 
concentrations in the brains of CII immunized mice by 
Luminex cytokine 20-Plex 
We performed a time-course study on the protein concentrations of various 
inflammatory mediators including the pro-inflammatory cytokines (IL-6, IL-1 β, 
TNF-α and IL-1α ), Th1 cytokines (IL-2, IL-12 and IFN-γ), Th2 cytokines (IL-4, IL-
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5, IL-10 and IL-13), chemokines (CXCL1, CXCL10, CCL2 and CCL3) and growth 
factors (FGF and VEGF) in half brain tissue homogenate samples of CIA and 
control mice from all experimental groups using a Luminex cytokine 20-Plex 
assay. We found longitudinal changes in protein concentrations of IL-2, CXCL1, 
VEGF and FGF2 in the brains of CII immunized mice. 
4.2.3.1 Time-course analysis of pro-inflammatory cytokine protein 
concentrations in the brains of CII immunized mice by Luminex 
cytokine 20-Plex assay 
The protein concentrations of pro-inflammatory cytokines including IL-6, IL-1 β, 
TNF-α and IL-1α were assayed in brain homogenates of mice from all 
experimental groups. However, the concentrations of these pro-inflammatory 
cytokines in all brain samples were lower than the assay detection limit.  
4.2.3.2 Time-course analysis of Th-1 cytokine protein concentrations in 
the brains of CII immunized mice by Luminex cytokine 20-Plex 
The protein concentration of Th-1 cytokines, including IL-12, IL-2 and IFN-γ, 
were assayed in the brain tissue of CII immunized mice and control mice culled 
on days 22, 28, 35 and 42. Two-way ANOVA analysis followed by Bonferroni 
posttests demonstrated that IL-2 protein concentrations in brain tissue were 
significantly higher in CII immunized versus naïve control mice on day 35 (P = 
0.0016). The mean value of brain IL-2 (CII immunized versus naïve control) on 
day 35 was 2.6 ± 0.9 pg/mg total brain protein versus 1.7 ± 0.4 pg/mg total brain 
protein (P = 0.0357) (Figure 4.8A).  The brain IL-2 concentrations of CII 
immunized mice increased significantly from day 28 to day 35. One-way ANOVA 
analysis showed that there was also no significant difference in brain IL-2 protein 
concentrations in different groups of CII immunized mice culled on day 22, day 
28, day 35 and day 42 (Figure 4.8B).  
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Figure 4.8 Time-course of a Th1 cytokine protein concentrations in brains of CII immunized 
mice by a Luminex assay  
(A) Mice immunized with type II collagen (filled squares) were culled on days 22, 28, 35, 42 
and brains from CII immunized mice at all time points were harvested. Brain samples 
collected from naïve control mice (open circle) culled on the days indicated were used as 
controls. IL-2 protein concentrations in brain tissue homogenate of mice from all 
experimental groups were determined using a Luminex assay. IL-2 concentrations in brain 
tissue, normalized against total brain protein, are expressed as pg/mg total brain protein. 
Data represent means ± SEM. (n = 6 CII immunised mice/group). Statistical analysis of data 
was performed using two-way ANOVA compared with naïve control mice: *P<0.05. (B) 
shows longitudinal changes of brain IL-2 in CII immunized mice culled on the days 
indicated. Bars represent mean values: (*P < 05; **P < 01; ***P < 001 by one-way ANOVA 
analysis). 
4.2.3.3 Time-course analysis of Th-2 cytokine protein concentrations in 
the brains of CII immunized mice by Luminex cytokine 20-Plex 
The protein concentrations of Th2 cytokines including IL-4, IL-5, IL-10 and IL-13 
were assayed in brains of mice from all experimental groups. However, the 
concentrations of these Th2 cytokines in all brain samples were lower than the 
assay detection limits.  
4.2.3.4  Time-course analysis of chemokine protein concentrations in 
the brains of CII mice by Luminex cytokine 20-Plex 
Among the chemokines quantified in mouse brains (CXCL1, CXCL10, CCL2 and 
CCL3), CXCL1 was the only chemokine that was detectable in mouse brain tissue 
within the detection limits of the assay. Two-way ANOVA analysis followed by 
Bonferroni posttests demonstrated that there was no significant difference 
between brain CXCL1 protein concentrations in CII immunized mice and naïve 
control mice across all time points (Figure 4.9A). One-way ANOVA analysis 
followed by Bonferroni posttests demonstrated that there was also no significant 
difference in brain CXCL1 protein concentrations in different groups of CII 
immunized mice culled on day 22, day 28, day 35 and day 42 (Figure 4.9B).  
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Figure 4.9 Time-course of a chemokine protein concentrations in brains of CII immunized 
mice by a Luminex assay  
(A) Mice immunized with type II collagen (filled squares) were culled on days 22, 28, 35, 42 
and brain from CII immunized mice at all time points were harvested. Brain samples 
collected from naïve control mice (open circle) culled on the days indicated were used as 
controls. CXCL1 protein concentrations in brain tissue homogenate of mice from all 
experimental groups were determined using a Luminex assay. CXCL1 concentrations in 
brain tissue, normalized against total brain protein, are expressed as pg/mg total brain 
protein. Data represent means ± SEM. (n = 6 CII immunised mice/group). Statistical analysis 
of data was performed using two-way ANOVA compared with naïve control mice: *P<0.05, 
**P<0.01, ***P<0.001. (B) shows longitudinal changes of brain CXCL1 in CII immunized mice 
culled on the days indicated. Bars represent mean values: (*P < 05; **P < 01; ***P < 001 by 
one-way ANOVA analysis). 
4.2.3.5 Time-course analysis of growth factor protein concentrations in 
the brains of CII immunized mice by Luminex cytokine 20-Plex assay 
The protein concentration concentrations of VEGF and FGF2 were detectable 
within the detection limits of the assay. Two-way ANOVA analysis followed by 
Bonferroni posttests demonstrated that FGF2 protein concentrations in brain 
tissue were significantly higher in CII immunized versus naïve control mice on 
day 42 (P<0.001). The mean value of brain FGF2 (CII immunized versus naïve 
control) on day 42 was 242.3 ± 46.4 pg/mg total brain protein versus 183.3 ± 
40.2 pg/mg total brain protein (P = 0.0402) (Figure 4.10A). There was a 
continuous downward trend in brain FGF protein concentrations of CII 
immunized mice. One-way ANOVA demonstrated that there were significant 
differences in FGF2 protein concentrations among the four groups of mice on day 
22, 28, 35 and 42 (P = 0.0006). Post hoc analysis with Bonferroni correction 
demonstrated that concentrations of brain FGF2 of CII immunized mice on day 
22 were significantly higher than those of immunized mice culled on day 28, day 
35 and day 42. The mean value of brain FGF2 of immunized mice (day 22 versus 
day 28) was 502.4 ± 133.5 pg/mg total brain protein versus 345.5 ± 72.6 pg/mg 
total brain protein (P < 0.05). The mean value of brain FGF2 of CII immunized 
mice (day 22 versus day 35) was 502.4 ± 133.5 pg/mg total brain protein versus 
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324.9 ± 83.0 pg/mg total brain protein (P < 0.05), while the mean value of brain 
FGF2 of CII immunized mice (day 22 versus day 42) was 502.4 ± 133.5 pg/mg 
total brain protein versus 242.3 ± 46.4 pg/mg total brain protein (P < 0.01) 
(Figure 4.10B). 
 
Figure 4.10 Time-course of a growth factor (FGF2) protein concentrations in brains of CII 
immunized mice by a Luminex assay  
(A) Mice immunized with type II collagen (filled squares) were culled on days 22, 28, 35, 42 
and brain from CII immunized mice at all time points were harvested. Brain samples 
collected from naïve control mice (open circle) culled on the days indicated were used as 
controls. FGF2 protein concentrations in brain tissue homogenate of mice from all 
experimental groups were determined using a Luminex assay. FGF2 concentrations in brain 
tissue, normalized against total brain protein, are expressed as pg/mg total brain protein. 
Data represent means ± SEM. (n = 6 CII immunised mice/group). Statistical analysis of data 
was performed using two-way ANOVA compared with naïve control mice: *P<0.05, **P<0.01, 
***P<0.001. (B) shows longitudinal changes of brain FGF2 in CII immunized mice culled on 
the days indicated. Bars represent mean values: (*P < 05; **P < 01; ***P < 001 by one-way 
ANOVA analysis). 
Two-way ANOVA analysis followed by Bonferroni posttests demonstrated that a 
significant difference in brain VEGF protein concentration was observed in 
immunized mice and control mice on day 42 (P = 0.0015). The mean value of 
brain VEGF protein concentration (CII immunized versus naïve control) on day 42 
was 9.3 ± 1.7 pg/mg total brain protein versus 7.0 ± 1.2 pg/mg total brain 
protein (P = 0.0219) (Figure 4.11A). One-way ANOVA demonstrated that there 
was also no significant difference in brain VEGF protein concentrations in 
different groups of CII immunized mice culled on day 22, day 28, day 35 and day 
42 (Figure 4.11B).  
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Figure 4.11 Time-course of a growth factor (VEGF) protein concentrations in brains of CII 
immunized mice by a Luminex assay 
 (A) Mice immunized with type II collagen (filled squares) were culled on days 22, 28, 35, 42 
and brain from CII immunized mice at all time points were harvested. Brain samples 
collected from naïve control mice (open circle) culled on the days indicated were used as 
controls. VEGF protein concentrations in brain tissue homogenate of mice from all 
experimental groups were determined using a Luminex assay. VEGF concentrations in brain 
tissue, normalized against total brain protein, are expressed as pg/mg total brain protein. 
Data represent means ± SEM. (n = 6 CII immunised mice/group). Statistical analysis of data 
was performed using two-way ANOVA compared with naïve control mice: *P<0.05. (B) 
shows longitudinal changes of brain VEGF in CII immunized mice culled on the days 
indicated. Bars represent mean values: (*P < 05; **P < 01; ***P < 001 by one-way ANOVA 
analysis). 
4.2.4 Time-course analysis of inflammatory mediator protein 
concentrations in the brain homogenates of CII immunized 
mice validated by ELISA assays 
In this chapter, we used a Luminex assay to determine longitudinal changes in 
protein concentrations in brains of CII immunized mice. We only found 
significant changes of IL-2, VEGF and FGF2 protein concentrations in brains of CII 
immunized mice compared to those in naïve control mice. In contrast, data from 
previous chapter showed a broader range of inflammatory mediator proteins that 
were up-regulated in the brains of CII immunized mice. In this chapter, we could 
not detect various inflammatory mediators such as IL-1α, IL-4, IL-5, IL-6, IL-10, 
IL-13 and CXCL10 that were detectable by the same Luminex assay in the brains 
of CII immunized mice in the last chapter.  We therefore repeated the analysis 
using potentially more sensitive ELISA assays as an alternative to determine 
longitudinal changes in these inflammatory mediators in brains of CII immunized 
mice. TNF-α, IL-1β, IL- 4, IL-5, IL-6, IL-10, IL-12, and IL-13, CCL2, VEGF ELISA 
kits were used to measure changes in inflammatory mediators that were 
undetectable by Luminex in brains of mice from all experimental groups. 
Longitudinal changes in TNF-α, IL-1β, IL- 4, IL-10, IL-12 and CCL2 protein 
concentrations were observed in brains of CII immunized mice.  
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4.2.4.1 Time-course analysis of pro-inflammatory cytokine protein 
concentrations in the brains of CII immunized mice by ELISA assays 
Pro-inflammatory cytokines, including IL-1β, IL-6 and TNF-α, were determined in 
brains of mice from all experimental groups using commercial ELISA kits. IL-1β 
and TNF-α protein concentrations in half brain tissue homogenate samples of 
mice from all experimental groups were detectable within the assay limits of 
detection. 
Two-way ANOVA analysis followed by Bonferroni posttests demonstrated that 
TNF-α protein concentrations in brains were significantly higher in immunized 
versus control mice on days 35 and 42 (P = 0.001). The mean value of brain TNF-
α (CII immunized versus naïve control) on day 35 was 44.1 ± 7.6 pg/mg total 
brain protein versus 29.1 ± 3.7 pg/mg total brain protein (P = 0.0113), while the 
mean value of TNF-α (CII immunized versus naïve control) on day 42 was 47.1 ± 
12.4 pg/mg total brain protein versus 29.1 ± 1.8 pg/mg total brain protein (P = 
0.0075) (Figure 4.12A). One-way ANOVA analysis showed that there was also no 
significant difference in brain TNF-α protein concentrations in different groups 
of CII immunized mice culled on day 22, day 28, day 35 and day 42. (Figure 
4.12B).  
 
Figure 4.12 Time-course of a pro-inflammatory cytokines (TNF-α) protein concentrations in 
brains of CII immunized mice by an ELISA assay  
(A) Mice immunized with type II collagen (filled squares) were culled on days 22, 28, 35, 42 
and brain from CII immunized mice at all time points were harvested. Brain samples 
collected from naïve control mice (open circle) culled on the days indicated were used as 
controls. TNF-α protein concentrations in brain tissue homogenate of mice from all 
experimental groups were determined using an ELISA assay. TNF-α concentrations in brain 
tissue, normalized against total brain protein, are expressed as pg/mg total brain protein. 
Data represent means ± SEM. (n = 6 CII immunised mice/group). Statistical analysis of data 
was performed using two-way ANOVA compared with naïve control mice: *P<0.05, **P<0.01, 
***P<0.001. (B) shows longitudinal changes of brain TNF-α in CII immunized mice culled on 
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the days indicated. Bars represent mean values: (*P < 05; **P < 01; ***P < 001 by one-way 
ANOVA analysis). 
Two-way ANOVA analysis followed by Bonferroni posttests demonstrated that 
brain IL-1β protein concentrations in CII immunized mice were significantly 
increased compared to those in naïve control mice on day 22 (P = 0.0011). The 
mean value of brain IL-1β (CII immunized versus naïve control) on day 22 was 
341.7 ± 68.5 pg/mg total brain protein versus 226.9 ± 60.1 pg/mg total brain 
protein (P = 0.0235) (Figure 4.13A). One-way ANOVA demonstrated that there 
were significant differences in IL-1β protein concentrations among the four 
groups of mice culled on day 22, 28, 35 and 42 (P = 0.0069). The concentration 
of IL-1β protein in brain of CII immunized mice seemed to peak on day 22. IL-1β 
protein concentrations in brains of CII immunized mice on day 22 were also 
significantly higher than those in brains of CII immunized mice on day 35 and day 
42. The mean value of brain IL-1β of CII immunized mice (day 22 versus day 35) 
was 341.7 ± 68.5 pg/mg total brain protein versus 225.6 ± 72.4 pg/mg total brain 
protein (P < 0.05), while the mean value of brain IL-1β of CII immunized mice 
(day 22 versus day 42) was 341.7 ± 68.5 pg/mg total brain protein total brain 
protein versus 190.8 ± 19.1 pg/mg total brain protein (P < 0.01) (Figure 4.13B).  
 
Figure 4.13 Time-course of a pro-inflammatory cytokines (IL-1β) protein concentrations in 
brains of CII immunized mice by an ELISA assay  
(A) Mice immunized with type II collagen (filled squares) were culled on days 22, 28, 35, 42 
and brain from CII immunized mice at all time points were harvested. Brain samples 
collected from naïve control mice (open circle) culled on the days indicated were used as 
controls. IL-1β protein concentrations in brain tissue homogenate of mice from all 
experimental groups were determined using an ELISA assay. IL-1β concentrations in brain 
tissue, normalized against total brain protein, are expressed as pg/mg total brain protein. 
Data represent means ± SEM. (n = 6 CII immunised mice/group). Statistical analysis of data 
was performed using two-way ANOVA compared with naïve control mice: *P<0.05, **P<0.01, 
***P<0.001. (B) shows longitudinal changes of brain IL-1β in CII immunized mice culled on 
the days indicated. Bars represent mean values: (*P < 05; **P < 01; ***P < 001 by one-way 
ANOVA analysis). 
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4.2.4.2 Time-course analysis of Th-1 cytokine protein concentrations in 
the brains of CII immunized mice by ELISA assays 
IL-12 was the only Th1 cytokine detectable using an ELISA assay in brain tissue of 
mice from all experimental groups. Two-way ANOVA analysis followed by 
Bonferroni posttests demonstrated that brain IL-12 concentrations were 
significantly elevated in CII immunized mice versus naïve control mice on days 
22, 28, 35 and 42 (P <0.0001).  The mean value of brain IL-12 (CII immunized 
versus naïve control) on day 22 was 1514.7 ± 714.3 pg/mg total brain protein 
versus 251.7 ± 26.4 pg/mg total brain protein (P = 0.0018). The mean value of 
brain IL-12 (CII immunized versus naïve control) on day 28 was 1011.9 ± 273.0 
pg/mg total brain protein versus 257.2 ± 32.1 pg/mg total brain protein (P = 
0.0009). The mean value of brain IL-12 (CII immunized versus naïve control) on 
day 35 was 949.6 ± 398.4 pg/mg total brain protein versus 442.0 ± 86.3 pg/mg 
total brain protein (P = 0.02). The mean value of brain IL-12 (CII immunized 
versus naïve control) on day 42 were 615.6 ± 86.2 pg/mg total brain protein 
versus 241.1 ± 74.5 pg/mg total brain protein (P<0.0001) (Figure 4.14A). A 
downward trend in the brain IL-12 protein concentrations was observed in CII 
immunized mice over the period of 21 days after immunization. One-way ANOVA 
demonstrated that there was a significant difference in IL-12 protein 
concentrations among the four groups of mice culled on day 22, 28, 35 and 42 (P 
= 0.0110). Post hoc analysis with Bonferroni correction demonstrated that the 
brain IL-12 protein concentrations in CII immunized mice on day 42 were 
significantly lower than those of CII immunized mice on day 22. The mean value 
of brain IL-12 of CII immunized mice (day 22 versus day 42) was 1514.7 ± 714.3 
pg/mg total brain protein versus 615.6 ± 86.2 pg/mg total brain protein (P < 
0.01) (Figure 4.14B). 
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Figure 4.14 Time-course of a Th1 cytokines (IL-12) protein concentrations in brains of CII 
immunized mice by an ELISA assay  
(A) Mice immunized with type II collagen (filled squares) were culled on days 22, 28, 35, 42 
and brain from CII immunized mice at all time points were harvested. Brain samples 
collected from naïve control mice (open circle) culled on the days indicated were used as 
controls. IL-12 protein concentrations in brain tissue homogenate of mice from all 
experimental groups were determined using an ELISA assay. IL-12 concentrations in brain 
tissue, normalized against total brain protein, are expressed as pg/mg total brain protein. 
Data represent means ± SEM. (n = 6 CII immunised mice/group). Statistical analysis of data 
was performed using two-way ANOVA compared with naïve control mice: *P<0.05, **P<0.01, 
***P<0.001. (B) shows longitudinal changes of brain IL-12 in CII immunized mice culled on 
the days indicated. Bars represent mean values: (*P < 05; **P < 01; ***P < 001 by one-way 
ANOVA analysis). 
4.2.4.3  Time-course analysis of Th-2 cytokine protein concentrations 
in the brains of CII immunized mice measured by ELISA assays 
IL-4 and IL-10 protein concentrations were detectable by ELISA in brain tissue of 
mice from all experimental groups.  
Two-way ANOVA analysis followed by Bonferroni posttests demonstrated that 
brain IL-4 protein concentrations were up-regulated significantly in CII 
immunized mice compared to those in naïve control mice on day 22 and day 28 
(P = 0.0002). The mean value of brain IL-4 (CII immunized versus naïve control) 
on day 22 was 1011.3 ± 267.1 pg/mg total brain protein versus 473.0 ± 54.1 
pg/mg total brain protein (P = 0.0015), while the mean value of brain IL-4 (CII 
immunized versus naïve control) on day 28 was 815.2 ± 188.4 pg/mg total brain 
protein versus 473.5 ± 38.6 pg/mg total brain protein (P = 0.0037) (Figure 
4.15A). The brain IL-4 protein concentrations in brain of CII immunized mice 
peaked during day 22 and day 28 after immunization. One-way ANOVA 
demonstrated that there were significant differences in IL-4 protein 
concentrations among the four groups of mice culled on day 22, 28, 35 and 42 (P 
= 0.0002). Post hoc analysis with Bonferroni correction demonstrated that brain 
IL-4 protein concentrations in CII immunized mice on day 22 were significantly 
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higher than those in CII immunized mice on day 35 and day 42. The mean value 
of brain IL-4 of CII immunized mice (day 22 versus day 35) was 1011.3 ± 267.1 
pg/mg total brain protein versus 483.4 ± 246.4 pg/mg total brain protein (P < 
0.01), while the mean value of brain IL-4 of CII immunized mice (day 22 versus 
day 42) was 1011.3 ± 267.1 pg/mg total brain protein versus 424.5 ± 145.2 
pg/mg total brain protein (P < 0.001). CII immunized mice on day 35 and day 42 
showed significant lower concentrations of brain IL-4 protein compared to those 
in CII immunized mice on day 28. The mean value of brain IL-4 of CII immunized 
mice (day 28 versus day 42) was 815.2 ± 188.4 pg/mg total brain protein versus 
424.5 ± 145.2 pg/mg total brain protein (P < 0.05) (Figure 4.15B). 
 
Figure 4.15 Time-course of a Th2 cytokine (IL-4) protein concentrations in brains of CII 
immunized mice by an ELISA assay  
(A) Mice immunized with type II collagen (filled squares) were culled on days 22, 28, 35, 42 
and brain from CII immunized mice at all time points were harvested. Brain samples 
collected from naïve control mice (open circle) culled on the days indicated were used as 
controls. IL-4 protein concentrations in brain tissue homogenate of mice from all 
experimental groups were determined using an ELISA assay. IL-4 concentrations in brain 
tissue, normalized against total brain protein, are expressed as pg/mg total brain protein. 
Data represent means ± SEM. (n = 6 CII immunised mice/group). Statistical analysis of data 
was performed using two-way ANOVA compared with naïve control mice: *P<0.05, **P<0.01, 
***P<0.001. (B) shows longitudinal changes of brain IL-4 in CII immunized mice culled on the 
days indicated. Bars represent mean values: (*P < 05; **P < 01; ***P < 001 by one-way 
ANOVA analysis). 
Two-way ANOVA analysis followed by Bonferroni posttests demonstrated that 
significant increases in IL-10 protein concentrations were observed in brains of 
CII immunized mice compared to naïve control mice on days 22, 28, 35, 42 
(P<0.0001). The mean value of brain IL-10 (CII immunized versus naïve control) 
on day 22 was 1175.6 ± 134.0 pg/mg total brain protein versus 381.1 ± 54.3 
pg/mg total brain protein (P<0.0001), while the mean value of brain IL-10 (CII 
immunized versus naïve control) on day 28 was 787.0 ± 94.6 pg/mg total brain 
protein versus 396.2 ± 38.4 pg/mg total brain protein (P <0.0001). The mean 
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value of brain IL-10 (CII immunized versus naïve control) on day 35 was 1030.9 ± 
221.2 pg/mg total brain protein versus 488.1 ± 80.9 pg/mg total brain protein (P 
= 0.0003), while the mean value of brain IL-10 (CII immunized versus naïve 
control) on day 42 was 932.6 ± 121.7 pg/mg total brain protein versus 429.1 ± 
34.3 pg/mg total brain protein (P = 0.0003) (Figure 4.16A). The brain IL-10 
protein concentration in CII immunized mice fluctuated throughout the 21 days 
after immunization. A significant drop in brain IL-10 protein concentration was 
observed during day 22 to day 28, followed by a significant increase brain IL-10 
protein concentration from day 28 to day 42.  One-way ANOVA demonstrated 
that there was a significant difference in IL-10 protein concentrations among the 
four groups of mice culled on day 22, 28, 35 and 42 (P = 0.0052). Post hoc 
analysis with Bonferroni correction demonstrated a significant down-regulation 
in brain IL-10 protein concentration in CII immunized mice on day 28 compared 
to those in CII immunized mice on day 22. The mean value of brain IL-10 of CII 
immunized mice (day 22 versus day 28) was 1175.6 ± 140.0 pg/mg total brain 
protein versus 787.00 ± 94.59 pg/mg total brain protein (P < 0.01). (Figure 
4.16B) 
 
Figure 4.16 Time-course of a Th2 cytokine (IL-10) protein concentrations in brains of CII 
immunized mice by an ELISA assay  
(A) Mice immunized with type II collagen (filled squares) were culled on days 22, 28, 35, 42 
and brain from CII immunized mice at all time points were harvested. Brain samples 
collected from naïve control mice (open circle) culled on the days indicated were used as 
controls. IL-10 protein concentrations in brain tissue homogenate of mice from all 
experimental groups were determined using an ELISA assay. IL-10 concentrations in brain 
tissue, normalized against total brain protein, are expressed as pg/mg total brain protein. 
Data represent means ± SEM. (n = 6 CII immunised mice/group). Statistical analysis of data 
was performed using two-way ANOVA compared with naïve control mice: ***P<0.001. (B) 
shows longitudinal changes of brain IL-10 in CII immunized mice culled on the days 
indicated. Bars represent mean values: (*P < 05; **P < 01; ***P < 001 by one-way ANOVA 
analysis). 
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4.2.4.4  Time-course analysis of chemokine protein concentrations in 
the brains of CII immunized mice by ELISA assays 
CCL2 was the only chemokine that could be detected using ELISA in brain tissue 
extracts of mice from all experimental groups. Two-way ANOVA analysis 
followed by Bonferroni posttests demonstrated that brain CCL2 protein 
concentrations were increased significantly in immunized mice compared to 
those in control mice on days 22, 28, and 42 (P < 0.05). The mean value of brain 
CCL2 (CII immunized versus naïve control) on day 22 was 268.5 ± 20.1 pg/mg 
total brain protein versus 102.3 ± 26.7 pg/mg total brain protein (P = 0.0118), 
The mean value of brain CCL2 (CII immunized versus control) on day 28 was 
234.8 ± 31.3 pg/mg total brain protein versus 122.1 ± 35.7 pg/mg total brain 
protein (P = 0.0238). The mean value of brain CCL2 (CII immunized versus naïve 
control) on day 42 was 193.1 ± 48.0 pg/mg total brain protein versus 93.7 ± 74.7 
pg/mg total brain protein (P = 0.0125) (Figure 4.17A). One-way ANOVA 
demonstrated that there was also no significant difference in brain CCL2 protein 
concentrations in different groups of CII immunized mice culled on day 22, day 
28, day 35 and day 42 (Figure 4.17B).  
 
Figure 4.17 Time-course of a chemokine (CCL2) protein concentrations in brains of CII 
immunized mice by an ELISA assay  
(A) Mice immunized with type II collagen (filled squares) were culled on days 22, 28, 35, 42 
and brain from CII immunized mice at all time points were harvested. Brain samples 
collected from naïve control mice (open circle) culled on the days indicated were used as 
controls. CCL2 protein concentrations in brain tissue homogenate of mice from all 
experimental groups were determined using an ELISA assay. CCL2 concentrations in brain 
tissue, normalized against total brain protein, are expressed as pg/mg total brain protein. 
Data represent means ± SEM. (n = 6 CII immunised mice/group). Statistical analysis of data 
was performed using two-way ANOVA compared with naïve control mice: *P<0.05. (B) 
shows longitudinal changes of brain CCL2 in CII immunized mice culled on the days 
indicated. Bars represent mean values: (*P < 05; **P < 01; ***P < 001 by one-way ANOVA 
analysis). 
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4.2.4.5  Differences in inflammatory mediator protein concentrations in 
brain of arthritic mice and non-arthritic mice 
3 mice out of 6 mice from immunized mice group 3 and 4, which were culled on 
day 35 and day 42 respectively, developed arthritis. In order to investigate 
differences in brain inflammatory mediator gene expression level and protein 
concentrations between mice with and without arthritis, cytokine, chemokine 
and growth factor mRNA and protein concentrations in arthritic mice and non-
arthritic mice were compared.  There was no difference in protein 
concentrations of IL-1β, TNF-α, IL-2, IL-12, IL-4, IL-10, CCL2 and FGF2 between 
brains of arthritic mice and non-arthritic mice. This was consistent with our data 
of the previous chapter showing non-significant difference in protein 
concentrations of IL-1β, IL-1α, IL-2, IL-5, IL-10, IL-13, CXCL10, VEGF and FGF2 
between brains of arthritic mice and non-arthritic mice (Figure 4.18A-Figure 
4.18H, Figure 4.19A). However, our data in this chapter showed that there was a 
significant difference in brain CXCL1 protein concentrations between arthritic 
and non-arthritic mice on day 42. This was inconsistent to data from the 
previous chapter showing no significant difference in brain CXCL1 protein 
between arthritic and non-arthritic mice at the same time point (day 42). The 
CXCL1 protein concentrations in brains of arthritic mice were significantly higher 
than those of non-arthritic mice on day 42. The mean value of CXCL1 of CII 
immunized mice on day 42 (arthritic versus non-arthritic) was 9 ± 0.5 pg/mg 
total brain protein versus 7 ± 0.6 pg/mg total brain protein (P = 0.0262) (Figure 
4.19B) 
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Figure 4.18 Differences in inflammatory mediator protein concentrations in brains of 
arthritic mice and non-arthritic mice  
(A), (B), (C), (D), (E), (F), (G), and (H) show inflammatory mediator protein concentrations 
(pg/mg total brain protein) in brains of CII immunized mice with and without arthritis (n =3 
CII immunised mice/group) on day 35 and day 42. Data are presented as the mean ± S.D. (*P 
< 05; **P < 01; ***P < 001 by Student’s t test.) 
 
Figure 4.19 Differences in VEGF and CXCL1 protein concentrations in brains of arthritic 
mice and non-arthritic mice  
Brain VEGF and CXCL1 protein concentrations (pg/mg total brain protein) in arthritic (n=3 
arthritic mice) and non-arthritic (n=3 non-arthritic mice) were compared on day 35 and day 
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42. Data are presented as the mean ± S.D. (*P < 0.05; **P < 0.02; ***P < 0.01 by Student’s t-
test.) 
4.2.5 Cytokine gene expression profiles in CIA mouse brains 
by Real-time PCR 
 
To further investigate local production of inflammatory mediators in brains of CII 
immunized mice, real-time PCR was used to quantify the gene expression of the 
same pro-inflammatory cytokines (IL-6, IL-1 β, TNF-α and IL-1 α), Th1 cytokines 
(IL-2, IL-12 and IFN-γ), Th2 cytokines (IL-4, IL-5, IL-10 and IL-13), chemokines 
(CXCL1, CXCL10, CCL2 and CCL3) and growth factors (FGF2 and, VEGF) in one 
half of the brain tissue of mice from all experimental groups. Longitudinal 
changes in gene expression of IL-1α, IL-2, IL-4, IL-5, IL-6, CXCL1, CXCL10 and 
FGF were observed in brains of CII immunized mice. 
4.2.5.1  Time course analysis of pro-inflammatory cytokine mRNA 
concentrations in the brains of CII immunized mice 
The gene expressions of pro-inflammatory cytokines including IL-6, IL-1 β, TNF-α 
and IL-1α were determined in brains of mice from all experimental groups. 
There was no pro-inflammatory cytokine gene expression detectable in brains of 
CII immunized mice by the real-time PCR assay.  
4.2.5.2  Time course analysis of Th1 cytokine mRNA expression levels 
in the brains of CII immunized mice 
Changes in gene expressions of Th-1 cytokines, including IL-12, IL-2 and IFN-γ, 
over time were determined in the brain of mice from all experimental groups. 
The expression of IL-12 was the only Th1 cytokine that was up-regulated 
significantly in CII immunized mouse brains compared to those in naïve control 
mice. Two-way ANOVA analysis followed by Bonferroni posttests demonstrated 
that a significant increase in IL-12 gene expression was observed in CII 
immunized mice on day 35 compared to those in naïve control mice (P = 0.0190). 
The mean value of brain IL-12 gene expression (CII immunized versus naïve 
control) on day 35 were 6318 ± 4120 versus 4872 ± 2088 (P = 0.0264) (Figure 
4.20A). One-way ANOVA demonstrated that there was also no significant 
difference in brain IL-12 gene expression in different groups of CII immunized 
mice culled on day 22, day 28, day 35 and day 42 (Figure 4.20B).  
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Figure 4.20 Time-course of a Th1 (IL-12) mRNA expression levels in brains of CII immunized 
mice by Real-time PCR  
(A) Mice immunized with type II collagen (filled squares) were culled on days 22, 28, 35, 42 
and brain from CII immunized mice at all time points were harvested. Brain samples 
collected from naïve control mice (open circle) culled on the days indicated were used as 
controls. IL-12 mRNA levels in brain tissue homogenate of mice from all experimental 
groups were determined using a real-time PCR assay. The expression levels of IL-12 mRNA 
were normalized against GAPDH expression and shown as arbitrary units. Data represent 
means ± SEM. (n = 6 CII immunised mice/group). Statistical analysis of data was performed 
using two-way ANOVA compared with naïve control mice: *P<0.05. (B) shows longitudinal 
changes of brain IL-12 in CII immunized mice culled on the days indicated. Bars represent 
mean values: (*P < 05; **P < 01; ***P < 001 by one-way ANOVA analysis). 
4.2.5.3 Time course analysis of Th2 cytokine mRNA levels in the brains 
of CII immunized mice 
Th-2 cytokines, including IL-4, IL-5, IL-10 and IL-13 gene expression were 
determined in the brains of mice from all experimental groups. There was no 
Th2 cytokine gene expression detectable in brains of CII immunized mice by the 
real-time PCR assay.  
4.2.5.4 Time course analysis of chemokine mRNA levels in the brains 
of CII immunized mice 
CXCL1, CXCL10, CCL-2 and CCL-3 gene expression were determined in the brains 
of control mice from all experimental groups. Among these chemokines, only 
brain CXCL1 and CXCL10 mRNA were detectable within the assay detection limit.   
Two-way ANOVA analysis followed by Bonferroni posttests demonstrated that 
brain CXCL1 gene expression levels were elevated in immunized mice compared 
to those in control mice on day 22 and day 42 (P < 0.0001). The mean value of 
brain CXCL1 gene expression (CII immunized versus naïve control) on day 22 
were 13406 ± 5054 versus 6140 ± 1700 (P < 0.0001), while the mean value of 
brain CXCL1 (CII immunized versus naïve control) on day 42 was 15935 ± 8744 
versus 6591 ± 2148 (P = 0.0067) (Figure 4.21A). One-way ANOVA demonstrated 
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that there were significant differences in CXCL1 gene expression among the four 
groups of mice culled on day 22, 28, 35 and 42 (P = 0.0017). Post hoc analysis 
with Bonferroni correction demonstrated that the levels of CXCL1 mRNA in 
brains of CII immunized mice on day 22 were significantly higher than those of 
day 28. The mean value of brain CXCL1 gene expression of CII immunized mice 
(day 22 versus day 28) was 14576 ± 1700 versus 4700 ± 2200 (P < 0.01). The 
levels of CXCL1 mRNA in brains of CII immunized mice on day 28 were 
significantly lower than those of day 42. The mean value of brain CXCL1 gene 
expression of CII immunized mice (day 35 versus day 42) was 8115 ± 1916 versus 
15935 ± 2148 (P < 0.01) (Figure 4.21B).   
 
Figure 4.21 Time-course of a chemokine (CXCL1) mRNA levels in brains of CII immunized 
mice by Real-time PCR 
 (A) Mice immunized with type II collagen (filled squares) were culled on days 22, 28, 35, 42 
and brain from CII immunized mice at all time points were harvested. Brain samples 
collected from naïve control mice (open circle) culled on the days indicated were used as 
controls. CXCL1 mRNA levels in brain tissue homogenate of mice from all experimental 
groups were determined using a real-time PCR assay. The levels of CXCL1 mRNA were 
normalized against GAPDH expression and shown as arbitrary units. Data represent means 
± SEM. (n = 6 CII immunised mice/group). Statistical analysis of data was performed using 
two-way ANOVA compared with naïve control mice: *P<0.05, **P<0.01, ***P<0.001. (B) shows 
longitudinal changes of brain CXCL1 in CII immunized mice culled on the days indicated. 
Bars represent mean values: (*P < 05; **P < 01; ***P < 001 by one-way ANOVA analysis). 
Two-way ANOVA analysis followed by Bonferroni posttests demonstrated that CII 
immunized mice showed significant increases in CXCL10 mRNA levels compared 
to those in control mouse brains on day 28 and day 35 (P = 0.0118). The mean 
value of brain CXCL10 gene expression (CII immunized versus naïve control) on 
day 28 were 2316 ± 681 versus 1244 ± 588 (P = 0.0154), while the mean value of 
brain CXCL10 gene expression (CII immunized versus naive control) on day 35 
were 4100 ± 2351 versus 1058 ± 289 (P = 0.0105) (Figure 4.22A). A peak in mRNA 
of CXCL10 in brains of CII immunized mice was observed on day 35 after 
immunization. However, one-way ANOVA demonstrated that there was also no 
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significant difference in brain CXCL10 gene expression in different groups of CII 
immunized mice culled on day 22, day 28, day 35 and day 42 (Figure 4.22B).  
 
Figure 4.22 Time-course of a chemokine (CXCL10) mRNA concentrations in brains of CII 
immunized mice by Real-time PCR  
(A) Mice immunized with type II collagen (filled squares) were culled on days 22, 28, 35, 42 
and brain from CII immunized mice at all time points were harvested. Brain samples 
collected from naïve control mice (open circle) culled on the days indicated were used as 
controls. CXCL10 mRNA concentrations in brain tissue homogenate of mice from all 
experimental groups were determined using a real-time PCR assay. The concentrations of 
CXCL10 mRNA were normalized against GAPDH expression and shown as arbitrary units. 
Data represent means ± SEM. (n = 6 CII immunised mice/group). Statistical analysis of data 
was performed using two-way ANOVA compared with naïve control mice: *P<0.05. (B) 
shows longitudinal changes of brain CXCL10 in CII immunized mice culled on the days 
indicated. Bars represent mean values: (*P < 05; **P < 01; ***P < 001 by one-way ANOVA 
analysis). 
4.2.5.5 Time course analysis of growth factor mRNA levels in the brains 
of CII immunized mice 
Gene expressions of growth factors including FGF2 and VEGF were detectable in 
the brains of mice from all experimental groups.  
Two-way ANOVA analysis demonstrated that there was no significant different in 
FGF2 gene expression levels in brains of CII immunized mice versus those of 
naïve control mice (Figure 4.23A). One-way ANOVA demonstrated that FGF2 
mRNA levels in brains of CII immunized mice from different time point groups 
were not significantly different (Figure 4.23B).  
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Figure 4.23 Time-course of a growth factor (FGF2) mRNA levels in brains of CII immunized 
mice by Real-time PCR  
(A) Mice immunized with type II collagen (filled squares) were culled on days 22, 28, 35, 42 
and brain from CII immunized mice at all time points were harvested. Brain samples 
collected from naïve control mice (open circle) culled on the days indicated were used as 
controls. FGF2 mRNA levels in brain tissue homogenate of mice from all experimental 
groups were determined using a real-time PCR assay. The levels of FGF2 mRNA were 
normalized against GAPDH expression and shown as arbitrary units. Data represent means 
± SEM. (n = 6 CII immunised mice/group). Statistical analysis of data was performed using 
two-way ANOVA compared with naïve control mice. (B) shows longitudinal changes of brain 
FGF2 in CII immunized mice culled on the days indicated. Bars represent mean values: (*P < 
05; **P < 01; ***P < 001 by one-way ANOVA analysis). 
Two-way ANOVA analysis followed by Bonferroni posttests demonstrated that 
brain VEGF gene expression levels were elevated in CII immunized mice 
compared to those in naïve control mice on day 28 and day 35 (P = 0.0005). The 
mean value of brain VEGF gene expression (CII immunized versus naïve control) 
on day 28 were 10265 ± 3384 versus 4261 ± 2141 (P = 0.0043), while the mean 
value of brain VEGF gene expression (CII immunized versus naïve control) on day 
35 were 16860 ± 8380 versus 4829 ± 1158 (P = 0.0059) (Figure 4.24A). One-way 
ANOVA demonstrated that there was no significant difference in brain VEGF 
mRNA level of immunized mice at different time points (Figure 4.24B).   
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Figure 4.24 Time-course of a growth factor (VEGF) mRNA levels in brains of CII immunized 
mice by Real-time PCR  
(A) Mice immunized with type II collagen (filled squares) were culled on days 22, 28, 35, 42 
and brain from CII immunized mice at all time points were harvested. Brain samples 
collected from naïve control mice (open circle) culled on the days indicated were used as 
controls. VEGF mRNA levels in brain tissue homogenate of mice from all experimental 
groups were determined using a real-time PCR assay. The levels of VEGF mRNA were 
normalized against GAPDH expression and shown as arbitrary units. Data represent means 
± SEM. (n = 6 CII immunised mice/group). Statistical analysis of data was performed using 
two-way ANOVA compared with naïve control mice: **P<0.01. (B) shows longitudinal 
changes of brain VEGF in CII immunized mice culled on the days indicated. Bars represent 
mean values: (*P < 05; **P < 01; ***P < 001 by one-way ANOVA analysis). 
4.2.5.6 Differences in inflammatory mediator mRNA levels in brain of 
arthritic mice and non-arthritic mice 
We also compared mRNA levels of inflammatory mediators including IL-12, 
CXCL1, CXCL10, FGF2 and VEGF. There were no significant differences in brain 
mRNA levels of IL-12 CXCL10, FGF2 and VEGF between arthritis and non-arthritis 
mice on day 35 and day 42 (Figure 4.25A-Figure 4.25D).   
 
Chapter 4  211 
 
Figure 4.25 Differences in inflammatory mediator mRNA levels in brains of arthritic mice and 
non-arthritic mice  
(A), (B), (C) and (D) show inflammatory mediator protein levels (pg/mg total brain protein) in 
brains of CII immunized mice with and without arthritis (n =3 CII immunised mice/group) on 
day 35 and day 42. Data are presented as the mean ± S.D. (*P < 05; **P < 01; ***P < 001 by 
Student’s t test.) 
Interestingly, a significant difference in brain CXCL1 mRNA levels between 
arthritic and non-arthritic mice was observed on day 35, which was similar to 
brain CXCL1 protein profile of arthritic and non-arthritic mice on day 42. 
Arthritic mice on day 35 showed a significant increase in brains CXCL1 gene 
expression levels compared to those in brains of non-arthritic mice on day 35. 
The mean value of brain CXCL1 gene expression (arthritic versus non-arthritic) 
on day 35 were 6908 ± 1255 versus 4283 ± 1037 (P = 0.0493) (Figure 4.26B).  
 
Figure 4.26 Differences in CXCL1 mRNA levels in brains of arthritic mice and non-arthritic 
mice  
Brain CXCL1 mRNA levels (pg/mg total brain protein) in arthritic (n=3 arthritic mice) and 
non-arthritic (n=3 non- arthritic mice) were compared on day 35 and day 42. Data are 
presented as the mean ± S.D. (*P < 05; **P < 01; ***P < 001 by Student’s t test.) 
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4.2.6  Comparison between time course changes in 
inflammatory mediator protein and mRNA levels in brain of 
CII immunized mice 
Both mRNA and protein expression of IL-12, CXCL1, VEGF and FGF2 were 
detectable and longitudinal changes of these inflammatory mediators were 
observed in brains of immunized mice. The comparison between overall trends 
in inflammatory mediator protein and mRNA levels may provide some evidence 
of how the periphery induces central inflammatory mediator production and the 
possible cellular sources of these inflammatory mediators in the brain of CII 
immunized mice. 
Our data showed that the overall trends of time course profiles of inflammatory 
mediator protein concentrations were not similar to the time course profiles of 
the same inflammatory mediator gene expression in brain of immunized mice. 
However, overlapping or parallel trends of time course profiles of brain 
inflammatory mediator protein concentrations and brain gene expression were 
observed at some time points. 
4.2.6.1 Comparison between time course changes in Th1 cytokine 
protein and mRNA expression levels in brain of CII immunized mice 
Longitudinal changes of both mRNA expression levels and protein concentrations 
of IL-12, a Th1 cytokine, were observed in brains of CII immunized mice 
compared to those of naïve control mice. Parallel trends of time course profiles 
of brain IL-12 protein concentration and gene expression in CII immunized mouse 
brains was observed during days 22 to 28 after immunization. Differences 
between IL-12 protein concentration and gene expression were observed from 
day 28 onwards. While brain IL-12 protein concentrations continued to decrease 
gradually, an increase in IL-12 gene expression levels was observed during the 
same period and this was followed by an unchanged IL-12 gene expression level 
(Figure 4.27). This data suggest that there may be migration of peripheral Th1 
cells into the brain or induction of local production of IL-12 during the period of 
onset of disease (day 22-day 28 after immunization). The migration of these 
peripheral Th1 cells may continued throughout the acute and chronic phases of 
CIA experimental course, indicated by the prolong expression of IL-12 protein 
during day 28 to day 42 after immunization. However, the concentrations of the 
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Th1 cytokine migration may be reduced over time during day 28-day 42 and not 
as much as the period of disease onset. By contrast, mRNA expression levels of 
IL-12 increased during day 28 to day 42 after immunization, suggesting that 
there may be induction of the local production of IL-12 in brains of CII 
immunized mice throughout the period of acute and chronic phases of disease 
(Figure 4.27).  
 
Figure 4.27 Longitudinal changes of a Th1 (IL-12) cytokine protein concentrations and 
mRNA expression levels in brains of CII immunized mice  
Brain samples collected from CII immunized mice culled on the days indicated were 
harvested. Half brain samples were processed for protein quantification by an ELISA assay 
(red filled squares), while the other half brain was processed for mRNA quantification and 
real-time PCR (blue filled squares). Data represent means ± SEM (n = 6 CII immunised 
mice/group). IL-12 protein concentrations in brain tissue, normalized against total brain 
protein, are expressed as pg/µg total brain protein. IL-12 mRNA levels in brain tissue, 
normalized against the expression of housekeeping gene GAPDH, are presented as 
arbitrary units. 
4.2.6.2  Comparison between time course changes in chemokine 
protein and mRNA levels in brain of CII immunized mice 
Trends of time course profiles of brain CXCL1 protein concentrations and gene 
expressions in immunized mouse brains fluctuated during day 22 to day 35 after 
immunization. Brain CXCL1 protein and gene expression levels decreased on day 
28 and then increased back on day 35. However, the divergence in trends of 
time course profiles of brain CXCL1 protein concentrations and gene expressions 
was observed during the final period. A gradual increase in CXCL1 gene 
expression was observed during day 35 to day 42, while CXCL1 protein 
concentrations in immunized mouse brains decreased slightly during the same 
period (Figure 4.28). CXCL1 in the brain is produced mainly by microglia (Brown 
et al., 2010). The overlap between CXCL1 gene and protein expression in brains 
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of CII immunized mice may suggest the local production of CXCL1 by microglia 
over the period of onset and acute phase of CIA experimental course. It was also 
possible the there may be the transportation of CXCL1 into the brains of these 
CII immunized mice, which was reduced during the late disease phase (day 35-
day 42 after immunization). However, in that period the gene expression of 
CXCL1 still increased, suggesting the continuous production of CXCL1 by CNS 
immune cells in the chronic phase of disease.   
 
Figure 4.28 Longitudinal changes of a chemokine (CXCL1) protein concentrations and 
mRNA expression levels in brains of CII immunized mice  
Brain samples collected from CII immunized mice (open circle) culled on the days indicated 
were harvested. Half brain samples were processed for protein quantification by a Luminex 
assay (red filled squares), while the other half brain was processed for mRNA quantification 
and real-time PCR (blue filled squares). Data represent means ± SEM (n = 6 CII immunised 
mice/group). CXCL1 protein concentrations in brain tissue, normalized against total brain 
protein, are expressed as pg/µg total brain protein. CXCL1 mRNA levels in brain tissue, 
normalized against the expression of housekeeping gene GAPDH, are presented as 
arbitrary units. 
4.2.6.3  Comparison between time course changes in growth factor 
protein and mRNA levels in brain of CII immunized mice 
The overall trends of longitudinal changes of brain FGF2 protein concentrations 
was similar to those of brain FGF2 gene expression in immunized mice across all 
the time points. Parallel trends of time course profiles of brain FGF protein 
concentrations and gene expressions in immunized mouse brains was observed 
during day 22 to day 28 after immunization. The trend of time course profile of 
brain FGF protein concentrations remained unchanged during day 28 and day 35, 
followed by a slight decrease until the terminal day. In contrast, brain FGF2 
gene expression levels slightly increased during day 28 and day 35 and then the 
expression level of FGF mRNA remained unchanged until day 42 (Figure 4.29). 
The similarity on the overall trends between FGF2 gene and protein expression 
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throughout the period of CIA experimental period may suggest local production 
of FGF2 in the brains (Figure 4.29).  
 
Figure 4.29 Longitudinal changes of a growth factor (FGF2) protein concentrations and 
mRNA expression levels in brains of CII immunized mice  
Brain samples collected from CII immunized mice (open circle) culled on the days indicated 
were harvested. Half brain samples were processed for protein quantification by a Luminex 
assay (red filled squares), while the other half brain was processed for mRNA quantification 
and real-time PCR (blue filled squares). Data represent means ± SEM (n = 6 CII immunised 
mice/group). FGF2 protein concentrations in brain tissue, normalized against total brain 
protein, are expressed as pg/µg total brain protein. FGF2 mRNA levels in brain tissue, 
normalized against the expression of housekeeping gene GAPDH, are presented as 
arbitrary units. 
The overall trends of longitudinal changes of VEGF protein concentrations were 
quite similar to those of time course profiles of VEGF gene expressions in brain 
of CIA mice across all the time points. The overall trends of time course profiles 
of VEGF protein concentrations overlapped those of VEGF gene expression levels. 
Increases in both brain VEGF gene expressions and protein concentrations were 
observed in immunized mouse brain during day 28 and day 35. However, trends 
of both brain VEGF gene and protein expression profiles were divergent during 
the last period. While brain VEGF gene expression levels remained unchanged 
from day 35 to 42, protein concentrations of VEGF decreased during the same 
period (Figure 4.30). These data suggest that the majority of VEGF detectable in 
CII immunized mice may be produced locally in the brain.  
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Figure 4.30 Longitudinal changes of a growth factor (VEGF) protein concentrations and 
mRNA expression levels in brains of CII immunized mice  
Brain samples collected from CII immunized mice (open circle) culled on the days indicated 
were harvested. Half brain samples were processed for protein quantification by a Luminex 
assay (red filled squares), while the other half brain was processed for mRNA quantification 
and real-time PCR (blue filled squares). Data represent means ± SEM (n = 6 CII immunised 
mice/group). VEGF protein concentrations in brain tissue, normalized against total brain 
protein, are expressed as pg/µg total brain protein. VEGF mRNA levels in brain tissue, 
normalized against the expression of housekeeping gene GAPDH, are presented as 
arbitrary units. 
4.2.7  Summary; longitudinal changes in mRNA and protein 
concentrations in brain of CII immunized mice 
In this experiment we determined changes in inflammatory mediators in brain of 
arthritic mice in 4 time points, which represented different stages of 
inflammatory joint disease. Therefore, 42 day period of CIA experimental course 
was divided into 3 phases. The period of disease onset was defined as day 22- 
day 28 after immunization, early disease phase was defined as day 28-day 35 
after immunization, and the transition to the late disease phase was defined as 
day 35 to day 42 after immunization. We found elevation of mRNA and protein 
concentrations of various brain inflammatory mediators, including IL-1β, TNF-α, 
IL-4, IL-12, IL-2, IL-10, CCL2, CXCL1, CXCL10, VEGF and FGF2 in different phases 
of CIA experimental course (Table 4.2). 
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Day 22 
 
 
Day 28 
 
Day 35 
 
Day 42 
 
 
 
Cytokies, 
chemokines 
Growth 
factors  
protein 
 
 
gene 
 
protein 
 
gene 
 
protein 
 
gene 
 
protein 
 
gene 
 
IL-1β 
 
 0.0235 
 
 
undt 
 
NS 
 
undt 
 
NS 
 
undt 
 
NS 
 
undt 
 
TNF-α 
 
NS 
 
 
undt 
 
NS 
 
undt 
 
 0.0113 
 
 
undt 
 
 0.0075 
 
 
undt 
 
IL-4 
 
 0.0015 
 
 
undt 
 
0.0037 
 
 
undt 
 
NS 
 
undt 
 
NS 
 
undt 
 
IL-10 
 
  <0.0001 
 
 
undt 
 
 <0.0001 
 
 
undt 
 
0.0003 
 
 
undt 
 
0.0003 
 
 
undt 
 
IL-2 
 
NS 
 
 
undt 
 
NS 
 
undt 
 
0.0357 
 
 
undt 
 
NS 
 
undt 
 
IL-12 
 
0.0018 
 
 
NS 
 
0.0009 
 
 
NS 
 
0.02 
 
 
  0.0264 
 
 
    <0.0001 
 
 
NS 
 
CCL2 
 
0.0118 
 
 
undt 
 
 0.0238 
 
 
undt 
 
NS 
 
undt 
 
0.0125 
 
 
undt 
 
CXCL1 
 
NS 
 
  0.0001  
 
NS 
 
NS 
 
NS 
 
NS 
 
NS 
 
   0.007 
 
 
CXCL10 
 
undt 
 
 
NS 
 
undt 
 
  0.0154 
 
 
undt 
 
 0.0105 
 
 
undt 
 
NS 
 
VEGF 
 
NS 
 
NS 
 
NS 
 
  0.0043 
 
 
NS 
 
  0.0059 
 
 
0.0219 
 
 
NS 
 
FGF2 
 
 
NS 
 
NS 
 
NS 
 
NS 
 
NS 
 
NS 
 
0.0402 
 
NS 
Table 4.2 Longitudinal changes in concentrations brain inflammatory mediator profiles in 
brains of CII immunized mice relative to those of those in control mice  
Red arrows represent an increase of inflammatory mediator protein concentrations, while 
blue arrows represent an increase of inflammatory mediator mRNA expression levels in 
brains of CII immunized mice compared to those in naïve control mice on day 22, day 28, 
day 35 and day 42 after immunization. Differences between inflammatory mediator 
concentrations in CII immunized mouse brains and naïve control groups were analyzed by 
Student's t- test (*P < 05; **P < 01; ***P < 001). NS = not statistically significant, untd = 
undetectable.  
During the period of onset of arthritis disease (day 22 – day 28 after 
immunization) in CII immunized mice, we found transient elevation of IL-1β 
protein concentrations in brains of these CII immunized mice. IL-1β has been 
reported to regulate the production of CXCL in the CNS (Shaftel et al., 2007). 
Therefore, the increased in concentrations of brain IL-1β protein may be 
associated with the elevation of CXCL1 mRNA, which was also increased 
transiently at the same period of time. From day 22 after immunization 
onwards, protein concentrations of both Th1 (IL-12 and IL-2) and Th2 (IL-4 and 
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IL-10) cytokines started to increase. The prolonged elevation of brain IL-12 
protein concentrations in CII immunized mice were observed throughout the CIA 
experimental course (day 22 – day 42 after immunization), while elevation of IL-
12 mRNA levels were only observed on day 35. This suggests that the majority of 
IL-12 protein may be transported from the periphery and may be via the 
recruitment of peripheral Th1 into the CNS. The concentrations of IL-2 in brains 
of CII immunized mice also peaked on day 35, at the end of the acute phase of 
the CIA experimental course. Interestingly, the IL-12 protein concentrations 
started at the beginning of disease onset before the peak of CXCL10, a potent 
recruiter of Th1 lymphocytes, during day 28 and day 35 after immunization. This 
may suggest the influx of Th1 cells may be apparent during the early phase of 
the disease course. The prolonged elevation of Th2 cytokines, particularly IL-10 
were also observed throughout the CIA experimental course (day 22 – day 42 
after immunization), although the brain IL-4 protein concentrations were only 
increased during the period of onset of arthritis disease and the concentrations 
were reduced towards the end of the CIA experimental course. Interestingly, the 
prolonged elevation of Th2 cytokines seemed to correspond to the prolonged up-
regulations of CCL2 protein in the brains of CII immunized mice throughout the 
period of the CIA experimental course. CCL2 is known to regulate the trafficking 
of Th2 cells into the inflamed site. Therefore, the coincidence between CCL2 
and Th2 cytokines suggested that there may be recruitment of Th2 lymphocytes 
from the periphery into the brain. We found increased concentrations of the 
growth factors FGF2 and VEGF, which are angiogenic factors that have been 
reported to be associated with BBB breakdown during the neuro-inflammatory 
process, especially during the early phase of the disease. The coincidental 
elevation of these growth factors (VEGF, FGF2) and chemokines such as CXCL1 
and CXCL10 during day 28 - day 35 after immunization may suggested that BBB 
breakdown and the recruitment of peripheral immune cells into the brain during 
the early phase of CIA experimental course may be regulated by peripheral 
inflammatory cytokine signals.  
4.3  Result chapter 4: Summary of major findings.  
The aim of this chapter was to investigate longitudinal changes of brain 
inflammatory mediators that may be associated with longitudinal changes in 
peripheral inflammatory mediators and the development and the progression of 
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arthritis disease in CII immunized mice. We determined changes in brain 
inflammatory mediators in CII immunized mice in 3 phases across the 42-day 
period of the CIA experimental course. Day 22 – day 28 after immunization was 
the period of disease onset, day 28 – day 35 after immunization was the acute 
phase of disease and day 35 – day 42 after immunization was the transition to 
chronic phase of the disease. We found:- 
1. Transient elevation of serum IL-1β, IL-5, CCL2 and FGF2 protein concentration 
during the period of onset of disease (day 22 – day 28 after immunization) in CII 
immunized mice. This was followed by a reduction in these serum inflammatory 
mediator concentrations during the acute and chronic phases of disease 
development.  
2. Transient elevation of pro-inflammatory cytokine IL-1β protein concentration 
during the onset of disease in the brains of CII immunized mice. In contrast, an 
elevation of brain TNF-α protein concentration was observed in brains of CII 
immunized mice during the late disease stage (day 35-day 42 after 
immunization).  
3. Prolonged elevation of the Th1 cytokine IL-12 concentration in brains of CII 
immunized mice throughout the CIA experimental period, while a peak of IL-2 
protein in the brains of CII immunized mice was observed on day 35 after 
immunization. 
4. Prolonged elevation of the Th2 cytokine IL-10 protein concentration in brains 
of CII immunized mice throughout the CIA experimental period, while IL-4 
protein concentration was elevated in brains of CII immunized mice only during 
the period of onset of the disease (day 22 – day 28 after immunization). 
5. Transient elevation of brain CXCL1 mRNA expression in brains of CII 
immunized mice during the onset of the disease (day 22 after immunization) and 
at the end of the CIA experimental course (day 42 after immunization) 
6. Prolonged elevation of the chemokine CCL2 protein concentration in brains of 
CII immunized mice throughout the CIA experimental period.  
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7. Coincidental increase of CXCL10 and VEGF mRNA expression levels in brains of 
CII immunized mice during the acute phase of the disease (day 28-day 35 after 
immunization).  
8. The FGF2 and VEGF protein concentrations and mRNA expression levels in 
brains of CII immunized mice started to increase from day 28 after immunization 
onwards.  
9. There was no significant difference in brain mRNA expression levels of IL-12, 
CXCL10, VEGF and FGF2 and protein concentrations of IL-1β, TNF-α, IL-2, IL-12, 
IL-4, IL-10, CCL2, VEGF and FGF2 between arthritic and non arthritic mice on 
day 35 and day 42. However, there were differences in CXCL1 gene expression 
levels and protein concentrations between arthritic and non-arthritic mice on 
day 35 and day 42.  
10. Overlapping or parallel trends of time course profiles of brain IL-12 and 
CXCL1 protein concentrations and gene expression in brains of CII immunized 
mice were observed at some time points across the 42-day period of CIA 
experimental course. However, the divergence between IL-12 and CXCL1 gene 
and protein concentrations was observed during the transition to the chronic 
phase of the disease. The concentrations of brain IL-12 and CXCL1 protein were 
reduced between day 35 and day 42 after immunization, while mRNA expression 
levels of IL-12 and CXCL1 in brains of were increased during that period.  
11. Overlapping or parallel trends of time course profiles of brain FGF2 and VEGF 
protein concentrations and gene expression in brains of CII immunized mice were 
observed at some time points across the 42-day period of CIA disease course. 
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4.4 Discussion 
In this chapter we investigated the possible mechanism by which peripheral 
inflammation, ie serum cytokines, induced production of brain inflammatory 
mediators in CII immunized mice. We found increased concentrations of serum 
IL-1β, IL-5, CCL2 and FGF2 in CII immunized mice (day 22 – day 28 after 
immunization), suggesting they provided a possible inflammatory signal during 
the onset and the early disease period. We also found increased concentrations 
of these same inflammatory mediators (IL-1β, CCL2 and FGF2) in the brain 
during the onset of the disease, suggesting the possible transportation of these 
inflammatory mediators from the periphery into the brain of CII immunized 
mice, or alternatively local synthesis. In addition, we demonstrated coincidental 
increase of serum concentrations and mRNA expression levels of inflammatory 
mediators, for example, IL-1β and CXCL1 or FGF2 and VEGF during the same CIA 
experimental period, and these cytokines can mutually regulate each other. This 
could be important evidence suggesting that the peripheral inflammatory 
cytokine signal may induce local production of inflammatory mediators in brains 
of CII immunized mice during the onset and the early disease period. For 
example, it is possible that the production of brain CXCL1 and VEGF production 
may be induced via the peripheral inflammatory cytokine signals of IL-1β and 
FGF2 during the onset and the early disease period. We demonstrated the up- 
and down-regulation of different inflammatory mediators in brains of CII 
immunized mice at different time point over the CIA disease course. In addition, 
we also showed a prolonged increase of the concentration of the Th1 
inflammatory cytokine IL-12, which was coincidental with down-regulation of 
Th2 anti–inflammatory cytokine IL-4 in brains of CII immunized mice. These data 
suggest that there may be an interplay and regulation between brain 
inflammatory mediators, which indicates the possible immune activation and 
inflammatory process in the brains of CII immunized mice. We therefore set out 
to discusse and interpreted our data in detail separately in 3 main aspects; (i) 
peripheral inflammation signal in CII immunized mice; (ii) peripheral 
inflammation-induced brain inflammation in CII immunized mice; (iii) the 
possible interplay between inflammatory mediators in brains of CII immunized 
mice. 
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4.4.1  Longitudinal changes in peripheral inflammatory 
mediators in CII immunized mice.  
We analysed changes in inflammatory mediator protein concentrations in the 
peripheral circulation of CIA mice by using a Luminex multi-analyte assay to 
determine changes in serum cytokines, chemokines and growth factor protein 
concentrations in CIA mice across all time points of the disease course. We found 
increased concentrations of serum IL-1β, IL-5, CCL2 and FGF2 in CII immunized 
mice during the onset of disease (day 22 and day 28), suggesting these 
inflammatory mediators may play crucial roles at different pathological stages in 
the development of disease. IL-1β is considered to be a key cytokine in the RA 
process (Koenders et al., 2008) and up-regulation of IL-1β has been reported in 
the joints of CIA mice during the onset of disease. A time course study in joint 
cytokine expression in CIA mice showed transient expression of pro-inflammatory 
cytokines IL-6, IL-1β and TNF-α during the period of 15 days after immunization. 
mRNA and protein concentrations of IL-6 increased sharply by day 1, while TNF-α 
concentration showed a significant increase occurring on days 4 to 8. IL-1β 
concentration was up-regulated on day 4 and its concentration remained 
significantly high until the onset of the disease. These data suggest that pro-
inflammatory cytokines may induce the disease development in this model 
shortly after the primary sensitisation / immunization, and that changes in 
serum cytokines may be observed in this model in the early (onset of the 
disease) period of time after immunization (Rioja et al., 2004). However, most 
studies in CIA models showed that the IL-1β concentrations in serum of CIA mice 
were low or undetectable. A time course study by Marije et al., showed that IL-
1β serum concentration in CIA mice did not increase over time throughout the 
CIA experimental course (Koenders et al., 2008). Another study by J-M Kim et 
al., showed that the IL-1β serum concentration in CIA mice on day 40 after 
immunization was undetectable, but there was marked increase of IL-1β in the 
joints of CIA mice, suggesting that IL-1β protein may not necessarily be 
increased in the blood during the joint inflammatory process, but the increase of 
IL-1β in the joint may be more important for the development of arthritis in the 
CIA model (Kim et al., 2003). We also found an increased concentration of the 
Th2 cytokine IL-5 in serum of these CII immunized mice during the period of 
onset of arthritis disease (day 22-day 28) after immunization. Our data was 
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consistent with a previous study by Schaefer et al., showing up-regulation of IL-5 
protein in serum of CIA mice (Schaefer et al., 1999). Our data, combined with 
this previous report, suggests that IL-5 and Th2 cells may play an important role 
in the development of arthritis. This premis is supported by clinical studies 
showing that raised concentrations of Th2 cytokines such as IL-4, IL-5, IL-10 and 
IL-13 were predominately detected in RA synovial fluid during the early stage of 
disease (Hitchon et al., 2004); (Hitchon and El-Gabalawy, 2002). A transient 
increase of serum CCL2 protein concentration was observed in these CII 
immunized mice during the period of onset of disease (day 22-day 28), followed 
by a marked decrease over time throughout the early and the late disease 
phases. A similar longitudinal change in serum CCL2 protein profile has been 
reported previously in a study in arthritic rats by Stolina et al., (Stolina et al., 
2009). CCL2 is chemotactic for monocytes and Th2 cells, and this chemokine has 
been detected in high concentrations in synovial fibroblasts from RA patients 
(Szekanecz et al., 2003), especially in response to IL-1 and TNF-α. The main 
function of CCL2 during the onset of arthritis disease may be the recruitment of 
Th2 cells into the joint. This premis is supported by our finding showing the 
coincidental increase of serum CCL2 and IL-5 concentrations in CII immunized 
mice during the same period of onset of disease. The association between CCL2 
and IL-5 has also been demonstrated in CCL2 deficient mice. Lower production 
of Th2 cytokines including IL-4, IL-5 and IL-10 and an inability to produce 
specific antibodies were observed in CCL2 deficient mice (Gu et al., 2000). This 
finding suggests that CCL2 might also regulate the production of Th2 cytokines. 
The presence of increased concentrations of this serum chemokine in immunized 
mice during the onset of the disease suggests that there could be increased 
immune cell migration into the inflamed tissue that may be associated with 
angiogenesis. We also found significantly increased concentrations of serum 
FGF2, an angiogenic factor, in immunized mice during the onset and 
development of disease. This increased concentration of FGF2 may be associated 
with the process of cartilage and bone erosion including synoviocyte 
proliferation and osteoclastogenesis, that has been shown to be highly active 
during the onset of disease (Malemud, 2007); (Stolina et al., 2009).  
However, during the early and late disease phase (day 28 – day 35 after 
immunization), our Luminex data showed reducing serum concentrations of 
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several inflammatory mediators, including IL-1β IL-5, CCL2 and FGF2 in 
immunized mice. Several studies report the same observation; showing transient 
increases in serum cytokine concentrations during the onset of disease that 
became undetectable during the period of clinical manifestation of disease. A 
study by Tsuji et al, in which time-course changes in serum cytokine profiles in 
CIA mice were also determined by Luminex over the course of the experimental 
disease (Tsuji et al., 2009). They reported transient increases of various 
cytokines, including IL-12, TNF-α, IFN-γ, IL-9, IL-17 and CCL4 in serum of CIA 
mice after the primary immunization and the concentrations of these serum 
cytokines reached their peak on day 22. This was followed by a reduction of 
serum protein concentrations of these cytokines from day 22 onwards (Tsuji et 
al., 2009).  Another study by Asquith et al., 2009 also demonstrated that protein 
concentrations of several cytokines and chemokines, including IL-1α, IL-6, IL-17, 
CCL2, CCL3 and CCL6 in serum of CIA mice on day 31 were at or lower than the 
detection limits of the assays, and this suggest that there was no elevation of 
serum inflammatory mediators in CIA mice during the early phase of disease 
(Asquith et al., 2009a). In addition, several studies demonstrated that serum 
cytokine concentrations in CIA mouse model were inconsistent and in many cases 
undetectable as was consistent with our results (Harnett et al., 2008); (Lu et al., 
2010); (del Rey et al., 2008). There are several explanations underlying the 
absence or the undetectable concentrations of serum cytokines in CIA mice 
during the late disease phase. One possibility is that these inflammatory 
mediators are generated locally at the inflammatory site and also function 
locally to induce bone and cartilage destructive process, but may not circulate 
in the bloodstream. This has been demonstrated by several studies in CIA mice 
showing high expression of inflammatory mediators in inflamed joints, but 
undetectable concentrations in the serum (Lu et al., 2010); (Palmblad et al., 
2001). Another possibility is that the distribution of inflammatory mediators and 
immune cells from inflamed sites to adjacent tissues may be mainly via the 
lymphatic system rather than via the bloodstream. This is supported by a study 
of lymphatic vessels draining foot joints of RA patients showing several-fold 
higher concentrations of lymph cytokines and chemokines than the serum 
cytokine concentrations. High flow rates of lymphatic vessels containing high 
cytokine concentrations through the regional lymph nodes observed in RA 
patients may reflect the activity of lymphatic vessels to transport immune cells 
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and inflammatory mediators from the inflammation site to the periphery 
(Olszewski et al., 2001). 
4.4.2 Association between peripheral inflammation and 
increased concentrations of brain inflammatory mediators: 
possible evidence that peripheral inflammatory cytokine 
signals induce neuro-inflammation. 
 
The model of systemic LPS challenge showing that peripheral inflammation could 
induce brain inflammation has been well documented (Datta and Opp, 2008), 
(Laye et al., 1994); (Quan et al., 1994); (Gatti and Bartfai, 1993); (Breder et al., 
1994); (Gabellec et al., 1996); (Grinevich et al., 2001). One study by de Ray et 
al is the only study that demonstrated an association between peripheral joint 
inflammation and inflammation in the brain of CIA rats, which is an equivalent 
model of a chronic autoimmune disease to the murine model used in this thesis 
(del Rey et al., 2008). However, the communication between joint-immune 
system-brain in the CIA model was not well documented in that study. We first 
investigated the possibility that peripheral inflammation induced brain 
inflammation in brains and serum of CII immunized mice by using a Luminex and 
PCR assays to quantify gene expression and protein concentrations of 
inflammatory mediators. We found that IL-1β, CCL2, FGF2 and Th2 cytokine 
proteins were increased in brains of CII immunized mice as well as in their 
serum, compared to those in naïve conrol mice. Our data suggest that the 
peripheral inflammation may signal brain inflammatory cytokine production via 
IL-1β, CCL2, FGF2 and Th2 cells during the course of arthritis.  
We found transient increases in brain IL-1β protein during the onset of disease in 
CII immunized mice, which corresponded to a transient elevation of serum IL-1β. 
A similar coincidental increase of IL-1β in the periphery and in the brain of CIA 
rats has been reported previously by del Ray et al (del Rey et al., 2008). 
However, we found no corresponding IL-1β mRNA expression levels in brains of 
these CII immunized mice, suggesting there may be no local IL-1β production in 
the brain. Our data, combined with the finding of the previous report suggest 
the possibility that there may be a contribution of IL-1β from the periphery into 
the brain of CII immunized mice during the course of disease. There was one 
study that suggested that IL-1β can be transported into the brain by a saturable 
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mechanism, suggesting a specific receptor (Banks et al., 1991). However, the 
mechanism of how IL-1β protein could be transported into the brain of CII 
immunized mice during the period of disease onset needs to be further 
investigated. The increase of IL-1β protein concentration in the serum of CII 
immunized mice was coincidental with transient increases in brain CXCL1 mRNA 
expression levels during the onset of the disease (day 22 after immunization). It 
is possible that peripheral IL-1β may signal brain immune cells such as microglia 
to produce CXCL1 in brain CII immunized mice. This is supported by in vivo and 
in vitro studies demonstrating that increases in concentrations of brain IL-1β can 
induce CXCL1 production in the brain by microglia (Shaftel et al., 2007). 
TNF-α was another pro-inflammatory cytokine that was up-regulated in the 
brains of arthritic mice during the early and late stages of disease. However, we 
could not define the source of this TNF-α protein in the brains of these CII 
immunized mice, since brain TNF-α mRNA and serum TNF-α were undetectable 
in CII immunized mice in this study. This is difficult to explain but is similar to a 
study by de Ray who also reported that TNF-α was detectable in the brain of 
arthritic rats, despite no detectable serum TNF-α. It has been reported that 
TNF-α protein was detected in high concentration in the peripheral tissue such 
as peritoneal cavity and spleen of CIA mice during the early and late stages of 
disease (Stasiuk et al., 1996); (Mussener et al., 1997). It is still unclear how TNF-
α from the periphery might have affected the brain during the period of clinical 
manifestation of disease, despite no TNF-α detectable in the serum. This 
problem needs to be further investigated, perhaps by using peripheral 
administration of TNF-blockade into the CII immunized mice during the early and 
late stage of disease and determine changes in brain cytokines. These 
experiments will form Chapter 6 of this thesis. 
Prolonged increased concentrations of CCL2 were observed in the brains of CII 
immunized mice throughout the CIA experimental course, which may be 
associated with transient increases of serum CCL2 during the period of disease 
onset (day 22 and day 28). Our data seem to suggest that there may be a 
contribution of CCL2 from the periphery into the brain during the period of 
disease onset (day 22 and day 28). The prolonged increased concentration of 
CCL2 in the brain of CII immunized mice continued until the end of the CIA 
experimental course, suggesting that there may be local production of CCL2 in 
Chapter 4  227 
the brain after the onset of disease. However, we found no CCL2 gene 
expression in brains of CII immunized mice over the period of early and late 
phases of the disease. This seems to suggest that there may be an accumulation 
of CCL2 in the brains of CII immunized mice after the period of the disease 
onset. Prolonged increased concentrations of CCL2, a potent chemotactic factor 
of Th2 lymphocytes, may potentially be associated with increased 
concentrations of Th2 cytokines, including IL-4 and IL-10 in the brains of CII 
immunized mice during the disease process. However, we could not demonstrate 
the presence of any Th2 cytokine in the brains of CII immunized mice in our 
study. However, we found a coincidental increase of CCL2 and Th2 cytokines in 
both serum and in the brains at the same period of time, suggesting that there 
may be trafficking of Th2 cells, regulated by CCL2, from the periphery into the 
brain of CII immunized mice. This premise was supported by a study in the 
mouse model of liver injury showing that peripheral hepatic inflammation 
induced brain micoglia to produce CCL2, which was followed by infiltration of 
monocytes into the brains (D'Mello et al., 2009). This evidence also suggest that 
CCL2 up-regulated during the early and late disease phase may be associated 
with an increase of TNF-α, which is produced mainly by monocytes, during the 
same period of time. However, the hypothesis that CCL2 recruits Th2 cells and 
monocytes into the brains of CII immunized mice needs to be further 
investigated perhaps by using immuno-histochemistry for Th2 cells and monocyte 
markers in CIA brain tissues.  
We also found prolonged increased concentrations of IL-12 in the brains of CII 
immunized mice across all CIA experimental periods. Increases in IL-12 mRNA 
expression levels were also observed in these CII immunized mice, particularly at 
the late phase of the disease. This is in contrast to brain Th2 cytokines, for 
which their mRNA expression levels were undetectable. This may suggest 
difference in the location at which these Th1 and Th2 were activated and the 
origin of these Th1 and Th2 cells before potentially migrating into the brains of 
these CII immunized mice. The pathological mechanism of the joint destruction 
in RA is thought to be driven by Th1 cells and Th1 cytokines, including IL-12, and 
IL-2 can be detected in lymph node, spleen and joints of CIA mice throughout 
the period of onset and early disease (Okamoto et al., 2000); (Mussener et al., 
1997). However, we found no IL-12 or any Th1 cytokine elevated in the serum of 
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these CII immunized mice. This suggests that there is a possibility that there was 
no trafficking of Th1 from the periphery into the brains of CII immunized during 
the course of arthritis. Instead, up-regulation of IL-12 mRNA in brains of these 
CII immunized mice suggests that IL-12 may be produced from CNS T cells. The 
mechanism of CNS T cells activation has been well documented in model of 
neuro-inflammatory disease such as EAE, where the inflammatory demyelination 
development is driven by autoreactive Th1 cells (Klein, 2004). Although the 
pathological mechanism of EAE is thought to be due to autoreactive Th1 T cells 
that invade the CNS, several studies in EAE suggested that the major source of 
Th1 cells were activated within the CNS. A study by Greter et al, in mice that 
lacked secondary lymphoid tissue showed that activation of T cells in the 
presence of a cognate antigen occurred in the brain, and that T-cell trafficking 
to APCs located in secondary lymphoid tissues was not necessarily to initiate 
tissue destruction (Greter et al., 2005). This has been confirmed by another 
study (Juedes and Ruddle, 2001) showing that CNS T cells produce cytokines such 
as TNF-α and IFN-γ only when stimulated with CNS APCs. These data suggest that 
the activation of T cells in the presence of a cognate antigen occurred in the 
secondary lymph node and that trafficking of autoreactive Th1 T cells into the 
brain may not be the main mechanism of the pathological condition of 
peripheral inflammation associated with neuro-inflammation. Instead, the 
activation of T cells in the presence of a cognate antigen is more important. 
Based on the fact that the aetiology of RA and MS are influenced by genes in the 
HLA region, particularly the class II genes, therefore, CD4+ T cells are thought to 
play a crucial role in both MS and RA pathogenesis (Zozulya and Wiendl, 2008), 
(McInnes and Schett, 2007). This, combined with our data showing undetectable 
Th1 cytokines and highly detectable brain IL-12 mRNA expression levels in CII 
immunized mice, allowed us to hypothesis that there may be activation of CNS T 
cells occurring in the brain of CII immunized mice during the course of arthritis. 
This hypothesis is supported by our finding showing that the increased expression 
of IL-12 mRNA and protein concentrations occurred from day 22 onwards before 
the peak of mRNA expression levels of CXCL10, a potent Th1 recruiter, in brains 
of CII immunized mice on day 35. This suggested that the activation of CNS T 
cells may have occurred in the CNS before Th1 cells actually trafficking into the 
brain. Similarly, the peak of IL-12 protein also preceded the peak of VEGF, an 
angiogenic factor implicated in BBB breakdown. This suggests that the presence 
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of Th1 cells in brains of CII immunized mice may have occurred before the BBB 
breakdown. Although the increase in VEGF concentration in the brains has been 
reported to be associated with BBB breakdown (Argaw et al., 2009) some studies 
reported that BBB breakdown is not necessary to be the cause of an increase in 
peripheral immune cells infiltration into the CNS (Carson et al., 2006); (D'Mello 
et al., 2009); (Shaftel et al., 2007). This raises one important question; how the 
peripheral cytokines signal to the brain in order to activate the CNS Th1 
lymphocytes to produced IL-12 in the brain? The only possibility that we could 
suggest from our data is that the production of IL-12 by CNS immune cells such 
as T cells may be induced via the peripheral inflammation signal from IL-1β that 
was found to be up-regulated in the serum and brain tissues of CII immunized 
mice during the onset of the disease (day 22- day28 after immunization). We 
also found a downward trend in longitudinal changes in brain IL-12, which 
corresponded to a reduction in serum IL-1β in CII immunized mice. Important 
evidence supporting our finding is that IL-1β can enhance the activation of 
encephalitogenic T lymphocytes, contributing to the development of EAE 
(Matsuki et al., 2006). This hypothesis can be tested by using peripheral 
administration of anti-IL-1β into the CII immunized mice and determining 
changes in Th1 cytokines in the brain.  
A recent study has shown BBB disruption in CIA mice, characterized by an 
increase in BBB permeability and changes in the tight junction structure of BBB 
during the progress of arthritis (Nishioku et al., 2010b). Our data also suggest 
the possible signs of BBB disruption in brains of CII immunized mice, indicated by 
increased concentrations of VEGF in the brains of CII immunized mice during the 
early and late stages of disease (day 28-day 42 after immunization). VEGF is an 
angiogenic factor that has been implicated in BBB breakdown in several 
inflammatory conditions of the CNS (Croll et al., 2004a). Our data also showed 
that both VEGF mRNA expression levels and protein concentrations were up-
regulated during the same period (day 35 -day 42 after immunization), 
suggesting that there may be local production of VEGF in the brain by CNS cells 
such as astrocytes, vascular endothelium, microglia or neurons (Croll et al., 
2004a); (Mani et al., 2005). However, the mechanism underlying how the 
peripheral inflammatory signals induce VEGF production and BBB breakdown in 
the brains of CII immunized mice during the early disease stage in our study is 
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still unclear. One possibility is that VEGF production in the brain may be induced 
via the peripheral inflammatory signal obtained from FGF2 protein that is up-
regulated in the serum of these CII immunize mice during the onset and the 
early disease stages. This is because FGF2 is considered to be a strong inducer of 
VEGF in endothelial cells (Seghezzi et al., 1998). FGF2 is detectable at high 
concentrations in the synovial fluid of RA patients as well as in the joints of 
arthritic mice (Manabe et al., 1999); (Yamashita et al., 2002). These 
observations suggest that FGF2 may play a role in the joint destruction by 
inducing osteoclastogenesis that is strongly increased during the onset of 
arthritis disease (Stolina et al., 2009). It is also possible that there may be a 
contribution of FGF2 from the joint into the peripheral circulation, and then 
from the circulation the FGF2 may be transported to the brain during the onset 
of disease. This can be seen by the up-regulation of serum FGF2 concentration 
during the onset of disease (day 22), followed by a reduction of serum FGF2 
concentration during the chronic phase as seen in our longitudinal data during 
disease progression in CII immunized mice. However, this hypothesis needs to be 
further investigated, perhaps by using peripheral administration of anti- FGF2 
into the CII immunized mice during the early and late stage of disease and 
determine changes in brain cytokines, particularly VEGF. 
4.4.3 The potential interplay between inflammatory mediators 
in brains of CII immunized mice: Possible evidence for 
ongoing immune activation and inflammatory processes. 
The data obtained from this time-course experiment provided interesting 
observations suggesting that there may be ongoing immune activation and 
inflammatory process in the brains of CII immunized mice over the course of 
disease development. We demonstrated up- and down-regulation of different 
inflammatory mediators in brains of CII immunized mice at different time points 
across the period of clinical manifestation in the CIA experimental course. These 
changes in mediators may reflect the biological interaction of brain cytokines 
during the course of disease. There was a prolonged increase in several brain 
inflammatory cytokines such as IL-12, IL-10 and CCL2 in brains of CII immunized 
mice throughout the course of disease. These longitudinal patterns of change in 
brain cytokine profiles are not common in acute inflammation such as the 
systemic LPS-challenge model. Several studies in the systemic LPS-challenge 
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model showed transient increases in brain cytokine, seen as single concentration 
peaks at different time points in the experimental period in various brain regions 
(Laye et al., 1994); (Quan et al., 1994); (Gatti and Bartfai, 1993); (Breder et al., 
1994); (Gabellec et al., 1996); (Grinevich et al., 2001). We found some brain 
inflammatory mediators such as IL-1β, CCL2 and FGF2 that were up-regulated 
corresponding to the up-regulation of the same cytokines in serum occurring 
during the onset of disease. However, we also found several inflammatory 
mediators such as TNF-α that were up-regulated in the brain, but not in the 
serum during the period of clinical disease (day 35 – day 42 after immunization). 
This suggests that there may be immune activation and cytokine production 
within the brains of arthritic mice. Interestingly, our data showing that IL-12 
protein concentrations were elevated in the brains of CII immunized mice during 
the onset of the disease and then were decreased towards the latter stages of 
the disease. This profile was similar to the longitudinal changes in IL-12 mRNA 
expression levels in the CNS of EAE model of chronic CNS disease (Issazadeh et 
al., 1995). This suggests that the inflammatory process in the brain may be 
chronic rather than acute. This premise is supported by a study by de Ray et al 
showing a prolonged increase of IL-6 mRNA expression levels in brains of CIA rats 
during the period of onset and early disease period. That study also showed an 
increase of IL-1β mRNA expression levels in brains of CIA rats during the period 
of disease onset; which is similar to our finding in the brains of CII immunized 
mice. Transient increases in brain IL-1β protein concentrations during the onset 
of disease may also be associated with sharp increases in IL-12 protein 
concentrations observed during the same period. Although we have discussed 
earlier in this chapter that the increase in IL-12 was possibly generated by CNS 
activated T cells, the possibility that IL-12 could also be produced from 
astrocytes and microglia should also be considered. An in vitro study suggested 
that brain astrocytes and microglia can produce IL-12 upon stimulation with pro-
inflammatory cytokines such as IL-1β and TNF-α (Stalder et al., 1997). This may 
also explain our finding showing a coincidental increase in IL-12 mRNA 
expression levels and TNF-α protein concentration in the brains of CII immunized 
mice during the late stage of disease. TNF-α not only activates CNS astrocytes 
and microglia, but also T cells causing them to produce Th1 cytokines. IL-2, 
another Th1 cytokine that is up-regulated as a single peak on day 35 may also be 
associated with the increase in TNF-α protein concentration at the same time 
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period. This could be explained by an in vivo study showing that IL-1 and TNF-α 
are required for IL-12-induced development of Th1 cells (Shibuya et al., 1998). 
Further indirect evidence for this was seen by adoptive transfer of antigen (PLP)-
primed T cells when pre-treated with TNF-α caused more severe EAE, along with 
a significant increase in TNF-α production (Leonard et al., 1995). These data 
together with the data presented in this thesis suggest that pro-inflammatory 
cytokines and Th1 cytokines may mutually regulate each other and may 
contribute to the development of cell-mediated immune responses within the 
central nervous system of CII immunized mice.   
 A longitudinal shift from a Th1-type to Th2-type response is one of the 
major characteristics of autoimmune disease. The temporal interplay and 
mutual inhibition between Th1 and Th2 cytokines has been demonstrated in 
several CNS inflammatory demyelinating disease models such as EAE and 
Theiler’s murine encephalomyelitis virus (TMEV). However, the specific roles of 
the Th1 and Th2 cytokines in neuro-inflammation in the CNS have not been fully 
elucidated. This is mainly because studies using different CNS inflammatory 
demyelinating models reported different temporal relationships and cytokine 
expression profiles. For example, IL-2, IL-6, IL-12 and IFN-γ concentrations in 
EAE mouse brains increased during the relapse stage, while brain concentrations 
of the Th2 cytokines such as IL-4 and IL-10 were up-regulated during the 
remission or recovery stages (Issazadeh et al., 1996). In contrast, the 
coincidental expression of Th1 and Th2 cytokines including IL-2, IFN-γ, IL-4, IL-5 
and IL-10 were observed during the remission phase of the TMEV-induced 
demyelinating disease model (Sato et al., 1997). Therefore, the neuro-
inflammation in the CIA model, which could be considered as a model of neuro-
inflammation induced by systemic autoimmunity, may demonstrate a different 
temporal interplay between Th1 and Th2 cytokines. Our data showed increased 
concentrations of brain Th2 cytokines, including IL-4 and IL-10 which occurred at 
the same time as up-regulation of Th1 cytokines IL-2 and IL-12, and pro-
inflammatory cytokines in CII immunized mouse brain during the course of 
disease. This suggests that there might be a Th1/Th2 shift that could promote an 
anti-inflammatory environment, perhaps in the joint in an attempt to suppress 
or regulate ongoing pro-inflammatory Th1 cell activation. The concentration of 
brain IL-4 peaked at day 22 and then declined, which was was at the same time 
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as the temporal expression profile of brain IL-1β in CII immunized mice, 
suggesting that IL-4 production might be up-regulated to suppress the pro-
inflammatory functions of IL-1β (te Velde et al., 1990). Alternatively, the 
observed reduction of brain IL-4 concentration could be the result of the up-
regulation of Th1 cytokines e.g. IL-2 and IL-12. However, IL-12 has also been 
reported to stimulate IL-10 production in the EAE model, therefore, the up-
regulation of IL-10 in CII immunized mouse brains might be associated with an 
increased concentration of brain IL-12 (Berghmans et al., 2006).  
Pro-inflammatory cytokines are known to stimulate the production of 
chemokines in the CNS, which may then initiate migration of immune cells from 
the blood into the CNS parenchyma. Cultured astrocytes stimulated by TNF-α 
and TGF-β produced CCL2 (Hurwitz et al., 1995), while cultured microglia 
stimulated by IL-1β and TNF-α produced CCL2, CCL3, CCL4 and CXCL8 (McManus 
et al., 1998). Our data showed a prolonged up-regulation of brain CCL2 protein 
concentration in CII immunized mice during the course of disease. This was 
coincidental with the up-regulation of brain IL-1β and TNF-α protein production 
in CII immunized mice, suggesting that CCL2 in CIA mouse brain may be 
generated by IL-1β /TNF-activated microglia/astrocytes. Temporal relations 
between chemokine and cytokine expression in the CNS have been demonstrated 
in a model of chronic relapsing experimental autoimmune encephalomyelitis 
(ChREAE) (Glabinski et al., 2003). During the relapse stage, which involves the 
migration of new autoantigen-specific T cells into the CNS, TNF-α, IFN-γ and IL-6 
production was increased at the same time as various chemokines including 
CCL1, CCL2, CCL3, CCL4, CCL5 and CXCL2–3 in the brains of mice with ChREAE. 
Another possibility is that CCL2 may move actively or passively from the 
periphery, or that peripheral IL-1β might induce brain production of CCL2 in CII 
immunized mice. This can be seen by up-regulation of serum IL-1β and CCL2 
during the onset of disease on day 22 and this was followed by a reduction of 
their serum concentrations over time, while brain protein concentrations of 
CCL2 remained increased in CIA mice. Our data also showed that the up-
regulation of brain CXCL1 mRNA expression levels occurred at the same time as 
the peak of brain IL-1β protein production. A similar observation has been 
reported in a study by Shaftel et al showing that chronic IL-β expression in 
mouse brains resulted in the up-regulation of brain CXCL1 mRNA (Shaftel et al., 
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2007). A study using a TNF-induced demyelination (TID) model, which is another 
MS model, showed that mRNA expression levels of CXCL10 and other chemokines 
including CCL1 and CXCL2 were up-regulated in the brains of mice with 
inflammatory demyelination during the acute phase of disease. This also 
correlated with marked immune cell infiltration into the CNS (Quinones et al., 
2008). This study suggested that the increased concentration of brain TNF-α is 
associated with the up-regulation of brain CXCL10 expression, which may partly 
explain our finding showing the coincidental expression of brain TNF-α and 
CXCL10 in CIA mice at day 35. These data collectively with the data presented in 
this thesis suggest that pro-inflammatory cytokines IL-1β and TNF-α may 
regulate chemokine production, which eventually contribute to immune cell 
trafficking from the periphery to the brains of CII immunized mice. We don’t 
present any supportive evidence for this in this thesis and this topic may be for 
future studies. 
Vascular endothelial growth factor is only not an angiogenic factor, but also 
functions to induce inflammation. In RA, VEGF can regulate angiogenesis 
contributing to the proliferation of the inflammatory synovial pannus, and can 
also promote leukocyte recruitment into the site of neovascularisation by 
inducing CCL2 production by endothelial cells (Marumo et al., 1999). In addition, 
VEGF has been reported to modulate T cells response and cytokine IL-8, CCL2, 
TNF-α and IL-1β production by peripheral blood monocytes (Selvaraj et al., 
2003). Very little is known about the role of VEGF-mediated inflammation in the 
brain. However, it has been reported that brain VEGF functions to regulate 
monocyte recruitment into the brain. VEGF has been shown to induce CCL3 
production by endothelial and brain parenchyma cells (Croll et al., 2004b). In 
addition, during the neuro-inflammation process, the production of VEGF in the 
brains is induced by pro-inflammatory cytokine such as IL-1β (Li et al., 1995). 
Our data showed coincidental increases of VEGF, CXCL10, CCL2, and TNF-α in 
brains of CII immunized mice during the early stage of disease (day 28 – day 35 
after immunization), suggesting there may be an association between VEGF and 
CXCL10, CCL2, and TNF-α that may also involve recruitment of leukocytes and 
monocytes into the brain. Another inflammatory action of VEGF is to regulate T 
cells. Administration of anti-VEGF antibody in CIA mice resulted in inhibition T-
cells responses and a reduction in the production of IL-6. In addition, VEGF-
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blockade also reduced TNF-α and IL-6 concentrations measured in peripheral 
blood mononuclear cells derived from RA synovial fluid (Yoo et al., 2005). 
Alternatively, T cells have been reported to produce VEGF after stimulation by 
IL-2 (Mor et al., 2004). This observation may explain our findings in which we 
demonstrated coincidental increases in VEGF, IL-2 and IL-12 in the brains of CII 
immunized mice during the early stage of disease (day 28 – day 35 after 
immunization). This data suggest that there may be an association between Th1 
cells and VEGF. However, this hypothesis needs to be further investigated, 
perhaps by an in vitro study of these CNS T cells and CNS immune cells isolated 
from CII immunized mice during the early stage of disease. Interestingly, there 
was no VEGF detectable in brains of CII immunized mice during day 22 to day 28 
after immunization, which is the period during which the anti-inflammatory 
cytokines IL-4 and IL-10 were up-regulated. It is possible that IL-4 and IL-10 
suppressed the expression of VEGF during that period since it has been reported 
that the combination of IL-4 and IL-10 inhibited the production of VEGF in 
rheumatoid synovial fibroblasts (Hong et al., 2007). The prolonged increase of 
IL-10 across the whole period of the clinical manifestation of disease may be 
associated with longitudinal decreases in FGF2 mRNA and protein in brains of CII 
immunized mice. This may be due to IL-10 which also has an anti-angiogenic 
effect inhibiting the expression of FGF2 as well as VEGF (Cervenak et al., 2000). 
However, the actual reason underlying the longitudinal reduction in FGF2 is still 
unclear. However, our data also showed that brain FGF2 concentrations in both 
normal and CII immunized mice decreased with the age, suggesting age-related 
alterations in FGF2 production. This is supported by a study comparing wound 
repairs of young mice and aged mice in which wounds of aged mice heal more 
slowly and contained less FGF2 than wounds in the young, indicating that age 
may be associated with macrophage production of FGF2 during the inflammatory 
process (Swift et al., 1999).  
A summary of the possible brain immune activation induced by peripheral 
inflammatory signals in CII immunized is shown in Figure 4.31. 
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Figure 4.31 Potential mechanisms of immune activation induced by peripheral inflammatory 
cytokine signals occurring in brains of CII immunized mice 
In this chapter we investigated longitudinal changes in brain inflammatory mediators in CII 
immunized mice during 3 stages of arthritis disease (onset of disease, early stage of 
disease and late stage of disease). We have shown that longitudinal changes in brain 
inflammatory mediators in CII immunized mice have been associated with changes in 
peripheral inflammatory mediators at different stages of disease progression. Increased 
concentrations of serum IL-1β, IL-5, CCL2 and FGF2 were observed during the onset of 
disease (day 22-day 28) at the same time as increased concentrations of brain IL-1β, CCL2 
and FGF2. This suggests that there may be the transudation of IL-1β, CCL2 and FGF2 from 
the periphery into the brain by an as yet unknown mechanism. At this early time period of 
disease, we found increased expression of CXCL1 mRNA, which potentially was generated 
from astrocytes induced by pro-inflammatory cytokines such as IL-1β. Up-regulation of both 
IL-12 mRNA and protein were also observed, suggesting the local production of IL-12 that 
could be the result of bystander activation of T cells in the brain. The peripheral 
inflammatory signal of IL-1β may also play a role to augment the activation of CNS T cells. 
Th2 cytokines IL-4 and IL-10 were up-regulated by the time of onset of disease, which may 
be due to the trafficking of Th2 cells into the brain regulated by the chemotactic activity of 
CCL2. During the early stage of the disease (day 28 – day 35), increased levels of VEGF 
mRNA expression were observed and may be generated from local CNS cells such as BBB 
endothelial cells after stimulation by peripheral inflammatory signal from FGF2. Both FGF2 
and VEGF may be down-regulated by IL-4 and IL-10 during the onset of disease during 
which there was no significant increase of FGF2 and VEGF concentrations in brains of CII 
immunized mice during that period. Also during that period, mRNA and protein 
concentrations of Th1 cytokines, IL-12 and IL-2 were increased. This could be due to more 
Th1 cells trafficking from the blood into the brain by the chemotactic activity of CXCL10. 
Another possibility is that CNS immune cells such as microglia and astrocytes could also 
produced IL-12 upon stimulation by pro-inflammatory cytokines TNF-α and IL-1β. IL-12 may 
also suppress the production of anti-inflammatory IL-4, because there was no further 
increase in IL-4 protein concentrations after the onset of disease. A prolonged increase of 
VEGF from the early stage of disease onwards may indicate a breakdown of the BBB during 
the period of clinical expression of disease.  TNF-α may activate astrocytes to produce 
CXCL1. There may also be the activation of T cells upon stimulation by IL-2, resulting in the 
production of VEGF in the brain of CII immunized mice during the late stage of 
disease.Purple arrows denote transportation of peripheral immune cells and inflammatory 
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mediators. Blue arrows denote activation and production of inflammatory mediators. Red 
arrows denote inhibition and suppression of productions of inflammatory mediators. Green 
arrows denote effects of chemokines on immune cells trafficking in brains of CII immunized 
mice.  Mic = microglia. 
Summary 
In summary, we have demonstrated the possibility that peripheral inflammatory 
signal derived from the cytokines IL-1β, IL-5, CCL2 and FGF2 may induce the 
production of brain inflammatory mediators associated with the onset and early 
disease stages of arthritis. There may also be trafficking of immune cells from 
the periphery into brains in response to the increased concentrations of 
chemokines including CCL2, CXCL10, CXCL1 and angiogenic factors such as VEGF 
and FGF2. These may be associated with increased permeability of the BBB 
which may have occurred during the early disease stage indicated by raised 
levels of VEGF mRNA expression in brains of CII immunized mice during the early 
and late stages of arthritis.  
One important question follows from this. How can inflammatory mediators such 
as TNF-α be up-regulated in the brain of CII immunized mice during the clinical 
expression of the arthritis, despite there being no serum inflammatory mediators 
detectable? In the next chapter, we therefore addressed the issue of the 
apparent lack of clear association between joint-immune-brain communication 
by using peripheral administration of TNF-blockade in the CII immunized mice 
during the early and late stages of disease and determining changes in brain 
cytokines. 
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5.1 Introduction 
Data described in Chapter 4 (Section 4.2.2, 4.2.4 and 4.2.5) demonstrated 
various longitudinal changes of inflammatory mediator expression profiles, 
including IL-1β, TNF-α, IL-2, IL-10, IL-4, IL-12, CCL2, CXCL1, CXCL10, VEGF and 
FGF2 in the brains of CII immunized mice throughout the course of disease 
development from onset, acute and chronic changes. These data suggested that 
there may be ongoing immune activation in the CNS of these mice, which may be 
associated with, or caused by peripheral inflammation during development of 
arthritis. Interestingly, we found increased concentrations of inflammatory 
mediators, including IL-1β, IL-5, CCL2 and FGF2 in the serum of these mice 
during the onset of disease (day 22 to day 28 after immunization). Some of these 
inflammatory mediators, IL-1β and CCL2 were also found in increased 
concentration in brains at the same time period, suggesting that the peripheral 
inflammatory signals from serum IL-1β and CCL2, associated with the onset of 
arthritis disease may induce the production of brain inflammatory mediators. 
However, during the early and the late stages of arthritis we could no longer 
detect serum inflammatory mediators (at day 28 to day 42 after immunization), 
but we could still detect increased concentrations of several inflammatory 
mediators, including TNF-α, IL-4, IL-10, IL-2, IL-12, CCL2, CXCL1, CXCL10, VEGF 
and FGF2 in the brains of these CII immunized mice. We could not address the 
question of how the cytokines associated with peripheral inflammation could 
signal to the brain in order to produce these inflammatory mediators.  
To confirm that the changes in inflammatory mediator profiles were a 
consequence of the peripheral inflammation during the period of clinical 
expression of arthritis, we blocked the peripheral inflammation in the CIA model 
and determined the effect of anti-inflammatory treatment on the brain 
inflammatory mediator profiles. In the CIA experiment of the present Chapter, 
we administrated etanercept, a drug that consists of a recombinant human 
soluble TNF receptor which can cause TNF blockade. It is an extremely effective 
treatment for RA (Haberhauer et al., 2010), and it can be administered 
successfully to the murine CIA model as a preventative therapy (Marinova-
Mutafchieva et al., 2000). A recent finding by Terrando et, al., demonstrated 
that peripheral administration of TNF blockade to a model of surgery-induced 
peripheral inflammation could also reverse an increase of brain IL-1β expression 
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(Terrando et al., 2010). Clinical evidence also demonstrated an improvement in 
mood in patients with chronic systemic inflammatory diseases such as psoriasis 
and RA when receiving etanercept. Psoriasis patients receiving long-term 
etanercept treatment showed 50% improvement in depression score compared 
with those receiving placebo as indicated by HAM-D and Beck Depression 
Inventory (BDI) (Tyring et al., 2006). In addition, a reduction in serotonin 
transporter (SERT) density and improvement in physical and mental functions 
have been reported in RA patients receiving anti-TNF-α treatment (Cavanagh et 
al., 2010). This clinical evidence suggests that etanercept not only inhibits 
peripheral inflammation at the site of disease, but may also contribute to the 
suppression of central neuro-inflammation often associated with systemic 
autoimmune diseases. This eventually inhibits changes in neurobiology 
contributing to the development of neuropsychiatric disorders such as depression 
occurring during the course of autoimmune disease. 
We hypothesise that ‘Using etanercept to treat peripheral inflammation in the 
CIA model by TNF blockade would affect the brain inflammatory mediator profile 
by suppressing disease-associated up-regulation of brain inflammatory 
mediators’. Therefore, the aim of this chapter is to investigate whether systemic 
etanercept treatment modulates the inflammatory mediator profiles, usually 
associated with peripheral inflammation, in the brains of mice during the 
development of arthritis using the experimental CIA model.  
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5.2 Results 
5.2.1  Effect of etanercept on development of collagen 
induced arthritis (CIA). 
Data from the previous chapter (Chapter 4; sections 4.2.3, 4.2.4 and 4.2.5) 
demonstrated up-regulation of production of various inflammatory mediators, 
including TNF-α, IL-4, IL-10, IL-2, IL-12, CCL2, CXCL10 and VEGF, in the brain of 
CII immunized mice during the period of clinical expression of arthritis (day 28 to 
day 35 after immunization). However, we found no inflammatory mediators in 
the serum of these CII immunized mice during this period. To further test the 
association between peripheral inflammation and the production of 
inflammatory mediators in the brain, we used etanercept to block peripheral 
inflammation during the period of clinical expression of arthritis in CII 
immunized mice and measured associated changes in brain inflammatory 
mediators. TNF neutralizing agents have been very effective in ameliorating 
joint disease and 300ug/mouse of etanercept has been suggested to be the 
appropriate dose to reduce the severity of joint inflammation in CIA model 
(Williams et al., 2000b). In this chapter, we investigated the effect of 
etanercept on the severity of arthritis and production of brain inflammatory 
mediators at 2 time points during the period of clinical expression of disease 
(day 32 and day 35 after immunization as time points of early and late stage of 
disease respectively). We also determine changes in brain inflammatory 
mediators during the before disease onset (day 14 after immunization) and 
before etanercept treatment on day 18, as a control time point. 
5.2.1.1 Administration of etanercept and induction of arthritis in DBA1 
mice 
Nineteen DBA1 mice were immunized by intradermal injection of type II collagen 
in Freund’s complete adjuvant on day 0. On day 14, 3 CII (collagen type II) 
immunized mice (Group 1) were culled and the brains and serum of these mice 
were harvested for the measurement of inflammatory mediator concentrations 
before the second immunization on day 21. There was no CII immunized mice in 
Group 1 that developed arthritis on day 14 after the primary immunization. The 
other 16 CII immunized mice were randomly divided into 2 groups of 8, namely 
the treatment and placebo groups. From day 18 onwards, CII immunized mice in 
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the treatment group received etanercept (300 µg/mice, i.p.) every 3 days, while 
the placebo group received PBS (i.p.) every 3 days. The signs of arthritis in CII 
immunized mice were monitored from day 16 after immunization onwards and 
arthritis severity scores in this experiment were verified independently by Dr. 
Bernard Leng. CII immunized mice from both groups were re-challenged by intra-
peritoneal injection of collagen II in PBS on day 21. CII immunized mice of the 
placebo (PBS treated) group started to show sign of arthritis earlier (day 19 after 
the primary immunization) than those of the treatment group (day 21 after the 
primary immunization). 3 CII immunized mice of the treatment group (Group 2) 
and 3 CII immunized mice of the placebo group (Group 3) were culled and serum 
and brains of these CII immunized mice were harvested on day 32. CII immunized 
mice of both treatment and placebo groups (Group 4 and Group 5; 5 CII 
immunized mice/group) were culled and serum and brains of these CII 
immunized mice were harvested on day 35; which is the peak day of disease. 
Another 8 sex- and age-matched untreated DBA1 mice were used as antigen-
naïve control mice. These naïve control mice were neither sensitized with type II 
collagen nor given etanercept treatment. 3 naïve control mice were culled on 
day 14, and a further 3 and 5 naïve control mice were culled on day 32 and day 
35 after the primary immunization respectively. Serum and brains of mice from 
all experimental groups were harvested on the day indicated and snap-frozen in 
liquid nitrogen and stored at –80˚C. Half of each brain was processed for protein 
extraction and inflammatory mediator proteins analysed by Luminex; the other 
half was processed for RNA extraction and the inflammatory mediator gene 
expression was determined by real-time PCR (Figure 5.1).  
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Figure 5.1 Administration of etanercept during the CIA experimental procedure 
19 DBA1 mice at 6-8 weeks of age were immunized with 100µg type II bovine collagen + 
complete Freund’s adjuvant (CFA) at day 0. On day 14, 3 CII immunized mice in Group 1 
were culled and brains and serum of these CII immunized mice from group 1 (3 mice/group) 
were harvested. At this time point, another 3 naïve control mice, which were neither 
sensitized nor challenged with type II collagen, were also culled and their brains and serum 
samples were used as controls to compared changes in brain inflammatory mediators with 
those of CII immunized mice culled on day 14. On day 18, CII immunized mice were 
randomly divided into 2 groups (8 CII immunized mice/group), which were a treatment group 
and a placebo group.  From this day onwards, 300 µg/mouse etanercept was administrated 
(i.p.) to CII immunized mice of the treatment group every 3 days, while PBS was injected to 
CII immunized mice of the placebo group every 3 days. CII immunized mice of both groups 
were challenged on day 21 with 200µg type II collagen. From day 21 onwards, etanercept 
treated CII immunized mice of etenercept group were randomly divided into 2 groups, 
namely Group 2 and Group 4. Etanercept treated CII immunized mice in Group 2 (3 CII 
immunized mice/group) were culled and serum and brains of these CII immunized mice were 
harvested on day 32, while etanercept treated CII immunized mice in Group 4 (5 CII 
immunized mice/group) were culled and serum and brains of these CII immunized mice were 
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harvested on day 35. Similarly, PBS treated CII immunized mice in the placebo group was 
randomly divided into 2 groups, namely Group 3 and Group 5. PBS treated CII immunized 
mice in Group 2 (3 CII immunized mice/group) were culled and serum and brains of these CII 
immunized mice were harvested on day, while PBS treated CII immunized mice in Group 4 (5 
CII immunized mice/group) were culled and serum and brains of these CII immunized mice 
were harvested on day 35. Another 8 naïve control mice were culled on the day indicated (3 
naïve mice for day 32 and 5 naïve mice for day 35) and their serum and brain were used as 
controls. Brain and serum from mice of all experimental groups were collected and 
processed for inflammatory mediator measurements using Luminex, ELISA and real-time 
PCR. 
5.2.1.2  Effect of etanercept on severity of arthritis in CII immunized 
mice on day 32 and day 35. 
To determine the effect of blocking TNF-α during the induction of arthritis, mice 
were given injections from days 18 onwards (before the second collagen booster 
immunization) with 300 µg etanercept every 3 days. Placebo groups received 
PBS. There were 4 mice in the treatment group 2 and the placebo group 3, both 
groups of mice were culled on day 32. Mice started to develop arthritis on day 22 
days after immunization in the etanercept-treated group 2, compared with 20 
days in the PBS treated group 3 (Figure 5.2). There was no significant difference 
in % incidence, mean paw thickness, and arthritis score between etanercept-
treated mice and PBS-treated mice.  
 
 
 
 
 
 
Chapter 5  245 
 
 
 
Figure 5.2 Effect of etanercept on severity of arthritis in CII immunized mice on day 32 
(groups 1-3)  
CII immunized mice in Group 2 (3 etanercept treated CII immunized mice/group; blue line) 
were given injections from days 18 onwards (before collagen booster immunization) with 
300 µg etanercept every 3 days. 3 CII immunized mice in Group 3 were given PBS as 
placebo (3 PBS treated CII immunized mice /group; red line). Mice in both Group 2 and 
Group 3 were culled on day 32. The signs of arthritis in CII immunized mice were monitored 
from day 16 after immunization onwards. (A) shows the percent of incidence of arthritis in 
etanercept-treated and PBS-treated CII immunized mice, which was calculated from number 
of CII immunized mice with arthritis per group/total number of CII immunized mice used per 
group. Mean clinical arthritis score and mean paw thickness were used as clinical 
evaluations to measure the severity of joint inflammation in arthritic mice. (B) shows mean 
paw thickness of etanercept-treated and PBS-treated CII immunized mice which was 
calculated from the sum of the paw thickness of all mice in each group divided by the 
number of mice per group. (C) shows mean clinical of etanercept-treated and PBS-treated 
CII immunized mice which was calculated from the sum of the clinical scores of all mice in 
the each group divided by the number of mice per group. Mean paw thickness, mean clinical 
score and % incidence in CII immunised mice (3 CII immunized mice/group) were compared 
with those values of antigen-naïve control mice (3 naïve mice; green line). These naïve 
control mice were neither sensitized with type II collagen nor given etanercept treatment. 
Data represent as mean ± SEM. (all 19 CII immunized mice in all groups). Statistical analysis 
of data was performed using two-way ANOVA for multiple comparison, compared with a 
group of control naïve mice; *P < 05; **P < 01; ***P < 001. 
However, the etanercept treatment significantly reduced the severity of 
arthritis and delayed the start of arthritis in treatment group 4 compared to the 
placebo group 5. There were 5 mice in the treatment group 4 and the placebo 
group 5, both groups of mice were culled on day 35.  Mice in group 4 started to 
develop arthritis on day 19 days after immunization in the etanercept-treated 
group, compared with 27 days in the PBS-treated group 5 (Figure 5.3A). Anti-
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TNF-a treatment caused a significant reduction in paw-swelling of etanercept-
treated mice in group 4 compared to those in PBS-treated mice in group 5. The 
mean paw thickness of mice in group 4 and 5 (etanercept-treated versus PBS-
treated) was 1.9 ± 0.89 mm versus 2.23 ± 0.33 mm (P=0.002) (Figure 5.3B). Mean 
clinical scores were also significantly reduced in the etanercept-treated mice in 
group 4, compared to those of PBS-treated mice in group 5. The mean clinical 
score of mice in group 4 and 5 (etanercept-treated versus PBS-treated) was 1.4 ± 
1.4 versus 3.8 ± 2.0 (P = 0.0014) (Figure 5.3C).  
 
Figure 5.3 Effect of etanercept on severity of arthritis in CII immunized mice on day 35 
(groups 4 and 5) 
CII immunized mice in Group 4 (5 etanecept treated CII immunizedc mice /group; blue line) 
were given injections from days 18 onwards before collagen immunization with 300 µg 
etanercept every 3 days. 3 CII immunized mice in Group 5 were given PBS as placebo (5 
PBS treated CII immunizedc mice /group; red line). Mice in both Group 4 and Group 5 were 
culled on day 35. The signs of arthritis in CII immunized mice were monitored from day 16 
after immunization onwards. (A) shows the percent of incidence of arthritis in etanercept-
treated and PBS-treated CII immunized mice, which was calculated from number of CII 
immunized mice with arthritis per group/total number of CII immunized mice used per 
group. Mean clinical arthritis score and mean paw thickness were used as clinical 
evaluations to measure the severity of joint inflammation in arthritic mice. (B) shows mean 
paw thickness of etanercept-treated and PBS-treated CII immunized mice which was 
calculated from the sum of the paw thickness of all mice in each group divided by the 
number of mice per group. (C) shows mean clinical of etanercept-treated and PBS-treated 
CII immunized mice which was calculated from the sum of the clinical scores of all mice in 
the each group divided by the number of mice per group. Mean paw thickness, mean clinical 
score and % incidence in CII immunised mice (5 CII immunized mice/group) were compared 
with those values of naïve control mice (5 naïve mice; green line). These naïve control mice 
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were neither sensitized with type II collagen nor given etanercept treatment. Data represent 
as mean ± SEM. (all 19 CII immunized mice in all groups). Statistical analysis of data was 
performed using two-way ANOVA for multiple comparison, compared with a group of 
control naïve mice; *P < 05; **P < 01; ***P < 001. 
Overall, there were 5 out of 8 PBS treated CII immunized mice from Group 3 and 
Group 5 (~62.5 % incidence) that showed clinical signs of arthritis from day 19. 
Etanercept treated-CII immunized mice showed a lower disease incidence 
compared to those in PBS treated-CII immunized mice. 3 out of 8 etanercept 
treated CII immunized mice from Group 2 and 4 developed arthritis from day 22 
(~37.5 % incidence) (Figure 5.4A). Clinical signs of arthritis were observed in 
PBS-treated CII immunized mice from Group 3 and 5 from day 19 after 
immunization onward and there were 5 out of 8 PBS-treated CII immunized mice 
developed arthritis (62.5% incidence). The cumulative mean paw-swelling 
diameter of all PBS treated CII immunized mice from Group 3 and Group 5 (n=8) 
was 2.2 ± 0.2 mm, which was significantly higher than those in naïve control 
mice (1.700 ± 0.08 mm; P= 0.0001). Etanercept-treated CII immunized mice 
showed significantly less swelling than PBS treated CII immunized mice (2.0 ± 
0.08 mm; P <0.0001). Two-way ANOVA analysis also indicated that the 
cumulative mean of swelling diameter of etanercept-treated CII immunized mice 
was significantly higher than those in control mice (1.70 ± 0.08 mm; P= 0.0005) 
(Figure 5.4B). The cumulative mean arthritis score of etanercept-treated CII 
immunized mice was significantly lower than those of PBS treated CII immunized 
mice (2.25 ± 1.21 mm versus 3.75 ± 1.35 mm, p=0.001) (Figure 5.4C). A summary 
of number of arthritic mice, mean arthritis score, maximum arthritis score, 
mean paw diameter of etanercept-treated and PBS-treated CII immunized mice 
is presented in Table 1.  
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Figure 5.4 Effect of etanercept on severity of arthritis in all CII immunized mice in Group 2, 
3, 4 and 5  
CII immunized mice in Group 2 and Group 4 (n=8 for both groups; blue line) were given 
injections from days 18 onwards before collagen immunization with 300 µg etanercept every 
3 days. 3 CII immunized mice in Group 3 and Group 5 were given PBS as placebo (n=8 CII 
immunized mice /for both groups; red line). Mice in both Group 4 and Group 5 were culled 
on day 32, while Mice in both Group 4 and Group 5 were culled on day 35. The signs of 
arthritis in CII immunized mice were monitor from day 16 after immunization onwards. (A) 
shows the cumulative percent of incidence of arthritis in all etanercept-treated and all PBS-
treated CII immunized mice, which was calculated from number of CII immunized mice with 
arthritis per group/total number of CII immunized mice used per group. Cumulative mean 
clinical arthritis score and cumulative mean paw thickness were used as clinical evaluations 
to measure the severity of joint inflammation in arthritic mice. (B) shows cumulative mean 
paw thickness of all etanercept-treated and all PBS-treated CII immunized mice which was 
calculated from the sum of the paw thickness of all mice in each group divided by the 
number of mice per group. (C) shows cumulative mean clinical of all etanercept-treated and 
all PBS-treated CII immunized mice which was calculated from the sum of the clinical 
scores of all mice in the each group divided by the number of mice per group. Cumulative 
mean paw thickness, cumulative mean clinical score and cumulative % incidence in CII 
immunised mice (n= 3 CII immunised mice /group) were compared with those values of 
naïve control mice (n = 8 naïve control mice; green line). These naïve control mice were 
neither sensitized with type II collagen nor given etanercept treatment. Data represent as 
mean ± SEM. (n=16 CII immunized mice). Statistical analysis of data was performed using 
two-way ANOVA for multiple comparison, compared with a group of control naïve mice; *P < 
05; **P < 01; ***P < 001. 
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Group 
 
Treatments 
 
 
Day of 
harvesting 
 
Arthritic/total 
number of 
mice 
 
Mean 
Arthritis 
scores 
 
Maximum 
Arthritis  
  scores 
 
Mean 
Paw    
Diameter 
 
 
2 
 
Etanercept 
 
32 
 
2/3 
 
3.67 ± 2.33 
 
8 
 
2.08 ± 0.23 
 
3 
 
PBS 
 
32 
 
2/3 
 
3.67 ± 1.86 
 
6 
 
2.2 ± 0.3 
 
4 
 
Etanercept 
 
35 
 
1/5 
 
1.4 ± 1.4 
 
7 
 
1.9 ± 0.9 
 
5 
 
PBS 
 
35 
 
3/5 
 
3.8 ± 2.0 
 
10 
 
2.2 ± 0.3 
Table 5.1 Numbers of arthritic mice, mean arthritis scores, and mean swelling scores of CIA 
mice in etanercept-treated and PBS-treated groups.  
Etanercept-treated mice and PBS-treated mice (Group 2 and 3) were culled on day 32, while 
etanercept-treated mice and PBS-treated mice (Group 4 and 5) were culled on day 35. 
Numbers of CII immunized mice developed arthritis from each time point group were 
counted on the harvesting day. Mean arthritis scores (total arthritis score/number of mice in 
the group), maximum arthritis score and mean swelling of CII immunized mice from each 
treatment time point group were calculated on the harvesting day. 
5.2.2 Effect of etanercept on serum inflammatory mediator 
protein concentrations in CII immunized mice on day 14, day 
32 and day 35 by Luminex cytokine 20-plex assay 
The aim of this experiment is to investigate whether etanercept has any effect 
on peripheral inflammatory mediator protein profiles of CII immunized mice 
during the early and the late stages of disease in the CIA model. Serum collected 
from etanercept-treated and PBS-treated control mice on day 32 and day 35 
were determined for changes in several cytokines, chemokines and growth 
factors using a Luminex cytokine 20-plex assay. However, all the inflammatory 
mediator protein concentrations in serum of mice from all experimental groups 
were lower than the detection limits of this assay.   
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5.2.3  Changes in inflammatory mediator protein 
concentrations in the brains of etanercept-treated and 
untreated CII immunized mice on day 14, day 32 and day 35  
Etanercept has shown its protective effect on the joint inflammation in this CIA 
model by delaying the onset of arthritis and reducing the severity of arthritis in 
CIA model (Williams et al., 2000b). In this study, etanercept was administrated 
to CII immunized mice as a protective therapy before the disease onset (from 
day 18 onwards). Results from the previous chapter (Chapter 4; sections 4.2.3 
and 4.2.4) demonstrated that longitudinal changes in several inflammatory 
mediators in brains of CII immunized mice throughout the period of clinical 
expression of the disease (onset of the disease, early and late phase of disease). 
Several inflammatory mediators were up-regulated in brains of CII immunized 
mice during the onset and early disease stage (day 22 – day 35 after 
immunization), and some of these inflammatory mediators were up-regulated 
during the late stage of the disease (day 35 – day 42 after immunization). In the 
previous chapter, we started to measured inflammatory mediators in brains of 
CII immunized mice from day 22 as a time point of disease onset. However, del 
Ray et al., reported the upregulation of IL-1β and IL-6 in brains of CIA rats 
before the onset of RA disease (during the first 20 days after the primary 
immunization) (del Rey et al., 2008). In our study, changes in these brain 
inflammatory cytokine concentrations before the onset of the disease have not 
been determined. To determine changes in brain inflammatory mediator protein 
concentrations in CII immunized mice before the onset of RA disease, we 
measured protein concentrations of brain inflammatory mediator in CII 
immunized mice on day 14 to represent a reasonale time point before disease-
onset and before the etanercept treatment.  
We investigated the effects of etanercept on brain inflammatory mediator 
profiles in treated and un-treated CII immunized mice during the period of 
clinical expression of the disease, and studied the association with its effect on 
the amelioration of joint disease during those time points.  We determined 
changes in brain inflammatory mediator protein concentrations on day 32 as the 
time point of early stage of disease and day 35 as the time point of late stage of 
the disease. Inflammatory mediators in brains of mice of all experimental groups 
were determined using a Luminex and ELISA assay. To investigate effects of 
Chapter 5  251 
etanercept on brain inflammatory mediator protein profiles, half brain tissue 
homogenates of CII immunized mice treated with etanercept on day 32 and day 
35 were determined for inflammatory mediator protein concentrations compared 
to those in CII immunized mice treated with PBS or control naive mice. 
5.2.3.1  Effects of etanercept on pro-inflammatory cytokine protein 
profiles in the brain of CII immunized mice on days 14, 32 and 35 
The protein concentrations of pro-inflammatory cytokines including IL-6, IL-1 β 
and TNF-α were determined by ELISA assays in brain homogenates of mice from 
all experimental groups. 
On day 14, the concentrations of brain TNF-α protein of CII immunized mice and 
naïve control mice were not significantly different (Figure 5.5A). During the 
period of clinical expression of disease on day 32 and day 35, there was no 
significant difference in the concentrations of brain TNF-α protein between PBS-
treated CII immunized mice and naïve control mice. However, etanercept-
treated mice showed a significant reduction in brain TNF-α protein 
concentrations compared to those in naïve control mice and in PBS-treated CII 
immunized mice (Figure 5.5A). One-way ANOVA analysis followed by Bonferroni's 
post-hoc comparison tests demonstrated that there were significant differences 
in protein concentration of TNF-α among the three groups of mice culled on day 
32 (P = 0.0006) (Figure 5.5A). The mean value of brain TNF-α protein 
concentrations on day 32 (etanercept-treated versus PBS-treated CII immunized) 
was 54.3 ± 2.9 pg/mg total brain protein versus 92.2 ± 8.9 pg/mg total brain 
protein (P < 0.01), while the mean value of brain TNF-α of on day 32 
(etanercept-treated versus naïve control) was 54.3 ± 2.9 pg/mg total brain 
protein versus 79.2 ± 4.2 pg/mg total brain protein (P < 0.001). A similar pattern 
of TNF-α protein concentrations was observed in brain of treated, PBS-treated 
CII immunized mice compared to those of the naïve control mice on day 35. 
However, one-way ANOVA analysis showed that there was no significant 
difference between TNF-α protein concentrations in brains of etanercept-
treated, PBS-treated CII immunized mice and naïve control mice on day 35 (P = 
0.1632) (Figure 5.5A). 
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During the pre-onset period (day 14) there was no significant difference in brain 
IL-1β protein concentrations between naïve control and CII immunized mice 
(Figure 5.5B). One-way ANOVA analysis showed that there was no significant 
difference between IL-1β protein concentrations in brains of etanercept-treated, 
PBS-treated CII immunized mice and naïve control mice on day 32 (P = 0.5619). 
However, one-way ANOVA analysis followed by Bonferroni's post-hoc comparison 
tests also demonstrated that there were significant differences in protein 
concentration of IL-1β among the three groups of mice culled on day 35 (P = 
0.0030). The brain IL-1β protein concentrations of PBS-treated CII immunized 
mice were significantly lower than those of naïve control mice. The mean value 
of brain IL-1β  protein concentrations on day 35 (PBS-treated versus naïve 
control ) was 62.6 ± 18.5 pg/mg total brain protein versus 75.9 ± 15.3 pg/mg 
total brain protein (P < 0.01). Similarly, the brain IL-1β protein concentrations of 
etanercept-treated CII immunized mice were also lower than those of PBS-
treated mice; the mean value of brain IL-1β protein concentrations on day 35 
(etanercept-treated versus naïve control) was 68.2 ± 6.6 pg/mg total brain 
protein versus 75.9 ± 15.3 pg/mg total brain protein (P < 0.05) (Figure 5.5B).  
Similar to TNF-α and IL-1β, there was no significant difference in brain IL-6 
protein concentrations between naïve control mice and CII immunized mice on 
day 14 (Figure 5.5C). One-way ANOVA analysis showed that there was no 
significant difference between IL-6 protein concentrations in brains of 
etanercept-treated, PBS-treated CII immunized mice and naïve control mice on 
day 32 (P = 0.7684). One-way ANOVA analysis showed that there was no 
significant difference between IL-6 protein concentrations in brains of 
etanercept-treated, PBS-treated CII immunized mice and naïve control mice on 
day 35 (P = 0.1368) (Figure 5.5C). 
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Figure 5.5 Effects of etanercept on brain pro-inflammatory cytokine protein profiles in CII 
immunized mice on days 14, 32 and 35  
CII immunized mice were treated with etanercept (gray bars), or PBS (black bars) from day 
18 after immunization onwards. The protein concentrations of brain pro-inflamamtory 
cytokines (TNF-α, IL-1β and IL-6) of CII immunized mice and naïve control mice were 
determined on day 14 as a time point of pre-onset of disease and before etanercept 
treatment. CII immunized mice treated with PBS as a placebo control, were described as 
PBS-treated CII immunized mice. Etanercept-treated and PBS-treated CII immunized mice 
were culled on day 32 and day 35, and brains were harvested and processed for 
inflammatory mediator protein determination. Brain samples collected from antigen-naïve 
control mice (white bars) culled on the days indicated were used as controls. TNF-α (A), IL-
1β (B) and IL-6 (C) protein concentrations in brain tissue homogenate of mice from all 
experimental groups were determined using ELISA assays. Pro-inflammatory cytokine 
protein concentrations in brain tissue, normalized against total brain protein, are expressed 
as pg/mg total brain protein. Error bars represent means ± SD (n = 3 mice on day 14 and day 
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32, n = 5 mice on day 35). Statistical analysis of data was performed using one-way ANOVA 
(*P < 05; **P < 01; ***P < 001). 
5.2.3.2 Effects of etanercept on Th1 cytokine protein profiles in the 
brain of CII immunized mice on days 14, 32 and 35 
IL-2 and IL-12 were the only Th1 cytokines that could be detected using ELISA 
assays in the brain tissue of mice from all experimental groups. Similar to the 
profile of pro-inflammatory cytokines, there were no significant changes in Th1 
cytokine (IL-2 and IL-12) protein concentrations in brains of CII immunized mice 
compared to naïve control mice during the pre-onset time point on day 14 
(Figure 5.6A and Figure 5.6B) 
One-way ANOVA analysis showed that there was no significant difference 
between IL-2 protein concentrations in brains of treated, PBS-treated CII 
immunized mice and naïve control mice on day 32 (P = 0.2046). One-way ANOVA 
demonstrated that there was a significant difference in protein concentration of 
IL-2 among the three groups of mice on day 35 (P = 0.0222). Post hoc analysis 
with Bonferroni correction demonstrated that there was a significant up-
regulation in brain IL-2 cytokine concentrations in etanercept-treated CII 
immunized mice compared to those of PBS-treated CII immunized mice on day 
35. The mean value of brain IL-2 protein concentrations on day 35 (etanercept-
treated versus PBS-treated) was 422.9 ± 45.4 pg/mg total brain protein versus 
337.5 ± 48.3 pg/mg total brain protein (P < 0.05) (Figure 5.6A). 
One-way ANOVA analysis demonstrated that there was a significant difference in 
protein concentration of IL-12 among the three groups of mice on day 32 (P = 
0.0110). Post hoc analysis with Bonferroni correction demonstrated that there 
was a significant reduction in brain IL-12 protein concentrations in etanercept-
treated mice compared with PBS-treated CII immunized mice on day 32. The 
mean value of brain IL-12 on day 32 (etanercept-treated versus PBS-treated) was 
35.0 ± 10.3 pg/mg total brain protein versus 265.6 ± 107.2 pg/mg total brain 
protein (P < 0.05). The similar pattern of brain IL-12 protein concentrations in 
mice from all experimental groups was also observed on day 35. One-way ANOVA 
followed by Bonferroni's post-hoc comparison tests demonstrated that there 
were significant differences in protein concentration of IL-12 among the three 
groups of mice on day 35 (P < 0.0001). Again, brain IL-12 protein concentrations 
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in etanercept-treated CII immunised mice were significantly lower than those in 
naïve control and PBS treated mice. The mean value of brain IL-12 protein 
concentrations on day 35 (etanercept-treated versus naïve control) was 37.9 ± 
7.8 pg/mg total brain protein versus 199.8 ± 13.4 pg/mg total brain protein (P < 
0.001), while the mean value of brain IL-12 protein concentrations on day 35 
(etanercept-treated versus PBS-treated) was 37.9 ± 7.8 pg/mg total brain 
protein versus 197.8 ± 21.7 pg/mg total brain protein (P < 0.001) (Figure 5.6B). 
 
Figure 5.6 Effects of etanercept on brain Th1 cytokine protein profiles in CII immunized mice 
on day 32 and day 35  
CII immunized mice were treated with etanercept (gray bars), or PBS (black bars) from day 
18 after immunization onwards; and antigen-naïve control mice (white bars). The protein 
concentrations of brain Th1 cytokines (IL-2 and IL-12) of CII immunized mice and naïve 
control mice were determined on day 14 as a time point of pre-onset of disease and before 
the etanercept treatment. CII immunized mice treated with PBS as a placebo were 
considered as PBS-treated CII immunized mice. Etanercept-treated and PBS-treated CII 
immunized mice were culled on day 32 and day 35, and brains were harvested and 
processed for inflammatory mediator protein determination. Brain samples collected from 
naïve control mice (white bars) culled on the days indicated were used as controls. IL-2 (A) 
and IL-12 (B) protein concentrations in brain tissue homogenate of mice from all 
experimental groups were determined using ELISA assays. Th1 cytokine protein 
concentrations in brain tissue, normalized against total brain protein, are expressed as 
pg/mg total brain protein. Error bars represent means ± SD (n = 3 mice on day 14 and day 
32, n = 5 mice on day 35). Statistical analysis of data was performed using one-way ANOVA 
(*P < 05; **P < 01; ***P < 001). 
5.2.3.3 Effects of etanercept on Th2 cytokine protein profiles in the 
brain of CII immunized mice on days 14, 32 and 35 
The Th2 cytokines IL-4, IL-5, IL-10 and IL-13 protein concentrations were 
detectable by ELISA assays in brain tissue of mice from all experimental groups. 
Again, there was no significant different in these Th2 cytokine protein 
concentrations between CII immunized mice and control mice on day 14 before 
the onset and the etanercept treatment (Figure 5.7A - Figure 5.7D) 
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One -way ANOVA analysis demonstrated that there was no significant difference 
between IL-4 protein concentrations in brains of etanercept-treated and PBS-
treated-CII immunized mice and naïve control mice on day 32 (P = 0.7808). 
There was no significant difference between IL-4 protein concentrations in 
brains of etanercept-treated, PBS-treated-CII immunized mice and naïve control 
mice on day 35 (P = 0.8415) (Figure 5.7A). 
One-way ANOVA analysis demonstrated that there were significant differences in 
protein concentration of IL-5 among the three groups of mice on day 32 (P = 
0.0183). Post hoc analysis with Bonferroni correction demonstrated that there 
was a significant reduction in brain IL-5 protein concentrations in etanercept-
treated mice compared with PBS-treated CII immunized mice on day 32. There 
was no significant difference in brain IL-5 protein concentrations between PBS-
treated CII immunized mice and naïve control mice. significant reductions in 
brain IL-5 protein concentrations of etanercept-treated CII immunized mice 
compared to those in naïve control mice and PBS-treated CII immunized mice 
were observed on day 32. The mean value of brain IL-5 protein concentrations 
on day 32 (etanercept-treated versus naïve control) was 4.4 ± 0.9 pg/mg total 
brain protein versus 9.3 ± 1.7 pg/mg total brain protein (P < 0.05), while the 
mean value of brain IL-5 protein concentrations on day 32 (etanercept-treated 
versus PBS-treated) was 4.4 ± 0.9 pg/mg total brain protein versus 8.9 ± 2.1 
pg/mg total brain protein (P < 0.05). One-way ANOVA analysis demonstrated that 
there were significant differences in protein concentration of IL-5 among the 
three groups of mice on day 35 (P = 0.0025). Post hoc analysis with Bonferroni 
correction demonstrated that there was a significant reduction in brain IL-5 
protein concentrations in etanercept-treated mice compared with PBS-treated 
CII immunized mice on day 35. PBS-treated CII immunized mice had lower brain 
IL-5 protein concentrations compared to those of naïve control mice. The mean 
value of brain IL-5 protein concentrations on day 35 (PBS-treated versus naïve 
control) was 6.5 ± 1.3 pg/mg total brain protein versus 9.7± 2.6 pg/mg total 
brain protein (P < 0.05). Interestingly, etanercept-treated CII immunized mice 
also show significant reductions in brain IL-5 protein concentrations compared to 
those in naïve control mice on day 35. The mean value of brain IL-5 protein 
concentrations on day 35 (etanercept-treated versus naïve control) was 4.8 ± 0.9 
Chapter 5  257 
pg/mg total brain protein versus 9.7± 2.6 pg/mg total brain protein (P < 0.01) 
(Figure 5.7B).  
One-way ANOVA analysis demonstrated that there was no significant difference 
between IL-10 protein concentrations in brains of etanercept-treated, PBS-
treated CII immunized mice and naïve control mice on day 32 (P = 0.6607). One-
way ANOVA analysis also showed that there was no significant difference 
between IL-10 protein concentrations in brains of etanercept-treated, PBS-
treated-CII immunized mice and naïve control mice on day 35 (P = 0.3533) 
(Figure 5.7C). 
One-way ANOVA analysis demonstrated that there was no significant difference 
between IL-13 protein concentrations in brains of etanercept-treated, PBS 
treated-CII immunized mice and control naïve mice on day 32 (P = 0.3703). 
However, one-way ANOVA demonstrated that there was a significant difference 
in protein concentration of IL-13 among the three groups of mice on day 35 (P = 
0.0185). Post hoc analysis with Bonferroni correction demonstrated that there 
was a significant reduction in brain IL-13 protein level in PBS-treated CII 
immunized mice compared to those of naïve control mice and treated CII 
immunized mice on day 35. The mean value of brain IL-13 protein concentrations 
on day 35 (PBS-treated versus naïve control) was 28.0 ± 15.9 pg/mg total brain 
protein versus 50.5 ± 9.0 pg/mg total brain protein (P < 0.05) (Figure 5.7D).  
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 Figure 5.7 Effects of etanercept on brain Th2 cytokine protein profiles in CII immunized 
mice on day 32 and day 35  
CII immunized mice were treated with etanercept (gray bars), or PBS (black bars) from day 
18 after immunization onwards; and antigen-naïve control mice (white bars). The protein 
concentrations of brain Th2 cytokines (IL-4, IL-5, IL-10 and IL-13) of CII immunized mice and 
naïve control mice were determined on day 14 as the time point of pre-onset and before the 
etanercept treatment. CII immunized mice treated with PBS as placebo, were considered as 
PBS-treated CII immunized mice. Etanercept-treated and PBS-treated CII immunized mice 
were culled on day 32 and day 35, and brains were harvested and processed for 
inflammatory mediator protein determination. Brain samples collected from naïve control 
mice (white bars) culled on the days indicated were used as controls. IL-4 (A), IL-5 (B), IL-10 
(C) and IL-13 (D) protein concentrations in brain tissue homogenate of mice from all 
experimental groups were determined using ELISA assays. Th2 cytokine protein 
concentrations in brain tissue, normalized against total brain protein, are expressed as 
pg/mg total brain protein. Error bars represent means ± SD (n = 3 mice on day 14 and day 
32, n = 5 mice on day 35). Statistical analysis of data was performed using one-way ANOVA 
(*P < 05; **P < 01; ***P < 001). 
5.2.3.4 Effects of etanercept on chemokine protein profiles in the brain 
of CII immunized mice on days 14, 32 and 35 
Changes in CXCL1 protein concentrations in brain tissue extracts of mice from all 
experimental groups were detected using a Luminex assay. There was no 
significant difference in brain CXCL1 protein concentrations between naïve 
control mice and CII immunized mice on day 14 before the onset of disease and 
the etanercept treatment. In addition, one-way ANOVA analysis demonstrated 
that there was no significant difference between CXCL1 protein concentrations 
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in brains of etanercept-treated, PBS-treated CII immunized mice and naïve 
control mice on day 32 (P = 0.0798). One-way ANOVA analysis also demonstrated 
that there were significant differences in protein concentration of CXCL1 among 
the three groups of mice on day 35 (P = 0.0004). Post hoc analysis with 
Bonferroni correction demonstrated that there was a significant increase in brain 
CXCL1 protein concentrations in PBS-treated CII immunized mice compared to 
those in the naïve control mice on day 35. The mean value of brain CXCL1 
protein concentrations on day 35 (PBS-treated versus naïve control) was 51.6 ± 
7.0 pg/mg total brain protein versus 26.9 ± 10.8 pg/mg total brain protein (P < 
0.001). Interestingly, etanercept decreased brain CXCL1 protein concentrations 
in CII immunized mice as etanercept-treated CII immunized showed a significant 
reduction in brain CXCL1 protein concentrations compared to those in PBS-
treated CII immunized mice. The mean value of brain CXCL1 protein 
concentrations on day 35 (etanercept-treated versus PBs-treated) was 51.6 ± 7.0 
pg/mg total brain protein versus 29.5 ± 6.3 pg/mg total brain protein (P < 0.01) 
(Figure 5.8). 
 
Figure 5.8 Effects of etanercept on brain chemokine (CXCL1) protein profiles in CII 
immunized mice on day 32 and day 35  
CII immunized mice were treated with etanercept (gray bars), or PBS (black bars) from day 
18 after immunization onwards; and antigen-naïve control mice (white bars). The protein 
concentrations of brain a chemokine CXCL1 of CII immunized mice and naïve control mice 
were determined on day 14 as the time point of pre-onset and before the etanercept 
treatment. CII immunized mice treated with PBS as a placebo, were considered as PBS-
treated CII immunized mice. Etanercept-Treated and PBS-treated CII immunized mice were 
culled on day 32 and day 35, and brains were harvested and processed for inflammatory 
mediator protein determination. Brain samples collected from naïve control mice (white 
bars) culled on the days indicated were used as controls. Chemokine CXCL1 protein 
concentrations in brain tissue homogenate of mice from all experimental groups were 
determined using a Luminex assay. Chemokine CXCL1 protein concentrations in brain 
tissue, normalized against total brain protein, are expressed as pg/mg total brain protein. 
Error bars represent means ± SD (n = 3 mice on day 14 and day 32, n = 5 mice on day 35). 
Statistical analysis of data was performed using one-way ANOVA (*P<0.05, **P<0.01, 
***P<0.001). 
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5.2.3.5 Effects of etanercept on growth factor protein profiles in the 
brain of CII immunized mice on days 14, 32 and 35 
VEGF and FGF2 growth factors were detected using an ELISA assay and a 
Luminex assay in brain tissue extracts of mice from all experimental groups. 
One-way ANOVA analysis showed that there was no significant difference 
between VEGF protein concentrations in brains of etanercept-treated, PBS-
treated-CII immunized mice and naïve control naïve mice on day 32 (P = 0.2730). 
However, one-way ANOVA analysis also demonstrated that there was a 
significant difference in protein concentration of VEGF among the three groups 
of mice on day 35 (P = 0.0115). Post hoc analysis with Bonferroni correction 
demonstrated that brain VEGF protein level was significantly increased in 
etanercept-treated CII immunized mice compared to those in PBS-treated CII 
immunized mice. The mean value of brain VEGF protein concentrations on day 
35 (PBS-treated versus etanercept-treated) was 431.6 ± 59.8 pg/mg total brain 
protein versus 332.6 ± 32.5 pg/mg total brain protein (P < 0.05) (Figure 5.9A). 
There was no significant difference between FGF2 protein concentrations in 
brains of etanercept-treated, PBS-treated CII immunized mice and naïve control 
mice on both day 32 and day 35 (Figure 5.9B).  
 
Figure 5.9 Effects of etanercept on brain growth factor protein profiles in CII immunized 
mice on day 32 and day 35  
CII immunized mice were treated with etanercept (gray bars), or PBS (black bars) from day 
18 after immunization onwards; and antigen-naïve control mice (white bars). The protein 
concentrations of brain growth factors (VEGF and FGF2) of CII immunized mice and naïve 
control mice were determined on day 14 as the time point of pre-onset and before the 
etanercept treatment. CII immunized mice treated with PBS as a placebo, were considered 
as PBS-treated CII immunized mice. Etanercept-treated and PBS-treated CII immunized mice 
were culled on day 32 and day 35, and brains were harvested and processed for 
inflammatory mediator protein determination. Brain samples collected from naïve control 
mice (white bars) culled on the days indicated were used as controls. VEGF (A) and FGF2 
(B) protein concentrations in brain tissue homogenate of mice from all experimental groups 
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were determined using ELISA assays. Growth factor protein concentrations in brain tissue, 
normalized against total brain protein, are expressed as pg/mg total brain protein. Error 
bars represent means ± SD (n = 3 mice on day 14 and day 32, n = 5 mice on day 35). 
Statistical analysis of data was performed using one-way ANOVA (*P<0.05, **P<0.01, 
***P<0.001). 
5.2.4  Changes in inflammatory mediator gene expression in 
the brains of etanercept treated and PBS treated CII 
immunized mice on day 14, day 32 and day 35 by real-time 
PCR 
We also investigated the effects of etanercept on the gene expression of 
inflammatory mediators in CII immunized mice. Real-time PCR was used to 
quantify the gene expression of the same pro-inflammatory cytokines (IL-6, IL-1 
β, TNF-α and IL-1α), Th1 cytokines (IL-2, IL-12 and IFN-γ), Th2 cytokines (IL-4, 
IL-5, IL-10 and IL-13), chemokines (CXCL1, CXCL10, CCL2 and CCL3) and growth 
factors (FGF2 and, VEGF) using one half of the brain tissue of mice from all 
experimental groups. Gene expression of IL-1β, CXCL1, CXCL10, FGF2 and VEGF 
were detectable within the assay detection limits.  
5.2.4.1  Effects of etanercept on pro-inflammatory cytokine mRNA 
profiles in brains of CII immunized mice on days 14, 32 and 35 by 
Real-time PCR assays 
The gene expression of pro-inflammatory cytokines including IL-6, IL-1β and TNF-
α and IL-1α were determined in brains of mice from all experimental groups. In 
our study, IL-1β was the only pro-inflammatory cytokine gene expression levels 
detectable within the detection limit of the assays.  
There was no significant difference in brain IL-1β mRNA levels between naïve 
control mice and CII immunized mice on day 14 before the etanercept treatment 
and onset of the disease. On day 32, one-way ANOVA analysis showed that there 
was no significant difference between IL-1β mRNA levels in brains of etanercept-
treated, PBS-treated CII immunized mice and naïve control mice (P = 0.2444). 
Brain IL-1β mRNA levels in PBS-treated CII immunized mice was higher, but not 
significant, than those of naïve control mice. One-way ANOVA analysis 
demonstrated that there were significant differences in IL-1β mRNA levels 
among the three groups of mice on day 35 (P = 0.0011). Post hoc analysis with 
Bonferroni correction demonstrated that PBS-treated CII immunized mice had a 
significantly higher brain IL-1β mRNA level compared to those in naïve control 
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mice on day 35. The mean value of brain IL-1β mRNA levels on day 35 (PBS-
treated versus naïve control) was 1261 ± 158 versus 702 ± 109 (P < 0.05). At this 
time point, IL-1β mRNA levels in brains of etanercept-treated CII immunized 
mice was decreased significantly compared to those of PBS-treated CII 
immunized mice. The mean value of IL-1β mRNA levels on day 35 (etanercept-
treated versus PBS-treated) was 478 ± 33 versus 1261 ± 158 (P < 0.01) (Figure 
5.10). 
 
Figure 5.10 Effects of etanercept on a brain pro-inflammatory cytokine gene expression 
profiles in CII immunized mice on day 32 and day 35  
CII immunized mice were treated with etanercept (gray bars), or PBS (black bars) from day 
18 after immunization onwards; and antigen-naïve control mice (white bars). The mRNA 
levels of a brain pro-inflammatory cytokine IL-1β of CII immunized mice and naïve control 
mice were determined on day 14 as the time point of pre-onset and before the etanercept 
treatment. CII immunized mice treated with PBS as a placebo, were considered as PBS-
treated CII immunized mice. Etanercept-treated and PBS-treated CII immunized mice were 
culled on day 32 and day 35, and brains were harvested and processed for inflammatory 
mediator protein determinations. Brain samples collected from normal mice (white bars) 
culled on the days indicated were used as controls. IL-1β mRNA levels in brain tissue 
homogenate of mice from all experimental groups were determined using Real-time PCR. 
mRNA levels of pro-inflammatory cytokines in brain tissue, normalized against the 
housekeeping gene GAPDH, are expressed as arbitrary units. Error bars represent means ± 
SD (n = 3 mice on day 14 and day 32, n = 5 mice on day 35). Statistical analysis of data was 
performed using one-way ANOVA (*P<0.05, **P<0.01, ***P<0.001). 
5.2.4.2 Effects of etanercept on Th1 cytokine mRNA profiles in brains 
of CII immunized mice on days 14, 32 and 35 by real-time PCR assays 
Changes in gene expression of Th-1 cytokines, including IL-12, IL-2 and IFN-γ, 
over time were determined in the brains of mice from all experimental groups. 
However, there was no significant difference between Th-1 cytokines mRNA 
levels in brains of treated, PBS treated CII immunized mice and control naïve 
mice on day 32 and day 35. 
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5.2.4.3 Effects of etanercept on Th2 mRNA profiles in brains of CII 
immunized mice on days 14, 32 and 35 by real-time PCR assays 
Th-2 cytokines, including IL-4, IL-5, IL-10 and IL-13 gene expression were 
determined in the brains of mice from all experimental groups. However, there 
was no significant different between Th-2 cytokines mRNA levels in brains of 
treated, PBS treated CII immunized mice and control naïve mice on day 32 and 
day 35. 
5.2.4.4 Effects of etanercept on chemokine mRNA profiles in brains of 
CII immunized mice on days 14, 32 and 35 by real-time PCR assays 
CXCL1, CXCL10, CCL2 and CCL3 gene expression levels were determined in the 
brains of control mice from all experimental groups. Among these chemokines, 
only CXCL1 and CXCL10 were detectable within the assay limits. During the pre-
onset time on day 14, there was no significant difference in CXCL1 and CXCL10 
mRNA levels between naïve control mice and CII immunized mice on day 14 
before the etanercept treatment.  
One-way ANOVA analysis demonstrated that there was no significant difference 
between CXCL1 mRNA levels in brains of etanercept-treated, PBS-treated CII 
immunized mice and naïve control mice on day 32 and day 35 (P = 0.0761 and P 
= 0.2627 respectively). Increases in brain CXCL1 mRNA levels was observed in 
PBS-treated CII immunized mice compared to those in naïve control and 
etanercept-treated CII immunized mice on both time points. However, a 
statistical analysis using one-way ANOVA analysis showed that the differences 
were not significant (Figure 5.11A).  
One-way ANOVA analysis demonstrated that there was no significant difference 
between CXCL10 mRNA levels in brains of treated, untreated CII immunized mice 
and naïve control mice on day 32 and day 35 (P = 0.5512 and P = 0.5347 
respectively) (Figure 5.11B). 
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Figure 5.11 Effects of etanercept on a brain chemokine gene expression profiles in CII 
immunized mice on day 32 and day 35  
CII immunized mice were treated with etanercept (gray bars), or PBS (black bars) from day 
18 after immunization onwards; and antigen-naïve control mice (white bars). The mRNA 
levels of a brain chemokine CXCL1 and CXCL10 of CII immunized mice and naïve control 
mice were determined on day 14 as the time point of pre-onset and before the etanercept 
treatment. CII immunized mice treated with PBS as a placebo, were considered as PBS-
treated CII immunized mice. Etanercept-treated and PBS-treated CII immunized mice were 
culled on day 32 and day 35, and brains were harvested and processed for inflammatory 
mediator protein determinations. Brain samples collected from normal mice (white bars) 
culled on the days indicated were used as controls. CXCL1 (A) and CXCL10 (B) mRNA levels 
in brain tissue homogenate of mice from all experimental groups were determined using 
Real-time PCR. mRNA levels of chemokines in brain tissue, normalized against the 
housekeeping gene GAPDH, are expressed as arbitrary units. Error bars represent means ± 
SD (n = 3 mice on day 14 and day 32, n = 5 mice on day 35). Statistical analysis of data was 
performed using one-way ANOVA (*P<0.05, **P<0.01, ***P<0.001). 
 
5.2.4.5  Effects of etanercept on growth factor mRNA profiles in brains 
of CII immunized mice on days 14, 32 and 35 by real-time PCR assays 
Gene expression of growth factor mRNA for FGF2 and VEGF were detectable in 
the brains of mice from all experimental groups. There was no significant 
difference in FGF2 and VEGF mRNA levels observed in brains of CII immunized 
mice and naïve control mice.  
One-way ANOVA analysis demonstrated that there was no significant difference 
between VEGF mRNA levels in brains of treated, PBS-treated CII immunized mice 
and naïve control mice on day 32 and day 35 (P = 0.6335 and P = 0.6188 
respectively) (Figure 5.12A). 
One-way ANOVA analysis demonstrated that, on day 32, there was no significant 
difference between FGF2 mRNA levels in brains of etanercept-treated, PBS-
treated CII immunized mice and naïve control mice (P = 0.1145). However, brain 
FGF2 mRNA levels in both etanercept-treated and PBS-treated CII immunized 
mice appeared lower than those in naïve control mice at that time point. On day 
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35, One-way ANOVA analysis also demonstrated that there was no significant 
difference in brain FGF2 mRNA levels among the three groups of mice on day 35 
(P = 0.0544) (Figure 5.12B). 
 
Figure 5.12 Effects of etanercept on a brain growth factor gene expression profiles in CII 
immunized mice on day 32 and day 35 
CII immunized mice were treated with etanercept (gray bars), or PBS (black bars) from day 
18 after immunization onwards; and antigen-naïve control mice (white bars). The mRNA 
levels of a brain chemokine VEGF and FGF2 of CII immunized mice and naïve control mice 
were determined on day 14 as the time point of pre-onset and before the etanercept 
treatment. CII immunized mice treated with PBS as a placebo, were considered as PBS-
treated CII immunized mice. Etanercept-treated and PBS-treated CII immunized mice were 
culled on day 32 and day 35, and brains were harvested and processed for inflammatory 
mediator protein determinations. Brain samples collected from normal mice (white bars) 
culled on the days indicated were used as controls. VEGF (A) and FGF2 (B) mRNA levels in 
brain tissue homogenate of mice from all experimental groups were determined using Real-
time PCR. mRNA levels of growth factors in brain tissue, normalized against the 
housekeeping gene GAPDH, are expressed as arbitrary units. Error bars represent means ± 
SD (n = 3 mice on day 14 and day 32, n = 5 mice on day 35). Statistical analysis of data was 
performed using one-way ANOVA (*P<0.05, **P<0.01, ***P<0.001). 
5.3  Summary; Effects of etanercept on inflammatory 
mediator mRNA and protein profiles in brains of CII 
immunized mice 
In this chapter, we investigated the effect of TNF-blockade therapy using 
etanercept on brain inflammatory mediator profiles, comparing etanercept-
treated and PBS-treated CII immunized mice during the period of clinical 
expression of the disease, and studied the association with its effect on the 
amelioration of joint disease during those time points.  We found that 
etanercept treatment not only alleviated arthritis, but also had effects on 
inflammatory mediator mRNA and protein profiles in the brains of CII immunized 
mice. These changes in mRNA expression and protein concentrations of IL-1β, 
TNF-α, IL-6, IL-4, IL-5, IL-10, IL-13, IL-2, IL-12, CXCL1, CXCL10, VEGF and FGF2 
are summarised in Table 5.2 
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Day 32 
 
 
Day 35 
 
 
Inflammatory 
mediators 
 
Protein 
 
mRNA 
 
 
Protein 
 
mRNA 
IL-1β NS NS NS P < 0.01 
 
TNF-α P < 0.01 UD NS 
 
UD 
IL-6 NS UD NS 
 
UD 
IL-4 NS UD NS UD 
IL-5 P < 0.01 
 
UD NS  UD 
IL-10 NS UD NS 
 
UD 
IL-13 NS NS UD 
 
UD 
IL-2 NS UD     P < 0.05 
 
UD 
IL-12 P < 0.05 
 
UD P < 0.001 
 
UD 
CXCL1 NS NS     P < 0.01 
 
NS 
CXCL10 UD NS UD 
 
N 
VEGF NS NS P < 0.05 
 
NS 
FGF2 NS NS NS NS  
 
Table 5.2 Effects of etanercept on inflammatory mediator protein and mRNA profiles in 
brains of etanercept-treated CII immunized mice relative to those of PBS-treated CII 
immunized mice  
Red arrows represent changes in of inflammatory mediator protein concentrations, while 
blue arrows represent changes in inflammatory mediator mRNA levels in brains of 
etanercept-treated CII immunized mice compared to PBS-treated CII immunized mice on day 
32 and day 35. Differences between inflammatory mediator concentrations in etanercept-
treated CII immunized mouse brains and PBS-treated CII immunized mouse brains were 
analyzed by Student's t- test (*P < 005; **P < 002; ***P < 001). NS = not statistically 
significant, UD= Undetectable (below assay detection limit. 
In this experiment, we investigated effects of etanercept on inflammatory 
mediator production in brains of CII immunized mice during the early stage of 
disease (day 32 after imunization) and late stage of disease (day 35 after 
immunization). We found that, at the early stage of RA disease, etanercept 
reduced the production of TNF-α and the Th1 cytokine IL-12, which are 
considered to be the main cytokines that initiate the RA disease process. 
However, at the late stage etanercept reduced IL-1β and TNF-α production, 
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while increasing IL-6 production. Surprisingly, etanercept showed contradictory 
effects on two different Th1 cytokines, IL-2 and IL-12. Etanercept reduced brain 
IL-12 protein concentrations, but increased brain IL-2 protein concentrations, 
suggesting that etanercept may induce different signals on Th1 cells to generate 
different types of Th1 cytokines, for example IL-2 is an autocrine T-cell growth 
factor that is produced early in T-cell activation (Lorre et al., 1990), whereas IL-
12 is produced later as a functional cytokine after T-cell polarisation (Feili-Hariri 
et al., 2005). Another possibility is that etanercept not only activated Th1 cells, 
but also could regulate other type of immune cell populations that can also 
produce Th1 cytokines in the brain such as astrocytes and microglia. Etanercept 
seemed to have no effect on brain Th2 cytokine production, including IL-4, IL-13 
and IL-10. However, etanercept significantly reduced brain IL-5 protein 
concentrations in the brains of etanercept-CII immunized mice throughout the 
period of clinical expression of disease. The most striking data in this section 
seems to be the effect of etanercept suppressing the increased production of 
brain CXCL1 and IL-1β that was seen in control PBS-treated CII immunized mice. 
These two cytokines are functionally related; IL-1β is known to be a potent 
cytokine that stimulates the expression of CXCL1. It has been shown that chronic 
expression of IL-1 β can induce the expression of CXCL1 in the mouse brain. 
Therefore, it is possible that etanercept acts by inhibiting IL-1β production 
resulting in a reduction of CXCL1 and potentially reduceing immune cells influx 
into the brain. Interestingly, at this stage, etanercept can also activate the 
production of VEGF and FGF2. These growth factors are known as angiogenic 
factors that may suggest BBB breakdown in the CIA mouse brain. However, these 
growth factors may also have other functions in the brain and whether or not 
etanercept may worsen BBB breakdown in CIA mouse brains via enhancement of 
these brain growth factors need to be further investigated.  
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5.4  Result chapter 5: Summary of major findings.  
The aim of this chapter was to investigate the effects of etanercept on the 
production of inflammatory mediators in the brain of CII immunized mice. We 
compared changes in brain inflammatory mediators among etanercept-treated 
CII immunized and control PBS-treated CII immunized mice at 3 time points 
across the 42 day experimental course of CIA. Day 14 after immunization was 
studied as a representative time–point prior to the onset of disease and before 
the etanercept treatment. The other 2 time points were during the period of 
clinical expression on day 32 representing the time point of early disease and at 
day 35 after immunization representing the time point of the late stage of 
disease. We found that: 
1. There was no significant difference in brain inflammatory mediators 
between antigen-naïve control mice and CII immunized at day 14 after 
immunization which is representative of a time point prior to the onset of 
disease and pre-etanercept treatment. 
2.  In the first of two experiments, etanercept treatment did not delay the 
onset of arthritis nor reduce the incidence at day 32. In addition, 
etanercept treatment did not decreasing the severity of arthritis by 
reducing the mean paw thickness and the clinical score compared to PBS-
treated CII immunized mice. However, etanercept treatment was 
associated with reductions in TNF-α, IL-5 and IL-12 protein concentrations 
in brains of etanercept-treated CII immunized mice.  
3. In the second experiment, etanercept treatment did delay the onset of 
arthritis and reduced the incidence at day 35, as well as attenuating the 
severity of arthritis by reducing the mean paw thickness and the clinical 
score compared to PBS-treated CII immunized mice. At this time point, 
etanercept treatment was associated with reductions in IL-12, CXCL1 
protein concentrations and with increases in IL-2 and VEGF protein 
concentrations in brains of etanercept- treated CII immunized mice. 
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5.5 Discussion 
To extend our investigation of the association between peripheral inflammation 
and changes in brain inflammatory mediator profiles in CII immunized mice, we 
attempted to reduce the peripheral inflammatory signal using the anti-
inflammatory drug etanercept as a preventive therapy for arthritis. We then 
examined the changes in the brain inflammatory mediator profile during the 
time course of the development of arthritis in CII immunized mice.  
We found that systemic administration of the TNF-α blockade drug 
etanercept not only had an effect on the amelioration of joint disease by 
reducing mean paw thickness and incidence of arthritis in CII immunized mice, 
but also had effects on brain inflammatory mediator profiles in these mice. We 
found increases in IL-6, IL-2, VEGF protein concentrations and FGF2 mRNA 
levels, along with decreases in TNF-α, IL-5, IL-12, CXCL1 protein concentrations 
and IL-1β mRNA levels in brains of etanercept-treated CII immunized mice 
compared to those of PBS-treated CII immunized mice. Our data suggest that 
changes in inflammatory mediators in brains of CII immunized mice may be a 
consequence of changes in the peripheral inflammatory cytokine signal during 
the clinical development of arthritis.  
5.5.1  Effect of etanercept on the amelioration of joint disease 
in CII immunized mice 
Etanercept is a recombinant human soluble p75 TNFR:Fc fusion protein that has 
been developed for the therapeutic treatment of RA. The administration of 
etanercept has been reported to attenuate the development of clinical arthritis 
and, in CIA mouse model, the development of experimental RA. Our data showed 
that the experimental arthritis disease process could be attenuated when the 
etanercept treatment was administrated therapeutically from day 18 after the 
immunization, as indicated by significant reductions in mean arthritis scores, in 
mean paw swelling and in disease percent incidence compared to PBS treated 
CIA mice. Our finding is in agreement with several reports on the prevention of 
arthritis in CIA and AIA models of RA by the administration of 300ug/mouse/3 
days of recombinant human/rodent TNFR:Fc fusion protein. In one of these 
reports, the administration of a recombinant soluble TNFR in CIA mice from day 
Chapter 5  270 
14 onwards resulted in the delay of arthritis disease development, along with 
reduced arthritis disease severity as determined by paw swelling. However, that 
study did not address the effect on disease incidence (Williams et al., 2000b). 
The ability to prevent arthritis in the CIA model by peripheral TNF blockade in 
the days (typically <21 days) before the disease onset might be due to the fact 
that TNF-α plays a critical role in initiating an immuno-inflammatory cascade 
leading to the development of arthritis. TNF-α is involved in regulating other 
cytokine and chemokine release, recruitment of immune cells and expression of 
endothelial adhesion molecules at the inflamed site. However, the precise 
action of human soluble p75 TNFR:Fc fusion protein on the immune response to 
collagen challenge in the CIA model is not currently clear. The few studies in 
print suggested that recombinant human soluble p75 TNFR inhibited the 
immune-mediated arthritis by suppressing IgG2a anti-collagen antibody 
production, this is the dominant antibody subclass in the CIA model and is 
induced by Th1-type cells (Mukherjee et al., 2003). A study of RA demonstrated 
that soluble p75 TNFR treated CIA mice had lower concentrations of 
inflammatory Th1 driven IgG2a antibodies to CII than controls (Mageed et al., 
1998). In addition, several studies also suggested that the immunosuppressive 
effects of this TNF-α blockade are related to inhibition of CD4+ activation and to 
down-regulation of the Th1 response. TNFR-p75 has been shown to be an 
essential co-stimulator for the survival of CD4+ T cells during clonal expansion, 
and p75-deficient T cells showed a defect in IL-2 production (Kim and Teh, 
2004). CIA mice treated with TNF-α blockade also showed reduced number of 
CD4+ T cells in the joint (Marinova-Mutafchieva et al., 2000).  
In this experiment, CII immunized mice after day 21 were randomly divided into 
4 groups (Group 2 - 5) consisting of 3 - 5 mice per group. Each group of mice 
were allocated a separate cage and set up as follows;  
Group 2: CII immunized mice treated with PBS and culled on day 32 
Group 3: CII immunized mice treated with etanercept and culled on day 32  
Group 4: CII immunized mice treated with PBS and culled on day 35 
 Group 4: CII immunized mice treated with etanercept and culled on day 35.  
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The incidences of RA appear to be around 60% for CII immunized mice in Group 
2, 3 and 5. However, the data shown for paw thickness and arthritis score in CII 
immunized mice in each group were different. This suggests that each group 
mice developed arthritis in different severity. Therefore the data shown for paw 
thickness and arthritis score in the mice culled at day 32 and day 35 are 
different (Figure 5.2Figure 5.3). The different patterns of the arthritis score and 
paw thickness between CII immunized mice on day 32 and 35 may have been due 
to the small sample size (n = 3-5 CII immunized mice) and the inequality in 
number of mice culled on day 32 and day 35. The small number of mice per 
group may help to explain the inconsistency in the data shown for paw thickness 
and arthritis score in the mice culled on day 32 and day 35. Therefore, 
repetition of this experiment using a greater group size to increase in statistical 
power may help to improve the consistency of the data.  
5.5.2  Effects of peripheral etanercept treatment on 
inflammatory mediators in brains of CII immunized mice; 
possible evidence of peripheral inflammatory signal 
inducing neuro-inflammation 
By blocking peripheral inflammatory cytokine signal using etanercept in CII 
immunized mice, we found interesting evidence of immune activation and 
inflammation in the brains of CII immunized mice during the development of 
arthritis. In this study, we also investigated changes in brain inflammatory 
mediators in CII immunized mice compared to those in naïve control mice during 
the period before the onset of arthritis disease on day 14 after immunization. 
That time point was also used as a control time point before the etanercept 
treatment began on day 18. At that time point, no CII immunized mice 
developed arthritis and we found no significant difference in brain inflammatory 
mediator concentrations between CII immunized mice and those in naïve control 
mice. However, changes in inflammatory mediators in brains of etanercept-
treated and PBS-treated CII immunized mice compared to those of naïve control 
mice were observed on day 32 and day 35 as the CII immunized mice developed 
arthritis. This finding suggested that the production in inflammatory mediators 
in brains of CII immunized mice may be stimulated by immune activation and 
inflammatory signals from cytokines in the peripheral circulation. This also 
suggests that etanercept may act at the peripheral blood level rather than at 
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the CNS level to regulate the production of brain inflammatory mediators in CII 
immunized mice. Another important piece of evidence suggesting that 
peripheral inflammation induced neuro-inflammation was that etanercept 
treatment was administrated peripherally, but we could still observe changes in 
inflammatory mediators in the brains of CII-immunized mice. In particular, a 
reduction of brain TNF-α and IL-12, initiators of the joint destructive pathology 
of RA, were observed in etanercept-treated CII immunized mice on both day 32 
and day 35. This suggested that etanercept may act mainly by inhibition of TNF-
α and subsequently Th1 cells. However, we could not detect serum inflammatory 
mediators in mice from any of the experimental groups in this study, suggesting 
that the Luminex assay may not have been sufficiently sensitive to detect 
biologically active concentrations of relevant cytokines in this system. We 
therefore could not conclude whether or not etanercept actually blocked any 
specific peripheral inflammatory cytokine signal by reducing serum TNF-α and 
other inflammatory mediators during the development of arthritis. It is also 
possible that TNF-α is present in the serum at low concentrations that is 
sufficient to initiate disease and/or it is transiently cleared after inflammatory 
challenge. A study by Goto et al has demonstrated rapid clearance (120 min) of 
recombinant TNF-α from the rat circulation following intravenous injection of 
LPS (Goto et al., 2001). We hypothesized that TNF-α may activate the 
production of inflammatory mediators in the circulation and that these may be 
rapidly cleared. This hypothesis is supported by a study in a model of surgical 
trauma showing that anti-TNF transiently reduced the protein concentrations of 
serum IL-1β both at 6 and 24 h following surgery (Terrando et al., 2010). 
Interestingly, in the brains of etanercept-treated CII immunized mice we found a 
significant reduction of IL-12, TNF-α, IL-5 on day 32, and a reduction of brain IL-
12 on day 35 associated with a significant lower mean clinical score and paw 
thickness compared to PBS-treated CII immunized mice on day 35.  
The transient effect of anti-TNF therapy on CNS cytokine production has 
also been demonstrated in recent studies; in a model of acute inflammatory 
brain injury in morphine-tolerant rats (Shen et al., 2011) and in traumatic brain 
injury (Chio et al., 2010).  
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5.5.3  Effects of peripheral etanercept treatment on pro-
inflammatory cytokines in brains of CII immunized mice 
We will now consider how CIA may be associated with brain inflammation. In the 
CNS, TNF-α and TNFR signalling play crucial roles in neuro-inflammatory 
processes.  The p75 TNFR was shown to be increased on peripheral blood 
monocytes and lymphocytes of MS patients (Jurewicz et al., 1999). In addition, 
TNF/TNFR signalling was shown to induce oligodendrocyte apoptosis and primary 
demyelination in an MS model (Akassoglou et al., 1998). In an EAE model, TNF-α 
plays an essential role in the initiation of clinical symptoms, and the therapeutic 
administration of TNFR-IgG could prevent the development of disease (Korner et 
al., 1997). In experimental cerebral ischemia, p75 TNFR signalling was 
demonstrated to initiate CNS inflammation as indicated by endothelial cell 
activation, meningeal inflammation, and vessel fibrosis in p75 TNFR transgenic 
mice (Akassoglou et al., 2003). Recently, etanercept, TNF blockade, has been 
shown to be effective treatment for both immune and non-immune-mediated 
CNS injury. A study by Genovese et al showed that the inflammation associated 
with acute spinal cord injury was significantly decreased by etanercept. 
Etanercept has shown to attenuate central endotoxin-induced brain injury 
(Campbell et al., 2007). Our data showing that peripheral administration of 
etanercept reduced the local concentrations of pro-inflammatory cytokines 
including TNF-α and IL-1β in the brains of CII immunized mice are in agreement 
with recent reports of models of morphine-tolerant rats (Shen et al., 2011) and 
traumatic brain injury (Chio et al., 2010).  
5.5.4  Effects of peripheral etanercept treatment on TNF-α in 
brains of CII immunized mice 
Our data showed down-regulation of brain TNF-α in etanercept treated- CII 
immunized mice compared to those in PBS treated-CII immunized mice on days 
32 and 35. We were not able to define the precise action of etanercept on this 
suppression of brain TNF-α in CII immunized mice mainly because  we could not 
detect TNF-α protein in serum or mRNA in the brains of etanercept-treated and 
PBS-treated CII immunized mice in our study. We could therefore speculate that 
one possible mechanism is that the etanercept binds systemic TNF-α and thereby 
prevent the transport of TNF-α through the blood brain barrier (Jiang et al., 
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2008). This is the most likely mechanism because etanercept does not cross the 
blood-brain barrier due to its hydrophilic property and high molecular weight 
(Francis et al., 2004), suggesting that it is unlikely that etanercept could inhibit 
production of TNF-α in the brains of CII immunized mice. However, in another 
study, TNF-α transport across the blood–brain barrier is shown to be mediated by 
p75 TNFR (Pan and Kastin, 2002), which was strongly up-regulated during CNS 
inflammation and injury (Pan et al., 2003). This suggests that an increase in p75 
TNFR may paradoxically enhance the transportation of peripheral TNF-α into the 
brain. The soluble form of p75 TNFR that is released from monocytes during 
inflammation is thought to function by modulating the availability and biological 
activity of TNF-α via neutralization or stabilization (Joyce and Steer, 1996). A 
study in an LPS-challenge mouse inflammation model suggested that dimeric 
sTNFR are effective inhibitors of TNF and, under some circumstances, could also 
function as TNF carriers. Administration of a mortality-reducing dose of sTNFR 
reduced the rise in serum TNF bioactivity that normally occured in response to 
LPS. However, a lower dose of sTNFR resulted in increased serum TNF 
concentrations compared to mice given LPS but no soluble receptor. The actual 
role of TNFR signalling and sTNFR as a TNF carrier during peripheral 
inflammation that could then induce neuro-inflammation has not been resolved. 
In addition, key sites of anti-inflammatory effects of etanercept on TNF-α 
transport from the periphery to the brain and the brain TNF-α production in this 
model needs to be investigated further (Mohler et al., 1993) perhaps by using 
immuno-histo-chemistry of brain tissue to identify cell producing local TNF-α 
during the disease process of arthritis. 
5.5.5  Effects of peripheral etanercept treatment on IL-1β in 
brains of CII immunized mice 
TNF-α stimulates the production of other pro-inflammatory cytokines such as IL-
1β. It was shown that blockade of TNF-α in CIA mice reduced IL-1β expression in 
the joint, suggesting that the production of IL-1β in the CIA model is driven by 
TNF-α (Williams et al., 2000b). In the CNS, brain IL-1β production has been 
shown to be inducible by peripheral inflammation. In addition, brain IL-1β has 
been reported to play a crucial role in cognitive decline and symptoms of 
sickness behaviour. Our data showed that brain IL-1β mRNA expression levels 
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were up-regulated significantly on day 35 in CII immunized mice compared to 
control mice. The increased brain IL-1β mRNA levels in these CII immunized mice 
were likely to be suppressed by etanercept, as indicated by a significant 
reduction in brain IL-1β mRNA levels in etanercept treated-CII immunized mice. 
Our finding suggested that TNF-α blockade may inhibit peripheral inflammation-
mediated brain IL-1β production. However, whether TNF-α blockade inhibits IL-
1β initially at the peripheral level or at the CNS level was not addressed in our 
study. A recent study in a model of surgical trauma suggested that TNF-α 
blockade may inhibit the production of IL-1β at the peripheral level. The 
administration of TNF-α blockade was demonstrated to reduce serum IL-1β after 
surgical trauma. The inhibition of brain IL-1β by TNF-α blockade during 
peripheral inflammation observed in our study was also seen in this study. The 
administration of TNF-α blockade resulted in a reduction in brain IL-1β protein 
caused by surgery-induced inflammation (Terrando et al., 2010). In addition, the 
effect of etanercept reversing IL-1β-induced depressive-like and sickness 
behaviour has been previously reported by (Jiang et al., 2008). In that study, 
etanercept inhibited peripheral TNF-α production following IL-1β challenge. In 
addition, the andedonic effects of IL-1β in the brain were blocked by pre-
treatment with etanercept. However, that study did not address the effect of 
etanercept on brain IL-1β production (Jiang et al., 2008). The combined 
evidence of our results and these reports demonstrated that TNF-α may be the 
main regulator for brain IL-1β production and action. However, the precise 
action of etanercept on the brain IL-1β production by local brain immune cells 
such as microglia in this CIA model needs to be further investigated perhaps by 
using immuno-histochemistry of brain tissue to identify cells producing local 
TNF-α as well as IL-1β to examine the dynamics of this response of these two 
cytokines during the development of arthritis.  
5.5.6 Effects of peripheral etanercept treatment on Th1 
cytokines in brains of CII immunized mice 
TNF/TNFR signalling plays a role in CD4+ activation and regulation of the Th1 
response via the production of IFN-γ and IL-12 (Marinova-Mutafchieva et al., 
2000). Our data showed a significant reduction in brain IL-12 concentration in 
etanercept treat-CII immunized mice compared to those in PBS treated-CII 
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immunized mice on days 32 and 35. To date, the precise role of p75 TNFR on Th1 
immune responses in the CNS has not been well addressed. A study by Becher 
and Dodelet 1996 showed that p75 TNFR could inhibit IL-12 production by 
activated human adult microglial cells (Becher et al., 1996). In addition, p75 
TNFR was shown to act on antigen presenting cell-derived IL-12 to inhibit Th1 
polarization in the EAE model (Becher et al., 1999). In contrast, TNFR-p75 has 
been reported to function as an essential co-stimulator for CD4+ T cell responses 
to cognate antigen (Kim et al., 2006). The effect of etanercept on Th1 immune 
responses in the CNS may also be associated with the role of TNF/TNFR signalling 
in recruiting T cells from the periphery into the CNS during neuro-inflammation, 
the mechanism of which has not been elucidated. Animals treated with TNFR:Fc 
after immunization with myelin basic protein or proteolipid protein in adjuvant, 
but before onset of clinical symptoms, did not develop disease but have 
continued inflammation as indicated by the number of CNS infiltrating T cells 
(Korner et al., 1997). Another study reported that p75 TNFR gene knockout mice 
exhibited exacerbated EAE, enhanced Th1 cytokine production, and enhanced 
CD4+T cell infiltration to the CNS (Suvannavejh et al., 2000). This evidence 
could help explain our finding that on the early time point of disease (day 32), 
TNF-blockade may inhibit the biologic activities of TNF on Th1 response, 
whereas at the later time point (day 35), p75 TNFR may function to activate CD4 
T cells and enhance CD4 T cell recruitment into the CNS by an as-yet unknown 
mechanism. Therefore, the role of TNF/TNFR signalling in Th1 immune responses 
in the CNS during peripheral inflammation in CIA model needs to be further 
investigated perhaps by using separate p75 and p55 TNFR gene-deleted mice to 
study the effects of etanercept on development arthritis in CIA mice. 
5.5.7 Effects of peripheral etanercept treatment on Th2 
cytokines in brains of CII immunized mice 
In considering the effects of etanercept on Th2 cytokine profiles in brains of CII 
immunized mice, we found that etanercept treatment had no effect on brain IL-
4 and IL-10 concentrations. However, etanercept reduced IL-5 concentrations in 
brains of CII immunized mice on days 35. To date, the details of any precise 
mutual regulation between TNF-α and Th2 cytokines is still not well understood 
in the CNS. 1L-10 and IL-4 are known to inhibit TNF-α production by monocytes 
(Joyce et al., 1994). In addition, TNF blockade in RA patients resulted in an 
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increase in the production of Th2 cytokine such as IL-10 by monocytes 
(Schuerwegh et al., 2003). However, the regulation between TNF-α and Th2 
cytokines could be divergent in the different cell types and tissue. In the CNS, 
TNF-α has been reported to stimulate the production of IL-10 by human 
microglia (Sheng et al., 1995). In a model of airway hyper-responsiveness, TNF-α 
has been shown to enhance Th2 responses, to up-regulate IL-5 and increase 
eosinophil recruitment in pulmonary fibrosis, a non-allergic model of lung 
inflammation (Zhang et al., 1997). In contrast, a recent study in model of 
allergic hyper-reactivity showed that etanercept treatment reduced eosinophil 
recruitment into the lungs (Nie et al., 2009), which may be associated with a 
reduced production of Th2 cytokine IL-5 essential for the bone marrow 
production, recruitment and activation of eosinophils (Holgate, 2004). Our data 
also showed a similar inhibitory effect of etanercept on IL-5 in the brains of CII 
immunized mice. However, the question of how etanercept regulated the 
production of IL-5 in the brain of CII immunized mice is still unclear and needs 
further investigation. We could not identify the cellular source of brain IL-5 in 
our experiments because this was beyond the scope of our work, but this might 
be important and could be done by immuno-histochemistry.  
In RA, IL-5 plays a role in the pathological mechanism of arthritis by 
promoting the production of specific IgG and IgE that can bind and activate mast 
cell degranulation and form immune complex with antigen, leading to the 
exacerbation of joint destruction (Xu et al., 2008). Since we could not detect IL-
5 mRNA in brains of mice from all experimental groups, but we could measure 
IL-5 protein in some, we concluded that there may be a contribution of IL-5 from 
the periphery into the brains of these CII immunized mice during the course of 
disease. It is also possible that etanercept may inhibit the peripheral production 
of IL-5. Although we could not detect IL-5 mRNA in the brain of CII immunized 
mice, the possibility that etanercept may inhibit the local production of IL-5 in 
the brain by CNS immune cells such as astrocyte should not be ignored. A study 
in CIA model also showed that anti-TNF-α therapy reduced astrocyte activity in 
the spinal cord of CIA mice (Inglis et al., 2007). To test these hypotheses, in 
vitro experiments of both peripheral and CNS immune cell cultures derived from 
CII immunized mice are required to investigate the regulatory effect of 
etanercept on the production of IL-5 in CIA model.  
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5.5.8 Effects of peripheral etanercept treatment on 
chemokines in brains of CII immunized mice 
TNF-α plays a critical role in inducing chemokine production and leukocyte 
trafficking. TNF blockade therapy in RA was shown to reduce the leukocyte 
migration to the joints and the expression of chemokines such as MCP-1 (Taylor 
et al., 2000). The inhibitory effect of TNF blockade therapy on chemokine 
expression has also been reported in neuro-inflammation. In the EAE murine 
model, p75 TNFR treatment decreased the expression of various chemokines 
including CCL3, CCL4, CXCL1 and CXCL2 in the CNS (Glabinski et al., 2003). Our 
data also showed that increased concentrations of brain CXCL1 protein in CIA 
mice was suppressed by etanercept treatment. TNF-α could induce the 
production of CXCL1 by brain microglia (Hayashi et al., 1995), astrocytes (Guo et 
al., 1998) and peripheral blood monocytes (Shea-Donohue et al., 2008) during 
peripheral inflammation. However, we could not determine the origin of the 
CXCL1 detected in the brain of CII immunized mice in our study. This could be 
done by appropriate immuno-histochemistry. In addition, an in vitro study of the 
effect of etanercept on the production of the immune cells isolate from CII 
immunized mice may help to address the underlying mechanism of the reduction 
in CXCL1 concentrations in the brains of CII immunized mice.  
5.5.9  Effects of peripheral etanercept treatment on growth 
factors in brains of CII immunized mice 
Angiogenesis and neovascularisation in inflammation, characterized by increases 
in several angiogenic factors such as VEGF and FGF, have been recently 
considered as a potential therapeutic target mechanisms of TNF blockade 
(Paleolog, 2002).  In RA patients, a decline in vascular permeability, along with a 
rapid reduction of VEGF concentration in serum were observed during early 
attenuation of joint swelling after anti-TNF therapy (Paleolog et al., 1998). 
Etanercept has also been reported to reduce VEGF concentrations in psoriatic 
lesions of psoriasis. However, the angiogenesis associated with changes in BBB 
permeability during neuroinflammatory processes has not been well elucidated. 
A recent report by (Wilson et al., 2009), showed TNF blockade resulted in a 
reduction in BBB permeability, suggesting a protective role of TNF blockade on 
BBB damage. However, that study did not address the effect of TNF blockade on 
changes in angiogenic factor concentrations. Our data showed significant 
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increases in brain VEGF protein concentrations in etanercept treated-CII 
immunized mice compared to those in control PBS treated-CII immunized mice. 
In addition, although the ANOVA did not detect a significant difference in FGF2 
gene expression levels between etanercept treated-CII immunized mice and 
those in control PBS treated-CII immunized mice, the FGF2 gene expression 
levels in etanercept treated-CII immunized mice were lower than to those in 
control PBS treated-CII immunized mice. This may be explained by the divergent 
effect of TNF-α that can be both a pro-angiogenic and an anti-angiogenic factor, 
depending on the TNF-α concentration and the duration of the exposure in the 
pathological conditions. These divergent roles for p55 and p75 TNFR contribute 
to different angiogenic signalling as described in a recent study. This report by 
Goukassian et al showed that p75 TNFR gene deficient mice failed to develop 
neovascularisation during post-ischemic recovery, along with reductions in VEGF 
and FGF2 concentrations (Goukassian et al., 2007). This finding suggested that 
p75 TNFR may be essential for the production of angiogenic factors during 
angiogenesis and neovascularisation. The data from that study implies that an 
increase in p75 TNFR level (etanercept) could possibly enhance the production 
of VEGF and FGF2 in the brain, rather than suppressing the production of these 
angiogenic growth factors. 
Summary 
In this section we demonstrated the effect of peripheral administration of 
etanercept on changes in inflammatory mediator profile associated with 
peripheral and local brain inflammation in the CIA arthritis model.  
This may provide preliminary evidence to support the clinical observation that 
etanercept could improve cognitive decline and depression in patients with 
chronic inflammatory diseases. However, a limitation of this study is that, 
because of its complexity, the experiment was conducted using small sample 
sizes (3-5 mice/group). Smaller samples yield larger standard errors and wider 
confidence intervals, which may impact the interpretion of the data by making it 
more difficult to determine significant differences between groups. In future 
studies, this experiment could be repeated using a greater group size to increase 
in statistical power, resulting in better biological interpretation. In addition, the 
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effect of etanercept on specific immune cell types involved in the production of 
these brain mediators associated with the inflammation in the CIA model is 
worthy of further study.   
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6.1  Introduction 
In Chapter 3 we reported increased concentrations of several inflammatory 
mediators that were observed in brains of CII immunized mice, particularly those 
with arthritis. In Chapter 4, we demonstrated that up-regulation of these 
inflammatory mediators in brains of arthritic mice may be associated with 
peripheral inflammation during the CIA experimental course. In Chapter 5, we 
reported that peripheral administration of etenercept treatment profoundly 
reduced the concentration of inflammatory cytokines in brains of CII immunized 
mice during the period of clinical manifestation of arthritis. One important 
question remains; do these inflammatory mediators up-regulated in the brain 
have biological functions and contribute to neurobiological changes in brains of 
CII immunized mice? To test this hypothesis, we investigated changes in 
hippocampal neurogenesis in CII immunized mice during the period of clinical 
manifestation. We also investigated whether TNF-blockade using the anti-
inflammatory drug etanercept (recombinant human soluble TNFR), could reverse 
the effects of peripheral inflammation on hippocampal neurogenesis. 
Accumulating evidence suggests that peripheral inflammation can contribute to 
neurobiological changes the brain. One neurobiological change that has been 
reported to be affected by peripheral inflammation is neurogenesis. Although 
the role of neurogenesis as part of hippocampal function is still unclear, some 
experimental evidence suggests it is involved in memory formation and in mood 
regulation. Impairment of hippocampal neurogenesis has been associated with 
cognitive decline in Alzheimer’s disease (AD), and in major depression (Ekdahl et 
al., 2003). Several studies have shown that peripheral inflammation generated 
by systemic administration of the innate immune response activator LPS, or by 
pro-inflammatory cytokines such as IL-1β, could cause impairment of 
hippocampal neurogenesis, leading to progressive cognitive deterioration (Monje 
et al., 2003); (Ekdahl et al., 2003); (Kaneko et al., 2006). However, less is 
known about the effect of peripheral inflammation on hippocampal neurogenesis 
in chronic inflammatory disease models.  
In this study, our hypothesis is that the activation of an immune response and 
systemic inflammation generated during the course of experimental arthritis 
may cause impairment in hippocampus neurogenesis. Data from the previous 
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result chapters (Chapter 4; Section 4.2.3, Section 4.2.4 and Section 4.2.5) has 
highlighted up-regulation of several inflammatory mediators, including TNF-α, 
IL-1β and IL-12 in the brains of CII immunized mice throughout the CIA 
experimental course. These brain inflammatory mediators, presumably 
generated by activated microglia, have been reported to promote the death of 
hippocampal progenitor cells in vitro (Monje et al., 2003). To investigate 
whether the impairment of neurogenesis observed during the development of 
arthritis is induced by a mechanism involving activation of the cytokine cascade, 
we applied TNF blockade using therapeutic recombinant soluble TNF receptor 
(Etanercept) peripherally into CIA mice. TNF-α is a potent pro-inflammatory 
cytokine that is thought to be an inducer of other inflammatory mediators in the 
inflammatory response. Data from our previous Chapter 5 (Chapter 5; Section 
5.2.3, Section 5.2.4) demonstrated that TNF blockade suppressed the up-
regulation of brain inflammatory mediators such as IL-1β and CXCL1. In addition, 
recent experimental evidence suggests that TNF-α may influence the survival of 
new neurons generated from the neural stem cells of the adult brain in the 
dentate gyrus subgranular zone (SGZ) and in the subventricular zone, lining the 
lateral ventricles (Iosif et al., 2006). TNF-α can trigger apoptosis and excito-
toxicity of dentate granule neurons through its receptor and intracellular 
signalling (Harry et al., 2008). Interestingly, Etanercept treatment has been 
shown to improve cognitive decline and depression symptoms in patients with 
chronic inflammatory diseases such as psoriasis, suggesting that Etanercept 
possibly reverses the impairment of hippocampal neurogenesis associated with 
chronic systemic inflammation (Tyring et al., 2006). Based on this experimental 
and clinical evidence, we propose a further hypothesis that TNF blockade may 
have a protective effect on dentate granule neurons by inhibiting the neurotoxic 
action of TNF-α and/or suppressing the neuro-inflammatory cascade initiated by 
TNF-α. Therefore, one aim of this chapter is to investigate whether systemic 
Etanercept treatment can reverse the impairment of hippocampal neurogenesis 
induced by peripheral inflammation in the brain of CIA mice during the course of 
experimental arthritis.  
The study in this Results chapter will be in 3 main stages.  
In the first stage we will evaluate the immunohistochemical expression of 
doublecortin (DCX), the neuronal marker for hippocampal neurogenesis in brain 
Chapter 6  284 
tissue of a normal DBA1 mouse. The optimal DCX antibody concentrations for 
both immunofluorescent staining and avidin-biotin-peroxidase immuno-
histochemistry were successfully evaluated. The biotin-peroxidase immuno-
histochemistry was used for quantitative analysis of hippocamapal neurogenesis.  
In the second stage, we conducted a CIA experiment using 10 DBA1 mice 
and performed DCX-immuno-histochemistry of brain of these CII immunized mice 
culled on day 42, using a biotin-peroxidase immuno-histochemistry technique. To 
investigate the changes in hippocampal neurogenesis that may be effect of 
peripheral inflammation, we then compared the number of DCX-positive cells 
the dentate gurus of CII immunized mice and those of naïve control mice 
sacrificed on the same day.  
In the third stage, we will investigate the effect of etanercept treatment 
on changes in hippocampal neurogenesis in CII immunized mice to test whether 
any changes may be associated with the peripheral inflammation.  
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6.2 Immunohistochemistry of Doublecortin (DCX) in 
mouse hippocampus 
Neurogenesis is the ongoing process of neuronal turnover in the dentate gyrus 
that regulates hippocampus-dependent learning and memory formation. The 
change in the number of proliferative and immature neurons during neuronal 
proliferation and maturation stages in the dentate gyrus reflects the level of 
hippocampal neurogenesis. In this study, we quantitatively evaluated 
neurogenesis by doublecortin (DCX) immuno-histochemistry. The first step was 
to optimize the concentration of DCX antibody for immuno-histochemistry to 
visualise the specific staining of DCX-positive neurons in the mouse dentate 
gyrus.  
6.2.1  Optimization of Doublecortin Immuno-histochemistry 
The concentration of DCX antibody for both immunofluorescent and avidin-
biotin-peroxidase immuno-histochemistry was optimized for the specificity of 
DCX immunostaining in mouse brains.  
Histologically, approximately 60% of the brain is fat, due to the myelin insulating 
the axons of neurons and glia. This high fat content may block the penetration of 
antibodies and thus lower the chance to identify target proteins. Therefore, in 
order to obtain successful staining, it is essential to optimize the ability of 
antibody to penetrate through the brain tissue. In the normal immuno-
histochemistry approach, the section mounted on the slide has only one side 
exposed, which limits the opportunity for reagents to penetrate the tissue 
completely. In contrast, the free-floating method enhances the permeability of 
antibody by exposing both sides of the section. Briefly, brain tissues from DBA1 
mice were cut using a cryostat machine set at 60 um. All the sections containing 
the hippocampus region were kept freely floating in an appropriate glass 
container during the staining process.  
6.2.1.1  Immunofluorescent staining in mouse brain tissue 
A study suggested that 1:500 is the appropriate dilution of DCX antibody used to 
develop an immunofluorescent staining in mouse brain tissue (Couillard-Despres 
et al., 2005). Thus, to optimize the concentration for staining, the DCX antibody 
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was diluted around this concentration; from 1:100, 1:200, 1:500 to 1:1000. The 
secondary antibody (1:500) containing Green Alexa fluor dye was added. 
Consistent with a previous report by Couillard-Despres et al., our results from 
confocal microscopy showed that 1:500 was the optimal dilution of DCX antibody 
because the best image of granule cell dendritic morphology was exhibited. As 
DCX is a cytoskeleton protein, the attached green fluorescent dye could be 
visualized in the cytoplasm of the soma and dendrite (Figure 6.1A). These DCX-
labelled cells, depicted by a neuronal cell body with extensive dendrites, 
gathered along the dentate gyrus (Figure 6.1B) 
 
 
Figure 6.1 Immunofluorescent staining of DCX   
(A) Confocal images (10 x magnification) of immature (doublecortin positive) neurons in the 
dentate gyrus of a DBA1 mouse labeled by Green AlexaFluor 488. (B) illustrates the 
anatomic location of dentate gyrus and the location of DCX staining. The red dashed lines 
showed the hippocampal region. 
A 
B 
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6.2.1.1.1 Triple immunofluorescent staining to define immature 
neuronal cells 
 
DCX is exclusively expressed on immature neurons, particularly during the 
maturation and differentiation stages, and has been widely used as an immature 
neuronal marker (Brown et al., 2003); (Rao and Shetty, 2004); (Couillard-Despres 
et al., 2005). Toward the final stage of neuronal maturation, precursor cells 
begin to express proteins typically present in mature neurons such as the nuclear 
neuronal marker NeuN (Brown et al., 2003). Neuronal precursor cells in the 
dentate gyrus of hippocampus begin to express DCX while actively dividing, and 
the expression of DCX lasts for up to 3 weeks as these neuronal precursor cells 
develop to be mature neurons. A reduction of DCX expression in these precursor 
cells begins after 2 weeks, and occurs at the same time that these cells begins 
to express NeuN, a marker for mature neurons (Brown et al., 2003). This 
suggests that neuronal precursor cells express different neuronal markers at 
different stages throughout the process of neurogenesis. For that reason, we 
used co-immunofluorescence of DCX and NeuN to distinguish the population of 
immature neurons in the dentate gyrus. Neurons in the immature differentiation 
stage should express only DCX, but not NeuN.    
Anti-DCX-Alexa green was used to define the morphology of immature neuron 
progenitor cells as mentioned. Anti-NeuN-Cy5, a nuclear antigen present in 
mature cells, was employed to identify the morphology of mature neuron cells. 
Thirdly, propidium iodide (PI) a fluorescent molecule that can bind DNA was 
used to stain the DNA inside the nucleus independent of the type and developing 
stage of cells. Therefore, overlapping PI staining with either DCX-Alexa green or 
NeuN-Cy5 demonstrates immature neuron cells and mature neuron cells, 
respectively. By this triple immunofluorescent staining, immature neuron cells 
can be clearly identified.  DCX-Alexa green staining shows a few immature 
neuron cells, characterized by a neuronal cell body with extensive dendrites 
(Figure 6.2A). The NeuN-Cy5 positive staining also shows a number of mature 
neuron cells (in blue) locating along the dentate gyrus and in the hippocampus 
(Figure 6.2B). The same population of these neurons was also stained positive for 
the nuclear DNA dye (propidium iodide) (Figure 6.2C).  
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Figure 6.2 Immunofluorescent staining of DCX, NeuN and PI 
(A) Confocal images (40 x magnification) show expression patterns of three neuronal 
markers in the dentate gyrus of a DBA1 mouse. Sections show the expression of 
doublecortin visualized with green fluorescence (A), the presence of NeuN was seen in blue 
(B), and the DNA staining by propidium iodide was detected as red (C).  
When these images are overlapped (Figure 6.3), it is clear that i) immature 
neuron cells doubly stained by DCX-Alexa green (green) and PI (red) exclusively 
distribute along the dentate gyrus; ii) mature neuron cells with dual staining of 
NeuN-Cy5 (blue) and PI (red) locate in the same area; iii) the absence of co-
A 
B 
C 
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localization of DCX-Alexa (green) and NeuN-Cy5 (blue) demonstrates that DCX is 
not on mature neuron cells, and may identify immature neurons.  
 
Figure 6.3 An overlay image of triple immunofluorescent staining of DCX, NeuN and PI in the 
dentate gyrus of a DBA1 mouse 
A confocal image (40 x magnification) shows co-expression of DCX together with PI 
observed in cells with no expression of NeuN, a mature neuronal marker. The circle 
surrounds a neuron that expresses both DCX and PI. However, this cell is negative for 
NeuN. 
6.2.1.2 Optimization of avidin-biotin-peroxidase immuno-
histochemistry 
Although these specific fluorescence labels successfully defined immature 
neuron cells and their distribution, it is necessary to conduct a further 
peroxidase staining to confirm that they locate in the dentate gyrus of the brain. 
Preliminary experiments demonstrated that the dilution (1:500) used in the 
fluorescence IHC protocol successfully detected DCX-positive cells. A further 10 
times dilution (1:5000) was suggested to identify DCX in the Avidin-biotin-
peroxidase immuno-histochemistry protocol to avoid non-specific binding and 
minimise background staining.  
The test dilutions of anti-DCX antibody have been varied from 1:1000, 1:5000, 
1:10,000. Normal goat IgG of the same concentrations as the primary antibody 
was used to generate negative controls for the immuno-histochemistry. The 
results from the light electron microscopy demonstrated that the DCX antibody 
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dilution at 1:1000 was the optimal for the Avidin-biotin-peroxidase immuno-
histochemistry protocol. However, at dilution 1:1000, there was some non-
specific staining of red blood cells and blood vessels observed on the slides (data 
not shown). This was the result of endogenous peroxidase in the blood vessels 
which reacts with the substrate DAB (3,3-diaminobenzidine). Therefore, to block 
the endogenous peroxidase in the brain sections, the treatment of 0.3% H2O2 in 
phosphate buffer for 30 min was used before primary antibody incubation. 
Consequently, most of the non-specific staining was eliminated and a higher 
intensity of DCX staining in the dentate gyrus was observed (Figure 6.4). DCX-
positive cells were distributed throughout the extent of the DG in normal DBA 1 
mice (Figure 6.5A). By contrast, the negative control antibody for immuno-
histochemistry did not show any non-specific binding (Figure 6.5B). DCX positive 
neurons in the DG exhibited the phenotype of immature neurons in their 
maturation stage (Jones et al., 2003). The cell bodies of DCX positive neurons 
were located in either the subgranular zone (SGZ) or granular cell layer (GCL) of 
the DG.  Apical dendrites of these DCX positive neurons extend their delicate 
dendritic tree branching into the molecular layer (ML) (Figure 6.6).  
 
Figure 6.4 Avidin-biotin-peroxidase immuno-histochemistry of DCX 
(A) An image (10 x magnification) from a light electron microscope shows 
immunoperoxidase-staining of DCX of immature (DCX-positive) neurons in the dentate 
gyrus of a DBA1. (B) Illustrates the anatomic location of dentate gyrus and the location of 
DCX staining.  
 
Chapter 6  291 
 
Figure 6.5 Avidin-biotin-peroxidase immuno-histochemistry of DCX in the dentate gyrus of a 
DBA 1 mouse 
An image (10 x magnification) represents the immunoperoxidase-staining for DCX and the 
distribution of DCX-positive neurons in the adult dentate gyrus of a DBA1 mouse (A). (B) 
shows a negative control of immuno-histochemistry generated by replacing DCX primary 
antibody with the same amount of normal goat IgG.  
 
Figure 6.6 High magnification of a representative image of DCX immuno-histochemistry in 
the dentate gyrus of a DBA1 mouse 
An image (20 x magnification) presents the morphology of DCX-positive neurons which 
have their cell bodies located either in the subgranular zone (SGZ) or the granular cell layer 
(GLC) of the dentate gyrus. These DCX-positive neurons extend their delicate dendritic tree 
branching into the molecular layer (ML) 
 
 
A B 
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6.3  Induction of arthritis in DBA1 mice 
6.3.1  CIA experimental procedure 
The aim of this experiment is to investigate whether the peripheral 
immune/inflammatory response occurring during arthritis in DBA1 mice induced 
by type II collagen can change hippocampal neurogenesis in the brain. In the 
second stage of this chapter, we conducted another CIA experiment and brains 
of these CII immunized mice were processed for doublecortin (DCX) immuno-
histochemistry in order to determine changes in the number of DCX-positive 
neurons.  Since DCX expression in neuronal precursor cells in the dentate gyrus is 
transient and persists for up to 3-4 weeks (Brown et al., 2003), it is difficult to 
estimate the optimal time point during the experimental course to determine 
changes in hippocampal neurogenesis in a chronic inflammatory model like the 
CIA model. However, a study by Wolf et al., in an AIA model showed that an 
increase in hippocampal neurogenesis was observed during the massive 
infiltration of inflammatory cells into the knee joint of arthritic mice. That study 
also showed a significant positive correlation between paw swelling and neuronal 
cell proliferation in these arthritic mice (Wolf et al., 2009b). These data suggest 
that change in hippocampal neurogenesis may occur during the clinical 
manifestation of arthritis in AIA mice. For that reason, we chose to determine 
changes in hippocampal neurogenesis on day 42 of the CIA experimental course. 
This time point is during the maximum clinical manifestation of disease. In 
addition, we determined changes in brain inflammatory mediator concentrations 
in CII immunized mice on day 42 in Chapter 3 (Section 3.2.3 and Section 3.2.4), 
and we found increases in several inflammatory mediator concentrations in 
brains of CII immunized mice at that time point. Therefore, we conducted 
another CIA experimental identical to the one in Chapter 3 (Section 3.2.1), but 
brains of mice in this CIA experiment were processed for DCX-immuno-
histochemistry. In doing so, we may be able to use the data of Chapter 3 
(Section 3.2.3 and Section 3.2.4) section to explain our data of changes in 
hippocampal neurogenesis in CII immunized mice at the same time point.  
10 DBA1 mice were immunized by intradermal injection of type II collagen in 
complete Freund’s adjuvant on day 0. On day 21, mice were given an i.p. 
booster injection of type II collagen dissolved in PBS. 6 DBA1 sex- and age-
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matched DBA1 mice were used as the antigen-naïve control group and were 
neither immunized nor challenged with type II collagen. Groups of both CII 
immunized and naïve control mice were sacrificed on day 42 and the brain of 
each mouse was fixed in formalin and cryoprotected in 30% sucrose buffer. Serial 
sections throughout the hippocampus were cut at 60-um and immunostained for 
DCX using the free-floating technique (Figure 6.7). 
 
Figure 6.7 The experimental procedure of collagen II-induced experimental arthritis model 
for hippocampal neurogenesis analysis 
DBA1 mice at 6-8 weeks of age were separated into two groups: i) naïve control, n=6 naïve 
control; ii) immunized mice, n=10 immunized mice.  Mice were immunized with 100µg type II 
bovine collagen + complete Freund’s adjuvant (CFA) at day 0 and then challenged on day 21 
with 200µg type II collagen. A group of 6 naïve DBA1 mice which were not immunized and 
not treated with type II collagen was use as a control group.  Serum and brains from control 
and CII-immunized mice were harvested at Day 42. The brain of each mouse from all 
experimental groups was fixed in formalin and cryoprotected in 30% sucrose buffer. Serial 
sections throughout the hippocampus were cut into 60-um sections and immunostained for 
DCX using the free-floating technique.  
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6.3.2  Clinical response 
 
Some of CII-immunized mice started to showed clinical signs of arthritis from day 
20 onwards and there were 6 out of the total 10 CII immunized mice that 
developed arthritis (60% incidence) on day 42 (Figure 6.8A). 4 of the 10 mice did 
not develop arthritis after immunization and challenge, and these formed a 
separate immunised but non-arthritis study group. CII immunized mice showed a 
significant increase in paw thickness compared to the naïve control mice 
(P<0.0001). The mean paw thickness and the mean arthritis score for the whole 
group of CII-immunized mice (n=10) on day 42 were 2.0 ± 0.08 mm and 3.9 ± 1.4 
respectively (Figure 6.8B), (Figure 6.8C).  
 
Figure 6.8 Development and severity of arthritis disease in CII immunized mice over 42 days 
of experimental arthritis course 
The signs of arthritis in CII immunized mice were monitored from day 16 after immunization 
onwards. (A) shows the percent incidence of arthritis in CII immunized mice, which was 
calculated from number of CII immunized mice with arthritis/total number of CII immunized 
mice used. The signs of arthritis were observed in CII immunized mice from day 20 onwards 
and there were 6 out of total 10 CII immunized mice developed arthritis on day 42. The mean 
clinical arthritis score and mean paw thickness were used as a clinical evaluation to 
measure the severity of joint inflammation in arthritic mice. (B) shows mean paw thickness 
of CII immunized mice which was calculated from the sum of the paw thickness of all mice 
divided by the number of mice. (C) shows mean clinical of CII immunized mice which was 
calculated from the sum of the clinical scores of all mice divided by the number of mice. 
Mean paw thickness, mean clinical score and %incidence in CII immunised mice (n= 10 CII 
immunised mice; filled squares) were compared with those values of naïve control mice (n = 
6 naïve control mice; open circles). Data represented as mean ± SEM. (n=10 CII immunized 
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mice). Statistical analysis of data was performed using two-way ANOVA for multiple 
comparison, compared with a group of control naïve mice; *P<0.05, ** P<0.01, *** P<0.001.  
6.4  Changes in number of DCX-positive neurons in 
the dentate gyrus in CII immunized mice 
To investigate whether peripheral inflammation affects changes in the 
neurogenesis, quantitative immuno-histochemistry of DCX positive neurons was 
performed in the brain sections containing the hippocampus region from mice of 
all experimental groups to determine changes in the number and the morphology 
of DCX-positive neurons in dentate gyrus of immunized mice compared to those 
in the control mice.   
6.4.1 Changes in number of DCX-positive neurons in 
the dentate gyrus in arthritic mice 
In this CIA experiment, there were 6 mice that developed arthritis. DCX-positive 
cells were detected in the dentate gyrus of both naïve control and arthritic 
mice. However, the light microscopy image showed that there were differences 
in the number of DCX-positive neurons between arthritic mice and naïve control 
mice (Figure 6.9A - Figure 6.9H and Figure 6.10A - Figure 6.10D). A reduction in 
the number of DCX-positive cells was observed in dentate gyrus of arthritic mice 
compared to those in naïve control mice. Figures 9A-9H and 10A-10D show the 
representative images of DCX-immuno-histochemistry in the dentate gyrus of 
arthritic mice with different arthritis scores. This was confirmed by the cell 
count data showing that the number of DCX-positive neurons in the dentate 
gurus of arthritic mice was significantly decreased; the mean number of DCX-
positive neurons in the dentate gyrus (arthritic versus naïve control) was 1322 ± 
285 cells versus 5417 ± 1673 cells (P = 0.0001) (Figure 6.11A). However, the 
reduction in DCX-positive neurons did not correlate with the arthritis score (r²= 
0.06948; P = 0.6138) (Figure 6.11B).  
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Figure 6.9 Changes in hippocampal neurogenesis in arthritic mice on day 42 
DCX-immuno-histochemistry in dentate gyrus of arthritic mice were randomly compared to 
those of naïve control mice. (A), (C), (E) and (G) show representative images of DCX 
immuno-histochemistry in the dentate gyrus of naïve control mice no 1, 2, 3 and 4 
respectively. (B), (D), (F) and (H) show representative images of DCX immuno-
histochemistry in the dentate gyrus of different arthritic mice (No. 24, 21, 30 and 28) with 
different arthritis scores (score 1, 6, 9 and 3 respectively). Clinical scores (RA scores) were 
calculated on the cull day 42. All images were at 10X magnification.  
Naïve control No. 1 
A. 
Arthritic mouse No. 24 (RA score 6) 
B. 
C. 
Naïve control No. 2 
D. 
Arthritic mouse No.21 (RA score 1) 
E. 
Naïve control No. 3 Arthritic mouse No. 30 (RA score 9 ) 
Naïve control No. 4 
F. 
G. H. 
Arthritic mouse No. 28 (RA score 3) 
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Figure 6.10 Changes in hippocampal neurogenesis in arthritic mice on day 42 
DCX-immuno-histochemistry images in the dentate gyrus of arthritic mice were randomly 
compared to those of naïve mice. (A) and (C) show representative images of DCX immuno-
histochemistry in the dentate gyrus of naïve control mice no 5 and 6 respectively. (B) and 
(D) show representative images of DCX immuno-histochemistry in the dentate gyrus of 
different arthritic mice (No. 22 and 27) with different arthritis scores (score 8 and 12 
respectively). Clinical scores (RA scores) were calculated on the cull day 42. All images 
were at 10X magnification. 
 
 
Figure 6.11 Changes in number of DCX-positive cells in dentate gyrus of arthritic mice on 
day 42  
(A) The dots represent the number of DCX positive cells in the hippocampus of individual 
naïve control mice (filled squares; n=6 naïve control mice) and arthritic mice (filled triangles; 
n=6 arthritic mice). The number of DCX positive cells in the hippocampus of mice from both 
naïve control and arthritic groups all experimental groups was determined by counting 
DCX-positive cells in every sixth serial brain section containing DCX immuno-
histochemistry in the dentate gyrus. Bars represent the mean values (***P < 0.01 by 
Student’s t-test). (B) Correlations of the number of DCX-positive cells and clinical (RA) 
score. Plots show relationships between the number of DCX-positive cells in the dentate 
gyrus of arthritic mice and their arthritic score (RA score) on day 42 analysed by Pearson’s 
correlation coefficient analysis.  
 
A. 
Naïve control No. 5 Arthritic mouse No. 22 (RA score 8) 
B. 
Naïve control No. 6 Arthritic mouse No 27 (RA score 12) 
C. D. 
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6.4.2 Changes in number of DCX-positive neurons in the 
dentate gyrus in non-arthritic mice 
Interestingly, immunized mice that did not develop arthritis (non-arthritic mice) 
also showed differences in the number of DCX-positive neurons compared to 
those in the naïve control mice. Figure 12A – 12I show the representative images 
of DCX-immuno-histochemistry in the dentate gyrus of non-arthritic mice 
compared to those in the control mice (Figure 6.12A – Figure 6.12I). Similar to 
arthritic mice, a reduction in hippocampal neurogenesis was also observed in 
non-arthritic mice. The mean number of DCX-positive neurons in the dentate 
gyrus (non-arthritic versus naïve control mice) was 1668 ± 329 cells versus 5417 ± 
1673 cells (P = 0.0025) (Figure 6.13).  
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Figure 6.12 Changes in hippocampal neurogenesis in non-arthritic mice on day 42 
DCX-immuno-histochemistry images of the dentate gyrus of non-arthritic mice were 
randomly compared to those of naïve control mice. (A), (C), (F) and (H) show representative 
images of DCX immuno-histochemistry in the dentate gyrus of naïve control mice no 1, 2, 3 
and 4 respectively. (B), (D), (G) and (I) show representative images of DCX immuno-
histochemistry in the dentate gyrus of different non-arthritic mice (No. 23, 25, 26 and 29) 
with clinical (RA) score 0. Clinical scores (RA scores) were calculated on the cull day 42. All 
images were at 10X magnification.  
A. 
Naïve control No. 1 
B. 
Non-arthritic mouse No.23 (RA score 0) 
Naïve control No. 2 
C. 
Non-arthritic mouse No.25 (RA score 0) 
F. 
D. 
Naïve control No. 3 Non-arthritic mouse No.26 (RA score 0) 
G. 
Naïve control No. 4 
H. 
Non-arthritic mouse No.29 (RA score 0) 
I. 
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Figure 6.13 Change in number of DCX-positive cells in dentate gyrus of non-arthritic mice 
on day 42 
The dots represent the number of DCX positive cells in the hippocampus of individual naïve 
control mice (filled squares; n=6 naïve control mice) and arthritic mice (filled triangles; n=4 
arthritic mice). The number of DCX positive cells in the hippocampus of mice from both 
naïve control and non-arthritic groups was determined by counting DCX-positive cells in 
every sixth serial brain section containing DCX immuno-histochemistry in the dentate 
gyrus. Bars represent the mean values (*P < 05; **P < 01; ***P < 001 by Student’s t-test) 
6.4.3 Comparison of changes in number of DCX-positive 
neurons in the dentate gyrus between naïve control, arthritic 
and non-arthritic mice  
A reduction in hippocampal neurogenesis indicated by decrease in number of 
DCX-positive neurons was observed in the dentate gyrus of both arthritic and 
non-arthritic mice compared to those of control naïve mice. One-way ANOVA 
followed by Bonferroni's post-hoc comparison tests demonstrated that there 
were significant differences in the number of DCX-positive neurons in the 
dentate gyrus among the three groups of mice (P < 0.0001) (Figure 6.14). The 
mean number of DCX-positive neurons in the dentate gyrus (arthritic versus 
naïve control) was 1322 ± 285 cells versus 5417 ± 1673 cells (P = 0.0001), while 
the mean number of DCX-positive neurons in the dentate gyrus (non-arthritic 
versus naïve control) was 1668 ± 329 cells versus 5417 ± 1673 cells (P = 0.0025). 
However, there was no significant difference in number of DCX-positive cells 
between arthritic and non-arthritic mice (Figure 6.14). This finding suggests that 
the immunization with CII/CFA may itself affect Hippocampal neurogenesis in a 
different mechanism of that affecting the joint in CII immunized mice.  
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Figure 6.14Changes in number of DCX-positive cells in dentate gyrus of arthritic and non-
arthritic mice on day 42 
The dots represent the number of DCX positive cells in the hippocampus of individual naïve 
control mice (filled squares; n=6 naïve control mice), non-arthritic mice (filled triangles; n=4 
non-arthritic mice) and arthritic mice (filled circles; n=6 arthritic mice). The number of DCX 
positive cells in the hippocampus of mice from all experimental groups was determined by 
counting DCX-positive cells in every sixth serial brain section containing DCX immuno-
histochemistry in the dentate gyrus. Bars represent the mean values (*P < 05; **P < 01; ***P 
< 001 by one-way ANOVA.) 
6.5 Effect of etanercept on hippocampal 
neurogenesis in CII immunized mice  
Data from the previous section of this Chapter 6 (section 6.4) showed a 
reduction of neurogenesis, indicated by a decrease in number of DCX-positive 
cells in the dentate gyrus of CII immunized mice on day 42. In Chapter 3 (Section 
3.2.3 and Section 3.2.4), we demonstrated up-regulation of several 
inflammatory mediators, including of IL-1α, IL-2, IL-5, IL-10, IL-13, CXCL1, 
CXCL10, VEGF and FGF2 in the brain of CII immunized mice at the same time 
point (day 42). This data from Chapter 3 combined with data in this chapter 
suggested that the reduction in neurogenesis in CII immunized mice may be 
associated with up-regulation of inflammatory mediators in the brain of CII 
immunized mice. In Chapter 5 (Section 5.2.3 and Section 5.2.4), we 
demonstrated that peripheral administration of etanercept treatment profoundly 
inhibited the production of inflammatory mediators, including TNF-α, IL-12 in 
brains of CII immunized mice during the period of clinical manifestation of 
arthritis. We hypothesized that the inhibitory effect of etanercept on 
inflammatory mediator production in the brain may also contribute to the 
protective effect against a reduction in hippocampal neurogenesis in CII 
immunized mice. We therefore conducted another CIA experiment, similar to 
the CIA experiment in Chapter 5 (Section 5.2.1). In this third stage of this 
chapter, we analysed changes in hippocampal neurogenesis in etanercept-
treated immunized mice compared to those of PBS-treated immunized mice and 
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control naïve mice on day 14 (pre-onset and pre-etanercept treatment time 
point), day 32 and day 35 (2 time points during the period of development of 
arthritis).  
6.5.1  Administration of etanercept and induction of arthritis 
in DBA1 mice; CIA experimental procedure 
Nineteen DBA1 mice were immunized by intradermal injection of type II collagen 
in Freund’s complete adjuvant on day 0. On day 14, 3 CII (collagen type II) 
immunized mice (Group 1) were sacrificed and the brains and serum of these 
mice were harvested for the measurement of inflammatory mediator levels 
before the second immunization on day 21. There was no CII immunized mice in 
Group 1 that developed arthritis on day 14. The other 16 CII immunized mice 
were randomly divided into 2 groups of 8, namely the treatment and placebo 
groups. From day 18 onwards, CII immunized mice of the treatment group 
received Etanercept (300 µg/mice, i.p.) every 3 days, while the placebo group 
received PBS (i.p.) every 3 days. The signs of arthritis in CII immunized mice 
were monitored from day 16 after immunization onwards and arthritis severity 
scores in this experiment were verified independently by Dr. Bernard Leng. CII 
immunized mice from both groups were re-challenged by intraperitoneal 
injection of collagen II in PBS on day 21. CII immunized mice in the placebo 
group started to show sign of arthritis earlier (day 19) than those of the 
treatment group (day 21). 3 CII immunized mice of the treatment group (Group 
2) and 3 CII immunized mice of the placebo group (Group 3) were sacrificed and 
serum and brains of these CII immunized mice were harvested on day 32. CII 
immunized mice of both treatment and placebo groups (Group 4 and Group 5; 5 
CII immunized mice/group) were sacrificed and serum and brains of these CII 
immunized mice were harvested on day 35; which is the peak day of disease. 
Another 11 sex- and age-matched untreated DBA1 mice were used as antigen-
naïve control mice. These naïve control mice were neither sensitized with type II 
collagen nor given etanercept treatment. 3 naïve control mice were sacrificed 
on day 14, and a further 3 and 5 naïve control mice were sacrificed on day 32 
and day 35 respectively. The brains of all experimental groups of mice were 
harvested and fixed in formalin and cryoprotected in 30% sucrose buffer. Serial 
60-um sections throughout the hippocampus were cut and immunostained for 
DCX using the free-floating technique (Figure 6.15). 
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Figure 6.15 Administration of etanercept and CIA experimental procedure for hippocampal 
neurogenesis analysis 
19 DBA1 mice at 6-8 weeks of age were immunized with 100µg type II bovine collagen + 
complete Freund’s adjuvant (CFA) at day 0. On day 14, 3 CII immunized mice in Group 1 
were culled and brains and serum of these CII immunized mice from group 1 (3 mice/group) 
were harvested. At this time point, another 3 naïve control mice, which were given neither 
sensitized with type II collagen, were also culled and their brains and serum samples were 
used as controls to compared changes in brain inflammatory mediators with those of CII 
immunized mice culled on day 14. On day 18, CII immunized mice were randomly divided 
into 2 groups (8 CII immunized mice/group), which were a treatment group and a placebo 
group.  From this day onwards, 300 µg/mouse etanercept was administrated (i.p.) to CII 
immunized mice of the treatment group every 3 days, while PBS was injected to CII 
immunized mice of the placebo group every 3 days. CII immunized mice of both groups 
were challenged on day 21 with 200µg type II collagen. From day 21 onwards, etanercept 
treated CII immunized mice of etenercept group were randomly divided into 2 groups, 
namely Group 2 and Group 4. etanercept treated CII immunized mice in Group 2 (3 CII 
immunized mice/group) were culled and brains of these CII immunized mice were harvested 
on day 32, while etanercept treated CII immunized mice in Group 4 (5 CII immunized 
mice/group) were culled and brains of these CII immunized mice were harvested on day 35. 
Similarly, PBS treated CII immunized mice in the placebo group was randomly divided into 2 
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groups, namely Group 3 and Group 5. PBS treated CII immunized mice in Group 2 (3 CII 
immunized mice/group) were culled and brains of these CII immunized mice were harvested 
on day, while PBS treated CII immunized mice in Group 4 (5 CII immunized mice/group) were 
culled and brains of these CII immunized mice were harvested on day 35. Another 8 naïve 
control mice were culled on the day indicated (3 naïve mice for day 32 and 5 naïve mice for 
day 35) and their serum and brain were used as controls. Brains from mice of all 
experimental groups were collected and brains processed for DCX immuno-histochemistry. 
6.5.2  Effect of etanercept on the development of collagen 
induced arthritis (CIA) 
6.5.2.1 Effect of etanercept on the severity of arthritis in CII immunized 
mice on day 32 
CII immunized mice in the treatment Group 2 (n=3) and the placebo Group 3 
were given etanercept (300 µg/mouse every 3 day) and PBS (placebo) 
respectively from day 18 after immunization onwards. Mice of both Group 2 and 
Group 3 were sacrificed on day 32. Some CII immunized mice in both Group 2 
and Group 3 started to show signs of arthritis from day 18 onwards. In addition, 
by day 32, there were 2 etanercept-treated CII immunized in Group 2 (66.66 % 
incidence), and 2 PBS-treated CII immunized mice in Group 3 (66.66 % incidence) 
developed arthritis. In this very small study sub-group, this suggests that 
etanercept treatment did not have an effect on the onset of disease and the 
incidence of disease in CII immunized mice in treatment Group 2 (Figure 6.16A). 
However, a significant reduction in mean paw thickness was observed in 
etanercept-treated mice in Group 2 compared to those in PBS-treated CII 
immunized mice (Figure 6.16B). The mean paw thickness of mice in Group 2 and 
3 (etanercept-treated versus PBS-treated) was 2.0 ± 0.1 mm versus 2.3 ± 0.3 mm 
(P = 0.084), while the mean clinical score of mice in Group 2 and 3 (etanercept-
treated versus PBS-treated) was 4 ± 2.1 versus 8 ± 4.2 (P = 0.029) (Figure 6.16C). 
However, the mean paw thickness and mean arthritis score of etanercept-
treated immunized mice was also significantly higher than those in naïve control 
mice. The mean paw thickness of mice (etanercept-treated versus control naïve) 
was 2.0 ± 0.1 mm versus 1.8 ± 0.0 mm (P = 0.0008). This suggests that 
etanercept treatment seemed to ameliorate joint inflammation in CII immunized 
mice, but not completely inhibit the onset and progression of arthritis on day 32, 
at least as seen in this small subset. 
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Figure 6.16 Effect of etanercept on severity of arthritis in CII immunized mice on day 32  
CII immunized mice in Group 2 (n=3 CII immunized mice/group blue line) were given 
injections from days 18 onwards before collagen immunization with 300 µg etanercept every 
3 days. 3 CII immunized mice in Group 3 were given PBS as placebo (n=3 CII immunized 
mice/group red line). Mice in both Group 2 and Group 3 were sacrificed on day 32. The signs 
of arthritis in CII immunized mice were monitor from day 16 after immunization onwards. (A) 
shows the percent of incidence of arthritis in etanercept-treated and PBS-treated CII 
immunized mice, which was calculated from number of CII immunized mice with arthritis per 
group/total number of CII immunized mice used per group. Mean clinical arthritis score and 
mean paw thickness were used as a clinical evaluation to measure the severity of joint 
inflammation in arthritic mice. (B) shows mean paw thickness of etanercept-treated and 
PBS-treated CII immunized mice which was calculated from the sum of the paw thickness of 
all mice in each group divided by the number of mice per group. (C) shows mean clinical 
score of etanercept-treated and PBS-treated CII immunized mice which was calculated from 
the sum of the clinical scores of all mice in the each group divided by the number of mice 
per group. Mean paw thickness, mean clinical score and %incidence in CII immunised mice 
(n= 3/group) were compared with those values of naïve control mice (n = 3 naïve control 
mice; green line). These naïve control mice were neither sensitized with type II collagen nor 
given etanercept treatment. Data represented as mean ± SEM. (n=6 CII immunized mice). 
Statistical analysis of data was performed using two-way ANOVA for multiple comparison, 
compared with a group of control naïve mice; *P<0.05, ** P<0.01, *** P<0.001. 
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6.5.2.2  Effect of etanercept on severity of arthritis in CII immunized 
mice on day 35. 
By day 35, the etanercept treatment seemed to prevent the arthritis disease 
progression in the etanercept-treated CII immunized mice in Group 4.  
Firstly, etanercept treatment delayed the disease onset and significantly 
reduced disease incidence compared with the PBS-treated arthritis controls 
(P=0.0002). Mice in Group 4 (n=5) started to develop arthritis on day 19 days 
after immunization in the PBS-treated group, compared with 33 days after 
immunization in the etanercept-treated Group 5 (n=5) (Figure 6.17A). There was 
only 1 etanercept-treated CII immunized mouse that developed arthritis (20% 
incidence), compared with 3 arthritic mice in the PBS-treated group (60% 
incidence).  
Secondly, etanercept significantly decreased mean paw thickness of 
etanercept-treated CII immunized mice compared to those of PBS-treated CII 
immunized mice. The mean paw thickness of mice in Group 4 and 5 (etanercept-
treated versus PBS-treated) was 2.1 ± 0.2 mm versus 2.8 ± 2.1 mm (P < 0.0001) 
(Figure 6.17B).  
Thirdly, a significant reduction in mean clinical score was observed in 
etanercept-treated CII immunized mice compared to those of PBS-treated CII 
immunized mice. The mean clinical score of mice in Group 4 and 5 (etanercept-
treated versus PBS-treated) was 2.8 ± 2.1 versus 0.4 ± 0.4 (P < 0.0001) (Figure 
6.17C). There was no significant difference in mean clinical score between 
etanercept-treated mice and naïve control mice. There was no significant 
difference in mean paw thickness and mean clinical score between etanercept-
treated CII immunized mice Group 4 and naïve control mice on day 35.  
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Figure 6.17 Effect of etanercept on severity of arthritis in CII immunized mice on day 35 
CII immunized mice in Group 4 (n=5 CII immunized mice/group blue line) were given 
injections from days 18 onwards before collagen immunization with 300 µg etanercept every 
3 days. 5 CII immunized mice in Group 5 were given PBS as placebo (n=5 CII immunized 
mice/group red line). Mice in both Group 4 and Group 5 were sacrificed on day 35. The signs 
of arthritis in CII immunized mice were monitor from day 16 after immunization onwards. (A) 
shows the percent incidence of arthritis in etanercept-treated and PBS-treated CII 
immunized mice, which was calculated from number of CII immunized mice with arthritis per 
group/total number of CII immunized mice used per group. Mean clinical arthritis score and 
mean paw thickness were used as a clinical evaluation to measure the severity of joint 
inflammation in arthritic mice. (B) shows mean paw thickness of etanercept-treated and 
PBS-treated CII immunized mice which was calculated from the sum of the paw thickness of 
all mice in each group divided by the number of mice per group. (C) shows mean clinical of 
etanercept-treated and PBS-treated CII immunized mice which was calculated from the sum 
of the clinical scores of all mice in the each group divided by the number of mice per group. 
Mean paw thickness, mean clinical score and %incidence in CII immunised mice (n= 5 CII 
immunized mice/group) were compared with those values of naïve control mice (n = 5; 
green line). These naïve control mice were neither sensitized with type II collagen nor given 
etanercept treatment. Data represented as mean ± SEM. (n=10 CII immunised mice). 
Statistical analysis of data was performed using two-way ANOVA for multiple comparison, 
compared with a group of control naïve mice; *P < 05; **P < 01; ***P < 001. 
6.5.2.3  Overall severity of arthritis in etanercept-treated groups to 
PBS-treated groups 
Overall, there were 5 out of 8 PBS treated CII immunized mice from Group 3 and 
Group 5 (~62.5 % incidence) that showed clinical signs of arthritis from day 18. 
Etanercept treated-CII immunized mice showed a lower disease incidence 
compared to those in PBS treated-CII immunized mice. 3 out of 8 Etanercept 
treated CII immunized mice from Group 2 and 4 developed arthritis from day 18 
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(~37.5 % incidence) (Figure 6.18A). Clinical signs of arthritis were observed in 
PBS-treated CII immunized mice from Group 3 and 5 from day 19 after 
immunization onward and there were 5 out of 8 PBS-treated CII immunized mice 
developed arthritis (62.5% incidence). The cumulative mean paw-swelling 
diameter of all PBS-treated CII immunized mice from Group 3 and Group 5 (n=8) 
was 2.1 ± 0.2 mm, which was significantly higher than those in naïve control 
mice (1.8 ± 0.0 mm; P< 0.0001). Etanercept-treated CII immunized mice showed 
significantly less swelling than PBS treated CII immunized mice (2.1 ± 0.2 mm; P 
<0.0001). Two-way ANOVA analysis also indicated that the cumulative mean of 
swelling diameter of Etanercept-treated CII immunized mice was significantly 
higher than those in control mice (1.8 ± 0.0 mm; P= P <0.0001) (Figure 6.18B). 
The cumulative mean arthritis score of Etanercept-treated CII immunized mice 
was significantly lower than those of PBS treated CII immunized mice (2.25 ± 
1.21 versus 3.75 ± 1.35) (Figure 6.18C). A summary of number of arthritic mice, 
mean arthritis score, maximum arthritis score, mean paw diameter of 
etanercept-treated and PBS-treated CII immunized mice is presented in Table 1. 
Overall, our data suggest that etanercept treatment before the onset of disease 
attenuated arthritis disease severity in CII immunized mice. 
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Figure 6.18 Effect of etanercept on severity of arthritis in all CII immunized mice in Group 2, 
3, 4 and 5 
CII immunized mice in Group 2 and Group 4 (n=8 CII immunized mice for both groups; blue 
line) were given injections of 300 µg etanercept every 3 days from days 18 onwards, before 
collagen immunization. 3 CII immunized mice in Group 3 and Group 5 were given PBS as 
placebo treatment (n=8 CII immunized mice for both groups; red line). Mice in both Group 4 
and Group 5 were sacrificed on day 32, while mice in both Group 4 and Group 5 were 
sacrificed on day 35. The signs of arthritis in CII immunized mice were monitored from day 
16 after immunization onwards. (A) shows the cumulative percent of incidence of arthritis in 
all etanercept-treated and all PBS-treated CII immunized mice, which was calculated from 
number of CII immunized mice with arthritis per group/total number of CII immunized mice 
used per group. Cumulative mean clinical arthritis score and cumulative mean paw 
thickness were used as a clinical evaluation to measure the severity of joint inflammation in 
arthritic mice. (B) shows cumulative mean paw thickness of all etanercept-treated and all 
PBS-treated CII immunized mice which was calculated from the sum of the paw thickness of 
all mice in each group divided by the number of mice per group. (C) shows cumulative mean 
clinical of all etanercept-treated and all PBS-treated CII immunized mice which was 
calculated from the sum of the clinical scores of all mice in the each group divided by the 
number of mice per group. Cumulative mean paw thickness, cumulative mean clinical score 
and cumulative %incidence in CII immunised mice (n= 8 CII immunized mice/group) were 
compared with those values of naïve control mice (n = 8; green line). These naïve control 
mice were neither sensitized with type II collagen nor given etanercept treatment. Data 
represented as mean ± SEM. (n=16 CII immunized mice). Statistical analysis of data was 
performed using two-way ANOVA for multiple comparison, compared with a group of 
control naïve mice; *P < 05; **P < 01; ***P < 001. 
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Group 
 
Treatment 
 
 
Day of 
harvesting 
 
Arthritic/total 
number of 
mice 
 
Mean 
Arthritis 
scores 
 
Maximum 
Arthritis 
scores 
 
Mean 
Paw    
Diameter 
(mm) 
 
2 
 
Etanercept 
 
32 
 
2/3 
 
4.0 ± 2.1 
 
7 
 
2.1 ± 0.1 
 
3 
 
PBS 
 
32 
 
2/3 
 
4.7 ± 2.4 
 
8 
 
2.1 ± 0.3 
 
4 
 
Etanercept 
 
35 
 
1/5 
 
0.4 ± 0.4 
 
2 
 
1.9 ± 0.0 
 
5 
 
PBS 
 
35 
 
3/5 
 
2.8 ± 2.1 
 
11 
 
2.1 ± 0.2 
Table 6.1 Numbers of arthritic mice, mean arthritis scores, and mean swelling scores of CIA 
mice in etanercept-treated and PBS-treated groups 
Etanercept-treated mice and PBS-treated mice (Group 2 and 3) were sacrificed on day 32, 
while etanercept-treated mice and PBS-treated mice (Group 4 and 5) were sacrificed on day 
35. Numbers of immunized mice developed arthritis from each time point group were 
counted on the harvesting day. Mean arthritis scores (total arthritis score/number of mice in 
the group), maximum arthritis score and mean swelling of immunized mice from each 
treatment time point group were calculated on the cull day. 
6.5.3 Changes in hippocampal neurogenesis in CII 
immunized mice before the onset of arthritis on day 14. 
Data from the previous section of this Chapter 6 (Section 6.4) showed a 
reduction in neurogenesis in CII immunized mice on day 42; during the period of 
clinical disease. However, it still remained unclear whether the reduction in 
neurogenesis is actually associated with peripheral inflammation. We therefore 
analysed the change in neurogenesis in CII immunized mice compared to those in 
naïve control mice before the disease onset. 14 days after the primary 
immunization on day 1, there were no CII immunized mice (n=19) that developed 
arthritis. We randomly sacrificed 3 CII immunized mice and the brains of these 
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mice were processed for DCX-immuno-histochemistry to investigate any change 
in hippocampal neurogenesis compared to brains from 3 naïve control mice 
harvested on the same day. Etanercept treatment (300 ug/animal i.p., every 3 
days) was not administrated to CII immunized mice until day 18 after 
immunization. Therefore, day 14 is also the control time point before etanercept 
treatment. The quantitative immuno-histochemistry of DCX positive neurons was 
performed on the brain sections from CII immunized mice and naïve control mice 
harvested on day 14 to investigate changes in hippocampal neurogenesis before 
etanercept treatment which was started on day 18. The microscopy images of 
stained brain sections showed no changes in the number of DCX positive neurons 
in the hippocampus of immunized mice compared to those of control untreated 
mice (Figure 6.19A - Figure 6.19F). This was confirmed by the cell count data 
showing that the number of DCX-positive neurons in the dentate gurus of 
arthritic mice was not significantly different from those in naïve control mice on 
day 14. The mean number of DCX-positive neurons in the dentate gyrus (CII 
immunized versus control) was 9528 ± 2040 cells versus 10938 ± 2244 cells (P = 
0.4643; n=3) (Figure 6.20). These data suggested that the changes in the 
hippocampal neurogenesis seen at day 42 may be associated with the subsequent 
peripheral inflammation. This also corresponded with data from Chapter 5 
(Section 5.2.3 and Section 5.2.4) also showing that there was no significant 
difference in brain inflammatory mediator concentrations in CII immunized mice 
on day 14 compared to those in naïve control mice. Our data from the previous 
chapter (Chapter 5 ; Section 5.2.3 and Section 5.2.4) combined with this 
hippocampal neurogenesis data of CII immunized mice on day 14 in this section 
suggest that brain inflammatory mediators in CII immunized mice may contribute 
to the reduction in hippocampal neurogenesis.  
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Figure 6.19 DCX immuno-histochemistry in the dentate gyrus of control untreated mice and 
CII immunized mice on day 14 
Control and CII immunized mice (3 mice/group) were sacrificed on day 14 and the brains of 
these were processed for DCX immuno-histochemistry. (A), (C) and (E) show representative 
images of DCX immuno-histochemistry in the dentate gyrus of control mice (numbers 1, 2 
and 3 respectively). (B), (D), (F) show representative images of DCX immuno-histochemistry 
in the dentate gyrus of CII Immunized mice. All images were 10X magnification.  
A. 
Naïve Control No. 1 
B. 
CII immunized mice No.1 
C. 
Naïve Control No. 2 CII immunized mice No.2 
D. 
E. 
Naïve Control No. 3 CII immunized mice No.3 
F. 
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Figure 6.20 Changes in number of DCX-positive cells in dentate gyrus of CII immunized 
mice on day 14 
The dots represent the number of DCX positive cells in the hippocampus of individual naïve 
control mice (filled squares; n=3 naïve control mice) and CII immunized mice (filled 
triangles; n=3 CII immunized mice) on day 14. Numbers of DCX positive cells in the 
hippocampus of mice from both naïve control and CII immunized groups were determined 
by counting DCX-positive cells in every sixth serial brain section containing hippocampal 
tissue. Bars represent the mean values. (*P < 05; **P < 01; ***P < 001 by Student’s t-test). 
 
6.5.4  Effect of etanercept on hippocampal neurogenesis 
during period of clinical manifestation of arthritis  
Data from Chapter 3 (section 3.2.3 and section 3.2.4) suggest that a reduction in 
hippocampal neurogenesis may be associated with peripheral joint inflammation 
that may due to inflammatory mediators that are up-regulated in brains of CII 
immunized mice during the period of clinical manifestation of arthritis on day 
42. In Chapter 5 (Section 5.2.3 and Section 5.2.4), we demonstrated that 
peripheral administration of etanercept resulted in decreases in brain 
inflammatory mediators, including TNF-α, IL-12 and IL-5. We therefore 
hypothesised that the reductions of these brain inflammatory mediators 
resulting from peripheral etanercept treatment may have the protective effect 
against the impairment of hippocampal neurogenesis in CII immunized mice.  
To determine whether the reduction in hippocampus neurogenesis in CII 
immunized mice could be prevented by anti-inflammatory drug therapy, 
etanercept (300 ug/animal i.p., every 3 days) was peripherally administrated to 
CII immunized mice from day 18 onwards. Etanercept-treated immunized mice 
(Group 2 and 4), PBS-treated CII immunized mice (Group 3 and 5), and naïve 
control mice were sacrificed on day 32 and day 35, which is typically during the 
period of clinical manifestation of arthritis. Brains of mice from all experimental 
groups were processed and immuno-histochemistry stained for DCX. In order to 
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compare the DCX staining pattern we used a strategy to compare subgroups 
using random images from one mouse in each group of naïve control mice, PBS-
treated and Etanercept treated CII immunized mice at each of the time points 
on day 32 and day 35. Each subgroup was labelled study groups A, B, C etc. A 
summary of the data showing arthritis score, paw diameter and number of DCX-
positive cells of individual mouse from each subgroup on each day is added at 
the end. 
6.5.4.1  Effect of etanercept on hippocampal neurogenesis in CII 
immunized mice on day 32 
There were 2 etanercept-treated CII immunized mice from Group 2 that 
developed arthritis on day 32. At that time point, there was 1 etanercept-
treated CII immunized mouse with no arthritis in that group. In Group 3, there 
were 2 PBS-treated CII immunized mice developed arthritis and 1 PBS-treated CII 
immunized mice that did not develop arthritis. We compared subgroups of 
images from one mouse in each group of naïve control mice, PBS-treated and 
etanercept-treated CII immunized mice. Each subgroup was labelled study 
groups as Set A, Set B and Set C. Since we had the same number of PBS-treated 
and etanercept-treated CII immunized mice that developed arthritis (n=2) on 
day 32, we decided to compare DCX immuno-histochemistry images from PBS-
treated mice with arthritis and etanercept-treated CII immunized mice that 
developed arthritis. Therefore, Set A and Set B consisted of DCX-staining images 
from etanercept-treated and PBS-treated CII immunized mice with arthritis and 
naïve control mice. Set C consisted of DCX-staining images from one etanercept-
treated mouse and one PBS-treated CII immunized mouse with arthritis and one 
naïve control mouse. The analysis plan of DCX immuno-histochemistry images of 
mice from all experimental groups is shown in Figure 6.21. 
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Figure 6.21 Analysis plan to compare DCX staining pattern in brains of PBS-treated, 
etanercept-treated CII immunized mice and naïve control mice on day 32 
DCX staining images from one mouse in each group of PBS-treated mice (n=3 PBS-treated 
mice; red mouse), naïve control mouse (n=3 naïve control mouse; green mouse) and 
etanercept-treated mice (n=3 etanercept-treated mice; blue mouse) were compared. DCX 
staining images of one PBS-treated mouse (red), one naïve control mouse (green) and one 
etanercept-treated mouse (blue) and were organized as subgroups, namely Set A, B and C. 
Set A and B consisted of DCX-staining images from PBS-treated, etanercept-treated CII 
immunized mice with arthritis and naïve control mice. Set C consisted of DCX-staining 
images from PBS-treated, etanercept-treated CII immunized mice without arthritis and a 
naïve control mouse.  
6.5.4.1.1  Effect of etanercept on the number of DCX-positive cells 
in CII immunized mice with arthritis on day 32 
Set A consisted of control mouse No.1, the PBS-treated arthritis mouse No.2 
(clinical score 8), and an etanercept-treated arthritis mouse No.1 (clinical score 
1). The microscopy images in Figure 6.22 showed differences in the number of 
DCX-positive neurons between the hippocampi of treated, untreated arthritic 
mice and control mice. A result from the cell count demonstrated that the 
hippocampus of the PBS-treated arthritis mouse No. 2 (clinical score 8) showed 
fewer DCX-positive cells compared to those of the naïve control mouse No. 1 
(4176 versus 8310 cells). Interestingly, the etanercept-treated mouse No.1 
showed a higher number of DCX-positive cells (10416 cells) compared to those of 
a naïve control mouse No.1 and PBS-treated arthritis mouse No.2 (Figure 6.22A - 
Figure 6.22C).  
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Figure 6.22 DCX immuno-histochemistry in the dentate gyrus of one naïve control, one PBS-
treated and one etanercept-treated CII immunized mouse in set A 
All the mouse brains from mice of set A were harvested on day 32. (A) shows a 
representative image of DCX immuno-histochemistry in the dentate gurus of control mice 
No.1. (B) shows a representative image of DCX of PBS-treated CII immunized mice No.2 
(clinical score 8). (C) shows a representative image of DCX of Etanercept-treated CII 
immunized mice No.1 (clinical score 1). RA score = clinical score. All images at 10X 
magnification. 
A similar pattern of changes in the number of DCX-positive cells in the dentate 
gyrus was observed in DCX staining images from naïve control, PBS-treated and 
etanercept-treated arthritic mice in Set B.  The PBS-treated-arthritic mouse No 
3 (clinical score 6) had less number of DCX-positive cells in the dentate gyrus 
compared those of naïve control mouse No 2 (Figure 6.23A and Figure 6.23B). 
The number of DCX-positive cells in dentate gyrus of the naïve control mouse 
was 9222 cells, while the number of DCX-positive cells in the dentate gyrus of 
the PBS-treated arthritis mouse No.3 was 2310 cells. The etanercept treated 
arthritic mouse No 3 (clinical score 6) showed a similar number of DCX-positive 
cells in the dentate gyrus (n=9204) compared to the naïve control mouse No.2, 
which higher than those of the PBS-treated CII immunized mice No.3 (Figure 
6.23A and Figure 6.23C). 
Naïve Control No.1 Placebo (PBS) 
Etanercept 
No.2 RA score 8 
No.1 RA score 1 
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Figure 6.23 DCX immuno-histochemistry in the dentate gyrus of one naïve control, one PBS-
treated arthritic and one etanercept-treated arthritic mouse in set B 
All mouse brains from mice of set B were harvested on day 32 and processed for DCX 
immuno-histochemistry. (A) shows a representative image of DCX immuno-histochemistry  
in the dentate gurus of the naïve control mice No.2. (B) shows a representative image of 
DCX immuno-histochemistry  in the dentate gurus of untreated CII immunized mice No.3 
(clinical  score 6). (C) shows a representative image of DCX immuno-histochemistry  in the 
dentate gurus of the etanercept-treated CII immunized mice No.3, (clinical score 6). RA 
score = clinical score. All images 10X magnification. 
A summary of the number of DCX-positive neurons in the hippocampus of 
individual naïve control mice, PBS-treated-arthritic mice and etanercept-treated 
arthritic mice and their arthritis scores is presented in Table 6.2. 
 
 
 
 
 
Naïve Control No.2 
Placebo (PBS) 
No.3 RA score 6 
Etanercept 
No.3 RA score 6 
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Individual Individual Number  
Mouse Clinical 
scores 
paw 
diameter 
(mm) 
of DCX-
positive 
neurons 
 
 Set A mice 
 
Naïve control mouse No.1 
 
0 
 
1.8 
 
8310 
 
 PBS-treated mouse No.2      
 
8 
 
2.5 
 
4176 
 
Etanercept-treated mouse No.1        
 
1 
 
2.2 
 
10416 
 
Set B mice 
 
Naïve control mouse No.2 
 
0 
 
1.8 
 
9222 
 
 PBS-treated mouse No.3     
 
6 
 
2.6 
 
2310 
 
Etanercept-treated mouse No.3        
 
6 
 
2.5 
 
9204 
Table 6.2 Individual arthritis score, individual paw swelling scores and number of DCX-
positive neurons of arthritic mice in etanercept-treated and PBS-treated groups 
Each set of mice (set A and set B) consisted of a naïve control mouse, a PBS treated 
arthritic mouse and an etanercept-treated arthritic mouse, which were sacrificed on day 32. 
DCX immuno-histochemistry and number of DCX-positive neurons in the dentate gyrus of 
mice in each set were compared. Individual arthritis score, paw diameter (sum of all 4 paws 
of each mouse divided by 4) and number of DCX positive neurons in the dentate gyrus of 
mice were calculated and measured on the cull day. 
6.5.4.1.2  Effect of etanercept on hippocampal neurogenesis of 
non- arthritic mice on day 32 
Set C of mice consisted of a naïve control mouse No. 3, a PBS-treated CII 
immunized mouse No.1 and an etanercept-treated CII immunized mouse No. 2. 
Both the PBS-treated and the etanercept-treated CII immunized mice did not 
develop arthritis by day 32. Despite this, there was a difference in the number 
of DCX-positive neurons observed in the dentate gyrus of both PBS-treated and 
etanercept-treated CII immunized mice with no arthritis compared to those of 
the naive control mouse (Figure 6.24A - Figure 6.24B). PBS-treated non-arthritic 
mouse No 1 had less DCX-positive cells in its dentate gyrus as compared with 
DCX-positive cells in the dentate gyrus of the naïve control mouse No 3 (n=2136 
cells versus 8904 cells). Interestingly, the dentate gyrus of the etanercept-
treated non arthritic mouse No 2 had a higher number of DCX-positive cells 
(n=7428) than those of the PBS-treated non arthritic mouse No 1 (Figure 6.24B - 
Figure 6.24C). A summary of number DCX-positive neurons in the dentate gyrus 
of individual mice PBS-treated non arthritic mouse, etanercept-treated non 
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arthritic mouse and the naïve control mouse in Set C and their clinical scores 
and paw diameters is presented in Table 6.3. 
 
Figure 6.24 DCX immuno-histochemistry in the dentate gyrus of one control, one PBS-
treated and one etanercept-treated CII immunized mouse in Set C (neither developed 
arthritis) 
All the mouse brains from the mice of Set C were harvested on day 32 and processed for 
DCX immuno-histochemistry. (A) shows a representative image of DCX immuno-
histochemistry  in the dentate gurus of the naïve control mice No.3. (B) shows a 
representative image of DCX immuno-histochemistry  in the dentate gurus of PBS-treated 
CII immunized mice No.1 (clinical score 0). (C) shows a representative image of DCX 
immuno-histochemistry  in the dentate gurus of the etanercept-treated CII immunized mice 
No.2 (clinical score 0). RA score = clinical score. All images at 10X magnification. 
  Number  
Mouse clinical 
scores 
paw 
diameter 
(mm) 
of DCX-
positive 
neurons 
 
Naïve control mouse No.3 
 
0 
 
1.8 
 
8904 
 
 PBS-treated mouse No.1      
 
0 
 
1.8 
 
2136 
 
Etanercept-treated mouse No.2       
 
0 
 
1.8 
 
7428 
Table 6.3 Individual arthritis score, individual paw swelling scores and number of DCX-
positive neurons of non-arthritic mice in etanercept-treated and PBS-treated CII immunized 
groups on day 32 
Set C consisted of a naïve control mouse No.3, PBS-treated non-arthritic mouse No.1 and 
etanercept-treated non-arthritic mouse No.2, which were sacrificed on day 32. DCX immuno-
histochemistry and number of DCX-positive neurons in the dentate gyrus of mice in each 
Naïve Control No.3 Placebo (PBS) 
Etanercept 
No.1 RA score 0 
No.2 RA score 0 
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set were compared. Individual arthritis score, paw diameter (sum of all 4 paws of each 
mouse divided by 4) and number of DCX positive neurons in the dentate gyrus of mice were 
calculated and measured on the cull day 32. 
6.5.4.1.3 Comparison of numbers of DCX-positive cells between 
etanercept-treated and PBS-treated groups on day 32 
Overall, the cell count data showed that DCX-positive neurons in the dentate 
gyrus of PBS-treated CII immunized mice on day 32 were significantly decreased 
compared to those in the naïve control mice on day 32. One-way ANOVA 
followed by Bonferroni's post-hoc comparison tests demonstrated that there 
were significant differences in the number of DCX-positive neurons in the 
dentate gyrus among the three groups of mice culled on day 32 (P = 0.0008) 
(Figure 6.25). The mean number of DCX-positive neurons in the dentate gyrus 
(PBS-treated CII immunized versus naïve control) was 2874 ± 1128 cells versus 
8814 ± 462 cells (P =0.0011) (Figure 6.25). The number of DCX-positive neurons 
in the dentate gyrus of etanercept-treated CII immunized mice was significantly 
increased compared to those in the PBS-treated-arthritic mice on day 32. The 
mean number of DCX-positive neurons in the dentate gyrus (etanercept-treated 
CII immunized versus PBS-treated CII immunized) was 9018 ± 1218 cells versus 
2874 ± 1128  cells (P = 0.0048) (Figure 6.25). However, there was no significant 
difference between the numbers of DCX-positive neurons in the dentate gyrus of 
etanercept-treated CII immunized compared to those of naïve control mice on 
day 32 (Figure 6.25). This finding suggests that etanercept treatment may have a 
protective effect against the impairment of hippocampal neurogenesis in CII 
immunized mice on day 32 
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Figure 6.25 Number of DCX-positive cells in dentate gyrus of PBS-treated and etanercept-
treated CII immunized mice on day 32 
The dots represent the number of DCX positive cells in the hippocampus of individual 
control untreated mice (filled squares; n=3 control untreated mice), CII immunized mice 
treated with PBS as the placebo group (filled triangles; n=3 CII immunized mice), and 
immunised etanercept-treated mice (filled circles; n=3 immunised etanercept-treated mice) 
on day 32. The number of DCX positive cells in the hippocampus of mice from all 
experimental groups was determined by counting DCX-positive cells in every sixth serial 
brain section containing DCX immuno-histochemistry in the dentate gyrus. Bars represent 
the mean values: Statistical analysis of data was performed using one-way ANOVA (*P<0.05, 
**P<0.01, ***P<0.001). 
6.5.4.2 Effect of Etanercept on hippocampal neurogenesis of CII 
immunized mice on day 35 
Quantitative immuno-histochemistry of DCX positive neurons was performed in 
the brain sections from immunized mice of the etanercept-treated Group 4 
(n=5), the PBS-treat Group 5 (n=5) and the naïve control roup (n=5) on day 35 to 
investigate the effect of etanercept on changes in hippocampal neurogenesis. At 
this time point, there were 3 out of 5 immunized mice from the PBS-treated 
Group 5 that developed arthritis. There was one out of 5 Etanercept-treated 
mouse that developed arthritis. Again, to compare DCX-staining pattern the 
dentate gyrus between PBS-treated, etanercept-treated and antigen-naïve 
control mice. Images of DCX immuno-histochamistry from one mouse in each 
group of naïve control, etanercept-treated and PBS-treated mice were randomly 
organized as subgroups, namely Set D, E, F, G and H. A summary of the data 
showing arthritis score, paw diameter and number of DCX-positive cells of 
individual mouse from each subgroup on each day is added at the end. The 
analysis plan for images of DCX-staining of mice from all experimental groups on 
day 35 is shown in Figure 6.26. 
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Figure 6.26 Analysis plan to compare DCX staining pattern in brains of PBS-treated, 
etanercept-treated CII immunized mice and naïve control mice on day 35 
DCX staining images from one mouse in each group of PBS-treated mice (n=5 PBS-treated 
mice; red mouse), naïve control mouse (n=5 naïve control mouse; green mouse) and 
etanercept-treated mice (n=5 etanercept-treated mice; blue mouse) were compared. DCX 
staining images of one PBS-treated mouse (red), one naïve control mouse (green) and one 
etanercept-treated mouse (blue) and were randomly organized as subgroups, namely Set D, 
E, F, G and H.  
Brain slices containing hippocampus from mice of all experimental groups on day 
35 were stained for DCX, and the differences in numbers of DCX positive cells 
between control, treated and untreated mice compared. The microscopy images 
showed that there were differences in the numbers of DCX-positive neurons 
between dentate gyrus of PBS-treated-arthritic mice and naïve control mice 
(Figure 6.27A - Figure 6.31A and Figure 6.27B - Figure 6.31B). PBS-treated CII 
immunized mice were likely to have less DCX-positive cells in their dentate gyrus 
compared to those of naïve control mice. Interestingly, PBS-treated-immunized 
mice, which did not develop arthritis also showed reduced numbers of DCX-
positive neurons compared to those of the naïve control mice (Figure 6.27A - 
Figure 6.31A and Figure 6.27B - Figure 6.31B). In comparison to PBS-treated CII 
immunized mice, etanercept-treated mice had a trend for more DCX-positive 
cells in their dentate gyrus (Figure 6.27B - Figure 6.31C). However, the number 
DCX-positive neurons in dentate gyrus of some etanercept-treated immunized 
mice were less than those of the naïve control mice (Figure 6.27A - Figure 
6.31C). 
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Figure 6.27 DCX immuno-histochemistry in the dentate gyrus of one naïve control, one PBS-
treated arthritic and one etanercept non-arthritic mouse in set D 
All the mouse brains from mice of Set D were harvested on day 35 and processed for DCX 
immuno-histochemistry. (A) shows a representative image of DCX immuno-histochemistry  
in the dentate gurus of a naïve control mouse No.4. (B) shows a representative image of 
DCX immuno-histochemistry  in the dentate gurus of the PBS-treated arthritic CII immunized 
mouse No.4, (clinical score 1). (C) shows a representative image of DCX immuno-
histochemistry  in the dentate gurus of the Etanercept-treated non-arthritic mouse No.4, 
(clinical score 0). RA score = clinical score. All images at 10X magnification. 
Naïve Control No.4 Placebo (PBS) 
No.4 RA score 1 
Etanercept 
No.4 RA score 0 
Chapter 6  324 
 
Figure 6.28 DCX immuno-histochemistry in the dentate gyrus of one naïve control, one PBS-
treated arthritic and one etanercept-treated non-arthritic mouse in Set E  
All the mouse brains from mice of Set E were harvested on day 35 and processed for DCX 
immuno-histochemistry. (A) shows a representative image of DCX immuno-histochemistry  
in the dentate gurus of the naïve control mice No.5. (B) shows a representative image of 
DCX immuno-histochemistry  in the dentate gurus of the PBS-treated arthritic untreated 
mouse No.6 (clinical score 11). (C) shows a representative image of DCX immuno-
histochemistry in the dentate gurus of etanercept-treated non-arthritic mouse No.5, (clinical 
arthritis score 0). RA score = clinical score. All images 10X magnification. 
 
 
Naïve Control No.5 Placebo (PBS) 
No.6 RA score 11 
No.5 RA score 0 
Etanercept 
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Figure 6.29 DCX immuno-histochemistry in the dentate gyrus of one naïve control, one PBS-
treated arthritic and one etanercept arthritic mice in Set F 
All the mouse brains from mice of Set F were harvested on day 35 and processed for DCX 
immuno-histochemistry. (A) shows a representative image of DCX immuno-histochemistry  
in the dentate gurus of the naïve control mouse No.7. (B) shows a representative image of 
DCX immuno-histochemistry  in the dentate gurus of the PBS-treated arthritic mouse No.8, 
(clinical score 4). (C) shows a representative image of DCX immuno-histochemistry in the 
dentate gurus of the etanercept-treated arthritic mouse No.7, (clinical score 2). RA score = 
clinical score. All images at 10X magnification. 
 
Naïve Control No.7 Placebo (PBS) 
No.8 RA score 4 
No.7 RA score 2 
Etanercept 
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Figure 6.30 DCX immuno-histochemistry in the dentate gyrus of one naïve control, one PBS-
treated non-arthritic and one etanercept non-arthritic mouse in Set G 
All the mouse brains from mice of Set G were harvested on day 35 and processed for DCX 
immuno-histochemistry. (A) shows a representative image of DCX immuno-histochemistry  
in the dentate gurus of the naïve control mouse No.6. (B) shows a representative image of 
DCX immuno-histochemistry  in the dentate gurus of PBS-treated non-arthritic mouse No.5, 
(clinical score 0). (C) shows a representative image of DCX immuno-histochemistry  in the 
dentate gurus of the etanercept-treated non-arthritic mouse No.6, (clinical score 0). RA 
score = clinical score. All images at 10X magnification. 
 
 
 
Naïve Control No.6 Placebo (PBS) 
No.5 RA score 0 
Etanercept 
No.6 RA score 0 
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Figure 6.31 DCX immuno-histochemistry in the dentate gyrus of one naïve control, one PBS-
treated non-arthritic and one etanercept non-arthritic mouse in Set H 
All the mouse brains from mice of Set H were harvested on day 35 and processed for DCX 
immuno-histochemistry. (A) shows a representative image of DCX immuno-histochemistry  
in the dentate gurus of the naïve control mice No.8. (B) shows a representative image of 
DCX immuno-histochemistry  in the dentate gurus of the PBS-treated non-arthritic mouse 
No.7, (clinical score 0). (C) shows a representative image of DCX immuno-histochemistry in 
the dentate gurus of the etanercept-treated non-arthritic mouse No.8, (clinical score 0). RA 
score = clinical score. All images at 10X magnification. 
A summary of the number of DCX-positive neurons in the dentate gyrus of 
individual naïve control mice, PBS-treated-arthritic mice and etanercept-treated 
CII immunized mice, their clinical scores and paw diameters is presented in 
Table 6.4.  
 
 
 
 
 
Naïve Control No.8 Placebo (PBS) 
No.7 RA score 0 
No.8 RA score 0 
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Individual Individual Number  
Mouse clinical 
scores 
paw 
diameter 
(mm) 
of DCX-
positive 
neurons 
 
 Set D mice 
 
Naïve control mouse No.4 
 
0 
 
1.8 
 
7422 
 
PBS-treated mouse No.4   
 
1 
 
1.8 
 
4638 
 
Etanercept-treated mouse No. 4   
 
0 
 
1.8 
 
5556 
 
Set E mice 
 
Control mouse No.2 
 
0 
 
1.8 
 
13860 
 
 Untreated mouse No.2   
 
11 
 
2.9 
 
2640 
 
Etanercept-treated mouse No. 2   
 
0 
 
1.8 
 
5034 
 
Set F mice 
 
Control mouse No.3 
 
0 
 
1.8 
 
7146 
 
 Untreated mouse No.5   
 
0 
 
1.8 
 
1680 
 
Etanercept-treated mouse No. 3   
 
0 
 
1.8 
 
3438 
 
Set G mice 
 
Control mouse No.1 
 
0 
 
1.8 
 
9276 
 
 Untreated mouse No. 5  
 
4 
 
2.1 
 
3414 
 
Etanercept-treated mouse No. 4   
 
2 
 
1.9 
 
7422 
 
Set H mice 
 
Control mouse No.1 
 
0 
 
1.8 
 
10998 
 
 Untreated mouse No.3   
 
0 
 
1.8 
 
3108 
 
Etanercept-treated mouse No.3.1 
 
0 
 
1.8 
 
7056 
Table 6.4 Inividual arthritis score, individual swelling scores and number of DCX-positive 
neurons of CII immunized mice in etanercept-treated and PBS-treated groups on day 35 
Each set of mice (Set D to H) consisted of one antigen-naïve control mouse, one PBS-
treated CII immunized mouse and one etanercept-treated CII immunized mouse, which were 
sacrificed on day 35. DCX immuno-histochemistry and number of DCX-positive neurons in 
the dentate gyrus of mice in each set were compared. Individual arthritis scores, paw 
diameters (sum of all 4 paws of each mouse divided by 4) and numbers of DCX positive 
neurons in the dentate gyrus of mice were calculated and measured on the cull day. 
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6.5.4.2.1  Comparison of numbers of DCX-positive cells between 
etanercept-treated and PBS-treated groups on day 35 
Overall, the cell count data demonstrated that DCX-positive neurons in the 
dentate gyrus of PBS-treated CII immunized mice were significantly decreased 
compared to those in of naïve control mice on day 35. One-way ANOVA followed 
by Bonferroni's post-hoc comparison tests demonstrated that there were 
significant differences in the number of DCX-positive neurons in the dentate 
gyrus among the three groups of mice on day 35 (P = 0.0005). The mean number 
of DCX-positive neurons in the dentate gyrus (PBS-treated CII immunized versus 
naïve control) was 516 ± 181 cells versus 1631 ± 456 cells (P < 0.001) (Figure 
6.32). The number of DCX-positive neurons in the dentate gyrus of etanercept-
treated CII immunized mice tended to be higher compared to those in the PBS-
treated CII immunized mice. The mean number of DCX-positive neurons in the 
dentate gyrus (etanercept-treated CII immunized versus PBS-treated CII 
immunized) was 5700 ± 1614 cells versus 3096 ± 1086 cells (Figure 6.32). 
However, post hoc analysis with Bonferroni correction showed that the 
difference in mean number of DCX-positive neurons in the dentate gyrus 
between etenercept-treated CII immunized and PBS-treated CII immunized was 
not statistically significant. Interestingly, the number of DCX-positive neurons in 
the dentate gyrus of etanercept-treated CII immunized mice was significantly 
lower compared to those in the naïve control mice. The mean number of DCX-
positive neurons in the dentate gyrus (etanercept treated CII immunized versus 
control) was 5700 ± 1614 cells versus 9786 ± 2736 cells (P < 0.05) (Figure 6.32). 
This data suggest that TNF-blockade therapy using etanercept showed no 
preventative effect on the impairment of hippocampal neurogenesis in the group 
of CII immunized mice on day 35. 
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Figure 6.32 Number of DCX-positive cells in the dentate gyrus of PBS-treated and 
etanercept-treated CII immunized mice on day 35, compared with antigen-naïve control mice 
The dots represent the number of DCX positive cells in the hippocampus of individual naïve 
control mice (filled squares; n=5), CII immunized mice treated with PBS as the placebo 
(filled triangles; n=5), and etanercept-treated mice (filled circles; n=5) on day 35. The 
number of DCX positive cells in the hippocampus of mice from all experimental groups was 
determined by counting of DCX-positive cells in every sixth serial brain section containing 
DCX immuno-histochemistry in the dentate gyrus. Bars represent the means values: 
Statistical analysis of data was performed using one-way ANOVA (*P<0.05, **P<0.01, 
***P<0.001). 
6.5.4.2.2 Correlation between hippocampal neurogenesis and 
arthritis score of PBS-treated CII immunized mice on day 35 
We investigated whether there was an association between the numbers of DCX-
positive neuron in the dentate gyrus of arthritic mice and their clinical score (RA 
score) on day 35. Using Pearson's correlation coefficient, we showed that the 
reduction in DCX-positive neurons did not correlated with the arthritis score (r²= 
0.868; P = 0.236) (Figure 6.33). This data is consistent with our data in the 
previous section of this Chapter 6 (section 6.4) showing that there was no 
significant correlation between the number of DCX-positive neurons in the 
dentate gyrus of arthritic mice and their RA score on day 42. We recognise that 
the low numbers of mice used in these experiments is likely to be a major 
limiting factor to this interpretation and would recommend that this is repeated 
with a sufficient number. 
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Figure 6.33 Correlation of the number of DCX-positive cells and RA score  
Plot showing the relationship between the number of DCX-positive cells in the dentate 
gyrus of arthritic mice and their clinical score (RA score) on day 35 analysed by Pearson’s 
correlation coefficient analysis. 
6.5.5  Longitudinal changes of hippocampal neurogenesis in 
PBS-treated CII immunized mice. 
We compared the number of DCX-positive cells in the dentate gyrus of untreated 
CII immunized mice and control mice at different time points in order to 
investigate the association between the development of inflammatory joint 
disease and changes in hippocapal neurogenesis. Significant reductions in the 
number of DCX-positive cells were observed in PBS-treated CII-immunized mice 
compared to those in the naïve control mice on day 32 and day 35. The mean 
numbers of DCX-positive cells in mice on day 32 (PBS-treated CII-immunized 
versus naïve control mice) were 2850 ± 1128 cells versus 8814 ± 462 cells (P = 
0.0011), while the mean numbers of DCX-positive cells on day 35 (PBS-treated 
CII-immunized versus naïve control mice) was 3096 ± 1086 cells versus 9786 ± 
2736 cells (P = 0.0009) (Figure 6.34).This suggests that the impairment in 
hippocampal neurogenesis occurred during the period of clinical manifestation of 
arthritis disease in CII immunized mice, but not during the period prior to the 
onset of disease.  
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Figure 6.34 Time-course of the number of DCX-positive neurons in the dentate gyrus of CII 
immunized mice  
Mice immunized with type II collagen (filled squares) were sacrificed on days 14 (n = 3 CII 
immunized mice), 32 (n = 3 CII immunized mice) and 35 (n = 5 CII immunized mice) and 
brains from CII immunized mice at all time points were harvested. Brain samples collected 
from untreated naïve mice (open circle) sacrificed on the days indicated were used as 
controls. Immuno-histochemistry of DCX was performed in brain tissue containing the 
hippocampus, and the number of DCX positive cells in the hippocampus of mice from all 
experimental groups was determined by counting DCX-positive cells in every sixth serial 
brain section containing DCX immuno-histochemistry in the dentate gyrus. Data represent 
means ± S.E.M. (n = 3-5 mice/group). Statistical analysis of data was performed using two-
way ANOVA compared with naïve control mice: (*P < 05; **P < 01; ***P < 001).   
We compared the number of DCX-positive cells in the dentate gyrus of CII 
immunized mice to investigate longitudinal changes in hippocampal neurogenesis 
with in the group of CII immunized mice. One-way ANOVA followed by 
Bonferroni's post-hoc comparison tests demonstrated that there were significant 
differences in the number of DCX-positive neurons in the dentate gyrus among 
the three groups of mice culled on day 14, day 32 and day 35 (P = 0.0004) 
(Figure 6.35). A decrease in the number of DCX-positive cells in the dentate 
gyrus was observed in CII immunized mice on day 32 and day 35 compared to 
those on day 14. The mean number of DCX-positive cells in CII immunized mice 
(day 32 versus day 14) was 2874 ± 1128 cells versus 9528 ± 2040 cells (P = 
0.0078), while the mean number of DCX-positive cells in CII immunized mice 
(day 35 versus day 14) was 3108 ± 1086 cells versus 9528 ± 2040 cells (P = 0.001) 
(Figure 6.35). There was a significant reduction in hippocampus neurogenesis on 
day 32 and day 35, which correspond to the development stage and the peak of 
arthritis in the CIA model respectively. There was no significant difference in the 
hippocampal neurogenesis between control mice and CII immunized mice on day 
14, suggesting that the reduction of hippocampus neurogenesis occurred after 
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the onset of arthritis and that this may be associated with the development 
peripheral joint inflammation. 
 
Figure 6.35 Longitudinal changes of DCX-positive neurons in dentate gyrus of CII 
immunized mice sacrificed on the day 14, 32 and 35 
Bars represent mean values: Statistical analysis of data was performed using one-way 
ANOVA (*P<0.05, **P<0.01, ***P<0.001). 
6.5.6 Longitudinal changes of hippocampal neurogenesis in 
antigen-naïve control mice. 
Time course experiments of doublecortin (DCX) expression in immature neurons 
of mouse adult dentate gyrus showed that hippocampal neurogenesis decreases 
with age (Kuhn et al., 1996). The detate gyrus of mice sacrificed on day 28 after 
administration of bromodeoxyuridine  (BrdU), a synthetic thymidine analogue 
which can be used as a marker of proliferation showed a significant reduction in 
BrdU positive neurons compared to those on day 14 (Couillard-Despres et al., 
2005). In addition, a study by Brown et al., 2003 showed a transient expression 
of DCX-positive neurons during adult neurogenesis, and the number of DCX-
positive neurons was also decreased over time (Brown et al., 2003).  
The expression of DCX in neurons persists for up to 3 weeks (Brown et al., 
2003), which could be a limitation of using DCX as the neuronal marker for 
testing changes in hippocampal neurogenesis and the effect of etanercept 
treatment on hippocampal neurogenesis in a chronic inflammatory disease like 
CIA model. We therefore compared the number of DCX-positive cells in the 
dentate gyrus of control mice to investigate the effect of age on hippocampal 
neurogenesis within the group of control mice.  
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We found no significant difference in the number of DCX-positive cells in 
the dentate gyrus of control mice at different time points (P = 0.5361 by one-
way ANOVA analysis) (Figure 6.36). This suggests that there was no effect of age 
on number of DCX-positive cells in the dentate gyrus, and therefore hippocampal 
neurogenesis of naïve control mice.  This also confirms that the reduction in 
numbers of DCX-positive neurons observed in the dentate gyrus of PBS-treated 
CII immunized mice may be due the effect of peripheral inflammation. 
Therefore we conclude that there is likely to be no effect of age affecting the 
result showing the impairment in hippocampal neurogesis in CII immunized mice 
in the previous sections of this Chapter 6 (Section 6.4 and Section 6.5.4). 
 
Figure 6.36 Longitudinal changes of DCX-positive neurons in dentate gyrus of control mice 
sacrificed on the day 14, 32 and 35  
Bars represent mean values: there were no significant differences. 
6.6 Result chapter 6: Summary of major findings.  
This aim of the chapter is to investigate changes in hippocampal neurogenesis in 
a murine chronic inflammatory disease model of rheumatoid arthritis, the 
collagen-induced arthritis (CIA) model. To investigate whether changes in 
hippocampal neurogenesis in collagen-II (CII) immunized mice is associated with 
peripheral inflammation, we tested the effects of anti-inflammatory treatment, 
using therapeutic TNF-blockade using recombinant human soluble TNF-receptor 
(etanercept) on changes of hippocampal neurogenesis in CII immunized mice. We 
found; 
1. An impairment in hippocampal neurogenesis was observed in CII immunized 
mice. This was observed by a reduction in number of DCX-positive cells in the 
dentate gurus compared with healthy age-matched antigen-naïve control mice. 
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2. This reduction in the number of DCX-positive cells in the dentate gurus was 
observed in CII immunized mice irrespective of whether they developed 
arthritis. In addition, there was no significant different in the reduced number of 
DCX-positive cells in the dentate gurus between arthritis and non-arthritis mice.  
3. There was no significant correlation between the number of DCX-positive cells 
in the dentate gurus and clinical scores of the CII immunized mice.  
4. There was no significant changes in hippocampal neurogenesis as estimated by 
the number of DCX-positive cells in the dentate gurus in CII immunized mice 
before the onset of arthritis (day 14) compared to those in antigen-naïve control 
mice. 
5. In the first of two experiments, etanercept treatment did not delay the onset 
of arthritis nor reduce the incidence at day 32, but attenuated the severity of 
arthritis by reducing the mean paw thickness and the clinical score compared to 
PBS-treated CII immunized mice. At this time point the ertanercept treatment 
protected against impairment of neurogenesis; there was no significant 
difference in the number of DCX-positive cells in the dentate gyrus between 
etanercept-treated CII immunized mice and antigen-naïve control mice. 
 In the second experiment, etanercept treatment did delay the onset of 
arthritis and reduced the incidence at day 35, as well as attenuating the severity 
of arthritis by reducing the mean paw thickness and the clinical score compared 
to PBS-treated CII immunized mice. At this time point the etanercept treatment 
did not protect against impairment of neurogenesis; there was a significant 
decrease in the number of DCX-positive cells in the dentate gyrus between 
etanercept-treated CII immunized mice and antigen-naïve control mice. 
However, a difference in the number of DCX-positive cells in the dentate gyrus 
between etanercept-treated CII immunized mice and PBS-treated CII-immunized 
mice was not statistically significant. 
6. Etanercept treatment seemed to have a protective effect on the brain and on 
the joints that appeared to be different at days 32 and 35. It may be that the 
disease process changes between these two time points. This aspects will 
require further experiments. 
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8. There was no effect of age involved in the reduction of hippocampal 
neurogenesis in CII immunized mice.  
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6.7 Discussion 
For clarity, I will set out the discussion in logical sections interpreting the results 
in sequence. I will summarise and draw conclusions from these at the end. 
6.7.1 The role of Doublecortin (DCX) in neuronal maturation 
in the adult hippocampus 
Doublecortin (DCX) is widely used as a marker in studies of hippocampal 
neurogenesis in both rodents and humans. Our data demonstrated the presence 
of DCX-positive cells with a neuronal-like morphology in the hippocampus of 
both antigen-naïve control and CII immunized mice. Triple-immunofluorescent 
staining demonstrated a lack of co-localization of DCX with NeuN, a neuronal 
marker of maturity, indicated an undifferentiated or immature phenotype, and 
this suggests that DCX-positive neurons are immature. These immature neurons 
developed during the process of hippocampus neurogenesis and have been 
demonstrated to play major roles in the induction of synaptic plasticity, leading 
to the encoding of new hippocampus-dependent memories. DCX is a 
microtubule-associated protein which is considered to be an important regulator 
of several steps in the process of neuronal maturation during neurogenesis.  
Neurogenesis in the dentate gyrus involves neural progenitor proliferation, 
neural cell production/differentiation/maturation, and final integration into the 
neuronal circuit network in the hippocampus (Li and Pleasure, 2010). The 
duration of the development of hippocampal granule neurons is usually about 
one or two months. Neuronal precursor cells are generated from neural stem 
cells in the subgranular zone of the dentate gyrus and continue to proliferate for 
a few more days. These neuronal precursor cells are characterized by the 
expression of the intermediate filament proteins glial fibrillary acidic protein 
(GFAP) and nestin. At approximately two weeks after mitosis, progenitors 
develop into either neuroblast or non-neuronal cells. Neuroblasts continue to 
elongate neurites and axons, and migrate from the subgranular zone to the 
granular layer of the dentate gyrus. Migrating neurons no longer express nestin, 
but the expression of DCX is up-regulated (Perera et al., 2008). DCX functions to 
regulate neuronal migration during development. DCX expression has been 
associated with neurite and axon elongation, and the generation of synapses 
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(Rao and Shetty, 2004). DCX gene-deficient mice showed morphological 
abnormalities in migrating neurons, including neuronal branching defects and 
shorter length of neuronal processes (Kappeler et al., 2006). At this stage, 
immature neurons develop primary apical dendrites and GABAergic synapses 
expressed on apical dendrite become excitatory. GABAergic synapses initially 
depolarize immature neurons and then gradually convert to hyperpolarization 
over a period of 2–3 weeks (Perera et al., 2008). Excitatory dendritic GABAergic 
synaptic activation during hippocampal neurogenesis plays a major role in the 
neuronal maturation and the encoding of new memory. The level of excitatory 
GABA signal indicates of the dynamic neuronal network activity, while GABAergic 
activation encodes input specific information (Ming and Song, 2005). In addition, 
GABAergic activation is also thought to be the initial step of immature neurons 
to integrate into the hippocampal neuronal circuit and extend their axonal 
projections along mossy fiber pathways to the CA3 pyramidal cell layer (Lledo et 
al., 2006). This is considered to be the most critical period of hippocampal 
neurogenesis since these immature neurons are selected for activation by 
external stimuli including environmental enrichment and spatial learning. These 
excitable immature neurons up-regulate NMDA receptors with the NR2B subunit 
and the presence of T-type Ca2+ channels and thus develop stronger electrical 
property for long-term potentiation (LTP), which is essential for encoding 
memory. DCX has been demonstrated to play a role in regulating the electrical 
property in the hippocampal immature neurons (Perera et al., 2008). DCX 
deficient mice showed a reduction in GABA-mediated synaptic activity in 
hippocampus neurons (Kerjan et al., 2009). This also suggests that DCX 
deficiency may also affect hippocampal-dependent memory function. Nyffeler et 
al demonstrated that an increase in the numbers of doublecortin (DCX) positive 
neurons in both subgranular zone and granule cell layers (SGZ-GCL) was 
associated with improvement in the working memory performance in rats 
(Nyffeler et al., 2010). This evidence suggests that DCX could be an efficient 
neuronal marker to analyse the absolute number and dendritic growth of 
immature neuron in the dentate gurus in the adult brain which reflects 
neurogenesis, memory formation, and cognitive function of the hippocampus. 
This is supported by several publications suggesting that DCX is a reliable and 
specific marker that reflects levels of adult neurogenesis and its modulation, 
since DCX is transiently expressed during the migration of immature neurons 
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(Brown et al., 2003); (Rao and Shetty, 2004); (Couillard-Despres et al., 2005). 
Using DCX-immuno-staining also provides the absolute number, the distribution 
and the differences in dendritic features of these immature neurons, which can 
reflect the pattern and dynamics of dendrite development (Plumpe et al., 2006). 
Several studies report the expression patterns of DCX in numerous combinations 
with markers of proliferation such as BrdU incorporation in the hippocampal 
dentate gyrus (DG) of animals. The in-vivo BrdU injection is the most commonly 
used method to study cell proliferation and survival in neurogenesis studies. 
However, there are several limitations using this approach to detect changes in 
neurogenesis. Firstly, the administration of BrdU can be toxic to animals since 
BrdU can interfere with DNA replication. Secondly, BrdU can be incorporated 
during DNA repair, resulting in inconsistent or partial labelling of proliferating 
cells (Ming and Song, 2005). Thirdly, BrdU can be non-specific to all types of 
proliferative cells, including neural stem cells, glial precursors or glial cells 
(Couillard-Despres et al., 2005). Thus, it is necessary to use other specific 
marker for the neuronal lineage to identify granular neurons in the 
hippocampus. This could be another advantage of using DCX-immuno-
histochemistry to study hippocampal neurogenesis in comparison of the in-vivo 
BrdU staining. This is because DCX specifically labels immature neurons in the 
dentate gyrus, which allows us to see the clear morphology of pyramidal neurons 
without co-staining with other markers. 
6.7.2 Reduction in hippocampal neurogenesis in CII 
immunized mice. 
An impairment in hippocampal neurogenesis has been implicated in mood and 
cognition disorders (Sahay and Hen, 2007); (Sahay et al., 2007). Several studies 
have demonstrated that antidepressants increase hippocampal neurogenesis in 
both animals and humans (Wang et al., 2008);  (Malberg et al., 2000); (Boldrini 
et al., 2009); (Jacobs et al., 2000). In addition, impairment in hippocampal 
neurogenesis may underlie the cognitive deficits seen in depression. Several 
animal behavioural studies showed that reduction or ablation of hippocampal 
neurogenesis in rodents had detrimental effects on hippocampus-dependent 
forms of cognition such as fear conditioning, long-term spatial memory and 
working memory (Saxe et al., 2006); (Winocur et al., 2006); (Snyder et al., 
2005). Accumulating evidence suggests that the patho-physiology of depression 
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might be associated with inflammation. Depression is common in chronic 
inflammatory diseases such as RA, multiple sclerosis (MS) and psoriasis. In 
addition, increases of pro-inflammatory cytokines including interleukin (IL)-1, IL-
6, IL-8, IL-12, interferon (IFN)-γ and tumor necrosis factor (TNF)-α have been 
reported in patients with depression (Schiepers et al., 2005); (Raison et al., 
2006). In animal models, peripheral inflammation induced by LPS has been 
shown to activate microglia to produce various brain inflammatory mediators, 
including IL-1β and IL-10 (Henry et al., 2009). The activation of microglia in the 
LPS-induced inflammation model has been reported to induce a reduction in 
hippocampal neurogenesis, which is associated with a cognitive decline in 
learning and memory (Ekdahl et al., 2003); (Monje et al., 2003). Taken together, 
this evidence suggests that suppression of hippocampal neurogenesis by 
inflammation may underlie the depression in chronic inflammatory disease.  
The data in this chapter demonstrated a significant reduction in a number of 
DCX-positive neurons in the dentate gyrus of collagen (CII)-immunized mice 
compared to those in antigen-naïve control mice on day 42. In addition, our 
longitudinal study showed that the reduction in hippocampal neurogenesis in 
these CII immunized mice occurred during the period of clinical manifestation of 
arthritis (day 32 and day 35), but not before the onset of disease on day 14. 
These findings suggest that the reduction in hippocampal neurogenesis may be 
associated with the peripheral inflammation associated with joint disease. The 
reduction in DCX positive cells in the dentate gyrus was described in several 
autoimmune disease models, including type II diabetic rats (Hwang et al., 2008) 
and autoimmune-prone cytokine B-cell-activating factor (Capuzzi et al.) 
transgenic mice (Crupi et al., 2010). However, our findings contrast with one 
previous study which demonstrated a transient increased in DCX positive cells in 
the dentate gyrus of antigen-induced arthritis (AIA) mice (Wolf et al., 2009b). In 
that study, an increase in hippocampal neurogenesis was observed during a 
particularly marked infiltration of inflammatory cells into the knee joint and the 
author suggested that this may be associated with the systemic activation of 
CD4-positive cells during the course of arthritis (Wolf et al., 2009b). There are 
several possible explanations that might underlie this contradictory data. Firstly, 
differences in the procedure for inducing arthritis and immuno-pathogenesis may 
account for contradictory results from the literature. Adjuvant induced arthritis 
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(AIA) is an arthritis model, induced by a single intradermal injection of complete 
Freund’s adjuvant (CFA) consisting of heat-killed Mycobacterium tuberculosis 
(Mt) in an oil-in water emulsion (Hossain et al., 2001). Unlike CIA, AIA is a 
transient model of arthritis in which antigens activate acute inflammation, 
leading to joint destruction. Polyarthritis rapidly develops around 10 days after 
immunization using adjuvant and the whole course of the disease lasts for 21 
days (Bendele, 2001). In addition, the AIA model is Th1-cell and neutrophil 
dependent, and complement-independent. There is no evidence demonstrating 
that B-cells play a role in the pathogenesis of AIA. By contrast, the immune 
response of CIA involves both CII-specific T-cells and B-cells, which produce 
antibodies to type II collagen. The difference in humoral immune response 
between the 2 arthritis models can be another explanation of the contradictory 
data. This is supported by evidence showing a reduction in DCX-positive cells in 
the dentate gyrus of transgenic mice over-expressing BAFF, which develop 
autoantibodies leading to an autoimmune syndrome of systemic lupus 
erythematosus, rheumatoid arthritis and Sjögren’s syndrome (Crupi et al., 2010).  
However, the role of B cells in neurogenesis needs to be further investigated. In 
addition, the precise effect of T cells on hippocampal neurogenesis is still 
controversial. A study by Wolf et al., suggeted that T cells enhance hippocapal 
neurogenesis in AIA model (Wolf et al., 2009b), which is supported by a study in 
transgenic mice lacking T cells (Ziv et al., 2006). However, it has also been 
reported that T cells could support and inhibit hippocampal neurogenesis (Wang 
et al., 2010). Secondly, the differences in the immuno-pathological mechanism 
of both arthritic models may cause different peripheral inflammatory mediator 
profiles. TNF, IFN-γ, IL-1, IL-6 and IL-17A are dominant in the circulation of AIA 
model, while several pro- and anti-inflammatory cytokines, including TNF-α and 
IL-1β, IL-6, IL-12, IL-1Ra, IL-10 and TGF-β, are highly expressed in the periphery 
of mice with CIA (Hegen et al., 2008).  Different inflammatory mediator profiles 
may cause different effects on hippocampal neurogenesis, therefore the effect 
of peripheral inflammation inducing changes in hippocampal neurogenesis may 
be contradictory in different arthritis models. 
Inflammation and inflammatory cytokines can affect hippocampal neurogenesis 
directly (Vallieres et al., 2002); (Monje et al., 2003); (Ekdahl et al., 2003). Our 
data in Chapter 1 and 2 showed increased in various inflammatory mediators 
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including TNF-α, IL-1α, IL-1β, IFN-γ, IL-2, IL-4, IL-5, IL-10, IL-13, CXCL1, CXCL10, 
VEGF and FGF2 in brains of CII immunized mice. It is possible that the reduction 
of neurogenesis observed in the CIA mice may be the result of the up-regulation 
of brain inflammatory mediators during the course of arthritis. Some of the 
inflammatory mediators, including IL-1α and IL-1β, that are increased in the 
brains of CII immunized mice in our study have been reported to have different 
regulatory effects on hippocampal neurogenesis. TNF-α (Seguin et al., 2009), IL-
1β (Kaneko et al., 2006) and IL-2 (Beck et al., 2005) have been demonstrated to 
be inhibitors of neurogenesis. CXCL10 not only exaggerates the brain 
inflammation by recruiting activated T cells into the brain, but also functions as 
a neuromodulator for immature neurons in the hippocampus (Muzio et al., 2010). 
CXCL10 has been shown to suppress hippocampal neurogenesis by inhibiting long-
term potentiation (LTP) in immature hippocampal neurons, probably via 
changing expression levels of synaptic proteins involved in synaptic transmission 
such as GABA receptor and NMDA receptor (Vlkolinsky et al., 2004); (Cho et al., 
2009). In contrast, IL-1α (Greco and Rameshwar, 2007), IL-4, IFN-γ (Butovsky et 
al., 2006), VEGF (Wang et al., 2007) and FGF2 (Jin et al., 2005) have been 
reported to support hippocampal neurogenesis. Therefore, the reduction in 
hippocampal neurogenesis observed in our CIA model may be due to the complex 
interplay between activated immune cells and inflammatory mediators. For 
example, an increase in hippocampal neurogenesis was observed in IL-2 deficient 
mice, along with up-regulation of brain IL-15, IL-12, CXCL10 and CCL2 (Beck et 
al., 2005). This finding suggests that IL-2 may either suppress hippocampal 
neurogenesis directly or via the production of other cytokines such as IL-15, IL-
12, CXCL10 and CCL2. Likewise, the detrimental effect of IL-1β on hippocampal 
neurogenesis may be regulated by IFN-α (Kaneko et al., 2006). However, it is not 
clear to what extent each individual cytokine contributes to the overall reduced 
hippocampal neurogenesis in CII immunized mice. Different concentrations of 
the same cytokines in the brain may also result in different effects on 
hippocampal neurogenesis. IFN-γ has been associated with pathology of CNS 
inflammation. IFN-γ (1000 ng/ml) activates the production of CXCL10 in 
microglia which could be detrimental to hippocampal neurogenesis (Ellis et al., 
2010). In contrast, activation of microglia by low concentrations of IFN-γ (20 
ng/ml) has been shown to support neurogenesis (Butovsky et al., 2006). 
Therefore, it will be necessary to conduct an in vitro study of hippocampal 
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neuronal progenitor cell culture and test the effects of different concentrations 
of cytokines on the differentiation and maturation of these cells.  
The mechanism, function and significance of the modulation of 
neurogenesis during inflammatory processes remain to be elucidated. It has been 
hypothesized that the same CNS immune response that blocks neurogenesis in 
the adult CNS under neurodegenerative conditions can also paradoxically support 
neurogenesis. This is supported by a study showing that neurogenesis is inhibited 
by LPS-activated microglia, but induced by the same microglia activated by IL-4 
or low concentration of IFN-γ (Butovsky et al., 2006). This could be a protective 
mechanism of the CNS against excessive inflammation in the brain, which may 
eventually cause irreversible neuronal loss or damage. In addition, peripheral 
and central cytokine signals have been shown to have different influences on 
hippocampal neurogenesis. A study has shown that peripheral administration of 
TNF-α resulted in suppression of neurogenesis, while intra-hippocampal injection 
of IL-1β and IL-6 caused increased neurogenesis (Seguin et al., 2009). This data 
suggest that cytokines produced locally in the brain under the condition of 
neuro-inflammation may play a protective role against excessive brain 
inflammation. Therefore, it is important to know the cellular source of 
inflammatory mediators up-regulated in brains of CII immunized mice in our 
study since cytokines from different sources (either peripheral circulation or 
CNS) may regulate neurogenesis differently.  
6.7.3  Effect of etanercept on impairment of hippocampal 
neurogenesis in CII immunized mice 
TNF-α has been implicated in the development of depressive disorders. A 
significant increase in serum TNF-α has been reported in depression patients. 
Etenercept is an anti-TNF agent that has been associated with the improvement 
of mood and anxiety disorders in patients with chronic inflammatory diseases 
such as psoriasis and RA (Uguz et al., 2009); (Tyring et al., 2006). In addition, 
one well known study by Tobinick et al demonstrated an immediate effect 
improving cognition in Alzheimer's disease (Tobinick and Gross, 2008). The 
mechanism that underlies the effects of etanercept on neurobiological functions 
that contribute to the improvement in psychiatric and cognitive problems in 
patients with chronic inflammator disaeses remains unclear. A recent study by 
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Terrando et al., showed that TNF-blockade can improve a hippocampal-
dependent form of cognitive decline induced by surgery-induced Inflammation 
(Terrando et al., 2010). In that study, etanercept also reduced IL-1β protein 
levels in both brain and periphery (Terrando et al., 2010). This suggests that 
etanercept can improve cognitive decline by inhibiting IL-1β, which may be 
associated with the improvement of hippocampal function. However, that study 
did not address the issue of the effects of etanercept on hippocampal 
neurogenesis, which may be associated with the improvement of the cognitive 
function of the hippocampus. To date, there are no animal studies that report 
the molecular mechanism of etanercept on hippocampal neurogenesis. We first 
demonstrated that peripheral etanercept treatment reversed impairment of 
neurogenesis in CII immunized mice. Our findings may help explain the 
mechanism by which etanercept improves cognitive decline observed in both 
human and animal studies.  
The combination of our data in Chapter 3 (Section 3.2.3 and Section 3.2.4), 
Chapter 4 (Section 4.2.3, Section 4.2.4 and Section 4.2.5) and this chapter 
suggests that the reduction in neurogenesis in CII immunized mice may be 
associated with increases in brain inflammatory mediators. Our data also showed 
that etanercept-treated CII immunized mice had more DCX-positive cells in their 
hippocampus compared to untreated CII immunized mice during the peak of the 
disease, whereas the severity of arthritic disease of these etanercept-treated CII 
immunized mice was lower compared to control PBS-treated CII immunized 
mice. This suggests that the neuro-protective effect of etanercept on 
hippocampal neurogenesis during disease development of inflammatory arthritis 
could be due to its anti-inflammatory effect on peripheral inflammation. We 
could not address the mechanism of how peripheral etanercept treatment could 
prevent the reduction of hippocampal neurogenesis in CII immunized mice during 
the period of clinical manifestation of arthritis. Etanercept may directly inhibit 
the peripheral inflammatory signal of TNF-α, which has been shown to be 
detrimental to neurogenesis (Seguin et al., 2009). This is also supported by a 
study by Jiang et al showing that the effect of peripheral treatment of 
etanercept on sickness behaviour induced centrally by IL-1β did not require 
transportation of the etanercept molecules across the blood-brain barrier into 
the brain. Instead, the peripheral etanercept treatment reversed sickness 
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behaviour in mice by suppressing the expression of IL-1β in the peripheral organs 
(Jiang et al., 2008). Another possibility is that peripheral etanercept treatment 
may prevent the reduction of hippocampal neurogenesis via the suppression of 
brain cytokine production. This possibility is supported by our data in Chapter 5 
(Section 5.2.3 and Section 5.2.4) showing that peripheral treatment of 
etanercept reduced brain inflammatory mediators, including TNF-α, IL-1β, IL-12 
and IL-5 in brains of CII immunized mice. As discussed previously, some of these 
inflammatory mediators including TNF-α, IL-1β and IL-12 have been reported to 
have detrimental effects on hippocampus neurogenesis.  Some of our data in 
that section is consistent with a recent report showing that peripheral treatment 
using etanercept reduced IL-1β protein levels in brains of the mouse model of 
surgery-induced brain inflammation (Terrando et al., 2010). A study by the same 
group also showed that IL-1β is a potent regulator of the hippocampus-
dependent form of cognition. Taken together, data from recent reports suggest 
that IL-1β may be the target for the action of etanercept to improve the 
function of the hippocampus.  
Interestingly, our data also demonstrated that the suppression of brain 
inflammatory mediators by etanercept may not be the only mechanism by which 
etanercept treatment protects against the reduction of hippocampal 
neurogenesis. In this chapter, we had 2 etanercept-treated CII immunized mice 
and PBS-treated CII immunized mice sacrificed on day 32 and day 35. On day 32, 
etanercept treatment attenuated severity of arthritis and prevented impairment 
of hippocampal neurogenesis in CII immunized mice. In contrast, etanercept 
treatment inhibited the progression of arthritis in etanercept-treated CII 
immunized mice, but the effect to prevent the impairment of hippocampus 
neurogenesis seemed to be weaker compared to those etanercept-treated CII 
immunized mice on day 35. Etanercept treatment only attenuated, but did not 
prevent the reduction of hippocampal neurogenesis in etanercept-treated CII 
immunized mice on day 35.  These data suggest that the effect of etanercept 
treatment on impairment of hippocampal neurogenesis may not be associated 
with the therapeutic effect of etanercept on peripheral joint inflammation of 
arthritis. Considering the brain inflammatory mediator profiles of etanercept-
treated CII immunized mice on day 35 and day 32 (Chapter 5; Section 5.2.3 and 
Section 5.2.4), we found that etanercept treatment reduced TNF-α, IL-5 and IL-
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12, which have detrimental effects on hippocampal neurogenesis in etanercept-
treated CII immunized mice on day 32. We could not measure changes in brain 
inflammatory mediators and hippocampal neurogenesis in the same brain since 
brain samples for both analyses were processed differently. However, data of 
both brain inflammatory mediator profiles and hippocampal neurogenesis in 
etanercept-treated CII immunized mice on the same time point (day 32 and day 
35 after immunization) seemed to correspond and support each other. It is 
possible that the prevention of the reduction of hippocampal neurogenesis by 
etanercept may be due to the reduction of these brain inflammatory mediators. 
Surprisingly, brains of etanercept-treated CII immunized mice on day 35 not only 
showed a reduction of IL-1β, CXCL1 and IL-12, but also showed increases in IL-2, 
VEGF and FGF2. VEGF and FGF2 have been reported to support hippocampal 
neurogenesis. These inflammatory mediators may enhance the action of 
etanercept, leading the greater effects of etanercept to prevent impairment of 
hippocampal neurogenesis. However, we found that etanercept did not prevent 
hippocampal neurogenesis in etanercept-treated CII immunized mice on day 35. 
These data suggest that changes in hippocampal neurogenesis may not only 
depend on direct effects of cytokines in the brain. There may be several 
explanations for this observation. Firstly, we do not know the actual function of 
these inflammatory mediators in the brain. Although VEGF and FGF2 have been 
shown to play neuroprotective roles, they could also have detrimental 
immunological effects on neurogenesis. For example, VEGF has been report to 
be a neuronal growth factor supporting growth of neurons (Rosenstein et al., 
2003). However, it is also an angiogenic factor and has been implicated in BBB 
breakdown (Sasaki et al., 2010) that is associated with more recruitment of 
immune cells into the brain, which could suppress hippocampal neurogenesis. 
Secondly, the effect of etanercept on hippocampal neurogenesis may be 
transient. This hypothesis is supported by a study in Alzheimer's disease showing 
that etanercept can improve mood within minutes (Tobinick and Gross, 2008). 
This could be the reason why the effect of etanercept on impairment of 
hippocampal neurogenesis was observed at the earlier time point (day 32) but 
not the later (day 35). However, this hypothesis needs to be further investigated 
by determining changes of hippocampal neurogenesis in etanercept-treated CII 
immunized mice in more time points across the CIA experimental period. 
Thirdly, etanercept may indirectly affect hippocampal neurogenesis via other 
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systems that regulate systemic inflammation such as HPA axis. The hypothalamo–
pituitary–adrenal (HPA) system is a combined regulatory system between the 
endocrine system and the immune system (Heiser et al., 2008). Peripheral 
inflammatory signals activate the HPA axis by stimulating the anterior pituitary 
gland to release adrenocorticotropic hormone (ACTH) into the circulation. 
Adrenocorticotropic hormone (ACTH) in turn activates the production of 
glucocorticoid-producing cortex cells in adrenal glands to release corticosteroid 
hormones including cortisol (in humans) (Lanfumey et al., 2008). These 
corticosteroids function as anti-inflammatory hormones and their levels are 
normally upregulated during inflammation and infection (Hadid et al., 1999). 
Chronic administration of corticosteroid hormones was shown to inhibit 
hippocampal neurogenesis and reduce hippocampal volume, along with 
increased anxiety (light dark box test) and depression (forced swim test)-like 
behaviour, suggesting that corticosterone not only induces depression via the 
serotonergic system, but also via neurogenesis (Murray et al., 2008). A recent 
study showed that after TNF-blockade, a rapid increase in corticosteroid 
hormones in RA patients during the first 12 week period of treatment, following 
by the reduction of corticosteroid hormones in the later period as the result of 
HPA adaptation (Straub et al., 2003). Based on this evidence, we hypothesized 
that etanercept may effect the level of peripheral corticosteroid hormones, 
which eventually effect changes in hippocampal neurogenesis. To test this 
hypothesis we could measure the level of corticosteroid hormones during the 
treatment of etanercept that may provide additional information underlying the 
protective effect of etanercept against impairment of hippocampal 
neurogenesis.  
6.7.4 Severity of arthritis was not associated changes in 
hippocampal neurogenesis in arthritic mice, and the 
reduction in hippocampal neurogenesis in non-arthritic 
mice 
Our data also showed that there was no significant correlation between clinical 
score and the number of DXC-positive cells in both untreated arthritic CII 
immunized mice and etanercept-treated arthritic CII immunized mice. Our data 
suggest that the reduction in hippocampal neurogenesis in arthritic mice and the 
preventive effect of etanercept against impairment in hippocampal neurogenesis 
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were not associated with severity of arthritis. This observation also contrasts 
with a previous study using AIA mice showing a significant correlation between 
degree of joint swelling and cell proliferation indicated by the number of BrdU-
positive cells (Wolf et al., 2009b). However, there was no significant correlation 
between the number of DCX-positive cells and joint swelling reported in that 
study, suggesting that the increase in proliferative brain immune cells such as 
microglia and astrocytes may reflect the increase inflammatory cells in the joint 
that may distribute to the brain. Our data also showed significant reduction in 
neurogenesis in immunized mice that did not develop arthritis (non-arthritic 
mice). In addition, the etanercept treatment also showed similar effects 
preventing the reduction in hippocampal neurogenesis in these non-arthritic 
mice as well as arthritic mice. This finding suggests that the impairment in 
hippocampal neurogenesis may be independent to inflammatory joint disease. 
There may be ongoing immune activation in the peripheral of non-arthritic mice 
that could signal the suppression of neurogenesis, but could not initiate joint 
inflammation due to difference in immune-tolerance mechanisms in individual 
mice. This premis is supported by our data in Chapter 3 (Section 3.2.3 and 
Section 3.2.4) and Chapter 4 (Section 4.2.3, Section 4.2.4 and Section 4.2.5) 
showing that there was no significant difference in brain inflammatory mediator 
concentrations between arthritic and non-arthritic mice. There are several 
explanation underlying these observations. One possible explanation is that the 
CFA given to the non-arthritic mice during the immunization may itself cause a 
reduction in hippocamapal neurogenesis without development of arthritis. 
Peripheral administration of CFA alone has been reported to activate brain 
immune response (Raghavendra et al., 2004), suggesting that the inhibition of 
hippocampal neurogenesis in non-arthritic mice may be the result of CFA itself 
that can induce brain inflammation. Our data also suggests that brain 
inflammation can cause a reduction in neurogenesis even at the subclinical 
level. So the presence of inflammatory phenotypes in terms of illness 
[manifestation of frank arthritis or not (sub-clinical) in CIA model] is not 
necessary directly connected with the depression (Tyring et al., 2006), where 
there is a separation of the effect of anti-inflammatory drug (TNF-blokadge) 
between the arthritis and the depression. So inflammatory mediators can impact 
on neurogenesis negatively eventhough the illness is not manifested. In addition, 
peripheral administration of CFA has also been reported to reduce hippocampal 
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neurogenesis via suppressing the gene expression of brain-derived growth factor 
(BDNF) in the hippocampus (Duric and McCarson, 2006). BDNF is a nerve growth 
factor that is constitutively expressed across subregions of the hippocampus and 
the adult forebrain (Lu et al., 2008) that has been implicated in the regulation 
of hippocampal neurogenesis. Interestingly, ablation of BDNF in the hippocampus 
resulted in a reduction in hippocampus neurogenesis, along with increased 
behaviour associated with depression, suggesting a role for BDNF-induced 
neurogenesis in the psychological aspect of depression (Taliaz et al., 2010). The 
production of BDNF in the brain could be suppressed by cytokines such as IL-β or 
LPS (Guan and Fang, 2006). This evidence suggests another indirect pathway of 
peripheral inflammation to modulate hippocampal neurogenesis via the 
production of brain neurotrophic factors. Therefore, it would be of interest to 
determine the concentrations of BDNF in the hippocampus in brains of CII 
immunized mice, which may be associated with brain cytokine concentrations 
and number of DCX-positive cells in dentate gyrus. 
Summary  
We demonstrated a reduction in hippocampal neurogenesis in CII immunized 
mice that may be induced by peripheral inflammation, which may/ may not be 
directly associated with peripheral joint inflammation. In addition, we also 
showed that peripheral treatment with etanercept prevented / attenuated the 
impairment of hippocampal neurogenesis in CII immunized mice. This could be 
important evidence suggesting that the reduction in hippocampal neurogenesis 
may be caused by peripheral inflammation in this chronic inflammatory disease 
model of arthritis. However, it would be of interest to conduct behavioural tests 
of hippocampal-dependent forms of cognition for the functional analysis of 
changes in hippocampal neurogenesis in both treated and etanercept-treated CII 
immunized mice. Our findings could also help explain the cognitive decline and 
depression associated with chronic inflammatory diseases like RA. In addition our 
findings could help explain the underlying mechanism of etanercept in transient 
improvement of mood in patients with chronic inflammatory diseases. 
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7 General discussion and conclusion 
Several lines of evidence have demonstrated that peripheral inflammation could 
induce neuro-inflammation, indicated by up-regulation of inflammatory 
mediator profiles. The model of systemic challenge with LPS showed increases in 
expression of several cytokines, including IL-1β, IL-6 and TNF-α in various regions 
of the brain (Henry et al., 2009); (Datta and Opp, 2008). These pro-inflammatory 
cytokines have been reported to be up-regulated in the spinal cord and brains of 
animal models of chronic inflammatory disease such as adjuvant-induced 
arthritis (Bao et al., 2001); (del Rey et al., 2008). IL-1β was increased in the 
hippocampus in a model of surgery-induced peripheral inflammation (Terrando 
et al., 2010a). Other inflammatory mediators such as CCL2 were shown to be up-
regulated in the brain of mice with liver injury (D'Mello et al., 2009). 
Importantly, this neuro-inflammation induced by peripheral inflammation may 
also contribute to changes in neurobiology, resulting in psychological disorder 
such as depression and cognitive dysfunction. A high rate of depression is 
commonly found in patients with RA (Isik et al., 2007), psoriasis (Biljan et al., 
2009) and MS (Lo Fermo et al., 2010), which is presumably associated with 
chronic inflammation. A reduction in serotonin transporter (SERT) density and an 
improvement in physical and mental function were observed in RA patients after 
receiving anti-TNF-α treatment (Cavanagh et al., 2010). Animal studies also 
showed that up-regulation of cytokines induced by peripheral inflammation 
caused a decline in hippocampal neurogenesis, resulting in cognitive decline and 
changes in emotional behaviour (Crupi et al., 2010); (Ekdahl et al., 2003), 
(Kaneko et al., 2006); (Terrando et al., 2010b); (Ziv et al., 2006). Interestingly, 
peripheral administration of anti-inflammatory drugs and the blockade of 
cytokines can inhibit production of some of the brain inflammatory mediators 
such as IL-1β that is generated during peripheral inflammation (Terrando et al., 
2010). Clinical and animal studies also showed that anti-inflammatory therapy 
and TNF–blockade can result in a reduction in hippocampal neurogenesis and 
improve cognitive impairment and depression symptoms in patients with chronic 
inflammatory diseases (Monje et al., 2003); (Tyring et al., 2006); (Tobinick and 
Gross, 2008); (Tobinick and Gross, 2008b). These data provide important 
evidence showing that the impairment of hippocampal neurogenesis and 
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cognition may be associated with and regulated by increases in brain 
inflammatory mediators during peripheral inflammation. 
Based on this evidence we hypothesized that the peripheral 
immune/inflammatory response during arthritis can affect the brain 
inflammatory mediator profiles and hippocampal neurogenesis which might help 
explain the psychological illness associated with RA. To explore this possibility, 
firstly, we determined changes in brain inflammatory mediators and the 
interplay between production of cytokines, chemokines and growth factors 
during experimental arthritis induced by type II collagen (CIA mice), a model of 
arthritis. Secondly, we investigate changes in hippocampal neurogenesis in this 
arthritis model. Finally, to confirm that all changes in brain inflammatory 
mediators and hippocampal neurogenesis are associated with inflammation, the 
effect of Etanercept, a recombinant humanised soluble TNF-receptor, on 
peripheral inflammation-induced neuro-inflammation and impairment in 
hippocampal neurogenesis in this CIA model was also investigated.  
The major findings from this thesis are summarised in Figure 7.1 
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Figure 7.1 Summary of the major findings from this thesis entitled; ‘Peripheral autoimmunity 
induces central neuro-inflammation and hippocampal neurogenesis impairment in a murine 
model of collagen induced Rheumatoid Arthritis’.  
Peripheral joint inflammation was induced by type II collagen in a mouse model of 
Rheumatoid Arthritis (CIA mice). Several inflammatory mediators were detected in the 
periphery (serum) during the course of arthritis and they may be transported through the 
blood brain barrier (BBB) into the brain by unknown mechanisms and induced neuro-
inflammation. Up-regulation of both gene and protein expression of inflammatory mediators 
observed in the brain of these collagen II immunized mice may be associated with 
impairment in hippocampal neurogenesis.  Peripheral TNF blockade treatment with 
Etanercept attenuated the arthritis in arthritic mice, along with a reduction of several 
inflammatory cytokines (including IL-1β, TNF-α, IL-12), chemokine (including CXCL1), and 
an increase of some inflammatory and remodelling mediators (including IL-2, FGF2, VEGF) 
in the brain of arthritic mice. Etanercept treatment was also associated with a reversal of the 
disease-associated reduction in hippocampal neurogenesis. The anti-inflammatory effect of 
Etanercept on neuro-inflammation may contribute to neuroprotection against impairment of 
hippocampal neurogenesis.  
We demonstrated that changes in inflammatory mediator profiles in brains of CII 
immunized mice may be associated with peripheral inflammation. Our time 
course data showed that there was no significant difference in levels of brain 
inflammatory mediators in CII immunized mice compared to those in the control 
mice on day 14, which is the time point typically just before the onset of 
arthritis which usually starts on day 19. However, changes in various 
inflammatory mediator profiles were observed after the onset of arthritis; on 
day 22, and towards the end of the course of arthritis disease at day 42. In 
addition, our time-course experiment showed longitudinal changes in various 
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inflammatory mediator gene/protein concentrations including IL-1β, TNF-α, IL-4, 
IL-2, CXCX1, CXCL10, VEGF and FGF2 in brains of CII immunized mice during the 
whole period of onset and clinical manifestation of arthritis disease. In addition, 
prolonged increases in protein concentrations of IL-12 and IL-4 were observed in 
brains of CII immunized mice during the onset and disease development periods 
of experimental arthritis. These data suggest that there may be immune 
activation and inflammation occurring in the brain of CII immunized mice during 
the developmental process of peripheral joint inflammatory disease. A previous 
study by del Rey et al is consistent with our findings by showing longitudinal 
changes in brain cytokines such as IL-1β, IL-6 and TNF-α and the up-regulation of 
some cytokines such as IL-6 during the ongoing stage and the peak of the 
arthritic disease in an adjuvant induced arthritis model (AIA) (del Rey et al., 
2008). Importantly, our data also showed that the anti-inflammatory effect of 
Etanercept could also suppress the up-regulations of some inflammatory 
mediators, including TNF-α, IL-1β, IL-12 and CXCL1 in the brain of CII immunized 
mice. These inflammatory mediators play important roles in initiating the 
immune response and the development of joint inflammation in RA. Similar 
findings were reported recently by Terrando et al., showing that anti-TNF-α 
could suppress up-regulation of brain IL-1β during peripheral inflammation 
induced by surgery in a model of surgical trauma (Terrando et al., 2010a).  
Up-regulation of inflammatory mediators in the brain of CII immunized mice may 
reflect immune activation and neuro-inflammatory processes. Increases in the 
levels of pro-inflammatory cytokines TNF-α and IL-1β may indicate microglial 
activation and innate immune responses in the brain of CII immunized mice. Up-
regulation of Th1 cytokines (IL-12, IL-2, IFN-γ) and Th2 cytokines may suggest 
the potential for adaptive immunity in the brain of CII immunized mice. 
Increases in chemokines, including CXCL1, CCL2 and CXCL10, and angiogenic 
factors such as FGF and VEGF may implicate trafficking of immune cells and 
blood brain barrier leakage in the brain of CII immunized mice. One of the most 
striking findings in this study is the up-regulation of CXCL10 in CII immunized 
mouse brains during the ongoing stage and peak of arthritis. Interestingly, mRNA 
levels of brain CXCL10 were higher in arthritic mice compared to those in 
similarly CII immunized mice but with no arthritis. The CXCL10 is thought to play 
an important role in neuro-inflammatory diseases because, during CNS neuro-
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inflammation, expression of CXCL10 is elevated several fold (Bajova et al., 
2008). In the CNS, CXCL10 regulates trafficking of Th1 cells into the CNS, which 
is thought to be the initiation of the development of inflammatory 
demyelination in MS and EAE (Klein, 2004). The lesions of CNS inflammatory 
demyelination have also been reported in brains of RA patients (Tsai et al., 
2008); (Tajima et al., 2004). It is possible that peripheral Th1 cells are recruited 
into the CNS by CXCL10 chemotactic signals which can then induce the 
development of inflammatory demyelination in the brain during the course of 
arthritis in these RA patients. This rational is feasible because of several 
similarities in pathological mechanisms of MS and RA. Particularly, CD4+T cells 
are thought to have a crucial role in both MS and RA pathogenesis (Zozulya and 
Wiendl, 2008); (McInnes and Schett, 2007). Therefore, the elevation of CXCL10 
in arthritic mouse brains may be the most important indicator of the presence of 
neuro-inflammation in the brain of arthritic mice, and this may be strongly 
associated with peripheral joint inflammation.  
Our longitudinal data of inflammatory mediators in the brain of CII immunized 
mice demonstrated some interesting observations about brain-immune system-
joint communication. The concentrations of brain inflammatory mediators such 
as TNF-α and IL-13 increased in parallel with arthritis development, while 
prolonged expressions of some brain inflammatory mediators such as IL-6, IL-10, 
IL-13, IL-12 and CXCL2 were observed over the course of arthritis. These data 
seem to suggest that inflammatory mediators can access the brain from the 
periphery during the development of “peripheral” chronic joint inflammatory 
diseases. However, our data of serum inflammatory mediators showed that the 
concentrations of several inflammatory mediators such as IL-5, IL-1β, CCL2 and 
FGF were elevated in serum immediately after the onset of arthritis and the 
concentrations then decreased in parallel with disease development. These data 
suggest a disruption in communication between the peripheral immune system 
and CNS during the course of arthritis. We cannot define a precise mechanism of 
how the inflamed joint signalled to the brain in order to produce inflammatory 
mediators. A similar finding was reported by del Rey et al in CIA rats. In that 
study, there were no significant serum cytokines detected, but the brains of 
these CIA rats showed elevations of IL-1β and IL-6 during the course of arthritis 
(del Rey et al., 2008). Two main questions remain: first, how can these 
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inflammatory mediators access the brain, and second, what are the cellular 
sources in the brain that produce these inflammatory mediators? Several studies 
suggest various mechanisms of how peripheral inflammation signals the CNS to 
produce inflammatory mediators. One putative mechanism is that the trafficking 
of the peripheral immune cells into the brain occurs during the blood brain 
barrier breakdown that is induced by the peripheral inflammation (Carson et al., 
2006). Our data showed that various inflammatory mediators were up-regulated 
in the brain of CII immunized mice, including IL-1β, TNF-α, IL-4, IL-10, IL-12 and 
CXCL1, on day 22, whereas VEGF and FGF, which are angiogenic factors that 
could be indicators of blood brain barrier damage, are elevated in the brain 
later on day 28. These data suggest that the brains of these CII immunized mice 
may be signalled to produce inflammatory mediators before the integrity of the 
blood brain barrier is compromised. Several pieces of experimental evidence 
supported this observation by showing that blood brain barrier breakdown during 
neuro-inflammation is not a simple case of increase recruitment of peripheral 
immune cells into the brain (Carson et al., 2006); (D'Mello et al., 2009); (Shaftel 
et al., 2007) . Brains of transgenic mice over-expressing IL-1β showed blood– 
brain barrier leakage, along with elevations of CXCL1 and CCL2, and dramatic 
infiltration of CD45+ leukocytes. However, transgene induction of IL-1β in brains 
of mice lacking CXCR2, a chemokine receptor that regulates neutrophil 
recruitment, showed disruption in neutrophil infiltration into the brain but failed 
to reduce leakage of the blood– brain barrier (Shaftel et al., 2007). The data of 
this study suggest that blood brain barrier breakdown is not associated with 
increased rate of leukocyte accumulation in the brain.  
We also found prolonged expression of Th2 cytokines including IL-4 and IL-10 in 
the brains of CII –immunized mice throughout the onset of disease (day 22), the 
ongoing stage of the disease (day 28) and during the peak of the disease (day 
35). However, in the periphery, during the onset of disease (day 19 to day 22) 
and on to the peak of the disease (day 35), the course of the arthritis in the CIA 
model is thought to be regulated predominantly by Th1 cells, whereas the Th2 
response is dominant during the remission phase (day 35 – day 42). This finding 
suggests there may be local production of IL-4 and IL-10 by CNS immune cells 
such as astrocytes and microglia. Several studies reported that inflamed 
peripheral organs can signal brain microglia and astrocytes to produce 
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inflammatory mediators in the brain by an unknown mechanism (D'Mello et al., 
2009); (Riazi et al., 2008). A study using a model of liver inflammation showed 
that microglia were activated to produce CCL2 before monocytes could migrate 
into the brain. This study also demonstrated that the inflamed liver signalled to 
the brain microglia to produce CCL2 and as a consequence cause monocyte 
trafficking to the brain via systemic TNFR signalling (D'Mello et al., 2009). We 
also showed similar observation in our study; systemic administration of 
Etanercept, which effectively induced TNF blockade, demonstrated reductions in 
various inflammatory mediators, including TNF-α, IL-1β, IL-12 and CXCL1 in the 
brain of CII immunized mice. 
Taken together, our data combined with findings from previous reports suggest 
that peripheral joint inflammation may provide a signal to the brain to produce 
inflammatory mediators by local CNS immune cells such as microglia and 
astrocytes. This is shown in the brains of CII immunized mice during the 
elevation of serum inflammatory mediators at the onset and clinical 
manifestation stages of the disease (day 22 – day 28 after immunization). The 
initial signal from the periphery may further activate the immune and 
inflammation response in the brain and recruit more peripheral immune cells 
into the brain.  
We also demonstrated that these inflammatory mediators that were elevated in 
the brains of CII immunized mice may contribute to neurobiological changes in 
the brain. This is demonstrated by the impairment in hippocampal neurogenesis, 
characterized by a decline in DCX-positive cells in the dentate gyrus that was 
observed in brains of CII immunized mice. This was reversed by the anti-
inflammatory effect of TNF blockade using Etanercept. Our data raised an 
important question; does neuro-inflammation in brains of CII –immunized mice 
contribute to neuron loss in the dentate gyrus by suppression of hippocampal 
neurogenesis, or by enhancing neurodegeneration? Several experimental studies 
reported various roles of innate immunity, adaptive immunity, cytokines, 
chemokines and growth factors, which contribute to different aspects of the 
regulation of hippocampal neurogenesis. For example, TLR2 agonists enhance 
neurogenesis, while TLR4 agonists suppress hippocampal neuronal proliferation 
(Rolls et al., 2007). T cells have been reported to maintain neurogenesis (Ziv et 
al., 2006), whereas B cells were shown to inhibit neurogenesis (Crupi et al., 
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2010). Chemokines such as CXCL12 acts as a neuromodulator to support 
maturation and neutrite extension of hippocampal neurons (Chalasani et al., 
2003). In contrast, IFN-α has been reported to inhibit neuronal proliferation in 
the dentate gyrus via IL-1β signalling (Kaneko et al., 2006). Therefore, brain 
inflammatory mediators up-regulated in brains of CII –immunized mice may 
function in a complex network to regulate hippocampal neurogenesis. 
Interestingly, a recent study by Julie Anne Seguin 2009 et al demonstrated 
different regulation of various pro-inflammatory cytokines on hippocampal 
neurogenesis depending upon the route and duration of administration. Systemic 
administration of TNF-α reduces hippocampal neurogenesis, while intra-
hippocampal infusion of IL-6 and IL-1β enhances neuronal proliferation. These 
data suggest that the inflammatory signals from the periphery are detrimental to 
hippocampal neurogenesis, whereas local inflammatory signals paradoxically 
play a protective role in hippocampal neurogenesis (Seguin et al., 2009). This 
would also explain our finding showing that peripheral treatment using TNF 
blockade could reverse the impairment of hippocampus neurogenesis in CII 
immunized mice, probably via the inhibition of inflammatory signals from the 
periphery. Preventing the TNF-induced apoptosis pathway could be another 
mechanism by which Etanercept could inhibit neuronal loss in the hippocampus. 
However, it is difficult to conclude the precise effect of TNF blockade on 
apoptosis-induced neuronal death in this study. This is because the two TNF 
receptor chains; p55 TNFR and p75 TNFR can play divergent roles in hippocampal 
neurogenesis. p55 TNFR (TNFR1) contains an intracellular “death domain” and 
activation of this receptor leads to apoptosis and neuronal death. In contrast, 
p75 TNFR (TNFR2) can be either neuroprotective (Marchetti et al., 2004) or 
induce apoptosis (Depuydt et al., 2005). Therefore, blocking TNFR signal by 
Etanercept can possibly prevent apoptosis and neuronal death as well as reduced 
neuroprotection.            
Our study has a number of strengths. Firstly, we used a CIA mouse model of 
arthritis, which shares similar immunopathology with human RA. This is also one 
of the best validated models of a chronic inflammatory disease. Secondly, we 
employed a novel high-throughput screening method, Luminex, to detect protein 
expression of multiple inflammatory mediators which allows analysis of the small 
volumes obtained from serum and brain homogenate samples. We also used a 
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highly sensitive real-time PCR for specific detection and quantification of mRNA 
levels of brain inflammatory mediators. Thirdly, we chose DCX as a neuronal 
marker for hippocampal neurogenesis because it specifically labels immature 
neurons in the dentate gyrus. It also allows us to see the clear morphology of 
pyramidal neurons without co-staining with other markers. However, it also had 
several important limitations.  
1. There were apparent inconsistencies in several concentrations of 
brain inflammatory mediators in the CII immunized mice. Part of 
this was because we used different number of mice and measured 
levels of brain inflammatory mediators in experimental time points 
in different CIA experiments. Therefore, increase statistical power 
by increasing number of mice per group per time point would have 
helped to improve the consistency of the data.  
2. The etanercept experiments in chapter 5 and 6, conducted using 
small sample size (3-5 mice/ group), are considered to be pilot 
studies which belongs to the exploratory phase of the research 
project. The preliminary data generated from small groups of mice 
may affect the power of statistical analysis and thus impact the 
ability to interpret the results. However, these pilot data can be 
very valuable and can guide to a more extensive experiment. 
Therefore, it is worthwhile to repeat these experiments using the 
larger numbers of animals.   
3. Most of our data, particularly in Chapter 3 and 4, demonstrated 
that there was a significant difference in increased inflammatory 
mediator gene/protein levels in arthritic compared with non-
arthritic mouse brains; both groups received CFA. In addition, we 
also found that there was no significant correlation between 
inflammatory mediator gene/protein levels and arthritis scores of 
arthritic mice, suggesting that the subclinical systemic 
inflammation may also be important in neurological response as 
seen in psoriasis (Tyring et al., 2006). Our neurogenesis study also 
showed that there was no significant different in the reduced 
number of DCX-positive cells in the dentate gurus between arthritis 
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and non-arthritis mice. Again, there is no correlation between 
number of DCX-positive cells in the dentate gyrus of arthritic mice 
and their arthritis score. Based on our data, it is difficult to 
conclude whether or not up-regulations of inflammatory mediator 
gene/protein levels and the reduction in neurogenesis are directly 
associated with clinical manifestations of rheumatoid arthritis. We 
hypothesized that the CFA given to the non-arthritic mice during 
the immunization may itself cause a reduction in hippocamapal 
neurogenesis and the activation of brain immune response in the 
subclinical level of rheumatoid arthritis. Therefore, it is important 
to include another control consisting of DBA1 mice that recive only 
CFA in the future study to investigate the extent of CFA in 
induction of inflammatory mediator gene/protein expression and of 
the reduction in neurogenesis in the subclinical level in this CIA 
model.  
4.  In an attempt to investigate the inflammatory signals from the 
periphery, we measured inflammatory mediator proteins in serum 
of CII immunized mice. However, we only detected increases in 
serum inflammatory mediator proteins during the earlier time 
points of the disease progression period (day 22-day 28 after 
immunization) but not during the period that the arthritis was 
manifested (day 35-day 42 afther immunization) in CII imminized 
mice. Our results were consistent with previous studies showing 
that serum cytokine concentrations in CIA model were inconsistent 
and in many cases undetectable at the arthritis phase (Harnett et 
al., 2008); (Lu et al., 2010); (del Rey et al., 2008). This may be 
explained by several studies showing that rheumatiod arthritis is a 
tissue specific autoimmune disease where inflammatory mediators 
are generated locally and induce bone and cartilage destructive 
process, but may not circulate in the bloodstream (Lu et al., 2010); 
(Palmblad et al., 2001). In addition, clinical evidence also suggests 
that the localization of inflammatory mediators from the inflamed 
sites to other peripheral organs may be mainly via the lymphatic 
system rather than the bloodstream (Olszewski et al., 2001). This 
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was also supported by several CIA studies revealling increases of 
various inflammatory mediators in several peripheral organs such 
as paws, draining lymph nodes and spleen during the peiod of 
clinical manifestation of arthritis (Thornton et al., 1999);(Rioja et 
al., 2004);(Mauri et al., 1996). Therefore, to futher investigate the 
communication between peripheral inflammatory signal and brain 
inflammation in CIA model, it would be important to measure 
expression of inflammatory mediators in other peripheral organs 
such as paws, draining lymph nodes and spleen which may be 
associated with the expression of these inflammatory mediators in 
the brain of CIA mice.  
                                                                                                                                               
In summary, our study demonstrated that peripheral inflammation in CII-
immunized mice induced changes in brain inflammatory mediator profiles and 
impairment in hippocampal neurogenesis. We also showed that peripheral 
treatment of TNF-blockade using Etanercept could inhibit cytokine production 
and activity within the brain of CII-immunized mice, resulting in the reversal of 
the arthritis-associated impairment in hippocampal neurogenesis. These 
observations suggest that inflammatory signals from the periphery can activate 
immune and inflammatory responses in the brain, which may contribute to 
neurobiological changes such as alterations in hippocampal function. This 
scenario may help explain the clinical observations of psychiatric disorders such 
as depression and cognitive impairment in chronic inflammatory diseases such as 
RA and psoriasis. Our findings also suggest that TNF-blockade may be a possible 
novel strategy to alleviate symptoms of depression and cognitive impairment 
associated with chronic inflammatory diseases. Studies have shown that 
depression in rheumatoid arthritis has an important impact on health-related 
quality of life. Therefore, further investigations of Etanercept as a novel 
approach to both the anti-inflammatory and antidepressant treatments are 
worthy.   
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7.1 Suggestions for future studies 
Based on the results of this thesis we propose the following hypotheses and 
studies that might address them: 
7.1.1  Hypothesis; there is migration of immune cells from 
the periphery into the brain of CII immunized mice.  
We found up-regulation of inflammatory mediators in the brain of CII immunized 
mice, which may be produced from immune cells migrating from the periphery.  
7.1.1.1 Investigate the migration of immune cells from the periphery 
into the brain of the CIA mouse model of arthritis.  
The questions of how peripheral joint inflammation signals to the brain to 
produce inflammatory mediators, and does that process involve migration of 
immune cells from the periphery into the brain remains unresolved. We suggest 
using an ex-vivo technique called ‘adaptive transfer’ to track the migration of 
labelled immune cells from the periphery into the CNS (D'Mello et al., 2009). 
This technique is commonly used to study the pathological mechanism of MS, in 
which inflammatory demyelination is thought to be induced by peripheral 
immune cells. The principle of this technique involves isolation of monocytes 
from peripheral blood and/or leukocyes from lymph nodes in the donor animals. 
Each type of peripheral immune cell is isolated and purified by magnetic beads 
linked to cell-specific antibodies. For example, beads with anti-CD11b can be 
used to purify monocytes (D'Mello et al., 2009), while CD45 and TCR can be used 
for the isolation of T cells (Lees et al., 2008). These CD11b+ monocytes and/or 
CD45+ T cells are then labelled with florescent dyes. These labelled immune 
cells are then adoptively transferred by i.v. injection into the recipient animals. 
The presence of these adoptively transferred immune cells is then detected in 
the brains of these recipient animals using fluorescent immunohistochemistry. 
This technique can also be used for measuring the cytokine production 
capabilities of immune cells present within the CNS at various time points 
following adoptive transfer. 
Chapter 7  363 
7.1.2  Hypothesis; there is local production of inflammatory 
mediators by astrocytes and microglia in the brain of CII 
immunized mice.  
We found up-regulation of protein and gene of inflammatory mediators in the 
brain of CII immunized mice, which may be produced from CNS immune cells 
such as astrocytes and micoglia.  
7.1.2.1 Investigate the local production of inflammatory mediators by 
CNS immune cells such as astrocytes and microglia.  
Previous reports suggest that peripheral inflammation can signal to the local 
immune cells in the brain to produce inflammatory mediators by an unknown 
mechanism. Although we demonstrated an increase of both protein and mRNA 
levels of some inflammatory mediators in the brain of CII immunized mice, it is 
still difficult to conclude the cellular sources of these inflammatory mediators. 
The activation of astrocytes and microglia and their cytokine production 
capabilities during the peripheral inflammatory process can be investigated by 
double staining for each cytokine and the microglia or astrocytic markers. We 
can use GFAP to label astrocytes and determine any increase in astrocyte 
number in the brain (Sofroniew and Vinters, 2010). Studies also showed that 
peripheral inflammation can induce cytokine production via microglial activation 
in the brain (D'Mello et al., 2009); (Riazi et al., 2008). CD11b and CD45 are 
commonly used as markers for microglia (Yang et al., 2010). Microglia activation 
is indicated by the change in morphology of microglia from inactive ramified 
microglia to active ameboid microglia (Riazi et al., 2008).  
7.1.3  Hypothesis; difference inflammatory mediators play 
different role in hippocampal neurogenesis.  
Up-regulation of protein and genes of various inflammatory mediators including 
IL-1α, IL-5, CXCL1, CXCL10, IL-10, IL-13, FGF2 and VEGF in brains of CII 
immunized mice on day 42. At that time point, we also found an impairment in 
hippocampal neurogenesis in the brains of CII immunized mice. Different 
inflammatory mediators play different roles in regulation of hippocampal 
neurogensis. Therefore, it is interesting to define the extent to which 
inflammatory mediators regulate hippocampal neurogenesis.  
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7.1.3.1 Investigate roles of inflammatory mediators in hippocampal 
neurogenesis using in vitro experiments.  
Different regulations of various inflammatory mediators on hippocampal 
neurogenesis are also worth investigating. We can generate an in vitro model of 
hippocampal neurogenesis by deriving and culturing neuronal progenitor cells 
from the adult hippocampal dentate gyrus. Single or multiple inflammatory 
mediators can be add into the culture of neuronal progenitor cells to determine 
the effect of individual or combined inflammatory mediators on the proliferation 
and maturation of dentate gyrus neurons. The hippocampal neurogenesis after 
the cytokine treatment can be analysed by labelling these dentate gyrus neurons 
with various neuronal markers identifying different stages of neurogenesis. For 
example, DCX is used to label neurons in the immature stage, while NeuN is used 
to label neurons in the immature stage. FACS (fluorescence activated cell 
sorting) can then be used to  determine the level of neurogenesis by analysing 
the number of neurons that are positive to immature neuronal markers such as 
DCX and Brdu (Ming and Song, 2005). 
7.1.4 Hypothesis; the reduction in the number of neurons in 
the hippocampus of CII immunized mice could be the result 
of neurodegeneration.  
We demonstrated that the reduction in the number of neurons in dentate gyrus 
of CII iimmunized mice was the result of the inhibition of neurogenesis using 
neuronal marker DCX. However, the neuronal loss in dentate gyrus of CII 
iimmunized mice may possibly the result of neurodegeneration process such as 
apoptosis. 
7.1.4.1 Investigate neurodegenerative effects of peripheral 
inflammation on neurons in the hippocampal dentate gyrus.  
We demonstrated the suppression in hippocampal neurogenesis in CII immunized 
mice using DCX, a neuronal marker for immature neurons in the maturation 
stage. This was indicated by a reduction in the number of DCX-positive neurons 
in the dentate gyrus. However, it is also possible that peripheral inflammation 
can induce neuronal loss in the hippocampal dentate gyrus via 
neurodegenerative pathways. We showed that TNF-blockade can reverse this 
neurogenesis impairment. The neuroprotective effect of Etanercept may involve 
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blocking the apoptosis pathway induced by TNF receptor. Therefore, using 
markers for apoptosis such as TUNEL may lead to better understanding of 
another mechanism underlying the process of neuronal loss in the hippocampal 
dentate gyrus by peripheral inflammation. 
7.1.5 Hypothesis; Peripheral inflammation has effects on 
neurotransmitter and neurotropic factors in brains of CII 
immunized mice, that are associated with the pathological 
mechanism of depression.  
We demonstrated that peripheral inflammation had a detrimental effect o 
hippocampal neurogenesis. Inflammatory mediators up-regulated in brains of CII 
immunized mice may have actions on neurochemical or neurotropic factors, 
which may be associated with the development of depression. 
7.1.5.1 Investigate effects of peripheral inflammation in other 
pathological mechanisms of depression.  
Animal studies suggest that peripheral inflammation can induce cognitive 
impairment and depressive-like symptoms via suppression of hippocampal 
neurogenesis. However, the implication of neurogenesis and neural network 
disturbance in the patho-physiology of depression is still a novel theory. The 
effect of peripheral inflammation on other classical pathological mechanisms, 
monoamine (eg., serotonin, dopamine), HPA axis, and neuronal growth factors 
(eg., BDNF) should not be ignored. A study by del Rey et al., showed an increase 
in serotonin levels in the hypothalamus of the CIA rat model. Interestingly, that 
study also showed an increase in noradrenaline (NA), corresponding to reduced 
glucocorticoid levels in the hypothalamus of CIA rat. The author suggests that 
this data demonstrated a reduction in HPA axis activity, which has also been 
reported in RA patients (del Rey et al., 2008). However, an increase in HPA axis 
activity and a decrease in brain serotonin level have been reported in depression 
patients (Lanfumey et al., 2008). Therefore, it is better to use anatomical 
analysis such as in situ hybridization and autoradiography to determine changes 
in monoamine levels and neurotransmitter receptors in various areas in the 
brain. It may also be interesting to study changes in animal behaviour in the CIA 
mouse model using animal behavioural tests to investigate changes in cognition 
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and depressive-like behaviour during different phases of disease; to quantify 
associated inflammatory mediators and to test the effects of TNF blockade.  
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9 Appendices 
 
Appendix 1A; Standard curves of the Luminex assay  
Validations of assay performance as assessed by Standard curves of IL-1α (A), IL-2 (B), IL-
10 (C) and IL-5 (D), IL-13 proteins obtained from Luminex cytokine 20-Plex assay. Standards 
were prepared according to manufacturer’s instructions, and all standards were run in 
triplicate. Readings were obtained using BioPlex 200 hardware running BioPlex Manager 
software. 
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Appendix 1B; Standard curves of the Luminex assay  
Validations of assay performance as assessed by Standard curves of IL-13 (E), CXCL-1 (F), 
CXCL10 (G) and FGF2 (H) proteins obtained from Luminex cytokine 20-Plex assay. 
Standards were prepared according to manufacturer’s instructions, and all standards were 
run in triplicate. Readings were obtained using BioPlex 200 hardware running BioPlex 
Manager software. 
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Appendix 2; Real-time PCR standard curve of inflammatory mediators 
Real-time PCR standard curves of IFN-γ (A), CXCL1 (B), CXCL10 (C), VEGF (D) were 
generated by amplifications of serial dilutions of known quantities of plasmids containing 
the target sequences. Plasmid containing IFN-γ, CXCL1, CXCL10, and VEGF genes was 10 
fold serially diluted to obtain dilutions ranging from 106 to 102 copies amplified by real-time 
PCR. These standard curves plotting each Ct value against the log quantity of each 
standard mRNA copy number were used to extrapolate absolute mRNA copy numbers of 
inflammatory mediator gene expressions in brain samples. Each dot plot on the standard 
curve linear dynamic range represents gene expression value (copy number) of each 
standard, while each point in the graph represents gene expression value (copy number) of 
each sample.  
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Appendix 3 Melting curves of IFN-γ (A), CXCL1 (B), CXCL10 (C), VEGF (D) confirm 
specificity of PCR amplification
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